{
    "cells": [
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "# Clinical Trial Navigator\n\nThis program is a tool to query the ClinicalTrials.gov database, build a formatted data table of clinical trials based on custom search criteria.  The data table will contain details on clinical trial design, protocol, indication, product, start/completion date, and outcome measures.  Outcome measures are specifically broken out in detail to allow for more in-depth analyses.\n\nUsers can then search across a data table containing all primary and secondary endpoints used in all clinical trials returned in the study data table, to identify how many studies reported a specific endpoint.\n\nThis database file can also be used to conduct detailed analyses, i.e. compare trial duration, sample size, primary / secondary endpoints, and outcome measure performance for all phase 3 trials in a specific indication or drug class."
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "I took a hybrid object-oriented / functional approach for the Clinical Trial Navigator tool.\n\nI designed a Query class to draft a query URL that will be used to search the ClinicalTrials.gov API.  I pre-selected a list of field names I found to be of greatest interest (the API allows up to 25 field values per query), and the full list of field names can be found at https://clinicaltrials.gov/api/info/study_structure. The list of field values included in the query can be modified as needed on an ad-hoc basis.  \n\nThe Query class then converts the JSON query result to a pandas dataframe to allow for easier analysis.\n\nThe Study class represents individual clinical studies, and will be used to extract the various clinical trial criteria (i.e. all primary + secondary endpoints) from the individual studies to allow for more detailed analyses.\n\nI built several functions to clean, format, search and analyze the data returned from each query and study."
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "import pandas as pd\nimport numpy as np\nimport matplotlib.pyplot as plt\nimport seaborn as sns\nimport requests\nimport json\nfrom pandas.io.json import json_normalize # tranform JSON file into a pandas dataframe\nimport time\nfrom textwrap import wrap\n\n#import nltk                                        # previous version of this project tried to leverage the NLTK package, but I decided against it for now\n#from nltk.tokenize import word_tokenize\n\n#nltk.download('punkt')\n    \npd.set_option('display.max_columns', None)\npd.set_option('display.max_rows', None)\npd.set_option('max_colwidth', 100)",
            "execution_count": 1,
            "outputs": []
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "class Query:        # class to create a query from the clinicaltrials API that will house the list of clinical trials returned from the API, with detailed information for each\n    \n    def __init__(self, name = 'Query_1'):\n        self.name = name\n        self.study_tracker = []         # build list that tracks which studies have been built via build_study within the query\n\n    def build_query(self):\n        self.query_terms = input('\\n\\nEnter the search query term: \\n\\n')           # input search terms used to query the clinicaltrials.gov API - tokenize into a list of search terms\n        \n        print('\\n\\nSearch Term: \\n\\n'+self.query_terms+'\\n\\n')\n        \n        query_tokenized = self.query_terms.split()\n        \n        field_values = ['NCTId', 'BriefTitle', 'Condition', 'Phase', 'StudyType',\n                        'EnrollmentCount', 'StartDate', 'PrimaryCompletionDate', 'EligibilityCriteria', 'InterventionName', \n                        'ArmGroupInterventionName', 'ArmGroupDescription', 'InterventionArmGroupLabel', 'OutcomeMeasureType', 'OutcomeMeasureTitle',\n                        'OutcomeMeasureDescription', 'OutcomeMeasureTimeFrame', 'OutcomeMeasurementValue', 'OutcomeMeasureUnitOfMeasure']\n        \n        max_rank = 1000             # max # of items returned by the API query (max for the clinicaltrials.gov API is 1000)\n        \n        \n        url = 'https://clinicaltrials.gov/api/query/study_fields?expr='\n        \n        for i, word in enumerate(query_tokenized):              # build query URL by adding all search terms and field values to the query URL, following the appropriate format\n            if i == 0:\n                url = url + word\n            else:\n                url = url + '+' + word\n            \n        url = url + '&fields='\n        \n        for i, word in enumerate(field_values):\n            if i == 0:\n                url = url + word\n            else:\n                url = url + '%2C' + word\n        \n        url = url + '&min_rnk=1&max_rnk=' + str(max_rank) + '&fmt=json' \n        url = url.strip()\n        self.url = url\n        \n        print('\\n\\nQuerying up to 1,000 trials from clinicaltrials.gov with the following url...\\n\\n'+url+'\\n\\n')\n        \n        return self.url\n        \n    def build_study_table(self, url):\n          \n        ## convert the clinicaltrials.gov JSON response to a pandas dataframe\n        \n        result = requests.get(url).json()\n        result_list = [result for result in result['StudyFieldsResponse']['StudyFields'] if result['OutcomeMeasureType']]     #loop through the list and identify ONLY studies with outcome measures reported \n        df_master = json_normalize(result_list[0])      # initialize dataframe using JSON result\n\n        try:\n            for study in result_list[1:]:        # concatenate each study to the dataframe to generate master dataframe\n                df = json_normalize(study)\n                df_master = pd.concat([df_master, df], axis=0, ignore_index=True)\n        except:\n            pass\n                                                                    # extract list entries, reformat data in these columns as strings\n        try:                                            \n            df_master['NCTId'] = [df_master['NCTId'][i][0] for i in range(len(df_master['NCTId'])) if len(df_master['NCTId'][i]) > 0]\n        except:\n            pass        \n        try:\n            df_master['BriefTitle'] = [df_master['BriefTitle'][i][0] for i in range(len(df_master['BriefTitle'])) if len(df_master['BriefTitle'][i]) > 0]\n        except:\n            pass       \n        try:\n            df_master['Condition'] = [df_master['Condition'][i][0] for i in range(len(df_master['Condition'])) if len(df_master['Condition'][i]) > 0]\n        except:\n            pass\n        try:\n            df_master['StudyType'] = [df_master['StudyType'][i][0] for i in range(len(df_master['StudyType'])) if len(df_master['StudyType'][i]) > 0]\n        except:\n            pass\n        \n        \n        for i in range(len(df_master['Phase'])):                    # extract clinical trial phase(s)\n            if df_master['Phase'][i]:\n                if len(df_master['Phase'][i]) > 1:\n                    df_master['Phase'][i] = df_master['Phase'][i][0] + ', ' + df_master['Phase'][i][1]\n                else:\n                    df_master['Phase'][i] = df_master['Phase'][i][0]\n            else:\n                df_master['Phase'][i] = 'Unknown'\n        \n        \n        try:\n            df_master['EnrollmentCount'] = [df_master['EnrollmentCount'][i][0] for i in range(len(df_master['EnrollmentCount'])) if len(df_master['EnrollmentCount'][i]) > 0]\n        except:\n            pass\n        try:\n            df_master['StartDate'] = [df_master['StartDate'][i][0] for i in range(len(df_master['StartDate'])) if len(df_master['StartDate'][i]) > 0]\n        except:\n            pass\n        try:\n            df_master['PrimaryCompletionDate'] = [df_master['PrimaryCompletionDate'][i][0] for i in range(len(df_master['PrimaryCompletionDate'])) if len(df_master['PrimaryCompletionDate'][i]) > 0]\n        except:\n            pass\n        try:\n            df_master['EligibilityCriteria'] = [df_master['EligibilityCriteria'][i][0] for i in range(len(df_master['EligibilityCriteria'])) if len(df_master['EligibilityCriteria'][i]) > 0]\n        except:\n            pass\n        \n        #df_master['StartDate'] = pd.to_datetime(df_master['StartDate'])\n        #df_master['PrimaryCompletionDate'] = pd.to_datetime(df_master['PrimaryCompletionDate'])            # future version of this project will convert starting / ending date to datetime format, to calculate/analyze trial duration\n        \n        self.df_master = df_master\n        \n        return self.df_master\n    \n    def build_outcome_table(self):\n        \n        # initialize an outcomes_df from the first study within the query study table\n        \n        query_df_master = self.get_df_master()\n        query_df_master = query_df_master[query_df_master['Phase'].str.match('.*3.*', na=False)].reset_index()          # filter ONLY phase 3 studies, which represent pivotal efficacy/safety trials used by the FDA when evaluating a new product \n        study_1 = Study(self, query_df_master['NCTId'][0])\n        \n        outcomes_df = study_1.extract_outcomes()\n        \n        study_x = Study(self, query_df_master['NCTId'][1])\n        df = study_x.extract_outcomes()\n        outcomes_df = pd.concat([outcomes_df, df], axis=0, ignore_index=False)\n        \n        for i in range(1, len(query_df_master)):                         # concatenate each study to the dataframe to generate master dataframe\n            study_x = Study(self, query_df_master['NCTId'][i])\n            df = study_x.extract_outcomes()\n            outcomes_df = pd.concat([outcomes_df, df], axis=0, ignore_index=False)\n        \n        outcomes_df = outcomes_df.reset_index().drop(columns='index')\n        \n        return outcomes_df\n\n    \n    def get_url(self):\n        return self.url\n\n    def get_study_tracker(self):\n        return self.study_tracker\n    \n    def get_df_master(self):\n        if len(self.df_master)>0:\n            return self.df_master\n        else:\n            return 'No df_master exists!'",
            "execution_count": 2,
            "outputs": []
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "class Study:\n    \n    def __init__(self, query, nct_id):                  # all studies are initialized within a query, and are identified via their unique NCT ID (created by clinicaltrials.gov)s\n        \n        self.nct_id = nct_id\n        self.entry = query.get_df_master()[query.get_df_master()['NCTId']==nct_id].reset_index().drop(columns='index')      #build a unique df entry for this NCT ID\n        self.df_outcomes = pd.DataFrame(columns=self.entry.columns)\n        \n        try:                            # identify the number of outcome measure values reported per outcome measure (i.e., measure at baseline, change at week N, P value, etc.)\n            self.measures_per_outcome = len(self.entry['OutcomeMeasurementValue'][0])//len(self.entry['OutcomeMeasureTitle'][0])\n        except:\n            self.measures_per_outcome = 1\n        \n        if self.nct_id not in query.study_tracker:              #add the study to the query's study tracker\n            query.study_tracker.append(self.nct_id)\n        \n    def get_entry(self):\n        return self.entry\n    \n    def get_indication(self):\n        return [item for item in self.entry['Condition']][0]     # returns the first list item within the list of indications\n\n    def extract_outcomes(self):            #iterate thru all outcome measures, create a dataframe with all required info\n        \n        try:\n            self.df_outcomes = self.df_outcomes.drop(columns=['Rank', 'Condition', 'StudyType', 'EnrollmentCount', 'StartDate', 'PrimaryCompletionDate', 'EligibilityCriteria', 'ArmGroupDescription'])\n        except:\n            pass\n        \n        for i, item in enumerate(self.entry['OutcomeMeasureType']):\n                \n            try:\n                self.df_outcomes['OutcomeMeasureType'] = [item for item in self.entry['OutcomeMeasureType']][0]\n            except:\n                pass\n            try:\n                self.df_outcomes['OutcomeMeasureTitle'] = [item for item in self.entry['OutcomeMeasureTitle']][0]\n            except:\n                pass\n            try:\n                self.df_outcomes['OutcomeMeasureDescription'] = [item for item in self.entry['OutcomeMeasureDescription']][0]\n            except:\n                pass\n            try:\n                self.df_outcomes['OutcomeMeasureTimeFrame'] = [item for item in self.entry['OutcomeMeasureTimeFrame']][0]\n            except:\n                pass\n            try:\n                self.df_outcomes['OutcomeMeasureUnitOfMeasure'] = [item for item in self.entry['OutcomeMeasureUnitOfMeasure']][0]\n            except:\n                pass\n\n        beginning = 0\n        increment = self.measures_per_outcome               # maps correct number of outcome measures reported in the study, as multiple performance values may pertain to each endpoint (i.e. value for each intervention arm + placebo)\n       \n        for i in range(len(self.df_outcomes)):\n            try:\n                self.df_outcomes['OutcomeMeasurementValue'][i] = self.entry['OutcomeMeasurementValue'][0][beginning:beginning+increment]\n                beginning += increment\n            except:\n                pass\n            try:\n                self.df_outcomes['InterventionArmGroupLabel'][i] = self.entry['InterventionArmGroupLabel'][0]\n            except:\n                pass\n            try:\n                self.df_outcomes['InterventionName'][i] = self.entry['InterventionName'][0]\n            except:\n                pass\n            try:\n                self.df_outcomes['ArmGroupInterventionName'][i] = self.entry['ArmGroupInterventionName'][0]\n            except:\n                pass\n        \n        self.df_outcomes['NCTId'] = [item for item in self.entry['NCTId']][0]\n        self.df_outcomes['Phase'] = [item for item in self.entry['Phase']][0]\n        self.df_outcomes['BriefTitle'] = [item for item in self.entry['BriefTitle']][0]\n        \n        return self.df_outcomes",
            "execution_count": 3,
            "outputs": []
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "def outcome_track(outcome_list, track_dict):  # function to build a dictionary counter object that tracks the count of each endpoint within the outcome list\n                                              ## can be used to plot the top N outcome measures used in clinical studies for a certain indication\n    \n    for outcome in outcome_list:\n        if outcome in track_dict.keys():\n            track_dict[outcome] += 1\n        else:\n            track_dict[outcome] = 1\n\ndef plot_outcomes(outcome_df, query):                   # function to plot the top 10 outcome measures used in the outcomes dataframe provided as input\n    \n    n_endpoints = 10                                      # how many endpoints will be plotted (top N endpoints)\n    fig = plt.figure(figsize=[36, 10]).tight_layout(w_pad=2.0, h_pad = 2.0)\n    ax = sns.barplot(data=outcome_df.head(n_endpoints), x='index', y='Frequency', estimator=sum, ci=None)\n\n    for p in ax.patches:\n        ax.text(x = p.get_x()+(p.get_width()/2),y = p.get_height()+0.05,s = '{}'.format(p.get_height(),ha = 'center'))\n\n    labels = []\n    \n    for label in ax.get_xticklabels():\n        labels.append(label.get_text())\n\n    labels = [ '\\n'.join(wrap(l, 20)) for l in labels]              # wrap label text to improve presentability (many endpoints are long text blocks)\n\n    ax.set_title('Top 10 Most Common Primary + Secondary Outcome Measures Reported in {} Clinical Trials'.format(query.query_terms.title()), fontsize=14)\n    ax.set_xticklabels(labels, fontsize=13, va='top', ha='center')\n    ax.set_xlabel('Outcome Measure', fontsize=14)\n    plt.show()\n\n    \ndef tokenize_column(outcome_table, column_name, new_column_name):           # function to convert the text contained in one column into a tokenized, lowercase list of terms (stripped of whitespace and parentheses characters)\n                                                                            ## in a new column\n    outcome_table[new_column_name] = outcome_table[column_name].str.split()\n    \n    for i in range(len(outcome_table[new_column_name])):\n        for j in range(len(outcome_table[new_column_name][i])):\n            outcome_table[new_column_name][i][j] = outcome_table[new_column_name][i][j].lower().strip(' ()')\n    \ndef search_outcomes(outcome_table, col_to_search):                           # function to search an outcomes table and determine how many times ALL the terms in a keyword search appear in the tokenized lise \n    \n    global search_term \n    search_term = input('Enter your search term here: \\n')\n    tokenized = search_term.split()\n    tokenized_clean = [word.lower().strip() for word in tokenized]\n\n    match_tracker = []\n\n    for i in range(len(outcome_table)):\n        matches=0    \n        for word in tokenized_clean:\n            if word in outcome_table[col_to_search][i]:\n                matches +=1\n        if matches == len(tokenized_clean):\n            match_tracker.append(i)\n    \n    # create empty dataframe with identical columns to outcomes df; iterate through index values in match_tracker; append outcomes_df.iloc[index]\n\n    outcome_table_filtered = pd.DataFrame(columns=outcome_table.columns)\n\n    for ind in match_tracker:\n        outcome_table_filtered.loc[ind] = outcome_table.loc[ind] \n            \n    outcome_table_filtered = outcome_table_filtered.reset_index()\n    outcome_table_filtered\n    \n    print('\\nSearching outcomes that contain the following key terms:\\n')\n    print(tokenized_clean)\n\n    return outcome_table_filtered\n\ndef plot_outcome_search(outcome_table_filtered):\n    \n    outcome_plot_dict = {}\n    outcome_plot_dict[search_term] = outcome_table_filtered.shape[0]\n\n    outcome_plot_df = pd.Series(outcome_plot_dict).to_frame('Frequency').reset_index().sort_values(by='Frequency', ascending=False).reset_index()\n\n    fig = plt.figure(figsize=[14,6]).tight_layout(pad=8.0)\n    ax = sns.barplot(data=outcome_plot_df, x='index', y='Frequency', estimator=sum)\n\n    for p in ax.patches:\n            ax.text(x = p.get_x()+(p.get_width()/2),y = p.get_height()*1.01,s = '{}'.format(p.get_height(),ha = 'center'), fontsize=14)\n\n    ax.set_title('Number of Endpoints Returned from Search')\n    ax.set_xlabel('search term')",
            "execution_count": 43,
            "outputs": []
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "# Below I will demonstrate how this tool works through a few use case examples.\n\n\n\n\nThe first example will involve a query for clinical trials for eosinophilic asthma, an uncommon, severe type of asthma involving increased levels of eosinophils in the blood."
        },
        {
            "metadata": {
                "scrolled": true
            },
            "cell_type": "code",
            "source": "asthma = Query()\nasthma.build_query()",
            "execution_count": 6,
            "outputs": [
                {
                    "output_type": "stream",
                    "name": "stdout",
                    "text": "\n\nEnter the search query term: \n\neosinophilic asthma\n\n\nSearch Term: \n\neosinophilic asthma\n\n\n\n\nQuerying up to 1,000 trials from clinicaltrials.gov with the following url...\n\nhttps://clinicaltrials.gov/api/query/study_fields?expr=eosinophilic+asthma&fields=NCTId%2CBriefTitle%2CCondition%2CPhase%2CStudyType%2CEnrollmentCount%2CStartDate%2CPrimaryCompletionDate%2CEligibilityCriteria%2CInterventionName%2CArmGroupInterventionName%2CArmGroupDescription%2CInterventionArmGroupLabel%2COutcomeMeasureType%2COutcomeMeasureTitle%2COutcomeMeasureDescription%2COutcomeMeasureTimeFrame%2COutcomeMeasurementValue%2COutcomeMeasureUnitOfMeasure&min_rnk=1&max_rnk=1000&fmt=json\n\n\n"
                },
                {
                    "output_type": "execute_result",
                    "execution_count": 6,
                    "data": {
                        "text/plain": "'https://clinicaltrials.gov/api/query/study_fields?expr=eosinophilic+asthma&fields=NCTId%2CBriefTitle%2CCondition%2CPhase%2CStudyType%2CEnrollmentCount%2CStartDate%2CPrimaryCompletionDate%2CEligibilityCriteria%2CInterventionName%2CArmGroupInterventionName%2CArmGroupDescription%2CInterventionArmGroupLabel%2COutcomeMeasureType%2COutcomeMeasureTitle%2COutcomeMeasureDescription%2COutcomeMeasureTimeFrame%2COutcomeMeasurementValue%2COutcomeMeasureUnitOfMeasure&min_rnk=1&max_rnk=1000&fmt=json'"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "### I now have my query URL written, and can generate a table of all clinical trials returned from the query (max of 1,000 trials, per clinicaltrials.gov API limit) using the Query class's build_study_table function."
        },
        {
            "metadata": {
                "scrolled": true
            },
            "cell_type": "code",
            "source": "asthma_study_table = asthma.build_study_table(asthma.get_url())\nasthma_study_table",
            "execution_count": 7,
            "outputs": [
                {
                    "output_type": "stream",
                    "text": "/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:52: FutureWarning: pandas.io.json.json_normalize is deprecated, use pandas.json_normalize instead\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:56: FutureWarning: pandas.io.json.json_normalize is deprecated, use pandas.json_normalize instead\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:84: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:86: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:82: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
                    "name": "stderr"
                },
                {
                    "output_type": "execute_result",
                    "execution_count": 7,
                    "data": {
                        "text/plain": "    Rank        NCTId  \\\n0      4  NCT01285323   \n1      6  NCT01287039   \n2      8  NCT01270464   \n3      9  NCT01290887   \n4     13  NCT02654145   \n5     22  NCT02555371   \n6     24  NCT02281318   \n7     27  NCT01312961   \n8     28  NCT03052725   \n9     45  NCT03021304   \n10    46  NCT03099096   \n11    47  NCT02377427   \n12    51  NCT01508936   \n13    58  NCT02937168   \n14    62  NCT02135692   \n15    75  NCT02836496   \n16    95  NCT02869438   \n17    98  NCT00283504   \n18   102  NCT02898662   \n19   106  NCT03299686   \n20   111  NCT01238861   \n21   112  NCT00587288   \n22   115  NCT00802438   \n23   126  NCT00123630   \n24   128  NCT03170271   \n25   129  NCT00712335   \n26   134  NCT01842607   \n27   136  NCT01691508   \n28   139  NCT02392481   \n29   147  NCT01821898   \n30   151  NCT01458418   \n31   168  NCT02104505   \n\n                                                                                             BriefTitle  \\\n0        A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n1   A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinic...   \n2   A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Pa...   \n3   Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/k...   \n4                         Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients   \n5         Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients   \n6   Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinoph...   \n7   Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe E...   \n8           A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma   \n9                                                     Study of Mepolizumab Safety Syringe in Asthmatics   \n10                                                      Study of Mepolizumab Autoinjector in Asthmatics   \n11         Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children   \n12  Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...   \n13  An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inf...   \n14     A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects   \n15    Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)   \n16  A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benraliz...   \n17  A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic an...   \n18                                                                                   AZD1419 Ph2a Study   \n19  Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Sever...   \n20             Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma   \n21                            Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma   \n22                                                     Eosinophilic Airway Inflammation and Mepolizumab   \n23                           A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab   \n24  A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontroll...   \n25                                                    The Effects of Montelukast on Smokers With Asthma   \n26                           A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects   \n27                          Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma   \n28                                                                               Asthma Biomarker Study   \n29                                           Eosinophilic Esophagitis Clinical Therapy Comparison Trial   \n30               A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children   \n31                       Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS   \n\n                     Condition             Phase       StudyType  \\\n0          Eosinophilic Asthma           Phase 3  Interventional   \n1          Eosinophilic Asthma           Phase 3  Interventional   \n2          Eosinophilic Asthma           Phase 3  Interventional   \n3          Eosinophilic Asthma           Phase 3  Interventional   \n4                       Asthma           Phase 4  Interventional   \n5                       Asthma           Phase 3  Interventional   \n6                       Asthma           Phase 3  Interventional   \n7                       Asthma           Phase 2  Interventional   \n8          Eosinophils, Asthma           Phase 3  Interventional   \n9                       Asthma           Phase 3  Interventional   \n10                      Asthma           Phase 3  Interventional   \n11                      Asthma           Phase 2  Interventional   \n12         Eosinophilic Asthma           Phase 3  Interventional   \n13                      Asthma           Phase 4  Interventional   \n14                      Asthma           Phase 3  Interventional   \n15  Hypereosinophilic Syndrome           Phase 3  Interventional   \n16                      Asthma           Phase 3  Interventional   \n17             ALLERGIC ASTHMA           Phase 4  Interventional   \n18                      Asthma           Phase 2  Interventional   \n19                      Asthma           Phase 2  Interventional   \n20                      Asthma           Phase 2  Interventional   \n21                      Asthma           Phase 2  Interventional   \n22                      Asthma    Not Applicable  Interventional   \n23                 Esophagitis           Phase 2  Interventional   \n24                      Asthma           Phase 3  Interventional   \n25           Asthmatic Smokers           Phase 4  Interventional   \n26                      Asthma           Phase 3  Interventional   \n27                      Asthma           Phase 3  Interventional   \n28                      Asthma           Unknown   Observational   \n29    Eosinophilic Esophagitis           Phase 2  Interventional   \n30    Eosinophilic Esophagitis    Not Applicable  Interventional   \n31       Mild, Allergic Asthma  Phase 1, Phase 2  Interventional   \n\n   EnrollmentCount          StartDate PrimaryCompletionDate  \\\n0              464         March 2011            April 2014   \n1              489         April 2011         December 2013   \n2              315      February 2011        September 2013   \n3             1052          June 2011          January 2015   \n4              145     March 17, 2016          May 31, 2017   \n5              306    January 7, 2016         July 24, 2019   \n6              556  December 11, 2014         June 10, 2016   \n7              104         March 2011          October 2012   \n8              391     March 10, 2017     February 22, 2018   \n9               56   February 1, 2017        August 8, 2017   \n10             159        May 4, 2017     November 30, 2017   \n11              36    August 25, 2015      December 7, 2016   \n12             511      February 2012           August 2013   \n13               5        May 8, 2017          May 24, 2017   \n14             339       May 29, 2014       October 5, 2017   \n15             108      March 7, 2017        August 8, 2019   \n16             233   November 9, 2016        August 1, 2018   \n17              13       January 2006          January 2009   \n18              81   October 12, 2016    September 25, 2018   \n19             118   November 6, 2017         April 8, 2019   \n20             964      December 2010            March 2013   \n21             106         April 2008            March 2010   \n22              38       June 1, 2008         March 1, 2013   \n23              30      November 2005          January 2010   \n24             660       July 7, 2017    September 25, 2019   \n25             105      February 2007              May 2011   \n26             651       May 27, 2013        March 13, 2015   \n27             135       October 2012         December 2013   \n28              69      July 16, 2015       January 3, 2017   \n29               3       July 9, 2013    September 24, 2018   \n30               4      December 2011         February 2015   \n31              23      November 2015        September 2016   \n\n                                                                                    EligibilityCriteria  \\\n0   Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...   \n1   Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...   \n2   Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...   \n3   Inclusion Criteria:\\n\\nWritten informed consent is obtained.\\nPatient must have completed treatm...   \n4   Inclusion Criteria:\\n\\nAt least 12 years of age at the time of signing the informed consent. For...   \n5   Inclusion Criteria:\\n\\nInformed Consent: Prior to commencing any study related activities, subje...   \n6   Inclusion Criteria:\\n\\nAge: At least 12 years of age at the time of signing the informed consent...   \n7   Inclusion criteria:\\n\\nMedical diagnosis of persistent asthma for at least 12 months whose:\\n\\na...   \n8   Inclusion Criteria:\\n\\n\u2022 Patient with eosinophilic asthma who completed the treatment period of ...   \n9   Inclusion Criteria:\\n\\nAge: At least 12 years of age inclusive, at the time of signing the infor...   \n10  Inclusion Criteria:\\n\\nAge: At least 12 years of age inclusive, at the time of signing the infor...   \n11  Inclusion Criteria:\\n\\nBetween 6 and 11 years of age inclusive, at the time of screening.\\nDiagn...   \n12  Inclusion criteria:\\n\\nPatients are included in the study if all of the following criteria are m...   \n13  Inclusion Criteria:\\n\\nMale or female, 18 through 50 years of age.\\nFemales that are either surg...   \n14  Inclusion Criteria:\\n\\nInformed Consent: Prior to commencing any study related activities, subje...   \n15  Inclusion Criteria:\\n\\nCapable of giving signed informed consent/assent which includes complianc...   \n16  Inclusion criteria\\n\\nWritten informed consent for study participation must be obtained prior to...   \n17  Inclusion Criteria:\\n\\nModerate to severe allergic asthma, uncontrolled on conventional therapy\\...   \n18  Inclusion Criteria:\\n\\nMale and female patients 18 years and above\\nPhysician-diagnosed asthma r...   \n19  Inclusion Criteria:\\n\\nPatients with a physician-diagnosed history of moderate to severe asthma ...   \n20  Inclusion Criteria:\\n\\nAge 18 through 75 years at the time of screening\\nAdequate contraception ...   \n21  Inclusion Criteria:\\n\\nwritten informed consent\\nmale or female subjects aged \u2265 18 to 75 years a...   \n22  Inclusion Criteria:\\n\\nMales or females age 18 to 50 yrs,\\nHistory of asthma based upon presence...   \n23  Inclusion Criteria:\\n\\nMale or female subjects aged 12-60 years of age with EE as defined above\\...   \n24  Inclusion Criteria:\\n\\nFemale and male patients aged 18 to 75 years inclusively at the time of V...   \n25  Inclusion Criteria:\\n\\nAsthmatics:\\n\\nclinical history of asthma for at least 1 year\\nwith evide...   \n26  Inclusion Criteria:\\n\\nFrench subjects: In France, a subject will be eligible for inclusion in t...   \n27  Inclusion Criteria:\\n\\nInformed Consent and Study Compliance: Subjects must be able to give writ...   \n28  Inclusion criteria:\\n\\nBody mass index (BMI) >=18 and <= 40 Non-smokers or ex-smokers with a cig...   \n29  Inclusion Criteria\\n\\nSigned written informed consent and assent if applicable prior to performi...   \n30  Inclusion Criteria:\\n\\nMales and females aged 2-17\\nPresence of more than 15 eosinophils per hpf...   \n31  Inclusion Criteria:\\n\\nAge 18-50 of both genders\\nNegative pregnancy test for females who are no...   \n\n                                                                                       InterventionName  \\\n0                                                                                 [Reslizumab, Placebo]   \n1                                                                                 [Reslizumab, Placebo]   \n2                                                                                 [Reslizumab, Placebo]   \n3                                                                                          [Reslizumab]   \n4                                         [Mepolizumab 100mg SC, Albuterol/salbutamol MDIs, Omalizumab]   \n5                                                                          [Mepolizumab 100mg, Placebo]   \n6                                                                           [Mepolizumab, Placebo, SOC]   \n7   [Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone mon...   \n8                                                                                          [reslizumab]   \n9                                                                                         [Mepolizumab]   \n10                                                                                        [Mepolizumab]   \n11                                                                                        [Mepolizumab]   \n12                                                                                [Reslizumab, Placebo]   \n13                                                    [Reslizumab, Fludeoxyglucose F 18 (FDG), Placebo]   \n14                                                                                   [Mepolizumab, SOC]   \n15  [Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or pre...   \n16                                                                              [Benralizumab, Placebo]   \n17                                                                          [ANTI-IGE THERAPY (XOLAIR)]   \n18                                                                                   [AZD1419, Placebo]   \n19                                                                          [CJM112, Placebo to CJM112]   \n20                                [Benralizumab 2 mg, Benralizumab 20 mg, Benralizumab 100 mg, Placebo]   \n21                                                                                 [Reslizumab, Saline]   \n22                                                                                        [mepolizumab]   \n23                                                                                [omalizumab, Placebo]   \n24                                                                   [Benralizumab (Medi-563), Placebo]   \n25                                                    [Fluticasone Propionate, Montelukast, Salmeterol]   \n26                                                                                        [Mepolizumab]   \n27                                                [Mepolizumab, Placebo, OCS (prednisone/prednisolone)]   \n28                                                                                  [Biofluid sampling]   \n29                                                                  [Oral Budesonide, Elimination diet]   \n30                                                             [Montelukast, placebo, 5 mg Montelukast]   \n31                                                         [Gamma Tocopherol 700 mg capsules,, Placebo]   \n\n                                                                               ArmGroupInterventionName  \\\n0                                                                     [Drug: Placebo, Drug: Reslizumab]   \n1                                                                     [Drug: Placebo, Drug: Reslizumab]   \n2                                                   [Drug: Placebo, Drug: Reslizumab, Drug: Reslizumab]   \n3                                                                                    [Drug: Reslizumab]   \n4                       [Drug: Mepolizumab 100mg SC, Drug: Albuterol/salbutamol MDIs, Drug: Omalizumab]   \n5                         [Biological: Mepolizumab 100mg, Biological: Mepolizumab 100mg, Drug: Placebo]   \n6                                        [Biological: Mepolizumab, Drug: SOC, Drug: Placebo, Drug: SOC]   \n7   [Drug: Placebo (for Dupilumab), Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticas...   \n8                                                                                    [Drug: reslizumab]   \n9                                                                                   [Drug: Mepolizumab]   \n10                                                                                  [Drug: Mepolizumab]   \n11                                                               [Drug: Mepolizumab, Drug: Mepolizumab]   \n12                                                                    [Drug: Placebo, Drug: Reslizumab]   \n13  [Drug: Fludeoxyglucose F 18 (FDG), Drug: Reslizumab, Drug: Fludeoxyglucose F 18 (FDG), Drug: Flu...   \n14                                                                 [Biological: Mepolizumab, Drug: SOC]   \n15  [Drug: Mepolizumab 300 mg, Drug: Active OCS capsules (5 mg prednisolone or prednisone), Drug: Pl...   \n16                                                                 [Drug: Benralizumab, Other: Placebo]   \n17                                                                    [Drug: ANTI-IGE THERAPY (XOLAIR)]   \n18                                                                       [Drug: AZD1419, Drug: Placebo]   \n19                                                             [Drug: CJM112, Other: Placebo to CJM112]   \n20  [Other: Placebo, Biological: Benralizumab 2 mg, Biological: Benralizumab 20 mg, Biological: Benr...   \n21                                                              [Biological: Reslizumab, Other: Saline]   \n22                                                                            [Biological: mepolizumab]   \n23                                                                    [Drug: Placebo, Drug: omalizumab]   \n24                                                       [Drug: Benralizumab (Medi-563), Drug: Placebo]   \n25  [Drug: Fluticasone Propionate, Drug: Salmeterol, Drug: Montelukast, Drug: Fluticasone Propionate...   \n26                                                                            [Biological: Mepolizumab]   \n27  [Drug: Mepolizumab, Drug: OCS (prednisone/prednisolone), Drug: Placebo, Drug: OCS (prednisone/pr...   \n28                                                                       [Procedure: Biofluid sampling]   \n29                                                     [Drug: Oral Budesonide, Other: Elimination diet]   \n30                                          [Drug: Montelukast, Drug: 5 mg Montelukast, Other: placebo]   \n31                                             [Drug: Gamma Tocopherol 700 mg capsules,, Drug: Placebo]   \n\n                                                                                    ArmGroupDescription  \\\n0   [Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses., Res...   \n1   [Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses., Res...   \n2   [Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses., 0.3 mg/kg,...   \n3   [Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 mon...   \n4   [Subjects with severe eosinophilic asthma who are receiving omalizumab will enter a run-in perio...   \n5   [There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up t...   \n6   [Participants will receive Mepolizumab 100 mg subcutaneously (SC) into the upper arm or thigh ev...   \n7   [Placebo (for Dupilumab) subcutaneous (SC) injection once weekly (qw) for 12 weeks added to back...   \n8   [Reslizumab was administered as 110 mg subcutaneous (sc) injection in the thigh, abdomen, or upp...   \n9   [Subjects will receive 3 doses of 100 mg mepolizumab, liquid drug product in safety syringe, sub...   \n10  [Three doses of mepolizumab liquid drug product in autoinjector will be self-administered by the...   \n11  [Participants with bodyweight < 40 kg will receive 0.4 milliliter (mL) of reconstituted mepolizu...   \n12  [Placebo intravenous injection every 4 weeks for a total of 4 doses., Reslizumab intravenous inj...   \n13  [Healthy participants will have 2 PET/CT scan in Part 1: within 7 days of eligibility being conf...   \n14  [All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approxi...   \n15  [Enrolled subjects will receive either mepolizumab 300 mg or placebo subcutaneous (SC) every 4 w...   \n16                      [Benralizumab administered subcutaneously, Placebo administered subcutaneously]   \n17                                                                                [One arm:active drug]   \n18        [Dose adaption of AZD1419, 4 mg or 8 mg or 1 mg based on occurence of AE's, Matching placebo]   \n19                                                                           [Study treatment, Placebo]   \n20  [EOS+ (defined as ELEN Index [proprietary mathematical algorithm to predict sputum eosinophil's ...   \n21  [Reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles, S...   \n22                                                    [up to 3 monthly doses of 750mg i.v. mepolizumab]   \n23                                                                        [placebo group, Xolair group]   \n24  [Benralizumab (Medi563) Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 da...   \n25  [Asthmatic smokers treated with combination therapy:\\n\\nFluticasone propionate dosage - DPI 250 ...   \n26  [Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously ...   \n27  [Mepolizumab 100 mg subcutaneous once every 4 weeks upto Week 20, Placebo subcutaneous once ever...   \n28                                                                                                   []   \n29                                                                  [Oral Budesonide, Elimination diet]   \n30  [Subjects will receive two 5mg tablets of Montelukast/day., Subjects will receive one 5mg tablet...   \n31                                                [Gamma Tocopherol supplement, Safflower oil capsules]   \n\n                                                                              InterventionArmGroupLabel  \\\n0                                                                       [Reslizumab 3.0 mg/kg, Placebo]   \n1                                                                       [Reslizumab 3.0 mg/kg, Placebo]   \n2                                             [Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg, Placebo]   \n3                                                                                [Reslizumab 3.0 mg/kg]   \n4   [Omalizumab switch to mepolizumab 100mg SC every 4 weeks, Omalizumab switch to mepolizumab 100mg...   \n5                                                    [Arm Mepolizumab 100 mg, Arm Placebo, Arm Placebo]   \n6                                              [Mepolizumab SC, Placebo SC, Mepolizumab SC, Placebo SC]   \n7   [Dupilumab 300 mg qw, Placebo (for Dupilumab), Dupilumab 300 mg qw, Placebo (for Dupilumab), Dup...   \n8                                                                                   [reslizumab 110 mg]   \n9                                             [Mepolizumab SC 100 mg/milliliter (mL) in Safety syringe]   \n10                                              [Mepolizumab SC 100 mg/milliliter (mL) in autoinjector]   \n11                              [Mepolizumab 100 mg in Part A and B, Mepolizumab 40 mg in Part A and B]   \n12                                                                      [Reslizumab 3.0 mg/kg, Placebo]   \n13      [Part 2: Reslizumab, Part 1: PET/CT Scan, Part 2: Placebo, Part 2: Reslizumab, Part 2: Placebo]   \n14                                                             [Mepolizumab 100 mg, Mepolizumab 100 mg]   \n15                                   [Mepolizumab, Placebo, Mepolizumab, Placebo, Mepolizumab, Placebo]   \n16                                                                      [Benralizumab arm, Placebo arm]   \n17                                                           [all patients received Xolair/active drug]   \n18                                                                                   [AZD1419, Placebo]   \n19                                                                          [CJM112, Placebo to CJM112]   \n20  [EOS+ Benralizumab (2 mg), EOS+ Benralizumab (20 mg), EOS+ Benralizumab (100 mg), EOS- Benralizu...   \n21                                                                        [Reslizumab 3 mg/kg, Placebo]   \n22                                                                                        [Mepolizumab]   \n23                                                                                [omalizumab, placebo]   \n24                                                                   [Benralizumab (Medi-563), Placebo]   \n25                                                                                   [1, 3, 2, 4, 1, 3]   \n26                                                                                    [Mepolizumab Arm]   \n27                                                         [Mepolizumab, Placebo, Mepolizumab, Placebo]   \n28                                                                                   [Healthy subjects]   \n29                             [Positive for food allergy: Group A, Positive for food allergy: Group B]   \n30                                                [Montelukast 10 mg/day, placebo, Montelukast 5mg/day]   \n31                                                    [700 mg Gamma Tocopherol daily x 14days, Placebo]   \n\n                                                                                     OutcomeMeasureType  \\\n0   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n1   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n2   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n3   [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Primary, Secondary, Se...   \n4                                                            [Primary, Secondary, Secondary, Secondary]   \n5                                                            [Primary, Secondary, Secondary, Secondary]   \n6                                                            [Primary, Secondary, Secondary, Secondary]   \n7   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n8   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n9                                                                                  [Primary, Secondary]   \n10                                                             [Primary, Primary, Secondary, Secondary]   \n11  [Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Prima...   \n12  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n13          [Primary, Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n14  [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n15                                                [Primary, Secondary, Secondary, Secondary, Secondary]   \n16  [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n17                                                                      [Primary, Secondary, Secondary]   \n18    [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n19                                     [Primary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n20  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n21                          [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n22                                                                                 [Primary, Secondary]   \n23                                                                                            [Primary]   \n24  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n25                          [Secondary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n26  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n27                                                [Primary, Secondary, Secondary, Secondary, Secondary]   \n28                                                             [Primary, Primary, Secondary, Secondary]   \n29                                                           [Primary, Secondary, Secondary, Secondary]   \n30                                                                                            [Primary]   \n31                                                           [Primary, Secondary, Secondary, Secondary]   \n\n                                                                                    OutcomeMeasureTitle  \\\n0   [Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment, Change From Ba...   \n1   [Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment, Change From Ba...   \n2   [Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed M...   \n3   [Participants With Treatment-Emergent Adverse Events, Participants With Treatment-Emergent Poten...   \n4   [Mean Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 32, Mean Chan...   \n5   [Percentage of Participants With First Clinically Significant Exacerbation in Part C, Ratio to B...   \n6   [Mean Change From Baseline (BL) in St. George's Respiratory Questionnaire (SGRQ) Score at Week 2...   \n7   [Percentage of Participants With Asthma Exacerbation, Time to First Asthma Exacerbation: Kaplan-...   \n8   [Participants With Treatment-Emergent Adverse Events (TEAEs), Participants With Potentially Clin...   \n9   [Percentage of Participants With Successful Self-administration of Their Observed Third Dose at ...   \n10  [Percentage of Participants With Successful Self-administration of Their Observed Third Dose at ...   \n11  [Maximum Plasma Concentration (Cmax) of Mepolizumab for Part A, Area Under Concentration Time Cu...   \n12  [Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis...   \n13  [Part 1: Average Global Lung Glycolysis (GLG) at Baseline (Day 1), Part 1: Average Global Lung G...   \n14  [Annualized Rate of On-treatment Exacerbations Per Year, Number of Participants With Any On-trea...   \n15  [Percentage of Participants Who Experienced an HES Flare or Who Withdrew From the Study During t...   \n16  [Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in ...   \n17  [Number of Participants With Change in Sputum Markers by End of Study, Number of Participants Wi...   \n18  [Number of Participants With Events for Time to Loss of Asthma Control (LOAC) up to Week 52 - Co...   \n19  [Change From Baseline in Forced Expiratory Volume in One Second (FEV1), Change From Baseline in ...   \n20  [Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants, Dose Resp...   \n21  [Mean Change From Baseline to End of Therapy in Asthma Control Questionnaire (ACQ) Score, Percen...   \n22  [The Primary Endpoint of the Study is the Percent of Eosinophils in the Bronchoalveolar Lavage F...   \n23  [Change in Eosinophil Numbers Per High Power Field Proximally and Distally Between Baseline and ...   \n24  [Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24), Change From ...   \n25  [Sputum Eosinophil Percentages, Sputum Neutrophil Percentages, Sputum IL-8 Levels, Sputum GM-CSF...   \n26  [Number of Participants With Adverse Events (AEs) Including Both Systemic (i.e. Allergic/Immunog...   \n27  [Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroi...   \n28  [Level of Tumour Necrosis Factor-alpha (TNF-\u03b1) in Blood at Baseline (Visit 1), Level of Interleu...   \n29  [Peak Number of Eosinophils/High Powered Field, Quality of Life Survey Score, Symptom Score, Exp...   \n30                                                                                   [Eosinophil Count]   \n31  [Comparison of Change in Sputum Percent Neutrophils (PMN)s Following Inhaled Clinical Center Ref...   \n\n                                                                              OutcomeMeasureDescription  \\\n0   [An exacerbation event was considered a CAE if the patient met either or both of the criteria li...   \n1   [An exacerbation event was considered a CAE if the patient met either or both of the criteria li...   \n2   [FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fr...   \n3   [An adverse event was defined in the protocol as any untoward medical occurrence that develops o...   \n4   [The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma co...   \n5   [Clinically significant exacerbation was defined as worsening of asthma which requires use of sy...   \n6   [SGRQ consisted of 50 questions (scored from 0 to 100 where 0 indicates best and 100 indicates w...   \n7   [An asthma exacerbation was defined as the occurrence of any of the following: \u226530% reduction fr...   \n8   [An adverse event is any untoward medical occurrence, regardless of whether it has a causal rela...   \n9   [During the clinic visits the Investigator or designee evaluated if the participants were able t...   \n10  [Due to differences in the labelling requirements among regulatory authorities around the world,...   \n11  [PK of mepolizumab was evaluated in participants using Cmax. PK samples were collected at pre-do...   \n12  [FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the ...   \n13  [GLG is the total FDG uptake in the whole lung. A region of interest (ROI) was drawn around lung...   \n14  [Exacerbations are defined as the worsening of asthma which requires use of systemic corticoster...   \n15  [Percentage of participants who experienced >=1 HES flare during the 32-Week treatment period or...   \n16  [The average over the mean differences between benralizumab and placebo for change from baseline...   \n17  [sputum markers were classified as eosinophilic or non eosinophilic, safety was assessed by meas...   \n18  [LOAC was defined as any of the following:\\n\\nIncrease of asthma control questionnaire-5 (ACQ-5)...   \n19  [The primary efficacy analysis assessed the effect of CJM112 on the absolute change from baselin...   \n20  [The annual asthma exacerbation rate (AER) was calculated as the total number of observed exacer...   \n21  [The ACQ is a 7 question instrument. Each question has 7 possible answers of 0, 1, 2, 3, 4, 5, a...   \n22  [Percent of eosinophils was determined in the bronchoalveolar lavage fluid collected from the pa...   \n23                                                                                                   []   \n24  [An asthma exacerbation was defined as a worsening of asthma that led to any of the following:\\n...   \n25  [Secondary endpoints of inflammatory markers (sputum eosinophil percentages at 24 weeks) were me...   \n26  [AEs were collected from the Baseline visit until the follow-up visit (approx. 12 weeks post-las...   \n27  [Baseline (BL) dose was the prescribed optimized prednisone/prednisolone dose following the OCS ...   \n28  [Level of Tumour Necrosis Factor-alpha (TNF-\u03b1) [picograms per milliliter (pg/mL)] in blood at ba...   \n29  [The primary outcome will be the peak eosinophil/high powered field on repeat biopsy after the t...   \n30  [Eosinophils/high powered field(hpf) in the mid esophagus will be measured after 12 weeks of the...   \n31  [In asthmatic individuals, exposure to CCRE is expected to increase PMNs in the sputum. The sput...   \n\n                                                                                OutcomeMeasureTimeFrame  \\\n0   [Day 1 to Month 12, Day 1 (baseline, pre-dose), Week 16, Day 1 (baseline, pre-dose), Weeks 4, 8,...   \n1   [Day 1 to Week 52, Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16, Day 1 (baseline, pre-dose)...   \n2   [Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16, Day 1 (baseline, pre-dose), Weeks 4, 8, 12, ...   \n3   [Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observa...   \n4            [Baseline and at Week 32, Baseline and at Week 32, Up to Week 32, Baseline and at Week 32]   \n5   [Weeks 12, 24, 36 and 52, Baseline and Weeks 12, 24, 36 and 52, Baseline and Weeks 12, 24, 36 an...   \n6   [Baseline and Week 24, Baseline and Week 24, Baseline (Visit 2-latest pre-dose assessment) and W...   \n7   [Baseline up to Week 12, Baseline up to Week 12, Baseline up to Week 12, Baseline, Week 12, Base...   \n8   [Day 1 to up to Day 269; for participants who discontinued early for reasons other than study te...   \n9                                                                                      [Week 8, Week 4]   \n10                                                                     [Week 8, Week 8, Week 4, Week 4]   \n11  [Pre-dose on Weeks 4 and 8; Weeks 9, 12, 16 and 20 post-dose, Pre-dose on Weeks 4 and 8; Weeks 9...   \n12  [Baseline (Day 1), Week 16, Baseline (Day 1), Weeks 4, 8, 12, 16, Baseline (Day 1), Weeks 4, 8, ...   \n13  [Baseline (Day 1) of Part 1, Day 8, Baseline, Week 4, Baseline, Week 4, Baseline, Week 4, Baseli...   \n14  [Baseline (Week 0) to Week 172, Baseline (Week 0) to Week 172, Baseline (Week 0) to Week 168, Ba...   \n15  [Up to Week 32, Week 20 to Week 32, Weeks 4, 8, 12, 16, 20, 24, 28 and 32, Up to Week 32, Baseli...   \n16  [From first IP dose to Day 84, From first IP dose to Day 84, From first IP dose to Day 84, From ...   \n17                                                   [32 weeks, 32 weeks, every 4 weeks up to 32 weeks]   \n18  [Baseline (Week 0) up to Week 52, Baseline (Week 0) up to Week 52, Baseline (Week 0) up to Week ...   \n19  [Baseline, Day 92, Baseline, Day 92, Baseline, Day 92, Baseline, Day 92, Baseline, Day 92, 85 days]   \n20  [Week 1 up to Week 52, Baseline up to Week 66, Pre-dose (0 hour), Post-dose on Day 1, 6, Week 4,...   \n21  [Baseline through End of Therapy (up to 15 weeks), Baseline, End of Therapy (up to 15 weeks), Ba...   \n22                  [before and after up to 3 months of Mepo., before and after up to 3 months of Mepo]   \n23                                                                                           [16 weeks]   \n24  [Baseline (Week 0) up to Week 24, Baseline (Week 0) and Week 24, Baseline (Week 0) and Week 24, ...   \n25                               [24 weeks, 24 weeks, 24 weeks, 24 weeks, 24 weeks, 24 weeks, 24 weeks]   \n26  [From Baseline visit until the follow-up visit (approximately [approx.] week 60 [12 weeks post-l...   \n27  [Baseline; Weeks 20 to 24, Baseline; Weeks 20 to 24, Weeks 20 to 24, Weeks 20 to 24, Baseline; W...   \n28  [Baseline (Visit 1), Baseline (Visit 1), follow-up visit 28 days after baseline (Visit 2), follo...   \n29                                                  [16 weeks, 16 weeks, 16 weeks, Conclusion of study]   \n30                                                                                           [12 weeks]   \n31  [after 14 days of gamma tocopherol or placebo treatment, after 14 days of gamma tocopherol or pl...   \n\n                                                                                OutcomeMeasurementValue  \\\n0   [2.115, 0.859, 0.122, 0.223, 0.094, 0.187, 0.777, 0.987, -0.660, -0.857, NA, NA, 0.080, 0.115, -...   \n1   [1.804, 0.904, 0.110, 0.248, 0.695, 0.933, -0.676, -0.941, 34.9, NA, 0.109, 0.167, -0.36, -0.64,...   \n2   [0.126, 0.242, 0.286, 0.172, 0.220, 0.301, -0.145, -0.114, 0.089, 0.8, 4.9, 7.5, 0.8, 5.5, 6.7, ...   \n3   [359, 385, 744, 31, 47, 78, 49, 41, 90, 6, 12, 18, 33, 45, 78, 1, 2, 3, 344, 367, 711, 78, 82, 1...   \n4                                                                            [-1.45, -19.0, 1.18, 0.22]   \n5   [31.8, 20.2, 49.3, 32.3, 56.0, 40.3, 60.7, 47.1, 6.03, 1.16, 6.58, 1.03, 6.48, 1.20, 6.17, 1.00,...   \n6                                                          [-7.9, -15.6, 56, 176, 55, 73, -0.40, -0.80]   \n7   [44.2, 5.8, 19.2, 1.9, 19.2, 1.9, 9.6, 1.9, 5.8, 0.0, 0.0, 0.0, 0.058, 0.038, 0.245, 0.058, 0.46...   \n8   [102, 114, 7, 6, 5, 11, 0, 0, 2, 0, 0, 0, 8, 5, 1, 0, 4, 2, 2, 0, 0, 1, 2, 0, 1, 1, 0, 1, 12, 10...   \n9                                                                                            [100, 100]   \n10                                                                                     [99, 98, 98, 96]   \n11  [12.8188, 16.3412, 10.1960, 508.23, 675.20, 454.39, 20.9583, 21.8420, 23.5582, 0.1968, 0.1481, 0...   \n12  [-0.2778, 0.0229, 0.175, 0.251, -0.614, -0.737, -0.2944, 0.0271, 0.164, 0.224, 0.199, 0.249, 0.1...   \n13                                                                               [668.08, 621.71, 1, 0]   \n14  [0.93, 315, 84, -0.16, -0.15, -0.21, -0.17, -0.18, -0.08, -0.03, -0.12, -0.06, -0.01, -0.09, 0.3...   \n15  [56, 28, 35, 17, 7.4, 5.6, 14.9, 7.4, 26.2, 9.3, 33.8, 13.0, 41.3, 13.0, 48.9, 14.8, 50.8, 20.5,...   \n16  [0.21, 0.132, 0.22, 0.203, 0.209, 0.149, -0.415, -0.208, -88.55, 11.55, 0.104, 0.081, 0.125, 0.0...   \n17                                                                                   [0, 0, 7, 6, 7, 6]   \n18  [24, 24, 24, 24, 0.56, 0.59, 0.79, 0.82, 13, 16, 100, 100, 2.24, 2.18, 2.36, 2.39, 325.33, 325.6...   \n19                               [0.043, 0.016, 1.064, 0.151, -0.93, -0.71, -0.83, -0.60, 38, 19, 8, 4]   \n20  [0.57, 0.65, 0.37, 0.34, 34.7, 182, 869, 17.3, 9.10, 8.69, 3.8, 42.0, 30.9, 25.6, 2.7479, 2.6479...   \n21  [-0.7, -0.3, 55, 36, 45, 64, 0.18, -0.08, 6.2, -2.4, -82.0, 45.9, 8, 19, 38, 42, 3, 1, 12, 8, 0,...   \n22                                                                                   [73, 31, 409, 447]   \n23                                                                                          [0.6, -7.5]   \n24  [0.94, 1.86, -23.06, -14.94, 0.30, 0.14, -1.47, -1.01, 123, 107, 27.17, 7.06, 16.47, -6.61, 17.7...   \n25  [2.33, 3.60, 1.60, 3.26, 86.00, 72.53, 89.33, 79.84, 334545, 26,300, 3602, 317778, 17.60, 15.18,...   \n26  [558, 119, 94, 1, 0, 31, 615, 0, 31, 0.93, -0.09, -0.11, -0.05, -0.10, -0.09, 0.20, 67, 50, 29, ...   \n27       [7, 16, 5, 12, 10, 9, 7, 7, 37, 25, 22, 37, 44, 32, 21, 37, 45, 32, 5, 10, 61, 59, 0.0, -50.0]   \n28       [5.3, 9.3, 10.6, 15.7, 71.3, 65.2, 245.0, 133.9, 5.8, 8.1, 5.2, 16.4, 47.7, 86.1, 105.1, 37.4]   \n29                                                                                                   []   \n30                                                                                                  [8]   \n31                                                       [11.7, 20.1, 2.6, 9.5, 20.2, 16.3, 21.4, 21.4]   \n\n                                                                            OutcomeMeasureUnitOfMeasure  \n0   [CAEs in 52 weeks, liters, liters, units on a scale, units on a scale, weeks, units on a scale, ...  \n1   [CAEs in 52 weeks, liters, units on a scale, units on a scale, weeks, units on a scale, puffs/da...  \n2   [liters, liters, liters/second, percentage of predicted FEV1, units on a scale, units on a scale...  \n3   [participants, participants, liters, percentage of predicted FEV1, liters, liters/second, # puff...  \n4                             [Scores on a scale, Scores on a scale, Exacerbation rate per year, Ratio]  \n5           [Percentage of participants, Ratio, Percentage of participants, Percentage of participants]  \n6                  [Scores on a scale, Milliliters (mL), Percentage of participants, Scores on a scale]  \n7   [percentage of participants, Probability of asthma exacerbation, percentage of participants, Lit...  \n8   [Participants, Participants, Participants, Participants, Participants, CAEs / year, CAEs / year,...  \n9                                              [Percentage of participants, Percentage of participants]  \n10  [Percentage of participants, Percentage of Participants, Percentage of participants, Percentage ...  \n11  [Microgram (ug) per mL, Day*ug per mL, Days, Liter (L) per day, Ratio of eosinophils in blood, P...  \n12  [FEV1 liters/ eosinophils 10^9/liter, liters, units on a scale, FEV1 liters/ eosinophils 10^9/li...  \n13                                                       [cubic centimeters (cm^3), cm^3, Participants]  \n14  [Exacerbations per year, Participants, Scores on a scale, Milliliter, Participants, Participants...  \n15  [Percentage of participants, Percentage of participants, Probability expressed as percentage, Fl...  \n16  [Liter, Liter, Percent change, Liter, Liter, Percentage of Participants, Score on a scale, Score...  \n17                                                           [Participants, Participants, Participants]  \n18  [Participants, Participants, scores on a scale, scores on a scale, Participants, percentage of p...  \n19              [Liters, Percent predicted, units on scale, units on scale, Participants, Participants]  \n20  [AER events/person-year, microgram per milliliter, microgram per milliliter, percentage of parti...  \n21  [units on a scale, percentage of participants, L, percent predicted FEV1, percent change in eosi...  \n22                                                      [percent of bronchoalveolar eosinophils, pg/ml]  \n23                                                            [perecentage of eos per high power field]  \n24  [Events/year, Scores on a scale, Liters (L), Scores on a scale, Participants, L/minute, Scores o...  \n25            [percentage of eosinophils, percentage of neutrophils, pg/ml, pg/ml, ratio, pg/ml, pg/ml]  \n26  [Participants, Participants, Exacerbations per year, Score on scale, Milliliters (mL), Participa...  \n27           [Participants, Participants, Participants, Participants, Percentage reduction in OCS dose]  \n28                                                                         [pg/mL, pg/mL, pg/mL, pg/mL]  \n29                                                                                                   []  \n30                                                                                    [Eosinophils/HPF]  \n31  [change in percentage of PMNs in sputum, eosinophils per mg sputum, % of labeled particles clear...  ",
                        "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Rank</th>\n      <th>NCTId</th>\n      <th>BriefTitle</th>\n      <th>Condition</th>\n      <th>Phase</th>\n      <th>StudyType</th>\n      <th>EnrollmentCount</th>\n      <th>StartDate</th>\n      <th>PrimaryCompletionDate</th>\n      <th>EligibilityCriteria</th>\n      <th>InterventionName</th>\n      <th>ArmGroupInterventionName</th>\n      <th>ArmGroupDescription</th>\n      <th>InterventionArmGroupLabel</th>\n      <th>OutcomeMeasureType</th>\n      <th>OutcomeMeasureTitle</th>\n      <th>OutcomeMeasureDescription</th>\n      <th>OutcomeMeasureTimeFrame</th>\n      <th>OutcomeMeasurementValue</th>\n      <th>OutcomeMeasureUnitOfMeasure</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>4</td>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>464</td>\n      <td>March 2011</td>\n      <td>April 2014</td>\n      <td>Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses., Res...</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment, Change From Ba...</td>\n      <td>[An exacerbation event was considered a CAE if the patient met either or both of the criteria li...</td>\n      <td>[Day 1 to Month 12, Day 1 (baseline, pre-dose), Week 16, Day 1 (baseline, pre-dose), Weeks 4, 8,...</td>\n      <td>[2.115, 0.859, 0.122, 0.223, 0.094, 0.187, 0.777, 0.987, -0.660, -0.857, NA, NA, 0.080, 0.115, -...</td>\n      <td>[CAEs in 52 weeks, liters, liters, units on a scale, units on a scale, weeks, units on a scale, ...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>6</td>\n      <td>NCT01287039</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinic...</td>\n      <td>Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>489</td>\n      <td>April 2011</td>\n      <td>December 2013</td>\n      <td>Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses., Res...</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment, Change From Ba...</td>\n      <td>[An exacerbation event was considered a CAE if the patient met either or both of the criteria li...</td>\n      <td>[Day 1 to Week 52, Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16, Day 1 (baseline, pre-dose)...</td>\n      <td>[1.804, 0.904, 0.110, 0.248, 0.695, 0.933, -0.676, -0.941, 34.9, NA, 0.109, 0.167, -0.36, -0.64,...</td>\n      <td>[CAEs in 52 weeks, liters, units on a scale, units on a scale, weeks, units on a scale, puffs/da...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>8</td>\n      <td>NCT01270464</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Pa...</td>\n      <td>Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>315</td>\n      <td>February 2011</td>\n      <td>September 2013</td>\n      <td>Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab, Drug: Reslizumab]</td>\n      <td>[Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses., 0.3 mg/kg,...</td>\n      <td>[Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed M...</td>\n      <td>[FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fr...</td>\n      <td>[Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16, Day 1 (baseline, pre-dose), Weeks 4, 8, 12, ...</td>\n      <td>[0.126, 0.242, 0.286, 0.172, 0.220, 0.301, -0.145, -0.114, 0.089, 0.8, 4.9, 7.5, 0.8, 5.5, 6.7, ...</td>\n      <td>[liters, liters, liters/second, percentage of predicted FEV1, units on a scale, units on a scale...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>9</td>\n      <td>NCT01290887</td>\n      <td>Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/k...</td>\n      <td>Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>1052</td>\n      <td>June 2011</td>\n      <td>January 2015</td>\n      <td>Inclusion Criteria:\\n\\nWritten informed consent is obtained.\\nPatient must have completed treatm...</td>\n      <td>[Reslizumab]</td>\n      <td>[Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 mon...</td>\n      <td>[Reslizumab 3.0 mg/kg]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Primary, Secondary, Se...</td>\n      <td>[Participants With Treatment-Emergent Adverse Events, Participants With Treatment-Emergent Poten...</td>\n      <td>[An adverse event was defined in the protocol as any untoward medical occurrence that develops o...</td>\n      <td>[Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observa...</td>\n      <td>[359, 385, 744, 31, 47, 78, 49, 41, 90, 6, 12, 18, 33, 45, 78, 1, 2, 3, 344, 367, 711, 78, 82, 1...</td>\n      <td>[participants, participants, liters, percentage of predicted FEV1, liters, liters/second, # puff...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>13</td>\n      <td>NCT02654145</td>\n      <td>Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients</td>\n      <td>Asthma</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>145</td>\n      <td>March 17, 2016</td>\n      <td>May 31, 2017</td>\n      <td>Inclusion Criteria:\\n\\nAt least 12 years of age at the time of signing the informed consent. For...</td>\n      <td>[Mepolizumab 100mg SC, Albuterol/salbutamol MDIs, Omalizumab]</td>\n      <td>[Drug: Mepolizumab 100mg SC, Drug: Albuterol/salbutamol MDIs, Drug: Omalizumab]</td>\n      <td>[Subjects with severe eosinophilic asthma who are receiving omalizumab will enter a run-in perio...</td>\n      <td>[Omalizumab switch to mepolizumab 100mg SC every 4 weeks, Omalizumab switch to mepolizumab 100mg...</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Mean Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 32, Mean Chan...</td>\n      <td>[The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma co...</td>\n      <td>[Baseline and at Week 32, Baseline and at Week 32, Up to Week 32, Baseline and at Week 32]</td>\n      <td>[-1.45, -19.0, 1.18, 0.22]</td>\n      <td>[Scores on a scale, Scores on a scale, Exacerbation rate per year, Ratio]</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>22</td>\n      <td>NCT02555371</td>\n      <td>Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>306</td>\n      <td>January 7, 2016</td>\n      <td>July 24, 2019</td>\n      <td>Inclusion Criteria:\\n\\nInformed Consent: Prior to commencing any study related activities, subje...</td>\n      <td>[Mepolizumab 100mg, Placebo]</td>\n      <td>[Biological: Mepolizumab 100mg, Biological: Mepolizumab 100mg, Drug: Placebo]</td>\n      <td>[There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up t...</td>\n      <td>[Arm Mepolizumab 100 mg, Arm Placebo, Arm Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Percentage of Participants With First Clinically Significant Exacerbation in Part C, Ratio to B...</td>\n      <td>[Clinically significant exacerbation was defined as worsening of asthma which requires use of sy...</td>\n      <td>[Weeks 12, 24, 36 and 52, Baseline and Weeks 12, 24, 36 and 52, Baseline and Weeks 12, 24, 36 an...</td>\n      <td>[31.8, 20.2, 49.3, 32.3, 56.0, 40.3, 60.7, 47.1, 6.03, 1.16, 6.58, 1.03, 6.48, 1.20, 6.17, 1.00,...</td>\n      <td>[Percentage of participants, Ratio, Percentage of participants, Percentage of participants]</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>24</td>\n      <td>NCT02281318</td>\n      <td>Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinoph...</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>556</td>\n      <td>December 11, 2014</td>\n      <td>June 10, 2016</td>\n      <td>Inclusion Criteria:\\n\\nAge: At least 12 years of age at the time of signing the informed consent...</td>\n      <td>[Mepolizumab, Placebo, SOC]</td>\n      <td>[Biological: Mepolizumab, Drug: SOC, Drug: Placebo, Drug: SOC]</td>\n      <td>[Participants will receive Mepolizumab 100 mg subcutaneously (SC) into the upper arm or thigh ev...</td>\n      <td>[Mepolizumab SC, Placebo SC, Mepolizumab SC, Placebo SC]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Mean Change From Baseline (BL) in St. George's Respiratory Questionnaire (SGRQ) Score at Week 2...</td>\n      <td>[SGRQ consisted of 50 questions (scored from 0 to 100 where 0 indicates best and 100 indicates w...</td>\n      <td>[Baseline and Week 24, Baseline and Week 24, Baseline (Visit 2-latest pre-dose assessment) and W...</td>\n      <td>[-7.9, -15.6, 56, 176, 55, 73, -0.40, -0.80]</td>\n      <td>[Scores on a scale, Milliliters (mL), Percentage of participants, Scores on a scale]</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>27</td>\n      <td>NCT01312961</td>\n      <td>Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe E...</td>\n      <td>Asthma</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>104</td>\n      <td>March 2011</td>\n      <td>October 2012</td>\n      <td>Inclusion criteria:\\n\\nMedical diagnosis of persistent asthma for at least 12 months whose:\\n\\na...</td>\n      <td>[Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone mon...</td>\n      <td>[Drug: Placebo (for Dupilumab), Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticas...</td>\n      <td>[Placebo (for Dupilumab) subcutaneous (SC) injection once weekly (qw) for 12 weeks added to back...</td>\n      <td>[Dupilumab 300 mg qw, Placebo (for Dupilumab), Dupilumab 300 mg qw, Placebo (for Dupilumab), Dup...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants With Asthma Exacerbation, Time to First Asthma Exacerbation: Kaplan-...</td>\n      <td>[An asthma exacerbation was defined as the occurrence of any of the following: \u226530% reduction fr...</td>\n      <td>[Baseline up to Week 12, Baseline up to Week 12, Baseline up to Week 12, Baseline, Week 12, Base...</td>\n      <td>[44.2, 5.8, 19.2, 1.9, 19.2, 1.9, 9.6, 1.9, 5.8, 0.0, 0.0, 0.0, 0.058, 0.038, 0.245, 0.058, 0.46...</td>\n      <td>[percentage of participants, Probability of asthma exacerbation, percentage of participants, Lit...</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>28</td>\n      <td>NCT03052725</td>\n      <td>A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma</td>\n      <td>Eosinophils, Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>391</td>\n      <td>March 10, 2017</td>\n      <td>February 22, 2018</td>\n      <td>Inclusion Criteria:\\n\\n\u2022 Patient with eosinophilic asthma who completed the treatment period of ...</td>\n      <td>[reslizumab]</td>\n      <td>[Drug: reslizumab]</td>\n      <td>[Reslizumab was administered as 110 mg subcutaneous (sc) injection in the thigh, abdomen, or upp...</td>\n      <td>[reslizumab 110 mg]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Participants With Treatment-Emergent Adverse Events (TEAEs), Participants With Potentially Clin...</td>\n      <td>[An adverse event is any untoward medical occurrence, regardless of whether it has a causal rela...</td>\n      <td>[Day 1 to up to Day 269; for participants who discontinued early for reasons other than study te...</td>\n      <td>[102, 114, 7, 6, 5, 11, 0, 0, 2, 0, 0, 0, 8, 5, 1, 0, 4, 2, 2, 0, 0, 1, 2, 0, 1, 1, 0, 1, 12, 10...</td>\n      <td>[Participants, Participants, Participants, Participants, Participants, CAEs / year, CAEs / year,...</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>45</td>\n      <td>NCT03021304</td>\n      <td>Study of Mepolizumab Safety Syringe in Asthmatics</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>56</td>\n      <td>February 1, 2017</td>\n      <td>August 8, 2017</td>\n      <td>Inclusion Criteria:\\n\\nAge: At least 12 years of age inclusive, at the time of signing the infor...</td>\n      <td>[Mepolizumab]</td>\n      <td>[Drug: Mepolizumab]</td>\n      <td>[Subjects will receive 3 doses of 100 mg mepolizumab, liquid drug product in safety syringe, sub...</td>\n      <td>[Mepolizumab SC 100 mg/milliliter (mL) in Safety syringe]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[Percentage of Participants With Successful Self-administration of Their Observed Third Dose at ...</td>\n      <td>[During the clinic visits the Investigator or designee evaluated if the participants were able t...</td>\n      <td>[Week 8, Week 4]</td>\n      <td>[100, 100]</td>\n      <td>[Percentage of participants, Percentage of participants]</td>\n    </tr>\n    <tr>\n      <th>10</th>\n      <td>46</td>\n      <td>NCT03099096</td>\n      <td>Study of Mepolizumab Autoinjector in Asthmatics</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>159</td>\n      <td>May 4, 2017</td>\n      <td>November 30, 2017</td>\n      <td>Inclusion Criteria:\\n\\nAge: At least 12 years of age inclusive, at the time of signing the infor...</td>\n      <td>[Mepolizumab]</td>\n      <td>[Drug: Mepolizumab]</td>\n      <td>[Three doses of mepolizumab liquid drug product in autoinjector will be self-administered by the...</td>\n      <td>[Mepolizumab SC 100 mg/milliliter (mL) in autoinjector]</td>\n      <td>[Primary, Primary, Secondary, Secondary]</td>\n      <td>[Percentage of Participants With Successful Self-administration of Their Observed Third Dose at ...</td>\n      <td>[Due to differences in the labelling requirements among regulatory authorities around the world,...</td>\n      <td>[Week 8, Week 8, Week 4, Week 4]</td>\n      <td>[99, 98, 98, 96]</td>\n      <td>[Percentage of participants, Percentage of Participants, Percentage of participants, Percentage ...</td>\n    </tr>\n    <tr>\n      <th>11</th>\n      <td>47</td>\n      <td>NCT02377427</td>\n      <td>Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children</td>\n      <td>Asthma</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>36</td>\n      <td>August 25, 2015</td>\n      <td>December 7, 2016</td>\n      <td>Inclusion Criteria:\\n\\nBetween 6 and 11 years of age inclusive, at the time of screening.\\nDiagn...</td>\n      <td>[Mepolizumab]</td>\n      <td>[Drug: Mepolizumab, Drug: Mepolizumab]</td>\n      <td>[Participants with bodyweight &lt; 40 kg will receive 0.4 milliliter (mL) of reconstituted mepolizu...</td>\n      <td>[Mepolizumab 100 mg in Part A and B, Mepolizumab 40 mg in Part A and B]</td>\n      <td>[Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Prima...</td>\n      <td>[Maximum Plasma Concentration (Cmax) of Mepolizumab for Part A, Area Under Concentration Time Cu...</td>\n      <td>[PK of mepolizumab was evaluated in participants using Cmax. PK samples were collected at pre-do...</td>\n      <td>[Pre-dose on Weeks 4 and 8; Weeks 9, 12, 16 and 20 post-dose, Pre-dose on Weeks 4 and 8; Weeks 9...</td>\n      <td>[12.8188, 16.3412, 10.1960, 508.23, 675.20, 454.39, 20.9583, 21.8420, 23.5582, 0.1968, 0.1481, 0...</td>\n      <td>[Microgram (ug) per mL, Day*ug per mL, Days, Liter (L) per day, Ratio of eosinophils in blood, P...</td>\n    </tr>\n    <tr>\n      <th>12</th>\n      <td>51</td>\n      <td>NCT01508936</td>\n      <td>Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...</td>\n      <td>Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>511</td>\n      <td>February 2012</td>\n      <td>August 2013</td>\n      <td>Inclusion criteria:\\n\\nPatients are included in the study if all of the following criteria are m...</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Placebo intravenous injection every 4 weeks for a total of 4 doses., Reslizumab intravenous inj...</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis...</td>\n      <td>[FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the ...</td>\n      <td>[Baseline (Day 1), Week 16, Baseline (Day 1), Weeks 4, 8, 12, 16, Baseline (Day 1), Weeks 4, 8, ...</td>\n      <td>[-0.2778, 0.0229, 0.175, 0.251, -0.614, -0.737, -0.2944, 0.0271, 0.164, 0.224, 0.199, 0.249, 0.1...</td>\n      <td>[FEV1 liters/ eosinophils 10^9/liter, liters, units on a scale, FEV1 liters/ eosinophils 10^9/li...</td>\n    </tr>\n    <tr>\n      <th>13</th>\n      <td>58</td>\n      <td>NCT02937168</td>\n      <td>An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inf...</td>\n      <td>Asthma</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>5</td>\n      <td>May 8, 2017</td>\n      <td>May 24, 2017</td>\n      <td>Inclusion Criteria:\\n\\nMale or female, 18 through 50 years of age.\\nFemales that are either surg...</td>\n      <td>[Reslizumab, Fludeoxyglucose F 18 (FDG), Placebo]</td>\n      <td>[Drug: Fludeoxyglucose F 18 (FDG), Drug: Reslizumab, Drug: Fludeoxyglucose F 18 (FDG), Drug: Flu...</td>\n      <td>[Healthy participants will have 2 PET/CT scan in Part 1: within 7 days of eligibility being conf...</td>\n      <td>[Part 2: Reslizumab, Part 1: PET/CT Scan, Part 2: Placebo, Part 2: Reslizumab, Part 2: Placebo]</td>\n      <td>[Primary, Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Part 1: Average Global Lung Glycolysis (GLG) at Baseline (Day 1), Part 1: Average Global Lung G...</td>\n      <td>[GLG is the total FDG uptake in the whole lung. A region of interest (ROI) was drawn around lung...</td>\n      <td>[Baseline (Day 1) of Part 1, Day 8, Baseline, Week 4, Baseline, Week 4, Baseline, Week 4, Baseli...</td>\n      <td>[668.08, 621.71, 1, 0]</td>\n      <td>[cubic centimeters (cm^3), cm^3, Participants]</td>\n    </tr>\n    <tr>\n      <th>14</th>\n      <td>62</td>\n      <td>NCT02135692</td>\n      <td>A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>339</td>\n      <td>May 29, 2014</td>\n      <td>October 5, 2017</td>\n      <td>Inclusion Criteria:\\n\\nInformed Consent: Prior to commencing any study related activities, subje...</td>\n      <td>[Mepolizumab, SOC]</td>\n      <td>[Biological: Mepolizumab, Drug: SOC]</td>\n      <td>[All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approxi...</td>\n      <td>[Mepolizumab 100 mg, Mepolizumab 100 mg]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Annualized Rate of On-treatment Exacerbations Per Year, Number of Participants With Any On-trea...</td>\n      <td>[Exacerbations are defined as the worsening of asthma which requires use of systemic corticoster...</td>\n      <td>[Baseline (Week 0) to Week 172, Baseline (Week 0) to Week 172, Baseline (Week 0) to Week 168, Ba...</td>\n      <td>[0.93, 315, 84, -0.16, -0.15, -0.21, -0.17, -0.18, -0.08, -0.03, -0.12, -0.06, -0.01, -0.09, 0.3...</td>\n      <td>[Exacerbations per year, Participants, Scores on a scale, Milliliter, Participants, Participants...</td>\n    </tr>\n    <tr>\n      <th>15</th>\n      <td>75</td>\n      <td>NCT02836496</td>\n      <td>Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)</td>\n      <td>Hypereosinophilic Syndrome</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>108</td>\n      <td>March 7, 2017</td>\n      <td>August 8, 2019</td>\n      <td>Inclusion Criteria:\\n\\nCapable of giving signed informed consent/assent which includes complianc...</td>\n      <td>[Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or pre...</td>\n      <td>[Drug: Mepolizumab 300 mg, Drug: Active OCS capsules (5 mg prednisolone or prednisone), Drug: Pl...</td>\n      <td>[Enrolled subjects will receive either mepolizumab 300 mg or placebo subcutaneous (SC) every 4 w...</td>\n      <td>[Mepolizumab, Placebo, Mepolizumab, Placebo, Mepolizumab, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Percentage of Participants Who Experienced an HES Flare or Who Withdrew From the Study During t...</td>\n      <td>[Percentage of participants who experienced &gt;=1 HES flare during the 32-Week treatment period or...</td>\n      <td>[Up to Week 32, Week 20 to Week 32, Weeks 4, 8, 12, 16, 20, 24, 28 and 32, Up to Week 32, Baseli...</td>\n      <td>[56, 28, 35, 17, 7.4, 5.6, 14.9, 7.4, 26.2, 9.3, 33.8, 13.0, 41.3, 13.0, 48.9, 14.8, 50.8, 20.5,...</td>\n      <td>[Percentage of participants, Percentage of participants, Probability expressed as percentage, Fl...</td>\n    </tr>\n    <tr>\n      <th>16</th>\n      <td>95</td>\n      <td>NCT02869438</td>\n      <td>A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benraliz...</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>233</td>\n      <td>November 9, 2016</td>\n      <td>August 1, 2018</td>\n      <td>Inclusion criteria\\n\\nWritten informed consent for study participation must be obtained prior to...</td>\n      <td>[Benralizumab, Placebo]</td>\n      <td>[Drug: Benralizumab, Other: Placebo]</td>\n      <td>[Benralizumab administered subcutaneously, Placebo administered subcutaneously]</td>\n      <td>[Benralizumab arm, Placebo arm]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in ...</td>\n      <td>[The average over the mean differences between benralizumab and placebo for change from baseline...</td>\n      <td>[From first IP dose to Day 84, From first IP dose to Day 84, From first IP dose to Day 84, From ...</td>\n      <td>[0.21, 0.132, 0.22, 0.203, 0.209, 0.149, -0.415, -0.208, -88.55, 11.55, 0.104, 0.081, 0.125, 0.0...</td>\n      <td>[Liter, Liter, Percent change, Liter, Liter, Percentage of Participants, Score on a scale, Score...</td>\n    </tr>\n    <tr>\n      <th>17</th>\n      <td>98</td>\n      <td>NCT00283504</td>\n      <td>A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic an...</td>\n      <td>ALLERGIC ASTHMA</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>13</td>\n      <td>January 2006</td>\n      <td>January 2009</td>\n      <td>Inclusion Criteria:\\n\\nModerate to severe allergic asthma, uncontrolled on conventional therapy\\...</td>\n      <td>[ANTI-IGE THERAPY (XOLAIR)]</td>\n      <td>[Drug: ANTI-IGE THERAPY (XOLAIR)]</td>\n      <td>[One arm:active drug]</td>\n      <td>[all patients received Xolair/active drug]</td>\n      <td>[Primary, Secondary, Secondary]</td>\n      <td>[Number of Participants With Change in Sputum Markers by End of Study, Number of Participants Wi...</td>\n      <td>[sputum markers were classified as eosinophilic or non eosinophilic, safety was assessed by meas...</td>\n      <td>[32 weeks, 32 weeks, every 4 weeks up to 32 weeks]</td>\n      <td>[0, 0, 7, 6, 7, 6]</td>\n      <td>[Participants, Participants, Participants]</td>\n    </tr>\n    <tr>\n      <th>18</th>\n      <td>102</td>\n      <td>NCT02898662</td>\n      <td>AZD1419 Ph2a Study</td>\n      <td>Asthma</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>81</td>\n      <td>October 12, 2016</td>\n      <td>September 25, 2018</td>\n      <td>Inclusion Criteria:\\n\\nMale and female patients 18 years and above\\nPhysician-diagnosed asthma r...</td>\n      <td>[AZD1419, Placebo]</td>\n      <td>[Drug: AZD1419, Drug: Placebo]</td>\n      <td>[Dose adaption of AZD1419, 4 mg or 8 mg or 1 mg based on occurence of AE's, Matching placebo]</td>\n      <td>[AZD1419, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Number of Participants With Events for Time to Loss of Asthma Control (LOAC) up to Week 52 - Co...</td>\n      <td>[LOAC was defined as any of the following:\\n\\nIncrease of asthma control questionnaire-5 (ACQ-5)...</td>\n      <td>[Baseline (Week 0) up to Week 52, Baseline (Week 0) up to Week 52, Baseline (Week 0) up to Week ...</td>\n      <td>[24, 24, 24, 24, 0.56, 0.59, 0.79, 0.82, 13, 16, 100, 100, 2.24, 2.18, 2.36, 2.39, 325.33, 325.6...</td>\n      <td>[Participants, Participants, scores on a scale, scores on a scale, Participants, percentage of p...</td>\n    </tr>\n    <tr>\n      <th>19</th>\n      <td>106</td>\n      <td>NCT03299686</td>\n      <td>Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Sever...</td>\n      <td>Asthma</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>118</td>\n      <td>November 6, 2017</td>\n      <td>April 8, 2019</td>\n      <td>Inclusion Criteria:\\n\\nPatients with a physician-diagnosed history of moderate to severe asthma ...</td>\n      <td>[CJM112, Placebo to CJM112]</td>\n      <td>[Drug: CJM112, Other: Placebo to CJM112]</td>\n      <td>[Study treatment, Placebo]</td>\n      <td>[CJM112, Placebo to CJM112]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Change From Baseline in Forced Expiratory Volume in One Second (FEV1), Change From Baseline in ...</td>\n      <td>[The primary efficacy analysis assessed the effect of CJM112 on the absolute change from baselin...</td>\n      <td>[Baseline, Day 92, Baseline, Day 92, Baseline, Day 92, Baseline, Day 92, Baseline, Day 92, 85 days]</td>\n      <td>[0.043, 0.016, 1.064, 0.151, -0.93, -0.71, -0.83, -0.60, 38, 19, 8, 4]</td>\n      <td>[Liters, Percent predicted, units on scale, units on scale, Participants, Participants]</td>\n    </tr>\n    <tr>\n      <th>20</th>\n      <td>111</td>\n      <td>NCT01238861</td>\n      <td>Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma</td>\n      <td>Asthma</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>964</td>\n      <td>December 2010</td>\n      <td>March 2013</td>\n      <td>Inclusion Criteria:\\n\\nAge 18 through 75 years at the time of screening\\nAdequate contraception ...</td>\n      <td>[Benralizumab 2 mg, Benralizumab 20 mg, Benralizumab 100 mg, Placebo]</td>\n      <td>[Other: Placebo, Biological: Benralizumab 2 mg, Biological: Benralizumab 20 mg, Biological: Benr...</td>\n      <td>[EOS+ (defined as ELEN Index [proprietary mathematical algorithm to predict sputum eosinophil's ...</td>\n      <td>[EOS+ Benralizumab (2 mg), EOS+ Benralizumab (20 mg), EOS+ Benralizumab (100 mg), EOS- Benralizu...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants, Dose Resp...</td>\n      <td>[The annual asthma exacerbation rate (AER) was calculated as the total number of observed exacer...</td>\n      <td>[Week 1 up to Week 52, Baseline up to Week 66, Pre-dose (0 hour), Post-dose on Day 1, 6, Week 4,...</td>\n      <td>[0.57, 0.65, 0.37, 0.34, 34.7, 182, 869, 17.3, 9.10, 8.69, 3.8, 42.0, 30.9, 25.6, 2.7479, 2.6479...</td>\n      <td>[AER events/person-year, microgram per milliliter, microgram per milliliter, percentage of parti...</td>\n    </tr>\n    <tr>\n      <th>21</th>\n      <td>112</td>\n      <td>NCT00587288</td>\n      <td>Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma</td>\n      <td>Asthma</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>106</td>\n      <td>April 2008</td>\n      <td>March 2010</td>\n      <td>Inclusion Criteria:\\n\\nwritten informed consent\\nmale or female subjects aged \u2265 18 to 75 years a...</td>\n      <td>[Reslizumab, Saline]</td>\n      <td>[Biological: Reslizumab, Other: Saline]</td>\n      <td>[Reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles, S...</td>\n      <td>[Reslizumab 3 mg/kg, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Mean Change From Baseline to End of Therapy in Asthma Control Questionnaire (ACQ) Score, Percen...</td>\n      <td>[The ACQ is a 7 question instrument. Each question has 7 possible answers of 0, 1, 2, 3, 4, 5, a...</td>\n      <td>[Baseline through End of Therapy (up to 15 weeks), Baseline, End of Therapy (up to 15 weeks), Ba...</td>\n      <td>[-0.7, -0.3, 55, 36, 45, 64, 0.18, -0.08, 6.2, -2.4, -82.0, 45.9, 8, 19, 38, 42, 3, 1, 12, 8, 0,...</td>\n      <td>[units on a scale, percentage of participants, L, percent predicted FEV1, percent change in eosi...</td>\n    </tr>\n    <tr>\n      <th>22</th>\n      <td>115</td>\n      <td>NCT00802438</td>\n      <td>Eosinophilic Airway Inflammation and Mepolizumab</td>\n      <td>Asthma</td>\n      <td>Not Applicable</td>\n      <td>Interventional</td>\n      <td>38</td>\n      <td>June 1, 2008</td>\n      <td>March 1, 2013</td>\n      <td>Inclusion Criteria:\\n\\nMales or females age 18 to 50 yrs,\\nHistory of asthma based upon presence...</td>\n      <td>[mepolizumab]</td>\n      <td>[Biological: mepolizumab]</td>\n      <td>[up to 3 monthly doses of 750mg i.v. mepolizumab]</td>\n      <td>[Mepolizumab]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[The Primary Endpoint of the Study is the Percent of Eosinophils in the Bronchoalveolar Lavage F...</td>\n      <td>[Percent of eosinophils was determined in the bronchoalveolar lavage fluid collected from the pa...</td>\n      <td>[before and after up to 3 months of Mepo., before and after up to 3 months of Mepo]</td>\n      <td>[73, 31, 409, 447]</td>\n      <td>[percent of bronchoalveolar eosinophils, pg/ml]</td>\n    </tr>\n    <tr>\n      <th>23</th>\n      <td>126</td>\n      <td>NCT00123630</td>\n      <td>A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab</td>\n      <td>Esophagitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>30</td>\n      <td>November 2005</td>\n      <td>January 2010</td>\n      <td>Inclusion Criteria:\\n\\nMale or female subjects aged 12-60 years of age with EE as defined above\\...</td>\n      <td>[omalizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: omalizumab]</td>\n      <td>[placebo group, Xolair group]</td>\n      <td>[omalizumab, placebo]</td>\n      <td>[Primary]</td>\n      <td>[Change in Eosinophil Numbers Per High Power Field Proximally and Distally Between Baseline and ...</td>\n      <td>[]</td>\n      <td>[16 weeks]</td>\n      <td>[0.6, -7.5]</td>\n      <td>[perecentage of eos per high power field]</td>\n    </tr>\n    <tr>\n      <th>24</th>\n      <td>128</td>\n      <td>NCT03170271</td>\n      <td>A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontroll...</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>660</td>\n      <td>July 7, 2017</td>\n      <td>September 25, 2019</td>\n      <td>Inclusion Criteria:\\n\\nFemale and male patients aged 18 to 75 years inclusively at the time of V...</td>\n      <td>[Benralizumab (Medi-563), Placebo]</td>\n      <td>[Drug: Benralizumab (Medi-563), Drug: Placebo]</td>\n      <td>[Benralizumab (Medi563) Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 da...</td>\n      <td>[Benralizumab (Medi-563), Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24), Change From ...</td>\n      <td>[An asthma exacerbation was defined as a worsening of asthma that led to any of the following:\\n...</td>\n      <td>[Baseline (Week 0) up to Week 24, Baseline (Week 0) and Week 24, Baseline (Week 0) and Week 24, ...</td>\n      <td>[0.94, 1.86, -23.06, -14.94, 0.30, 0.14, -1.47, -1.01, 123, 107, 27.17, 7.06, 16.47, -6.61, 17.7...</td>\n      <td>[Events/year, Scores on a scale, Liters (L), Scores on a scale, Participants, L/minute, Scores o...</td>\n    </tr>\n    <tr>\n      <th>25</th>\n      <td>129</td>\n      <td>NCT00712335</td>\n      <td>The Effects of Montelukast on Smokers With Asthma</td>\n      <td>Asthmatic Smokers</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>105</td>\n      <td>February 2007</td>\n      <td>May 2011</td>\n      <td>Inclusion Criteria:\\n\\nAsthmatics:\\n\\nclinical history of asthma for at least 1 year\\nwith evide...</td>\n      <td>[Fluticasone Propionate, Montelukast, Salmeterol]</td>\n      <td>[Drug: Fluticasone Propionate, Drug: Salmeterol, Drug: Montelukast, Drug: Fluticasone Propionate...</td>\n      <td>[Asthmatic smokers treated with combination therapy:\\n\\nFluticasone propionate dosage - DPI 250 ...</td>\n      <td>[1, 3, 2, 4, 1, 3]</td>\n      <td>[Secondary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Sputum Eosinophil Percentages, Sputum Neutrophil Percentages, Sputum IL-8 Levels, Sputum GM-CSF...</td>\n      <td>[Secondary endpoints of inflammatory markers (sputum eosinophil percentages at 24 weeks) were me...</td>\n      <td>[24 weeks, 24 weeks, 24 weeks, 24 weeks, 24 weeks, 24 weeks, 24 weeks]</td>\n      <td>[2.33, 3.60, 1.60, 3.26, 86.00, 72.53, 89.33, 79.84, 334545, 26,300, 3602, 317778, 17.60, 15.18,...</td>\n      <td>[percentage of eosinophils, percentage of neutrophils, pg/ml, pg/ml, ratio, pg/ml, pg/ml]</td>\n    </tr>\n    <tr>\n      <th>26</th>\n      <td>134</td>\n      <td>NCT01842607</td>\n      <td>A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>651</td>\n      <td>May 27, 2013</td>\n      <td>March 13, 2015</td>\n      <td>Inclusion Criteria:\\n\\nFrench subjects: In France, a subject will be eligible for inclusion in t...</td>\n      <td>[Mepolizumab]</td>\n      <td>[Biological: Mepolizumab]</td>\n      <td>[Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously ...</td>\n      <td>[Mepolizumab Arm]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Number of Participants With Adverse Events (AEs) Including Both Systemic (i.e. Allergic/Immunog...</td>\n      <td>[AEs were collected from the Baseline visit until the follow-up visit (approx. 12 weeks post-las...</td>\n      <td>[From Baseline visit until the follow-up visit (approximately [approx.] week 60 [12 weeks post-l...</td>\n      <td>[558, 119, 94, 1, 0, 31, 615, 0, 31, 0.93, -0.09, -0.11, -0.05, -0.10, -0.09, 0.20, 67, 50, 29, ...</td>\n      <td>[Participants, Participants, Exacerbations per year, Score on scale, Milliliters (mL), Participa...</td>\n    </tr>\n    <tr>\n      <th>27</th>\n      <td>136</td>\n      <td>NCT01691508</td>\n      <td>Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma</td>\n      <td>Asthma</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>135</td>\n      <td>October 2012</td>\n      <td>December 2013</td>\n      <td>Inclusion Criteria:\\n\\nInformed Consent and Study Compliance: Subjects must be able to give writ...</td>\n      <td>[Mepolizumab, Placebo, OCS (prednisone/prednisolone)]</td>\n      <td>[Drug: Mepolizumab, Drug: OCS (prednisone/prednisolone), Drug: Placebo, Drug: OCS (prednisone/pr...</td>\n      <td>[Mepolizumab 100 mg subcutaneous once every 4 weeks upto Week 20, Placebo subcutaneous once ever...</td>\n      <td>[Mepolizumab, Placebo, Mepolizumab, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroi...</td>\n      <td>[Baseline (BL) dose was the prescribed optimized prednisone/prednisolone dose following the OCS ...</td>\n      <td>[Baseline; Weeks 20 to 24, Baseline; Weeks 20 to 24, Weeks 20 to 24, Weeks 20 to 24, Baseline; W...</td>\n      <td>[7, 16, 5, 12, 10, 9, 7, 7, 37, 25, 22, 37, 44, 32, 21, 37, 45, 32, 5, 10, 61, 59, 0.0, -50.0]</td>\n      <td>[Participants, Participants, Participants, Participants, Percentage reduction in OCS dose]</td>\n    </tr>\n    <tr>\n      <th>28</th>\n      <td>139</td>\n      <td>NCT02392481</td>\n      <td>Asthma Biomarker Study</td>\n      <td>Asthma</td>\n      <td>Unknown</td>\n      <td>Observational</td>\n      <td>69</td>\n      <td>July 16, 2015</td>\n      <td>January 3, 2017</td>\n      <td>Inclusion criteria:\\n\\nBody mass index (BMI) &gt;=18 and &lt;= 40 Non-smokers or ex-smokers with a cig...</td>\n      <td>[Biofluid sampling]</td>\n      <td>[Procedure: Biofluid sampling]</td>\n      <td>[]</td>\n      <td>[Healthy subjects]</td>\n      <td>[Primary, Primary, Secondary, Secondary]</td>\n      <td>[Level of Tumour Necrosis Factor-alpha (TNF-\u03b1) in Blood at Baseline (Visit 1), Level of Interleu...</td>\n      <td>[Level of Tumour Necrosis Factor-alpha (TNF-\u03b1) [picograms per milliliter (pg/mL)] in blood at ba...</td>\n      <td>[Baseline (Visit 1), Baseline (Visit 1), follow-up visit 28 days after baseline (Visit 2), follo...</td>\n      <td>[5.3, 9.3, 10.6, 15.7, 71.3, 65.2, 245.0, 133.9, 5.8, 8.1, 5.2, 16.4, 47.7, 86.1, 105.1, 37.4]</td>\n      <td>[pg/mL, pg/mL, pg/mL, pg/mL]</td>\n    </tr>\n    <tr>\n      <th>29</th>\n      <td>147</td>\n      <td>NCT01821898</td>\n      <td>Eosinophilic Esophagitis Clinical Therapy Comparison Trial</td>\n      <td>Eosinophilic Esophagitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>3</td>\n      <td>July 9, 2013</td>\n      <td>September 24, 2018</td>\n      <td>Inclusion Criteria\\n\\nSigned written informed consent and assent if applicable prior to performi...</td>\n      <td>[Oral Budesonide, Elimination diet]</td>\n      <td>[Drug: Oral Budesonide, Other: Elimination diet]</td>\n      <td>[Oral Budesonide, Elimination diet]</td>\n      <td>[Positive for food allergy: Group A, Positive for food allergy: Group B]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Peak Number of Eosinophils/High Powered Field, Quality of Life Survey Score, Symptom Score, Exp...</td>\n      <td>[The primary outcome will be the peak eosinophil/high powered field on repeat biopsy after the t...</td>\n      <td>[16 weeks, 16 weeks, 16 weeks, Conclusion of study]</td>\n      <td>[]</td>\n      <td>[]</td>\n    </tr>\n    <tr>\n      <th>30</th>\n      <td>151</td>\n      <td>NCT01458418</td>\n      <td>A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children</td>\n      <td>Eosinophilic Esophagitis</td>\n      <td>Not Applicable</td>\n      <td>Interventional</td>\n      <td>4</td>\n      <td>December 2011</td>\n      <td>February 2015</td>\n      <td>Inclusion Criteria:\\n\\nMales and females aged 2-17\\nPresence of more than 15 eosinophils per hpf...</td>\n      <td>[Montelukast, placebo, 5 mg Montelukast]</td>\n      <td>[Drug: Montelukast, Drug: 5 mg Montelukast, Other: placebo]</td>\n      <td>[Subjects will receive two 5mg tablets of Montelukast/day., Subjects will receive one 5mg tablet...</td>\n      <td>[Montelukast 10 mg/day, placebo, Montelukast 5mg/day]</td>\n      <td>[Primary]</td>\n      <td>[Eosinophil Count]</td>\n      <td>[Eosinophils/high powered field(hpf) in the mid esophagus will be measured after 12 weeks of the...</td>\n      <td>[12 weeks]</td>\n      <td>[8]</td>\n      <td>[Eosinophils/HPF]</td>\n    </tr>\n    <tr>\n      <th>31</th>\n      <td>168</td>\n      <td>NCT02104505</td>\n      <td>Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS</td>\n      <td>Mild, Allergic Asthma</td>\n      <td>Phase 1, Phase 2</td>\n      <td>Interventional</td>\n      <td>23</td>\n      <td>November 2015</td>\n      <td>September 2016</td>\n      <td>Inclusion Criteria:\\n\\nAge 18-50 of both genders\\nNegative pregnancy test for females who are no...</td>\n      <td>[Gamma Tocopherol 700 mg capsules,, Placebo]</td>\n      <td>[Drug: Gamma Tocopherol 700 mg capsules,, Drug: Placebo]</td>\n      <td>[Gamma Tocopherol supplement, Safflower oil capsules]</td>\n      <td>[700 mg Gamma Tocopherol daily x 14days, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Comparison of Change in Sputum Percent Neutrophils (PMN)s Following Inhaled Clinical Center Ref...</td>\n      <td>[In asthmatic individuals, exposure to CCRE is expected to increase PMNs in the sputum. The sput...</td>\n      <td>[after 14 days of gamma tocopherol or placebo treatment, after 14 days of gamma tocopherol or pl...</td>\n      <td>[11.7, 20.1, 2.6, 9.5, 20.2, 16.3, 21.4, 21.4]</td>\n      <td>[change in percentage of PMNs in sputum, eosinophils per mg sputum, % of labeled particles clear...</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "asthma_study_table.shape",
            "execution_count": 84,
            "outputs": [
                {
                    "output_type": "execute_result",
                    "execution_count": 84,
                    "data": {
                        "text/plain": "(32, 20)"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "The eosinophilic asthma query returned 32 unique studies across all phases.  As can be seen in the table above, each study contains multiple points of outcome data, contained in lists in the respective columns of interest.\n\n\nUsing the Study class's extract_outcomes function, and the Query class's build_outcomes_table functions, I will extract all the individual outcomes found in each study, and compile a master data table containing individual entries for each outcome measure."
        },
        {
            "metadata": {
                "scrolled": true
            },
            "cell_type": "code",
            "source": "asthma_outcome_table = asthma.build_outcome_table()\nasthma_outcome_table.shape",
            "execution_count": 8,
            "outputs": [
                {
                    "output_type": "execute_result",
                    "execution_count": 8,
                    "data": {
                        "text/plain": "(187, 12)"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "Looks like across the 32 studies returned in the eosinophilic asthma query, there were 187 total endpoints reported.  I want to better understand how many times a certain endpoint was reported (i.e., change from baseline in forced expiratory volume in 1 second, \"FEV1\").  However, I notice many of the studies report the same outcome, but the outcome measure title / description are written slightly differently.\n\nI built a search function to take a series of keywords and identify how many individual endpoints contain all of the search keywords in the 'OutcomeMeasureTitle' column.  First I tokenize the 'OutcomeMeasureTitle' column for each endpoint, and strip all whitespace and parentheses to help control for inconsistent reporting of endpoints - I then do the same for the list of keywords in the user's search expression.  A match is identified if all keywords are found in the tokenized list in the 'OutcomeMeasureTitleTokenized' column."
        },
        {
            "metadata": {
                "scrolled": false
            },
            "cell_type": "code",
            "source": "tokenize_column(asthma_outcome_table, 'OutcomeMeasureTitle', 'OutcomeMeasureTitleTokenized')",
            "execution_count": 9,
            "outputs": []
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "asthma_outcome_table.head(10)",
            "execution_count": 12,
            "outputs": [
                {
                    "output_type": "execute_result",
                    "execution_count": 12,
                    "data": {
                        "text/plain": "         NCTId  \\\n0  NCT01285323   \n1  NCT01285323   \n2  NCT01285323   \n3  NCT01285323   \n4  NCT01285323   \n5  NCT01285323   \n6  NCT01285323   \n7  NCT01285323   \n8  NCT01285323   \n9  NCT01285323   \n\n                                                                                       BriefTitle  \\\n0  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n1  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n2  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n3  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n4  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n5  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n6  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n7  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n8  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n9  A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n\n     Phase       InterventionName           ArmGroupInterventionName  \\\n0  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n1  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n2  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n3  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n4  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n5  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n6  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n7  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n8  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n9  Phase 3  [Reslizumab, Placebo]  [Drug: Placebo, Drug: Reslizumab]   \n\n         InterventionArmGroupLabel OutcomeMeasureType  \\\n0  [Reslizumab 3.0 mg/kg, Placebo]            Primary   \n1  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n2  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n3  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n4  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n5  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n6  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n7  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n8  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n9  [Reslizumab 3.0 mg/kg, Placebo]          Secondary   \n\n                                                                                   OutcomeMeasureTitle  \\\n0                      Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment   \n1                       Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) At Week 16   \n2  Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...   \n3                       Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) to Week 16   \n4  Change From Baseline in Asthma Control Questionnaire (ACQ) Over 16 Weeks Using Mixed Model for R...   \n5                          Kaplan-Meier Estimates for Time to First Clinical Asthma Exacerbation (CAE)   \n6  Change From Baseline in Asthma Symptom Utility Index (ASUI) Over 16 Weeks Using Mixed Model for ...   \n7  Change From Baseline in Short-Acting Beta-Agonist (SABA) Use Over 16 Weeks Using Mixed Model for...   \n8  Change From Baseline in Blood Eosinophil Count Over 16 Weeks and 52 Weeks Using Mixed Model for ...   \n9                                            Participants With Treatment-Emergent Adverse Events TEAE)   \n\n                                                                             OutcomeMeasureDescription  \\\n0  An exacerbation event was considered a CAE if the patient met either or both of the criteria lis...   \n1  FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...   \n2  FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...   \n3  The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The que...   \n4  The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions ...   \n5  An exacerbation event was considered a CAE if the patient met either or both of the criteria lis...   \n6  The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma sympto...   \n7  SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit p...   \n8  The blood eosinophil counts were measured using a standard complete blood count (CBC) with diffe...   \n9  An adverse event (AE) was defined in the protocol as any untoward medical occurrence that develo...   \n\n                                                                               OutcomeMeasureTimeFrame  \\\n0                                                                                    Day 1 to Month 12   \n1                                                                  Day 1 (baseline, pre-dose), Week 16   \n2                                                    Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16   \n3                                                                  Day 1 (baseline, pre-dose), Week 16   \n4                                                       Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16   \n5                                               Day 1 to Day 526 (longest treatment time plus 2 weeks)   \n6                                                       Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16   \n7                                                       Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16   \n8  Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early with...   \n9  Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observat...   \n\n                               OutcomeMeasurementValue  \\\n0    [2.115, 0.859, 0.122, 0.223, 0.094, 0.187, 0.777]   \n1        [0.987, -0.660, -0.857, NA, NA, 0.080, 0.115]   \n2  [-0.44, -0.50, -0.076, -0.555, -0.076, -0.565, 201]   \n3                       [177, 36, 67, 140, 98, 25, 12]   \n4                          [27, 34, 14, 22, 13, 11, 0]   \n5                              [1, 9, 8, 0, 0, 23, 18]   \n6                [1.660, 0.646, 0.047, 0.033, 5, 4, 0]   \n7                                [1, 5, 2, 3, 2, 7, 3]   \n8                              [11, 9, 3, 3, 3, 10, 0]   \n9                            [1, 5, 6, 10, 8, 168, 10]   \n\n  OutcomeMeasureUnitOfMeasure  \\\n0            CAEs in 52 weeks   \n1                      liters   \n2                      liters   \n3            units on a scale   \n4            units on a scale   \n5                       weeks   \n6            units on a scale   \n7          SABA puffs per day   \n8     10^9 blood eosinophil/L   \n9                participants   \n\n                                                                          OutcomeMeasureTitleTokenized  \n0            [frequency, of, clinical, asthma, exacerbations, caes, during, 12, months, of, treatment]  \n1          [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16]  \n2  [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...  \n3           [change, from, baseline, in, asthma, quality, of, life, questionnaire, aqlq, to, week, 16]  \n4  [change, from, baseline, in, asthma, control, questionnaire, acq, over, 16, weeks, using, mixed,...  \n5                 [kaplan-meier, estimates, for, time, to, first, clinical, asthma, exacerbation, cae]  \n6  [change, from, baseline, in, asthma, symptom, utility, index, asui, over, 16, weeks, using, mixe...  \n7  [change, from, baseline, in, short-acting, beta-agonist, saba, use, over, 16, weeks, using, mixe...  \n8  [change, from, baseline, in, blood, eosinophil, count, over, 16, weeks, and, 52, weeks, using, m...  \n9                                      [participants, with, treatment-emergent, adverse, events, teae]  ",
                        "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>NCTId</th>\n      <th>BriefTitle</th>\n      <th>Phase</th>\n      <th>InterventionName</th>\n      <th>ArmGroupInterventionName</th>\n      <th>InterventionArmGroupLabel</th>\n      <th>OutcomeMeasureType</th>\n      <th>OutcomeMeasureTitle</th>\n      <th>OutcomeMeasureDescription</th>\n      <th>OutcomeMeasureTimeFrame</th>\n      <th>OutcomeMeasurementValue</th>\n      <th>OutcomeMeasureUnitOfMeasure</th>\n      <th>OutcomeMeasureTitleTokenized</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Primary</td>\n      <td>Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment</td>\n      <td>An exacerbation event was considered a CAE if the patient met either or both of the criteria lis...</td>\n      <td>Day 1 to Month 12</td>\n      <td>[2.115, 0.859, 0.122, 0.223, 0.094, 0.187, 0.777]</td>\n      <td>CAEs in 52 weeks</td>\n      <td>[frequency, of, clinical, asthma, exacerbations, caes, during, 12, months, of, treatment]</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) At Week 16</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...</td>\n      <td>Day 1 (baseline, pre-dose), Week 16</td>\n      <td>[0.987, -0.660, -0.857, NA, NA, 0.080, 0.115]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16]</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16</td>\n      <td>[-0.44, -0.50, -0.076, -0.555, -0.076, -0.565, 201]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) to Week 16</td>\n      <td>The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The que...</td>\n      <td>Day 1 (baseline, pre-dose), Week 16</td>\n      <td>[177, 36, 67, 140, 98, 25, 12]</td>\n      <td>units on a scale</td>\n      <td>[change, from, baseline, in, asthma, quality, of, life, questionnaire, aqlq, to, week, 16]</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Asthma Control Questionnaire (ACQ) Over 16 Weeks Using Mixed Model for R...</td>\n      <td>The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions ...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16</td>\n      <td>[27, 34, 14, 22, 13, 11, 0]</td>\n      <td>units on a scale</td>\n      <td>[change, from, baseline, in, asthma, control, questionnaire, acq, over, 16, weeks, using, mixed,...</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Kaplan-Meier Estimates for Time to First Clinical Asthma Exacerbation (CAE)</td>\n      <td>An exacerbation event was considered a CAE if the patient met either or both of the criteria lis...</td>\n      <td>Day 1 to Day 526 (longest treatment time plus 2 weeks)</td>\n      <td>[1, 9, 8, 0, 0, 23, 18]</td>\n      <td>weeks</td>\n      <td>[kaplan-meier, estimates, for, time, to, first, clinical, asthma, exacerbation, cae]</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Asthma Symptom Utility Index (ASUI) Over 16 Weeks Using Mixed Model for ...</td>\n      <td>The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma sympto...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16</td>\n      <td>[1.660, 0.646, 0.047, 0.033, 5, 4, 0]</td>\n      <td>units on a scale</td>\n      <td>[change, from, baseline, in, asthma, symptom, utility, index, asui, over, 16, weeks, using, mixe...</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Short-Acting Beta-Agonist (SABA) Use Over 16 Weeks Using Mixed Model for...</td>\n      <td>SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit p...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16</td>\n      <td>[1, 5, 2, 3, 2, 7, 3]</td>\n      <td>SABA puffs per day</td>\n      <td>[change, from, baseline, in, short-acting, beta-agonist, saba, use, over, 16, weeks, using, mixe...</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Blood Eosinophil Count Over 16 Weeks and 52 Weeks Using Mixed Model for ...</td>\n      <td>The blood eosinophil counts were measured using a standard complete blood count (CBC) with diffe...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early with...</td>\n      <td>[11, 9, 3, 3, 3, 10, 0]</td>\n      <td>10^9 blood eosinophil/L</td>\n      <td>[change, from, baseline, in, blood, eosinophil, count, over, 16, weeks, and, 52, weeks, using, m...</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Participants With Treatment-Emergent Adverse Events TEAE)</td>\n      <td>An adverse event (AE) was defined in the protocol as any untoward medical occurrence that develo...</td>\n      <td>Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observat...</td>\n      <td>[1, 5, 6, 10, 8, 168, 10]</td>\n      <td>participants</td>\n      <td>[participants, with, treatment-emergent, adverse, events, teae]</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "# \n\nI would now like to know how many endpoints relate to Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1), a common asthma endpoint.\n\n# "
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "search_results = search_outcomes(asthma_outcome_table, 'OutcomeMeasureTitleTokenized')\nsearch_results",
            "execution_count": 13,
            "outputs": [
                {
                    "output_type": "stream",
                    "name": "stdout",
                    "text": "Enter your search term here: \nchange baseline FEV1\n\nSearching outcomes that contain the following key terms:\n\n['change', 'baseline', 'fev1']\n"
                },
                {
                    "output_type": "execute_result",
                    "execution_count": 13,
                    "data": {
                        "text/plain": "    index        NCTId  \\\n0       1  NCT01285323   \n1       2  NCT01285323   \n2      15  NCT01287039   \n3      28  NCT01287039   \n4      40  NCT01270464   \n5      43  NCT01270464   \n6      71  NCT02281318   \n7      97  NCT01508936   \n8      98  NCT01508936   \n9     100  NCT01508936   \n10    101  NCT01508936   \n11    102  NCT01508936   \n12    116  NCT02135692   \n13    132  NCT02869438   \n14    135  NCT02869438   \n15    157  NCT03170271   \n16    170  NCT01842607   \n\n                                                                                             BriefTitle  \\\n0        A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n1        A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n2   A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinic...   \n3   A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinic...   \n4   A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Pa...   \n5   A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Pa...   \n6   Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinoph...   \n7   Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...   \n8   Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...   \n9   Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...   \n10  Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...   \n11  Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...   \n12     A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects   \n13  A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benraliz...   \n14  A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benraliz...   \n15  A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontroll...   \n16                           A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects   \n\n      Phase                    InterventionName  \\\n0   Phase 3               [Reslizumab, Placebo]   \n1   Phase 3               [Reslizumab, Placebo]   \n2   Phase 3               [Reslizumab, Placebo]   \n3   Phase 3               [Reslizumab, Placebo]   \n4   Phase 3               [Reslizumab, Placebo]   \n5   Phase 3               [Reslizumab, Placebo]   \n6   Phase 3         [Mepolizumab, Placebo, SOC]   \n7   Phase 3               [Reslizumab, Placebo]   \n8   Phase 3               [Reslizumab, Placebo]   \n9   Phase 3               [Reslizumab, Placebo]   \n10  Phase 3               [Reslizumab, Placebo]   \n11  Phase 3               [Reslizumab, Placebo]   \n12  Phase 3                  [Mepolizumab, SOC]   \n13  Phase 3             [Benralizumab, Placebo]   \n14  Phase 3             [Benralizumab, Placebo]   \n15  Phase 3  [Benralizumab (Medi-563), Placebo]   \n16  Phase 3                       [Mepolizumab]   \n\n                                          ArmGroupInterventionName  \\\n0                                [Drug: Placebo, Drug: Reslizumab]   \n1                                [Drug: Placebo, Drug: Reslizumab]   \n2                                [Drug: Placebo, Drug: Reslizumab]   \n3                                [Drug: Placebo, Drug: Reslizumab]   \n4              [Drug: Placebo, Drug: Reslizumab, Drug: Reslizumab]   \n5              [Drug: Placebo, Drug: Reslizumab, Drug: Reslizumab]   \n6   [Biological: Mepolizumab, Drug: SOC, Drug: Placebo, Drug: SOC]   \n7                                [Drug: Placebo, Drug: Reslizumab]   \n8                                [Drug: Placebo, Drug: Reslizumab]   \n9                                [Drug: Placebo, Drug: Reslizumab]   \n10                               [Drug: Placebo, Drug: Reslizumab]   \n11                               [Drug: Placebo, Drug: Reslizumab]   \n12                            [Biological: Mepolizumab, Drug: SOC]   \n13                            [Drug: Benralizumab, Other: Placebo]   \n14                            [Drug: Benralizumab, Other: Placebo]   \n15                  [Drug: Benralizumab (Medi-563), Drug: Placebo]   \n16                                       [Biological: Mepolizumab]   \n\n                                    InterventionArmGroupLabel  \\\n0                             [Reslizumab 3.0 mg/kg, Placebo]   \n1                             [Reslizumab 3.0 mg/kg, Placebo]   \n2                             [Reslizumab 3.0 mg/kg, Placebo]   \n3                             [Reslizumab 3.0 mg/kg, Placebo]   \n4   [Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg, Placebo]   \n5   [Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg, Placebo]   \n6    [Mepolizumab SC, Placebo SC, Mepolizumab SC, Placebo SC]   \n7                             [Reslizumab 3.0 mg/kg, Placebo]   \n8                             [Reslizumab 3.0 mg/kg, Placebo]   \n9                             [Reslizumab 3.0 mg/kg, Placebo]   \n10                            [Reslizumab 3.0 mg/kg, Placebo]   \n11                            [Reslizumab 3.0 mg/kg, Placebo]   \n12                   [Mepolizumab 100 mg, Mepolizumab 100 mg]   \n13                            [Benralizumab arm, Placebo arm]   \n14                            [Benralizumab arm, Placebo arm]   \n15                         [Benralizumab (Medi-563), Placebo]   \n16                                          [Mepolizumab Arm]   \n\n   OutcomeMeasureType  \\\n0           Secondary   \n1           Secondary   \n2           Secondary   \n3           Secondary   \n4             Primary   \n5           Secondary   \n6           Secondary   \n7             Primary   \n8           Secondary   \n9           Secondary   \n10          Secondary   \n11          Secondary   \n12          Secondary   \n13            Primary   \n14          Secondary   \n15          Secondary   \n16          Secondary   \n\n                                                                                    OutcomeMeasureTitle  \\\n0                        Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) At Week 16   \n1   Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...   \n2   Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...   \n3   Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...   \n4   Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...   \n5   Change From Baseline in % Predicted Expiratory Volume In 1 Second (FEV1) at Week 16 and at Endpoint   \n6   Mean Change From Baseline in Clinic Pre-bronchodilator Forced Expiratory Volume in One Second (F...   \n7   Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis Set   \n8   Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...   \n9   Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in FEV1 Subpopula...   \n10        Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Weeks 4, 8, 12, and 16   \n11  Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (% Predicted FEV1...   \n12                             Mean Change From Baseline in On-treatment Clinic Pre-bronchodilator FEV1   \n13  Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in P...   \n14                                Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1   \n15  Change From Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in First Second (FEV1) ...   \n16        Mean Change From Baseline in Clinic Pre-bronchodilator FEV1 Over the 52-week Treatment Period   \n\n                                                                              OutcomeMeasureDescription  \\\n0   FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...   \n1   FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...   \n2   FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...   \n3   FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...   \n4   FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...   \n5   The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a fo...   \n6   FEV1 is the volume of air that can be forced out in one second after taking a deep breath. The c...   \n7   FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...   \n8   FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...   \n9   FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...   \n10  FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...   \n11  The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a fo...   \n12  FEV1 is defined as the volume of air forcefully expelled from the lungs in 1 second. Pre-broncho...   \n13  The average over the mean differences between benralizumab and placebo for change from baseline ...   \n14  Post baseline visits include Day 3, Day 7, Day 14, Day 28, Day 56, Day 84. [Note: Day 28, 56, 84...   \n15  Lung function was assessed by FEV1 which was measured by spirometry. Spirometry was performed by...   \n16  FEV1 is defined as the volume of air forcefully expelled from the lungs in 1 second. Pre-broncho...   \n\n                              OutcomeMeasureTimeFrame  \\\n0                 Day 1 (baseline, pre-dose), Week 16   \n1   Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16   \n2   Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16   \n3   Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16   \n4   Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16   \n5       Day 1 (baseline, pre-dose), Week 16, endpoint   \n6                                Baseline and Week 24   \n7                           Baseline (Day 1), Week 16   \n8                Baseline (Day 1), Weeks 4, 8, 12, 16   \n9                           Baseline (Day 1), Week 16   \n10           Baseline (Day 1), Weeks 4, 8, 12, and 16   \n11           Baseline (Day 1), Weeks 4, 8, 12, and 16   \n12                      Baseline (Week 0) to Week 168   \n13                       From first IP dose to Day 84   \n14                       From first IP dose to Day 84   \n15                      Baseline (Week 0) and Week 24   \n16                    From Baseline and up to Week 52   \n\n                                                    OutcomeMeasurementValue  \\\n0                             [0.987, -0.660, -0.857, NA, NA, 0.080, 0.115]   \n1                       [-0.44, -0.50, -0.076, -0.555, -0.076, -0.565, 201]   \n2                    [34.9, NA, 0.109, 0.167, -0.36, -0.64, -0.118, -0.584]   \n3                    [34.9, NA, 0.109, 0.167, -0.36, -0.64, -0.118, -0.584]   \n4    [0.126, 0.242, 0.286, 0.172, 0.220, 0.301, -0.145, -0.114, 0.089, 0.8]   \n5                                       [66, 59, 61, 4, 2, 7, 8, 6, 12, 10]   \n6                                                                 [56, 176]   \n7   [-0.2778, 0.0229, 0.175, 0.251, -0.614, -0.737, -0.2944, 0.0271, 0.164]   \n8               [0.224, 0.199, 0.249, 0.152, 0.277, 0.187, 0.255, 4.8, 6.7]   \n9           [0.235, 0.179, 0.243, 0.176, 0.284, 0.234, 0.246, 0.210, 0.184]   \n10             [0.270, 0.240, 0.136, 0.256, 0.179, 0.241, -0.1, -0.2, -0.2]   \n11             [-0.3, -0.2, -0.3, -0.4, -0.3, 0.010, -0.226, 0.036, -0.239]   \n12         [35, 3, 0, 1, 77, 199, 28, 0, 1.8, 0.6, 1.5, 2.0, 1.2, 1.8, 1.4]   \n13                                        [0.21, 0.132, 0.22, 0.203, 0.209]   \n14                                         [0.1, 0.122, 0.11, 0.138, 0.099]   \n15                                                  [123, 107, 27.17, 7.06]   \n16                                              [4, 0, 1, 0, 0, 0, 0, 0, 0]   \n\n            OutcomeMeasureUnitOfMeasure  \\\n0                                liters   \n1                                liters   \n2                                liters   \n3                                liters   \n4                                liters   \n5          percentage of predicted FEV1   \n6                      Milliliters (mL)   \n7   FEV1 liters/ eosinophils 10^9/liter   \n8                                liters   \n9   FEV1 liters/ eosinophils 10^9/liter   \n10                               liters   \n11         percentage of predicted FEV1   \n12                           Milliliter   \n13                                Liter   \n14                                Liter   \n15                           Liters (L)   \n16                     Milliliters (mL)   \n\n                                                                           OutcomeMeasureTitleTokenized  \n0           [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16]  \n1   [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...  \n2   [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...  \n3   [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...  \n4   [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...  \n5   [change, from, baseline, in, %, predicted, expiratory, volume, in, 1, second, fev1, at, week, 16...  \n6   [mean, change, from, baseline, in, clinic, pre-bronchodilator, forced, expiratory, volume, in, o...  \n7   [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16, in, ...  \n8   [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...  \n9   [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16, in, ...  \n10  [change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, weeks, 4,, 8,,...  \n11  [change, from, baseline, in, percent, predicted, forced, expiratory, volume, in, 1, second, %, p...  \n12                   [mean, change, from, baseline, in, on-treatment, clinic, pre-bronchodilator, fev1]  \n13  [change, from, baseline, visit, 4, to, day, 28, visit, 8),, day, 56, visit, 9),, and, day, 84, v...  \n14                     [change, from, baseline, visit, 4, to, post, baseline, visits, in, pre-bd, fev1]  \n15  [change, from, baseline, in, pre-bronchodilator, bd, forced, expiratory, volume, in, first, seco...  \n16  [mean, change, from, baseline, in, clinic, pre-bronchodilator, fev1, over, the, 52-week, treatme...  ",
                        "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>index</th>\n      <th>NCTId</th>\n      <th>BriefTitle</th>\n      <th>Phase</th>\n      <th>InterventionName</th>\n      <th>ArmGroupInterventionName</th>\n      <th>InterventionArmGroupLabel</th>\n      <th>OutcomeMeasureType</th>\n      <th>OutcomeMeasureTitle</th>\n      <th>OutcomeMeasureDescription</th>\n      <th>OutcomeMeasureTimeFrame</th>\n      <th>OutcomeMeasurementValue</th>\n      <th>OutcomeMeasureUnitOfMeasure</th>\n      <th>OutcomeMeasureTitleTokenized</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>1</td>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) At Week 16</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...</td>\n      <td>Day 1 (baseline, pre-dose), Week 16</td>\n      <td>[0.987, -0.660, -0.857, NA, NA, 0.080, 0.115]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16]</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>2</td>\n      <td>NCT01285323</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16</td>\n      <td>[-0.44, -0.50, -0.076, -0.555, -0.076, -0.565, 201]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>15</td>\n      <td>NCT01287039</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinic...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16</td>\n      <td>[34.9, NA, 0.109, 0.167, -0.36, -0.64, -0.118, -0.584]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>28</td>\n      <td>NCT01287039</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinic...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...</td>\n      <td>Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16</td>\n      <td>[34.9, NA, 0.109, 0.167, -0.36, -0.64, -0.118, -0.584]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>40</td>\n      <td>NCT01270464</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Pa...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab, Drug: Reslizumab]</td>\n      <td>[Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg, Placebo]</td>\n      <td>Primary</td>\n      <td>Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fro...</td>\n      <td>Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16</td>\n      <td>[0.126, 0.242, 0.286, 0.172, 0.220, 0.301, -0.145, -0.114, 0.089, 0.8]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>43</td>\n      <td>NCT01270464</td>\n      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Pa...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab, Drug: Reslizumab]</td>\n      <td>[Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in % Predicted Expiratory Volume In 1 Second (FEV1) at Week 16 and at Endpoint</td>\n      <td>The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a fo...</td>\n      <td>Day 1 (baseline, pre-dose), Week 16, endpoint</td>\n      <td>[66, 59, 61, 4, 2, 7, 8, 6, 12, 10]</td>\n      <td>percentage of predicted FEV1</td>\n      <td>[change, from, baseline, in, %, predicted, expiratory, volume, in, 1, second, fev1, at, week, 16...</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>71</td>\n      <td>NCT02281318</td>\n      <td>Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinoph...</td>\n      <td>Phase 3</td>\n      <td>[Mepolizumab, Placebo, SOC]</td>\n      <td>[Biological: Mepolizumab, Drug: SOC, Drug: Placebo, Drug: SOC]</td>\n      <td>[Mepolizumab SC, Placebo SC, Mepolizumab SC, Placebo SC]</td>\n      <td>Secondary</td>\n      <td>Mean Change From Baseline in Clinic Pre-bronchodilator Forced Expiratory Volume in One Second (F...</td>\n      <td>FEV1 is the volume of air that can be forced out in one second after taking a deep breath. The c...</td>\n      <td>Baseline and Week 24</td>\n      <td>[56, 176]</td>\n      <td>Milliliters (mL)</td>\n      <td>[mean, change, from, baseline, in, clinic, pre-bronchodilator, forced, expiratory, volume, in, o...</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>97</td>\n      <td>NCT01508936</td>\n      <td>Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Primary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis Set</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...</td>\n      <td>Baseline (Day 1), Week 16</td>\n      <td>[-0.2778, 0.0229, 0.175, 0.251, -0.614, -0.737, -0.2944, 0.0271, 0.164]</td>\n      <td>FEV1 liters/ eosinophils 10^9/liter</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16, in, ...</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>98</td>\n      <td>NCT01508936</td>\n      <td>Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Mo...</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...</td>\n      <td>Baseline (Day 1), Weeks 4, 8, 12, 16</td>\n      <td>[0.224, 0.199, 0.249, 0.152, 0.277, 0.187, 0.255, 4.8, 6.7]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, over, 16, weeks, u...</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>100</td>\n      <td>NCT01508936</td>\n      <td>Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in FEV1 Subpopula...</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...</td>\n      <td>Baseline (Day 1), Week 16</td>\n      <td>[0.235, 0.179, 0.243, 0.176, 0.284, 0.234, 0.246, 0.210, 0.184]</td>\n      <td>FEV1 liters/ eosinophils 10^9/liter</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, week, 16, in, ...</td>\n    </tr>\n    <tr>\n      <th>10</th>\n      <td>101</td>\n      <td>NCT01508936</td>\n      <td>Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Weeks 4, 8, 12, and 16</td>\n      <td>FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the v...</td>\n      <td>Baseline (Day 1), Weeks 4, 8, 12, and 16</td>\n      <td>[0.270, 0.240, 0.136, 0.256, 0.179, 0.241, -0.1, -0.2, -0.2]</td>\n      <td>liters</td>\n      <td>[change, from, baseline, in, forced, expiratory, volume, in, 1, second, fev1, at, weeks, 4,, 8,,...</td>\n    </tr>\n    <tr>\n      <th>11</th>\n      <td>102</td>\n      <td>NCT01508936</td>\n      <td>Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...</td>\n      <td>Phase 3</td>\n      <td>[Reslizumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Reslizumab]</td>\n      <td>[Reslizumab 3.0 mg/kg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (% Predicted FEV1...</td>\n      <td>The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a fo...</td>\n      <td>Baseline (Day 1), Weeks 4, 8, 12, and 16</td>\n      <td>[-0.3, -0.2, -0.3, -0.4, -0.3, 0.010, -0.226, 0.036, -0.239]</td>\n      <td>percentage of predicted FEV1</td>\n      <td>[change, from, baseline, in, percent, predicted, forced, expiratory, volume, in, 1, second, %, p...</td>\n    </tr>\n    <tr>\n      <th>12</th>\n      <td>116</td>\n      <td>NCT02135692</td>\n      <td>A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects</td>\n      <td>Phase 3</td>\n      <td>[Mepolizumab, SOC]</td>\n      <td>[Biological: Mepolizumab, Drug: SOC]</td>\n      <td>[Mepolizumab 100 mg, Mepolizumab 100 mg]</td>\n      <td>Secondary</td>\n      <td>Mean Change From Baseline in On-treatment Clinic Pre-bronchodilator FEV1</td>\n      <td>FEV1 is defined as the volume of air forcefully expelled from the lungs in 1 second. Pre-broncho...</td>\n      <td>Baseline (Week 0) to Week 168</td>\n      <td>[35, 3, 0, 1, 77, 199, 28, 0, 1.8, 0.6, 1.5, 2.0, 1.2, 1.8, 1.4]</td>\n      <td>Milliliter</td>\n      <td>[mean, change, from, baseline, in, on-treatment, clinic, pre-bronchodilator, fev1]</td>\n    </tr>\n    <tr>\n      <th>13</th>\n      <td>132</td>\n      <td>NCT02869438</td>\n      <td>A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benraliz...</td>\n      <td>Phase 3</td>\n      <td>[Benralizumab, Placebo]</td>\n      <td>[Drug: Benralizumab, Other: Placebo]</td>\n      <td>[Benralizumab arm, Placebo arm]</td>\n      <td>Primary</td>\n      <td>Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in P...</td>\n      <td>The average over the mean differences between benralizumab and placebo for change from baseline ...</td>\n      <td>From first IP dose to Day 84</td>\n      <td>[0.21, 0.132, 0.22, 0.203, 0.209]</td>\n      <td>Liter</td>\n      <td>[change, from, baseline, visit, 4, to, day, 28, visit, 8),, day, 56, visit, 9),, and, day, 84, v...</td>\n    </tr>\n    <tr>\n      <th>14</th>\n      <td>135</td>\n      <td>NCT02869438</td>\n      <td>A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benraliz...</td>\n      <td>Phase 3</td>\n      <td>[Benralizumab, Placebo]</td>\n      <td>[Drug: Benralizumab, Other: Placebo]</td>\n      <td>[Benralizumab arm, Placebo arm]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1</td>\n      <td>Post baseline visits include Day 3, Day 7, Day 14, Day 28, Day 56, Day 84. [Note: Day 28, 56, 84...</td>\n      <td>From first IP dose to Day 84</td>\n      <td>[0.1, 0.122, 0.11, 0.138, 0.099]</td>\n      <td>Liter</td>\n      <td>[change, from, baseline, visit, 4, to, post, baseline, visits, in, pre-bd, fev1]</td>\n    </tr>\n    <tr>\n      <th>15</th>\n      <td>157</td>\n      <td>NCT03170271</td>\n      <td>A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontroll...</td>\n      <td>Phase 3</td>\n      <td>[Benralizumab (Medi-563), Placebo]</td>\n      <td>[Drug: Benralizumab (Medi-563), Drug: Placebo]</td>\n      <td>[Benralizumab (Medi-563), Placebo]</td>\n      <td>Secondary</td>\n      <td>Change From Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in First Second (FEV1) ...</td>\n      <td>Lung function was assessed by FEV1 which was measured by spirometry. Spirometry was performed by...</td>\n      <td>Baseline (Week 0) and Week 24</td>\n      <td>[123, 107, 27.17, 7.06]</td>\n      <td>Liters (L)</td>\n      <td>[change, from, baseline, in, pre-bronchodilator, bd, forced, expiratory, volume, in, first, seco...</td>\n    </tr>\n    <tr>\n      <th>16</th>\n      <td>170</td>\n      <td>NCT01842607</td>\n      <td>A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects</td>\n      <td>Phase 3</td>\n      <td>[Mepolizumab]</td>\n      <td>[Biological: Mepolizumab]</td>\n      <td>[Mepolizumab Arm]</td>\n      <td>Secondary</td>\n      <td>Mean Change From Baseline in Clinic Pre-bronchodilator FEV1 Over the 52-week Treatment Period</td>\n      <td>FEV1 is defined as the volume of air forcefully expelled from the lungs in 1 second. Pre-broncho...</td>\n      <td>From Baseline and up to Week 52</td>\n      <td>[4, 0, 1, 0, 0, 0, 0, 0, 0]</td>\n      <td>Milliliters (mL)</td>\n      <td>[mean, change, from, baseline, in, clinic, pre-bronchodilator, fev1, over, the, 52-week, treatme...</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "17 individual endpoints were reported concerning change from baseline in FEV1. I note in the 'InterventionName' column that most of the approved biologic treatments available for severe/eosinophilic asthma (reslizumab, benralizumab, mepolizumab) report change from baseline in FEV1. I will use the plot_outcome_search function to plot the number of endpoints returned from this search."
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "plot_outcome_search(search_results)",
            "execution_count": 14,
            "outputs": [
                {
                    "output_type": "display_data",
                    "data": {
                        "text/plain": "<Figure size 1008x432 with 1 Axes>",
                        "image/png": "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\n"
                    },
                    "metadata": {
                        "needs_background": "light"
                    }
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "# \nI will repeat the above process using a different example - I will search for any clinical trials involving 'severe atopic dermatitis', or eczema, an inflammatory skin condition.\n# "
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "atopic_derm = Query()\natopic_derm.build_query()",
            "execution_count": 15,
            "outputs": [
                {
                    "output_type": "stream",
                    "name": "stdout",
                    "text": "\n\nEnter the search query term: \n\nsevere atopic dermatitis\n\n\nSearch Term: \n\nsevere atopic dermatitis\n\n\n\n\nQuerying up to 1,000 trials from clinicaltrials.gov with the following url...\n\nhttps://clinicaltrials.gov/api/query/study_fields?expr=severe+atopic+dermatitis&fields=NCTId%2CBriefTitle%2CCondition%2CPhase%2CStudyType%2CEnrollmentCount%2CStartDate%2CPrimaryCompletionDate%2CEligibilityCriteria%2CInterventionName%2CArmGroupInterventionName%2CArmGroupDescription%2CInterventionArmGroupLabel%2COutcomeMeasureType%2COutcomeMeasureTitle%2COutcomeMeasureDescription%2COutcomeMeasureTimeFrame%2COutcomeMeasurementValue%2COutcomeMeasureUnitOfMeasure&min_rnk=1&max_rnk=1000&fmt=json\n\n\n"
                },
                {
                    "output_type": "execute_result",
                    "execution_count": 15,
                    "data": {
                        "text/plain": "'https://clinicaltrials.gov/api/query/study_fields?expr=severe+atopic+dermatitis&fields=NCTId%2CBriefTitle%2CCondition%2CPhase%2CStudyType%2CEnrollmentCount%2CStartDate%2CPrimaryCompletionDate%2CEligibilityCriteria%2CInterventionName%2CArmGroupInterventionName%2CArmGroupDescription%2CInterventionArmGroupLabel%2COutcomeMeasureType%2COutcomeMeasureTitle%2COutcomeMeasureDescription%2COutcomeMeasureTimeFrame%2COutcomeMeasurementValue%2COutcomeMeasureUnitOfMeasure&min_rnk=1&max_rnk=1000&fmt=json'"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "ad_study_table = atopic_derm.build_study_table(atopic_derm.get_url())\nad_study_table",
            "execution_count": 16,
            "outputs": [
                {
                    "output_type": "stream",
                    "text": "/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:52: FutureWarning: pandas.io.json.json_normalize is deprecated, use pandas.json_normalize instead\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:56: FutureWarning: pandas.io.json.json_normalize is deprecated, use pandas.json_normalize instead\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:84: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:82: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
                    "name": "stderr"
                },
                {
                    "output_type": "execute_result",
                    "execution_count": 16,
                    "data": {
                        "text/plain": "     Rank        NCTId  \\\n0      13  NCT03054428   \n1      14  NCT03831191   \n2      15  NCT03334422   \n3      16  NCT01785602   \n4      17  NCT03443024   \n5      18  NCT02002208   \n6      19  NCT01945086   \n7      20  NCT03334396   \n8      21  NCT03435081   \n9      22  NCT00832585   \n10     23  NCT02925117   \n11     24  NCT02087943   \n12     31  NCT01859988   \n13     37  NCT03733301   \n14     39  NCT01548404   \n15     42  NCT02277743   \n16     45  NCT02260986   \n17     49  NCT02277769   \n18     57  NCT01732510   \n19     63  NCT01639040   \n20     68  NCT03428100   \n21     70  NCT03864627   \n22     72  NCT03363854   \n23     74  NCT03912259   \n24     75  NCT03847389   \n25     80  NCT03349060   \n26     81  NCT03345914   \n27     83  NCT03575871   \n28     91  NCT03055195   \n29     93  NCT03131648   \n30     94  NCT03160885   \n31     96  NCT03720470   \n32    105  NCT01149759   \n33    106  NCT02780167   \n34    111  NCT03496974   \n35    113  NCT02576938   \n36    121  NCT02683928   \n37    127  NCT02755649   \n38    137  NCT03100344   \n39    138  NCT01979016   \n40    139  NCT02210780   \n41    140  NCT02595073   \n42    145  NCT03585296   \n43    152  NCT01299610   \n44    166  NCT02680301   \n45    172  NCT02594098   \n46    175  NCT02525094   \n47    176  NCT03796676   \n48    180  NCT02424253   \n49    182  NCT02347176   \n50    183  NCT01737710   \n51    184  NCT03151148   \n52    191  NCT03562377   \n53    199  NCT01337635   \n54    206  NCT03386032   \n55    210  NCT02795832   \n56    213  NCT02595008   \n57    218  NCT02407756   \n58    223  NCT00179959   \n59    236  NCT03389893   \n60    240  NCT00717769   \n61    245  NCT00119158   \n62    254  NCT00817063   \n63    261  NCT00914186   \n64    264  NCT01132651   \n65    265  NCT03683719   \n66    272  NCT01806662   \n67    273  NCT01049243   \n68    278  NCT01856764   \n69    279  NCT01652885   \n70    280  NCT00886587   \n71    284  NCT03911401   \n72    285  NCT02684097   \n73    286  NCT00819507   \n74    287  NCT01326910   \n75    288  NCT01941537   \n76    290  NCT02324972   \n77    292  NCT01840605   \n78    294  NCT01756898   \n79    296  NCT03908970   \n80    297  NCT02118766   \n81    298  NCT02120833   \n82    302  NCT03954158   \n83    303  NCT01469767   \n84    305  NCT01393158   \n85    311  NCT01037881   \n86    312  NCT00690833   \n87    313  NCT03050294   \n88    317  NCT01996748   \n89    318  NCT02118792   \n90    323  NCT03011892   \n91    325  NCT03903822   \n92    326  NCT02914548   \n93    333  NCT03107611   \n94    335  NCT00828412   \n95    336  NCT02317276   \n96    339  NCT01602341   \n97    340  NCT00375713   \n98    344  NCT02002871   \n99    354  NCT00654355   \n100   356  NCT00557284   \n101   359  NCT01065714   \n102   360  NCT01915914   \n103   361  NCT00924508   \n104   365  NCT00931242   \n105   372  NCT01301508   \n106   376  NCT01064947   \n107   382  NCT00903357   \n108   383  NCT00329784   \n109   388  NCT02289989   \n110   392  NCT02001181   \n111   397  NCT03233529   \n112   398  NCT02752776   \n113   401  NCT00143819   \n\n                                                                                              BriefTitle  \\\n0    Efficacy and Safety of Dupilumab in Participants \u226512 to <18 Years of Age, With Moderate-to-sever...   \n1                               A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis   \n2                 Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n3    Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic ...   \n4          A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis   \n5                                             Effect of OC000459 on Moderate to Severe Atopic Dermatitis   \n6         A Study of Ustekinumab (STELARA\u00ae) in Adult Japanese Participants With Severe Atopic Dermatitis   \n7               A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n8     A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis   \n9    Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Se...   \n10        A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis   \n11         Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis   \n12           Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis   \n13   A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Mo...   \n14              Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis   \n15   Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Der...   \n16   Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Part...   \n17   Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-...   \n18   A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-822...   \n19   Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topi...   \n20   A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderat...   \n21   A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topica...   \n22   Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatiti...   \n23           Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis   \n24                         Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis   \n25   Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Mo...   \n26   Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticostero...   \n27   Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Mod...   \n28        Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis   \n29   Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinuma...   \n30   Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinuma...   \n31   Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderat...   \n32                 Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy   \n33                   Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis   \n34          A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis   \n35          A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis   \n36   To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-se...   \n37   A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermat...   \n38                                                Dose-ranging Study of Nemolizumab in Atopic Dermatitis   \n39   Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis ...   \n40                         Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)   \n41    Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis   \n42                            A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis   \n43   A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also I...   \n44                                                             Topical Steroid Formulation and Wet Wraps   \n45                                                        Secukinumab for Treatment of Atopic Dermatitis   \n46       Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis   \n47                   JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis   \n48                   A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis   \n49    Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis   \n50                                     Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study   \n51                                                   Targeted Microbiome Transplant in Atopic Dermatitis   \n52   Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Tria...   \n53                                                            Vitamin D Deficiency and Atopic Dermatitis   \n54                                                         8-Week Atopic Dermatitis (AD) Treatment Study   \n55   A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects Wi...   \n56   Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients ...   \n57   A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Ag...   \n58   The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity...   \n59                   Effect of Dupilumab (Anti-IL4R\u03b1) on the Host-Microbe Interface in Atopic Dermatitis   \n60   A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects ...   \n61                                                             Combination Therapy for Atopic Dermatitis   \n62                      Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema   \n63                          Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)   \n64                                                                  Cooling Pillow for Atopic Dermatitis   \n65   Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delg...   \n66                                Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis   \n67   A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Derma...   \n68                                                  Topical Roflumilast in Adults With Atopic Dermatitis   \n69                          Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis   \n70   To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic...   \n71                   Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis   \n72                     A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata   \n73                                                                 VANOS Cream and Skin Barrier Function   \n74                              Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema   \n75   Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-09...   \n76                                      Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis   \n77                          A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis   \n78   Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjec...   \n79               Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome   \n80   Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 ...   \n81           A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin   \n82   Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Parti...   \n83    Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis   \n84                                            Apremilast for Atopic Dermatitis - A Pilot Study in Adults   \n85                                                 LEO 29102 Cream in the Treatment of Atopic Dermatitis   \n86      Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis   \n87                                                     Evaluating Treatment Resistant Dermatitis TaroIIR   \n88   Clinical Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in the Treatment o...   \n89   Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 ...   \n90   A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to ...   \n91   Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 ...   \n92                                        Study of OPA-15406 Ointment in Patients With Atopic Dermatitis   \n93   Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel\u00ae Cream, 1% in Mild to Moderate Atopic ...   \n94           Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis   \n95   A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticostero...   \n96            Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis   \n97   Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal\u00ae (Levocetirizine) vs Zyr...   \n98                                                                        Blue Light for Treating Eczema   \n99   Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Re...   \n100                         Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens   \n101  A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons Wi...   \n102  A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Flutic...   \n103                                                           Hydrogel Patch for the Treatment of Eczema   \n104                                                  Study of Apremilast in Atopic or Contact Dermatitis   \n105  Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Derm...   \n106  Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic De...   \n107                                     The Effectiveness of Montelukast on Atopic Dermatitis in Koreans   \n108                                                  Promoting Tolerance to Peanut in High-Risk Children   \n109                              Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis   \n110                                           Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)   \n111                             Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis   \n112          A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.   \n113                                          Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis   \n\n                                Condition             Phase       StudyType  \\\n0    Moderate-to-Severe Atopic Dermatitis           Phase 3  Interventional   \n1                       Atopic Dermatitis           Phase 2  Interventional   \n2                       Atopic Dermatitis           Phase 3  Interventional   \n3                       Atopic Dermatitis           Phase 2  Interventional   \n4                       Atopic Dermatitis           Phase 2  Interventional   \n5                       Atopic Dermatitis           Phase 2  Interventional   \n6                      Dermatitis, Atopic           Phase 2  Interventional   \n7                       Atopic Dermatitis           Phase 3  Interventional   \n8                       Atopic Dermatitis           Phase 3  Interventional   \n9                       Atopic Dermatitis           Phase 4  Interventional   \n10                      Atopic Dermatitis           Phase 2  Interventional   \n11          Dermatitis, Atopic Dermatitis           Phase 2  Interventional   \n12                      Atopic Dermatitis           Phase 2  Interventional   \n13                      Atopic Dermatitis           Phase 3  Interventional   \n14                      Atopic Dermatitis           Phase 2  Interventional   \n15                     Dermatitis, Atopic           Phase 3  Interventional   \n16                      Atopic Dermatitis           Phase 3  Interventional   \n17                     Dermatitis, Atopic           Phase 3  Interventional   \n18                      Atopic Dermatitis           Phase 1  Interventional   \n19                      Atopic Dermatitis           Phase 2  Interventional   \n20                      Atopic Dermatitis           Phase 3  Interventional   \n21                      Atopic Dermatitis           Phase 2  Interventional   \n22                      Atopic Dermatitis           Phase 3  Interventional   \n23                      Atopic Dermatitis           Phase 3  Interventional   \n24                      Atopic Dermatitis  Phase 1, Phase 2  Interventional   \n25                     Dermatitis, Atopic           Phase 3  Interventional   \n26                     Dermatitis, Atopic           Phase 3  Interventional   \n27                     Dermatitis, Atopic           Phase 3  Interventional   \n28                     Dermatitis, Atopic           Phase 2  Interventional   \n29                      Atopic Dermatitis           Phase 3  Interventional   \n30                      Atopic Dermatitis           Phase 3  Interventional   \n31                             Dermatitis           Phase 3  Interventional   \n32                      Atopic Dermatitis    Not Applicable  Interventional   \n33                      Atopic Dermatitis           Phase 2  Interventional   \n34                      Atopic Dermatitis           Phase 2  Interventional   \n35                      Atopic Dermatitis           Phase 2  Interventional   \n36                      Atopic Dermatitis           Phase 2  Interventional   \n37                      Atopic Dermatitis           Phase 3  Interventional   \n38                      Atopic Dermatitis           Phase 2  Interventional   \n39                 Atopic Dermatitis (AD)           Phase 2  Interventional   \n40                      Atopic Dermatitis           Phase 2  Interventional   \n41                      Atopic Dermatitis           Phase 3  Interventional   \n42                      Atopic Dermatitis           Phase 2  Interventional   \n43                     Dermatitis, Atopic           Phase 2  Interventional   \n44                     Dermatitis, Atopic           Phase 4  Interventional   \n45                      Atopic Dermatitis           Phase 2  Interventional   \n46                      Atopic Dermatitis           Phase 2  Interventional   \n47                      Atopic Dermatitis           Phase 3  Interventional   \n48                      Atopic Dermatitis           Phase 2  Interventional   \n49                      Atopic Dermatitis           Phase 2  Interventional   \n50                     Dermatitis, Atopic    Not Applicable  Interventional   \n51                 Atopic Dermatitis (AD)  Phase 1, Phase 2  Interventional   \n52                      Atopic Dermatitis           Phase 2  Interventional   \n53                      Atopic Dermatitis    Not Applicable  Interventional   \n54               Atopic Dermatitis Eczema           Phase 3  Interventional   \n55                      Atopic Dermatitis  Phase 1, Phase 2  Interventional   \n56                     Dermatitis, Atopic           Phase 2  Interventional   \n57                      Atopic Dermatitis           Phase 2  Interventional   \n58                      Atopic Dermatitis           Phase 4  Interventional   \n59                 Atopic Dermatitis (AD)           Phase 4  Interventional   \n60                      Atopic Dermatitis           Phase 2  Interventional   \n61                      Atopic Dermatitis           Phase 4  Interventional   \n62                                 Eczema           Phase 3  Interventional   \n63                      Atopic Dermatitis           Phase 2  Interventional   \n64                      Atopic Dermatitis    Not Applicable  Interventional   \n65                    Chronic Hand Eczema           Phase 2  Interventional   \n66                      Atopic Dermatitis           Phase 2  Interventional   \n67                      Atopic Dermatitis           Phase 4  Interventional   \n68                      Atopic Dermatitis           Phase 2  Interventional   \n69                     Dermatitis, Atopic  Phase 1, Phase 2  Interventional   \n70                      Atopic Dermatitis    Not Applicable  Interventional   \n71                      Atopic Dermatitis           Phase 3  Interventional   \n72                        Alopecia Areata           Phase 2  Interventional   \n73                      Atopic Dermatitis           Phase 4  Interventional   \n74                      Atopic Dermatitis    Not Applicable  Interventional   \n75                      Atopic Dermatitis           Phase 2  Interventional   \n76                      Atopic Dermatitis           Phase 2  Interventional   \n77                             Dermatitis           Phase 3  Interventional   \n78                      Atopic Dermatitis           Phase 2  Interventional   \n79                      Atopic Dermatitis           Phase 3  Interventional   \n80                     Dermatitis, Atopic           Phase 3  Interventional   \n81                                 Eczema           Phase 3  Interventional   \n82                      Atopic Dermatitis           Phase 2  Interventional   \n83                      Atopic Dermatitis           Phase 2  Interventional   \n84                      Atopic Dermatitis           Phase 2  Interventional   \n85                      Atopic Dermatitis           Phase 2  Interventional   \n86                      Atopic Dermatitis           Phase 4  Interventional   \n87                      Atopic Dermatitis           Phase 4  Interventional   \n88                            Otic Eczema           Phase 3  Interventional   \n89                     Dermatitis, Atopic           Phase 3  Interventional   \n90                      Atopic Dermatitis           Phase 2  Interventional   \n91                      Atopic Dermatitis           Phase 2  Interventional   \n92                      Atopic Dermatitis           Phase 2  Interventional   \n93                      Atopic Dermatitis           Phase 3  Interventional   \n94                      Atopic Dermatitis           Phase 4  Interventional   \n95                     Dermatitis, Atopic           Phase 4  Interventional   \n96                     Dermatitis, Atopic           Phase 2  Interventional   \n97                             Dermatitis           Phase 3  Interventional   \n98                                 Eczema    Not Applicable  Interventional   \n99                      Atopic Dermatitis           Phase 4  Interventional   \n100                     Atopic Dermatitis           Phase 4  Interventional   \n101                     Atopic Dermatitis           Phase 4  Interventional   \n102                         Skin Diseases           Phase 4  Interventional   \n103                                Eczema    Not Applicable  Interventional   \n104                     Atopic Dermatitis           Phase 2  Interventional   \n105                    Dermatitis, Atopic           Phase 2  Interventional   \n106                     Atopic Dermatitis           Phase 4  Interventional   \n107                     Atopic Dermatitis    Not Applicable  Interventional   \n108                                Eczema           Phase 2  Interventional   \n109                     Atopic Dermatitis    Not Applicable  Interventional   \n110                    Dermatitis, Atopic           Phase 2  Interventional   \n111                    Dermatitis, Atopic           Phase 2  Interventional   \n112                      Plaque Psoriasis           Phase 4  Interventional   \n113                             Psoriasis           Phase 2  Interventional   \n\n    EnrollmentCount           StartDate PrimaryCompletionDate  \\\n0               251      March 21, 2017         April 4, 2018   \n1               136   February 12, 2019     February 27, 2020   \n2               615   November 27, 2017     December 12, 2018   \n3               103           June 2013         November 2014   \n4               280    January 30, 2018      February 7, 2019   \n5               142        October 2013        September 2015   \n6                79      September 2013         December 2014   \n7               660   November 23, 2017      December 6, 2018   \n8               440   February 20, 2018      December 9, 2019   \n9                 5        January 2008        September 2009   \n10              167    October 25, 2016       August 10, 2017   \n11              191           June 2014          October 2015   \n12              380            May 2013              May 2014   \n13              329   November 16, 2018         July 29, 2019   \n14              109          April 2012            March 2013   \n15              671        October 2014         November 2015   \n16              740      September 2014           August 2015   \n17              708   November 30, 2014      October 31, 2015   \n18               65   December 21, 2012      October 20, 2014   \n19               31           July 2012         December 2012   \n20              463        May 15, 2018     November 25, 2019   \n21               33      March 25, 2019     February 27, 2020   \n22              380   February 22, 2018         March 8, 2019   \n23              165   December 19, 2018     February 14, 2020   \n24                8   September 9, 2019           May 2, 2020   \n25              387    December 7, 2017        March 26, 2019   \n26              367   November 17, 2017         June 20, 2019   \n27              391       June 29, 2018       August 13, 2019   \n28               34      March 21, 2017      December 6, 2017   \n29              802        May 30, 2017        August 7, 2018   \n30              794       June 12, 2017     September 4, 2018   \n31              838    October 29, 2018     December 27, 2019   \n32                9           June 2010         December 2014   \n33              269          April 2016            March 2017   \n34               38        May 21, 2018      December 4, 2018   \n35              124       February 2016         February 2017   \n36               64          March 2016             June 2017   \n37              325    January 31, 2016       January 4, 2017   \n38              226       June 14, 2017         July 19, 2018   \n39               54   December 31, 2013     December 31, 2014   \n40              194      August 5, 2014    September 15, 2015   \n41              124   September 4, 2015      January 17, 2017   \n42               22       July 10, 2018        April 25, 2019   \n43               25    December 1, 2010         March 1, 2011   \n44               40          March 2016            March 2017   \n45               41       November 2015      January 30, 2018   \n46              113     August 15, 2015           May 9, 2016   \n47              287   February 18, 2019         April 8, 2020   \n48               98        May 18, 2015          January 2016   \n49              204    January 23, 2015     November 27, 2015   \n50              368        October 2012              May 2013   \n51               54  September 28, 2017          May 14, 2019   \n52              215       July 13, 2018    September 17, 2019   \n53                7       November 2010         December 2012   \n54               65   November 27, 2017       August 18, 2018   \n55               53           June 2016         March 1, 2017   \n56               24     August 28, 2015     February 22, 2017   \n57               78      March 31, 2015        March 31, 2016   \n58               31      September 2005            March 2011   \n59               72       July 11, 2018         April 3, 2020   \n60              270       July 16, 2008         April 9, 2009   \n61               90        October 2004             June 2005   \n62              599     January 8, 2009        April 26, 2012   \n63              122           June 2009              May 2010   \n64                9            May 2010         December 2010   \n65              258   November 28, 2018         March 6, 2020   \n66               32          March 2013            March 2015   \n67               20          March 2009        September 2009   \n68               40           June 2013            March 2014   \n69               23           July 2012          October 2012   \n70               82          April 2009             June 2009   \n71              251         May 7, 2019     December 13, 2019   \n72               22        January 2016     November 28, 2017   \n73               25        January 2009          January 2010   \n74               90          March 2011              May 2011   \n75               60        October 2013         February 2016   \n76               54       December 2014         November 2015   \n77              303          March 2013         November 2013   \n78              370   November 28, 2012      January 14, 2014   \n79              364      March 25, 2019     December 28, 2019   \n80              763          March 2014            April 2015   \n81               51          March 2014         November 2014   \n82               81       June 15, 2019     December 16, 2019   \n83               10    February 1, 2012       August 17, 2013   \n84               16            May 2009             July 2011   \n85              183       December 2009             June 2010   \n86               41         August 2007         December 2007   \n87               24    February 1, 2017          June 1, 2017   \n88              135       February 2012            March 2012   \n89              764          March 2014            April 2015   \n90              307     January 9, 2017      January 10, 2018   \n91              292        May 13, 2019           May 7, 2020   \n92              200      September 2016             June 2017   \n93              654   February 29, 2016          May 15, 2017   \n94              100          March 2009           August 2009   \n95               11       December 2014         April 6, 2017   \n96               86         August 2012          January 2013   \n97              466        October 2005              May 2006   \n98               21        October 2013            March 2014   \n99               30          April 2008        September 2009   \n100              20          March 2008              May 2009   \n101              20       February 2010         November 2010   \n102             107   December 23, 2013     February 15, 2015   \n103              23           July 2008        September 2011   \n104              10           June 2009            March 2010   \n105              46            May 2011     November 11, 2011   \n106              29       February 2010          January 2012   \n107              54         August 2009           August 2010   \n108             640       December 2006              May 2014   \n109               1       November 2014          January 2017   \n110              69       December 2013        September 2014   \n111              40       July 31, 2017           May 4, 2018   \n112            1660      March 17, 2016        March 28, 2018   \n113              13      September 2005         February 2010   \n\n                                                                                     EligibilityCriteria  \\\n0    Inclusion Criteria:\\n\\nMale or female \u226512 to <18 years of age at time of screening visit\\nDiagno...   \n1    Inclusion Criteria:\\n\\nParticipants must have diagnosis of AD >= 12 months according to the Amer...   \n2    Inclusion Criteria:\\n\\nHave been diagnosed with moderate to severe Atopic Dermatitis for at leas...   \n3    Key Inclusion Criteria:\\n\\nPresence of atopic dermatitis confirmed by Itchy skin condition in th...   \n4    Inclusion Criteria:\\n\\nMale or female, 18 years or older.\\nChronic AD as defined by Hanifin and ...   \n5    Inclusion Criteria:\\n\\nAtopic dermatitis as defined by a score of at least 9 on the Nottingham E...   \n6    Inclusion Criteria:\\n\\nMust be Japanese\\nMust have a diagnosis of atopic dermatitis, with childh...   \n7    Inclusion Criteria:\\n\\nHave been diagnosed with moderate to severe Atopic Dermatitis for at leas...   \n8    Inclusion Criteria:\\n\\nHave a diagnosis of atopic dermatitis (AD) at least 12 months before scre...   \n9    Inclusion Criteria:\\n\\nSigned Informed Consent Form(s)\\nAge of l8 years or older\\nA diagnosis of...   \n10   Inclusion Criteria:\\n\\nAtopic dermatitis with a diagnosis confirmed by a dermatologist (accordin...   \n11   Inclusion Criteria:\\n\\nMales or females, aged \u2265 18 years (\u2265 20 for Japanese subjects) at the tim...   \n12   The inclusion criteria included, but were not limited to, the following:\\n\\nChronic Atopic Derma...   \n13   Inclusion Criteria:\\n\\nHave been diagnosed with moderate to severe atopic dermatitis for at leas...   \n14   Inclusion Criteria:\\n\\nThe inclusion criteria included, but were not limited to the following:\\n...   \n15   Inclusion Criteria:\\n\\nMale or female, 18 years or older\\nChronic AD (according to American Acad...   \n16   Key Inclusion Criteria:\\n\\nChronic AD that had been present for at least 3 years before the scre...   \n17   Inclusion Criteria:\\n\\nChronic AD that has been present for at least 3 years before the screenin...   \n18   Inclusion Criteria:\\n\\nBody weight >=40 kg\\nClinical diagnosis of atopic dermatitis for at least...   \n19   Inclusion Criteria:\\n\\nMale and female patients aged 18 years or older\\nChronic AD that had been...   \n20   Inclusion Criteria:\\n\\nHave been diagnosed with moderate to severe Atopic Eczema (Atopic Dermati...   \n21   Inclusion Criteria:\\n\\nA BMI 18 - 40 kilogram per meter square (kg/m^2), inclusive.\\nDiagnosis o...   \n22   Inclusion Criteria:\\n\\nAge 18 and above.\\nDiagnosis of AD as defined by the Hanifin and Rajka (1...   \n23   Inclusion criteria:\\n\\nMale or female, 18 years or older.\\nAD (according to American Academy of ...   \n24   Inclusion Criteria:\\n\\nMale or female subjects in good general health confirmed by medical histo...   \n25   Inclusion Criteria:\\n\\n12 years of age or older with a minimum body weight of 40 kg\\nDiagnosis o...   \n26   Key Inclusion Criteria:\\n\\nDiagnosis of AD according to the American Academy of Dermatology cons...   \n27   Inclusion Criteria:\\n\\n12 years of age or older with a minimum body weight of 40 kg\\nDiagnosis o...   \n28   Inclusion Criteria\\n\\nAge between 18 and 70 years of age inclusive, at the time of signing the i...   \n29   Inclusion Criteria:\\n\\nAge 18 and above\\nDiagnosis of AD as defined by the Hanifin and Rajka (19...   \n30   Inclusion Criteria:\\n\\nAge 18 and above.\\nDiagnosis of AD as defined by the Hanifin and Rajka (1...   \n31   Inclusion Criteria:\\n\\nMale or female subjects aged 18 years or older at the time of informed co...   \n32   Inclusion Criteria:\\n\\nSevere AD (defined as having a mean SCORAD score> 40,, with significant d...   \n33   Inclusion Criteria:\\n\\nMale or female subjects between 18 75 years of age, inclusive, at time of...   \n34   Inclusion Criteria:\\n\\nWritten informed consent provided by the patient\\nAge 18 years or greater...   \n35   Inclusion Criteria:\\n\\nHave moderate-to-severe Atopic Dermatitis (AD), as determined by all of t...   \n36   Inclusion Criteria:\\n\\nMale or female, 18 years or older\\nAtopic dermatitis involvement that of ...   \n37   Inclusion Criteria:\\n\\nMale or female, 18 years or older\\nSevere, Chronic AD, (according to Amer...   \n38   Inclusion Criteria:\\n\\nMale or female subjects \u2265 18 years (or legal age when higher)\\nChronic AD...   \n39   Inclusion Criteria:\\n\\nMale or female, 18 years or older;\\nChronic AD that had been present for ...   \n40   Key Inclusion Criteria:\\n\\nMale or female adults ages 18 to 64 years with Chronic AD (according ...   \n41   Inclusion Criteria:\\n\\n- male and non-pregnant females, age 6 months or older, with a confirmed ...   \n42   Inclusion Criteria:\\n\\nMale or non-pregnant, non-nursing female subjects \u2265 18 years old at the t...   \n43   Inclusion Criteria:\\n\\nSubjects with a diagnosis of atopic dermatitis who are otherwise healthy....   \n44   Inclusion Criteria:\\n\\nPatients between the ages of 3-17 experiencing a symmetric, bilateral fla...   \n45   Inclusion Criteria:\\n\\nMale or female subject at least 18 years of age\\nIf female, the subject i...   \n46   Inclusion Criteria:\\n\\nAD meeting Hanifin and Rajka criteria\\nAge 18-75 years inclusive at scree...   \n47   Inclusion Criteria:\\n\\nAged between 12 and to 17 with a minimum body weight of 40 kg\\nDiagnosis ...   \n48   Inclusion Criteria:\\n\\nMales and females aged 18-65 years inclusive with physician documented hi...   \n49   Inclusion Criteria:\\n\\nPhysician diagnosis of atopic dermatitis for greater than (>) 1 year\\nAto...   \n50   Inclusion Criteria:\\n\\nEnrolled in the ADRN Registry study;\\nActive, mild to severe AD (lesions ...   \n51   Inclusion Criteria:\\n\\nIndividuals who meet all of the following criteria are eligible for enrol...   \n52   Inclusion Criteria:>\\n\\nAge 18 to 54 years>\\nDiagnosis of AD as defined by Hanifin and Rajka (19...   \n53   Inclusion Criteria:\\n\\nSerum 25-hydroxyvitamin D level <20 ng/ml (<50 nmol/L)\\nDiagnosed with at...   \n54   Inclusion Criteria:\\n\\nIs a generally healthy, male or female, 12-65 years old, inclusive;\\nDiag...   \n55   Inclusion Criteria:\\n\\nHealthy males or females, aged between 18 and 55 years, inclusive (health...   \n56   Inclusion Criteria:\\n\\nPatients with a definite clinical diagnosis of stable atopic dermatitis\\n...   \n57   Key Inclusion Criteria:\\n\\nMale or female patients \u22656 to <18 years of age with a diagnosis of 1....   \n58   Inclusion Criteria:\\n\\n6 months to 17 years of age\\nModerate to severe atopic dermatitis\\n\\nExcl...   \n59   Inclusion Criteria:\\n\\nMust be able to understand and provide informed consent\\nChronic AD, (acc...   \n60   Inclusion Criteria:\\n\\nMale or female participants between 18 and 65 years of age.\\nA diagnosis ...   \n61   Inclusion Criteria:\\n\\nAge 2 to 65 years\\nClinical diagnosis of (Atopic Dermatitis) AD according...   \n62   Inclusion Criteria:\\n\\nall types of chronic hand eczema, lasting for at least 6 months since ini...   \n63   Inclusion Criteria:\\n\\nAdults, males or females, 18 - 65 years of age at the time of obtaining t...   \n64   Inclusion Criteria:\\n\\nDiagnosis of AD by dermatologist\\nAD located on the head and neck\\nInvest...   \n65   Key Inclusion Criteria:\\n\\nAge 18 years or above.\\nDiagnosis of chronic hand eczema defined as h...   \n66   Inclusion Criteria:\\n\\nAre male or female and ages 18-75.\\nHave moderate to severe AD (as determ...   \n67   Inclusion Criteria:\\n\\nMale or female with mild to severe atopic dermatitis, 12 years of age or ...   \n68   Inclusion Criteria:\\n\\nIs male or female between 18 to 65 years of age, inclusive, with atopic d...   \n69   Inclusion Criteria:\\n\\nMale or female 12 to 17 years of age, inclusive\\nClinical diagnosis of at...   \n70   Inclusion Criteria:\\n\\nPost-menarchal female subjects must have a negative urine pregnancy test\\...   \n71   Inclusion Criteria:\\n\\nDiagnosis of AD based on the Japanese Dermatological Association's criter...   \n72   Inclusion Criteria:\\n\\nMale or female, aged from 18 to 75 years, inclusively at the time of sign...   \n73   Inclusion Criteria:\\n\\nDiagnosis of AD according to Hanifin-Rajka criteria (see Appendix B)\\nAge...   \n74   Inclusion Criteria:\\n\\nChildren ages 6 mo- 18 years\\nAny ethnicity\\nDiagnosed with atopic dermat...   \n75   -Inclusion Criteria:\\n\\nSigned and dated an IRB-approved informed consent form before any study-...   \n76   Inclusion Criteria:\\n\\nMale or female aged from 18 to 65 years old\\nConfirmed clinical diagnosis...   \n77   Inclusion Criteria:\\n\\nPatients aged between 7 and 15 years\\nPatients giving assent and whose le...   \n78   Inclusion Criteria:\\n\\nAdult subjects ages 18 to 65 years\\nA diagnosis of atopic dermatitis (AD)...   \n79   Inclusion Criteria:\\n\\nDiagnosis of AD based on the Japanese Dermatological Association's criter...   \n80   Inclusion Criteria:\\n\\nMales or females 2 years and older\\nHas a clinical diagnosis of AD accord...   \n81   Inclusion Criteria\\n\\nAble to comprehend and follow the requirements of the study (including ava...   \n82   Inclusion Criteria:\\n\\nMale or female participants ages; Cohort 1: 12 years and older at the tim...   \n83   Inclusion Criteria:\\n\\nMale or female with mild to severe atopic dermatitis, 12 years of age or ...   \n84   Inclusion Criteria:\\n\\nDisease severity of Moderate, Severe, or Very Severe by Investigator Glob...   \n85   Inclusion Criteria:\\n\\nClinical diagnosis of atopic dermatitis defined according to Hanifin and ...   \n86   Inclusion Criteria:\\n\\nMale or female, age 3 months or greater.\\nSubjects must have diagnosis of...   \n87   Inclusion Criteria:\\n\\nMale or female \u226518 years of age at baseline visit.\\n\\nDocumentation of pl...   \n88   Inclusion Criteria:\\n\\n12 years or older\\nClinical diagnosis of otic eczema suitable for local t...   \n89   Inclusion Criteria:\\n\\nMales or females 2 years and older\\nHas a clinical diagnosis of Atopic De...   \n90   Inclusion Criteria:\\n\\nParticipants diagnosed with atopic dermatitis (AD) as defined by the Hani...   \n91   Inclusion Criteria:\\n\\nClinical diagnosis of Atopic Dermatitis for at least 3 months\\nInvestigat...   \n92   Inclusion Criteria:\\n\\nDiagnosis of atopic dermatitis based on the criteria of Hanifin and Rajka...   \n93   Inclusion Criteria:\\n\\nNon-immuno compromised male or female aged 8 years and older\\nClinical di...   \n94   Inclusion Criteria:\\n\\nat least 3 months of age and less than 13 years of age\\natopic dermatitis...   \n95   Inclusion Criteria:\\n\\nMale or female patients 18-75 years of age\\nAD diagnosed by the Rajka/Han...   \n96   Inclusion Criteria:\\n\\nMale or female 12 to 17 years of age, inclusive\\nClinical diagnosis of at...   \n97   Inclusion Criteria:\\n\\nSubjects diagnosed as having atopic dermatitis, contact dermatitis, pruri...   \n98   Inclusion Criteria:\\n\\nSigned and dated informed consent prior to any study-mandated procedure\\n...   \n99   Inclusion Criteria:\\n\\nMale or female subjects age 2-15.\\nStable or worsening atopic dermatitis ...   \n100  Inclusion Criteria:\\n\\nMild to moderate atopic dermatitis involving greater than or equal to 5% ...   \n101  Inclusion Criteria:\\n\\nDefinitive diagnosis of atopic dermatitis as characterized by Hanifin and...   \n102  Inclusion Criteria:\\n\\nSpecific information regarding warnings, precautions, contraindications, ...   \n103  Inclusion Criteria:\\n\\nSubject has signed the informed consent form and Health Insurance Portabi...   \n104  Inclusion Criteria:\\n\\nMust understand and voluntarily sign an informed consent form.\\nMust be m...   \n105  Inclusion Criteria:\\n\\nClinical diagnosis of atopic dermatitis that has been clinically stable f...   \n106  Inclusion Criteria:\\n\\nFemale subjects of childbearing potential must have a negative urine preg...   \n107  Inclusion Criteria:\\n\\nThe ages of 2 to 6 years old, 54 children with moderate to severe atopic ...   \n108  Inclusion Criteria:\\n\\nAble to consume solid food\\nAllergy to eggs and/or severe eczema\\nInforme...   \n109  Inclusion Criteria:\\n\\nMale or non-pregnant female subjects aged 2-17 years of age.\\nIndividuals...   \n110  Inclusion Criteria:\\n\\nHave a clinical diagnosis of atopic dermatitis (also known as atopic ecze...   \n111  Inclusion Criteria:\\n\\nConfirmed diagnosis of active atopic dermatitis (AD) with at least 6 mont...   \n112  Inclusion Criteria:\\n\\nMen or women aged at least 18 years at time of Screening.\\nModerate to se...   \n113  Inclusion Criteria\\n\\nMust be at least 18 years of age\\nHave psoriasis or eczema on both sides o...   \n\n                                                                                        InterventionName  \\\n0                                                                                   [Dupilumab, Placebo]   \n1                                                                                   [LY3375880, Placebo]   \n2                                                                                 [Baricitinib, Placebo]   \n3                                                                                      [QAW039, Placebo]   \n4                                                                                [Lebrikizumab, Placebo]   \n5                                                                                             [OC000459]   \n6                          [Ustekinumab, Placebo, Concomitant topical medications for atopic dermatitis]   \n7                                                                                 [Baricitinib, Placebo]   \n8                                                                                 [Baricitinib, Placebo]   \n9                                                                                            [Alefacept]   \n10                                                                               [Upadacitinib, Placebo]   \n11                                                            [Apremilast, Apremilast, Placebo, Placebo]   \n12                                                                                  [Dupilumab, Placebo]   \n13                                                        [Baricitinib, Topical corticosteroid, Placebo]   \n14                                                                                  [Placebo, Dupilumab]   \n15                                                                  [Dupilumab, Placebo (for Dupilumab)]   \n16                                    [Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)]   \n17                                                                  [Dupilumab, Placebo (for Dupilumab)]   \n18                                                                                    [MK-8226, Placebo]   \n19                                    [Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)]   \n20                                                        [Baricitinib, Placebo, Topical corticosteroid]   \n21                                                                                     [MOR106, Placebo]   \n22                                                                               [Tralokinumab, Placebo]   \n23                                                         [Dupilumab, Placebo, Emollient (moisturizer)]   \n24                                                             [Clobetasol propionate 0.05% Topical Oil]   \n25                                                     [PF-04965842 100 mg, PF-04965842 200 mg, Placebo]   \n26   [Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatmen...   \n27                                                     [PF-04965842 100 mg, PF-04965842 200 mg, Placebo]   \n28                                                    [Mepolizumab 100 mg, Placebo matching mepolizumab]   \n29                                                                               [Tralokinumab, Placebo]   \n30                                                                               [Tralokinumab, Placebo]   \n31                 [PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo]   \n32                                                                                      [Cyclosporine A]   \n33                                         [PF-04965842, PF-04965842, PF-04965842, PF-04965842, Placebo]   \n34                        [Bermekimab Monoclonal Antibody 200 mg, Bermekimab Monoclonal Antibody 400 mg]   \n35                                                      [Baricitinib, Placebo, Triamcinolone (Optional)]   \n36                                                                                    [GBR 830, Placebo]   \n37                                                                         [Dupilumab, Matching Placebo]   \n38                                                                                [Nemolizumab, Placebo]   \n39                                                            [Dupilumab, Placebo, Background treatment]   \n40                                                                                  [Dupilumab, Placebo]   \n41                                                                                       [DSXS, Placebo]   \n42                                                                                             [ATI-502]   \n43                                                     [GW870086 2.0%, GW870086 0.2%, FP 0.05%, Placebo]   \n44                                               [0.1% triamcinolone CREAM, 0.1% triamcinolone OINTMENT]   \n45                                                                                [Secukinumab, Placebo]   \n46                                                                                   [MEDI9929, Placebo]   \n47                                                                    [Placebo, PF-04965842, PF04965842]   \n48                                                                                [ZPL-3893787, Placebo]   \n49                              [Placebo, Tralokinumab Dose 1, Tralokinumab Dose 2, Tralokinumab Dose 3]   \n50                                      [Fluzone\u00ae Intradermal Vaccine, Fluzone\u00ae (Intramuscular) vaccine]   \n51                                                                          [TMT Lotion, Placebo Lotion]   \n52                                          [Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine]   \n53                                                                                           [Vitamin D]   \n54                                            [Investigational OTC Cream, 0.05% Desonide, Placebo Cream]   \n55                                               [ZPL-5212372 1% w/w Ointment BID, Placebo Ointment BID]   \n56                                                                                                [DSXS]   \n57                                                                                           [Dupilumab]   \n58                  [Sodium hypochlorite (bleach) baths, Mupirocin ointment, Water, Petrolatum Ointment]   \n59                                                                                  [Dupilumab, Placebo]   \n60                                                                                   [SUN13834, Placebo]   \n61                                           [Combination of pimecrolimus and fluticasone, pimecrolimus]   \n62                                                                               [alitretinoin, Placebo]   \n63                                                                                      [TS022, Vehicle]   \n64              [Current standard eczema treatment and standard pillow at night, Chillow cooling pillow]   \n65                                                      [Delgocitinib cream, Delgocitinib cream vehicle]   \n66                                                                                [Ustekinumab, Placebo]   \n67                                                                             [Fluocinonide Cream 0.1%]   \n68                                                               [0.5% Roflumilast Cream, Vehicle Cream]   \n69                                                                         [AN2728 Topical Ointment, 2%]   \n70                                                                          [F# 11054-010, F# 10495-053]   \n71                                                              [0.3% OPA-15406, 1% OPA-15406, Placebos]   \n72                                                                               [Tralokinumab, Placebo]   \n73                                                                                        [Fluocinonide]   \n74                                                                    [Colloidal Oatmeal, Topical Cream]   \n75                                                                         [ILV-094, Placebo Comparator]   \n76                                                                                   [AQX-1125, Placebo]   \n77                                                            [Bepotastine besilate, ketotifen fumarate]   \n78                                              [5 mg ASB17061, Placebo, 10 mg ASB17061, 20 mg ASB17061]   \n79                                                                              [1% OPA-15406, Placebos]   \n80                                               [AN2728 Topical Ointment, 2%, Matching vehicle control]   \n81                                            [EpiCeram\u00ae Skin Barrier Emulsion, Colloidal Oatmeal Cream]   \n82                                  [Crisaborole ointment 2%, Vehicle, Crisaborole ointment 2%, Vehicle]   \n83                                                                                  [Fluocinonide cream]   \n84                                                                                          [Apremilast]   \n85                                                                                  [LEO 29102, Elidel\u00ae]   \n86                                                                     [topical desonide hydrogel 0.05%]   \n87                                                             [Phone calls, Desoximetasone 0.25% spray]   \n88                                                                                      [DF277, Placebo]   \n89                                               [AN2728 Topical Ointment, 2%, Matching vehicle control]   \n90   [Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD, Ruxolitinib 1...   \n91                                                                      [PF-06700841, Vehicle (Placebo)]   \n92                                                                                  [OPA-15406, Placebo]   \n93                                       [Pimecrolimus Cream, 1%, Placebo Cream, Pimecrolimus Cream, 1%]   \n94                                                [EpiCeram Skin Barrier Emulsion, Desonide Cream 0.05%]   \n95                                                                                  [Triamcinolone 0.1%]   \n96   [AN2728 Topical Ointment, 2% QD, AN2728 Topical Ointment, 0.5% QD, AN2728 Topical Ointment, 2% B...   \n97   [Levocetirizine, Cetirizine, Placebo-Levocetirizine, Placebo-Cetirizine, Standard topical steroi...   \n98                                                                                     [PSO-CT02 device]   \n99                                                                                 [tacrolimus ointment]   \n100                                                                               [Montelukast, Placebo]   \n101                                                                   [Hydrogel vehicle, Eucerin Lotion]   \n102                                                                             [Fluticasone propionate]   \n103                                                     [hydrogel patch, Triamcinolone (TAC) 0.1% cream]   \n104                                                                                         [Apremilast]   \n105         [AN2728 ointment, 2%, AN2898 ointment, 1%, AN2898 ointment vehicle, AN2728 ointment vehicle]   \n106                                                                                     [Retapamulin 1%]   \n107                                   [Montelukast first, then placebo, Placebo first, then Montelukast]   \n108                                                                           [Peanut Consumption Group]   \n109                                                              [Oregano extract cream, Hydrocortisone]   \n110                                            [Tofacitinib ointment 20mg/g, Placebo ointment (Vehicle)]   \n111                                            [Crisaborole ointment 2% BID, Placebo ointment (vehicle)]   \n112                                                                                        [Secukinumab]   \n113                                                               [Neuroskin Forte, Placebo Application]   \n\n                                                                                ArmGroupInterventionName  \\\n0                                                      [Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n1                                     [Drug: LY3375880, Drug: LY3375880, Drug: LY3375880, Drug: Placebo]   \n2    [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n3                                                                          [Drug: QAW039, Drug: Placebo]   \n4    [Biological: Lebrikizumab, Drug: Placebo, Biological: Lebrikizumab, Drug: Placebo, Biological: L...   \n5                                                                       [Drug: OC000459, Drug: OC000459]   \n6    [Drug: Ustekinumab, Other: Concomitant topical medications for atopic dermatitis, Drug: Ustekinu...   \n7    [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n8                    [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Placebo]   \n9                                                                                      [Drug: Alefacept]   \n10   [Drug: Upadacitinib, Drug: Placebo, Drug: Upadacitinib, Drug: Placebo, Drug: Upadacitinib, Drug:...   \n11   [Drug: Apremilast, Drug: Apremilast, Drug: Apremilast, Drug: Placebo, Drug: Apremilast, Drug: Pl...   \n12   [Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab, Drug: Placebo, Drug: Dupilumab, Drug: Placebo,...   \n13   [Drug: Baricitinib, Drug: Topical corticosteroid, Drug: Placebo, Drug: Baricitinib, Drug: Topica...   \n14                                                                      [Drug: Placebo, Drug: Dupilumab]   \n15      [Drug: Placebo (for Dupilumab), Drug: Dupilumab, Drug: Dupilumab, Drug: Placebo (for Dupilumab)]   \n16   [Drug: Placebo (for Dupilumab), Other: Topical Corticosteroid (TCS), Drug: Dupilumab, Drug: Plac...   \n17      [Drug: Placebo (for Dupilumab), Drug: Dupilumab, Drug: Placebo (for Dupilumab), Drug: Dupilumab]   \n18   [Drug: MK-8226, Drug: MK-8226, Drug: MK-8226, Drug: MK-8226, Drug: Placebo, Drug: MK-8226, Drug:...   \n19   [Drug: Placebo (for Dupilumab), Other: Topical Corticosteroid (TCS), Drug: Dupilumab, Other: Top...   \n20   [Drug: Baricitinib, Drug: Placebo, Drug: Topical corticosteroid, Drug: Baricitinib, Drug: Placeb...   \n21                                                                         [Drug: Placebo, Drug: MOR106]   \n22   [Drug: Tralokinumab, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, ...   \n23        [Drug: Placebo, Drug: Emollient (moisturizer), Drug: Dupilumab, Drug: Emollient (moisturizer)]   \n24                                                       [Drug: Clobetasol propionate 0.05% Topical Oil]   \n25                                   [Drug: PF-04965842 100 mg, Drug: PF-04965842 200 mg, Drug: Placebo]   \n26   [Drug: Dupilumab, Other: Background Treatment: Topical Corticosteroids, Other: Background Treatm...   \n27                                   [Drug: PF-04965842 100 mg, Drug: PF-04965842 200 mg, Drug: Placebo]   \n28                                        [Drug: Mepolizumab 100 mg, Drug: Placebo matching mepolizumab]   \n29   [Drug: Tralokinumab, Drug: Placebo, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, Drug:...   \n30   [Drug: Tralokinumab, Drug: Placebo, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, Drug:...   \n31   [Drug: PF-04965842 100 mg, Drug: Injectable Placebo, Drug: PF-04965842 200 mg, Drug: Injectable ...   \n32                                                                                [Drug: Cyclosporine A]   \n33           [Drug: PF-04965842, Drug: PF-04965842, Drug: PF-04965842, Drug: PF-04965842, Drug: Placebo]   \n34            [Drug: Bermekimab Monoclonal Antibody 200 mg, Drug: Bermekimab Monoclonal Antibody 400 mg]   \n35    [Drug: Baricitinib, Drug: Triamcinolone (Optional), Drug: Placebo, Drug: Triamcinolone (Optional)]   \n36                                                            [Biological: GBR 830, Biological: Placebo]   \n37                                            [Drug: Matching Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n38                              [Drug: Nemolizumab, Drug: Nemolizumab, Drug: Nemolizumab, Drug: Placebo]   \n39            [Drug: Placebo, Other: Background treatment, Drug: Dupilumab, Other: Background treatment]   \n40                                                                      [Drug: Placebo, Drug: Dupilumab]   \n41                                                                           [Drug: DSXS, Drug: Placebo]   \n42                                                                                       [Drug: ATI-502]   \n43   [Drug: GW870086 2.0%, Drug: GW870086 0.2%, Drug: Placebo, Drug: GW870086 2.0%, Drug: FP 0.05%, D...   \n44   [Drug: 0.1% triamcinolone CREAM, Drug: 0.1% triamcinolone OINTMENT, Drug: 0.1% triamcinolone CRE...   \n45                                                                    [Drug: Secukinumab, Drug: Placebo]   \n46                                                           [Biological: MEDI9929, Biological: Placebo]   \n47                                                  [Drug: Placebo, Drug: PF-04965842, Drug: PF04965842]   \n48                                                                    [Drug: ZPL-3893787, Drug: Placebo]   \n49   [Other: Placebo, Biological: Tralokinumab Dose 1, Biological: Tralokinumab Dose 2, Biological: T...   \n50   [Biological: Fluzone\u00ae Intradermal Vaccine, Biological: Fluzone\u00ae Intradermal Vaccine, Biological:...   \n51                                                        [Biological: TMT Lotion, Drug: Placebo Lotion]   \n52   [Drug: Tralokinumab, Biological: Tdap vaccine, Biological: Meningococcal vaccine, Drug: Placebo,...   \n53                                                                    [Drug: Vitamin D, Drug: Vitamin D]   \n54   [Drug: Investigational OTC Cream, Other: Placebo Cream, Drug: 0.05% Desonide, Other: Placebo Cream]   \n55   [Drug: ZPL-5212372 1% w/w Ointment BID, Drug: Placebo Ointment BID, Drug: ZPL-5212372 1% w/w Oin...   \n56                                                                                          [Drug: DSXS]   \n57                                                                    [Drug: Dupilumab, Drug: Dupilumab]   \n58   [Drug: Sodium hypochlorite (bleach) baths, Drug: Mupirocin ointment, Drug: Water, Drug: Petrolat...   \n59                                      [Drug: Dupilumab, Drug: Placebo, Drug: Dupilumab, Drug: Placebo]   \n60                                                                       [Drug: SUN13834, Drug: Placebo]   \n61           [Drug: pimecrolimus, Drug: Combination of pimecrolimus and fluticasone, Drug: pimecrolimus]   \n62                                                                   [Drug: alitretinoin, Drug: Placebo]   \n63                                                [Drug: Vehicle, Drug: TS022, Drug: TS022, Drug: TS022]   \n64   [Other: Chillow cooling pillow, Other: Current standard eczema treatment and standard pillow at ...   \n65   [Drug: Delgocitinib cream, Drug: Delgocitinib cream, Drug: Delgocitinib cream, Drug: Delgocitini...   \n66                                [Drug: Ustekinumab, Other: Placebo, Drug: Ustekinumab, Other: Placebo]   \n67                                                                       [Drug: Fluocinonide Cream 0.1%]   \n68                                                   [Drug: 0.5% Roflumilast Cream, Drug: Vehicle Cream]   \n69                                                                   [Drug: AN2728 Topical Ointment, 2%]   \n70                                                          [Device: F# 11054-010, Device: F# 10495-053]   \n71                                            [Drug: 0.3% OPA-15406, Drug: 1% OPA-15406, Drug: Placebos]   \n72                                                                   [Drug: Tralokinumab, Drug: Placebo]   \n73                                                                                  [Drug: Fluocinonide]   \n74                                                      [Drug: Colloidal Oatmeal, Device: Topical Cream]   \n75                                                             [Drug: ILV-094, Drug: Placebo Comparator]   \n76                                                                       [Drug: AQX-1125, Drug: Placebo]   \n77                                                [Drug: Bepotastine besilate, Drug: ketotifen fumarate]   \n78                      [Drug: 5 mg ASB17061, Drug: 10 mg ASB17061, Drug: 20 mg ASB17061, Drug: Placebo]   \n79                                                                  [Drug: 1% OPA-15406, Drug: Placebos]   \n80                                   [Drug: AN2728 Topical Ointment, 2%, Drug: Matching vehicle control]   \n81                              [Device: EpiCeram\u00ae Skin Barrier Emulsion, Drug: Colloidal Oatmeal Cream]   \n82          [Drug: Crisaborole ointment 2%, Drug: Vehicle, Drug: Crisaborole ointment 2%, Drug: Vehicle]   \n83                                                                            [Drug: Fluocinonide cream]   \n84                                                                  [Drug: Apremilast, Drug: Apremilast]   \n85   [Drug: LEO 29102, Drug: LEO 29102, Drug: LEO 29102, Drug: LEO 29102, Drug: LEO 29102, Drug: LEO ...   \n86                                                               [Drug: topical desonide hydrogel 0.05%]   \n87   [Drug: Desoximetasone 0.25% spray, Behavioral: Phone calls, Drug: Desoximetasone 0.25% spray, Dr...   \n88                                                                          [Drug: DF277, Drug: Placebo]   \n89                                   [Drug: AN2728 Topical Ointment, 2%, Drug: Matching vehicle control]   \n90   [Drug: Vehicle Cream BID, Drug: Triamcinolone 0.1% Cream BID, Drug: Vehicle Cream BID, Drug: Rux...   \n91   [Drug: PF-06700841, Drug: PF-06700841, Drug: PF-06700841, Drug: PF-06700841, Drug: PF-06700841, ...   \n92                                                     [Drug: OPA-15406, Drug: OPA-15406, Drug: Placebo]   \n93                     [Drug: Pimecrolimus Cream, 1%, Drug: Pimecrolimus Cream, 1%, Drug: Placebo Cream]   \n94                                  [Device: EpiCeram Skin Barrier Emulsion, Drug: Desonide Cream 0.05%]   \n95                                                                            [Drug: Triamcinolone 0.1%]   \n96   [Drug: AN2728 Topical Ointment, 2% QD, Drug: AN2728 Topical Ointment, 0.5% QD, Drug: AN2728 Topi...   \n97   [Drug: Levocetirizine, Drug: Placebo-Cetirizine, Drug: Standard topical steroid (1% hydrocortiso...   \n98                                                                             [Device: PSO-CT02 device]   \n99                                                                           [Drug: tacrolimus ointment]   \n100                                                                   [Drug: Montelukast, Drug: Placebo]   \n101                                                       [Drug: Hydrogel vehicle, Drug: Eucerin Lotion]   \n102                                         [Drug: Fluticasone propionate, Drug: Fluticasone propionate]   \n103                                       [Device: hydrogel patch, Drug: Triamcinolone (TAC) 0.1% cream]   \n104                                                                                   [Drug: Apremilast]   \n105  [Drug: AN2898 ointment, 1%, Drug: AN2898 ointment vehicle, Drug: AN2728 ointment, 2%, Drug: AN27...   \n106                                                                                                   []   \n107  [Drug: Montelukast first, then placebo, Drug: Placebo first, then Montelukast, Drug: Montelukast...   \n108                                                               [Biological: Peanut Consumption Group]   \n109                                                  [Drug: Hydrocortisone, Drug: Oregano extract cream]   \n110                                [Drug: Tofacitinib ointment 20mg/g, Drug: Placebo ointment (Vehicle)]   \n111                                [Drug: Crisaborole ointment 2% BID, Drug: Placebo ointment (vehicle)]   \n112                                                                                  [Drug: Secukinumab]   \n113                                                   [Drug: Neuroskin Forte, Drug: Placebo Application]   \n\n                                                                                     ArmGroupDescription  \\\n0    [Participants received placebo matching dupilumab once every 2 weeks (Q2W) (including doubling t...   \n1    [Induction Period:\\n\\nParticipants received 50 mg LY3375880 administered SC Q4W., Induction Peri...   \n2    [4mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every...   \n3    [Participants received QAW039 450 mg daily by mouth., Participants received matching placebo to ...   \n4    [125 mg Lebrikizumab administered subcutaneously (SC) once Q4W.\\n\\nBaseline: Loading dose 250 mg...   \n5                                                           [50 mg orally once a day, Orally once a day]   \n6                                                                                                     []   \n7    [4 mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally ever...   \n8    [2 mg Baricitinib administered orally every day. Placebo administered orally to maintain the bli...   \n9    [Amevive\u00ae has been shown to be a safe and effective agent in the treatment of psoriasis but may ...   \n10   [Participants randomized to receive placebo once daily (QD) for 16 weeks in Period 1. At Week 16...   \n11   [Apremilast 40 mg administered orally twice daily (BID) for 12 weeks (following dose titration) ...   \n12   [Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a...   \n13   [4 mg Baricitinib administered orally once daily in combination with topical corticosteroids (TC...   \n14   [Placebo (for Dupilumab) once weekly for 12 weeks by subcutaneous (SC) injection., Dupilumab 300...   \n15   [Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a...   \n16   [Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a...   \n17   [Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a...   \n18   [MK-8226 administered intravenously (IV) at a weight-based dose every 2 weeks for a period of 12...   \n19   [Placebo (for Dupilumab) once weekly (QW) for 4 weeks by subcutaneous injection with the backgro...   \n20   [4 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Pl...   \n21   [Participants will receive MOR106 matching placebo via s.c. injection every other week on Day 1,...   \n22   [Week 0 to 16 (initial period):\\n\\nTralokinumab loading SC injection on Day 0 followed by tralok...   \n23   [Placebo matched to dupilumab 600 milligrams (mg) (loading dose), subcutaneously (SC) on Day 1 f...   \n24                [clobetasol propionate 0.05% topical oil applied as thin film twice daily for 2 weeks]   \n25                                                                                                    []   \n26   [Participants will receive dupilumab, dosing regimen 1, Participants will receive dupilumab, dos...   \n27                                                                                                    []   \n28   [Eligible subjects will receive mepolizumab 100 mg subcutaneously every 4 weeks on Day 1, Week 4...   \n29   [Week 0 to Week 16:\\n\\nTwo subcutaneous (SC) injections of tralokinumab as a loading dose on Day...   \n30   [Week 0 to Week 16\\n\\nTwo subcutaneous (SC) injections of tralokinumab as a loading dose on Day ...   \n31   [Once-daily oral PF-04965842 100 mg + Placebo injected subcutaneously once every 2 weeks from Da...   \n32   [5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation a...   \n33   [10 mg of PF-04965842 QD, 30 mg of PF-04965842 QD, 100 mg of PF-04965842 QD, 200 mg of PF-049658...   \n34   [The dose of bermekimab for Group A is 200 mg (2ml of the 100 mg/ml formulation), The dose of be...   \n35   [Administered once daily in multiple oral dose cohorts for 16 weeks\\n\\n(Triamcinolone 0.1% topic...   \n36   [Two doses of GBR 830, 10 mg/kg (solution for infusion, prepared in normal saline) administered ...   \n37   [Participants received one subcutaneous (SC) injection of dupilumab matching placebo once per we...   \n38     [Nemolizumab (low dose), Nemolizumab (medium dose), Nemolizumab (high dose), Nemolizumab placebo]   \n39   [Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a...   \n40   [Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a...   \n41                                                            [DSXS Active treatment, Placebo treatment]   \n42                                              [ATI-502 topical solution applied daily for four weeks.]   \n43   [GW870086 2.0%, GW870086 0.2% &amp; Placebo each applied to a separate specific lesion for 21\u00b12 ...   \n44   [Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on right side and 0.1% triamcin...   \n45   [Secukinumab (300 mg) via subcutaneous injection using 2 prefilled syringes, Placebo via subcuta...   \n46   [Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, w...   \n47                                                                             [Placebo, active, active]   \n48          [30 mg ZPL-3893787 orally once daily for 8 weeks., 1 capsule orally once daily for 8 weeks.]   \n49   [Placebo matched to Tralokinumab will be administered subcutaneously to participants once every ...   \n50   [Non-atopic controls who will receive a single dose of the seasonal 2012-2013 Fluzone\u00ae Intraderm...   \n51   [The targeted microbiome transplant (TMT) lotion will be provided in single-dose sealed packets....   \n52   [Week 0 to 16:> Tralokinumab will be given as subcutaneous injections. >\\n\\n> Subjects will rece...   \n53   [Treatment with cholecalciferol 400 IU daily at home., Treatment with ergocalciferol 300,000 IU ...   \n54   [Investigational Over the Counter (OTC) Cream will be applied topically, twice daily, for 8 week...   \n55   [ZPL-5212372 1% w/w Ointment BID, Placebo Ointment BID, ZPL-5212372 1% w/w Ointment BID, Placebo...   \n56                                                         [treatment with DSXS twice daily for 28 days]   \n57   [Cohort 1 will receive dupilumab dosing regimen 1, Cohort 2 will receive dupilumab dosing regime...   \n58   [Intranasal mupirocin ointment and sodium hypochlorite (bleach) baths, Intranasal petrolatum oin...   \n59   [Participants will receive a loading dose of dupilumab (two 300 mg subcutaneous (subcut) injecti...   \n60                                                                                                    []   \n61                                                                                       [Placebo cream]   \n62   [Patients will receive alitretinoin 30mg capsule for up to 24 weeks, Patients will receive place...   \n63                                                                                                    []   \n64   [This group of subjects will follow their current eczema regimen with the addition of using the ...   \n65   [Delgocitinib cream applied twice daily for 16 weeks., Delgocitinib cream applied twice daily fo...   \n66   [Since there is a crossover design, each patient will be in the treatment arm for 16 weeks of th...   \n67                                                                  [Fluocinonide Cream 0.1% open label]   \n68   [Roflumilast 0.5%, cream, topically, twice daily for up to 15 days., Roflumilast formulation veh...   \n69                                  [AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days]   \n70                                        [F# 11054-010 Investigational Device, F# 10495-053 Atopiclair]   \n71                                                               [Twice daily, Twice daily, Twice daily]   \n72   [Tralokinumab subcutaneous injection every two weeks for 24 weeks, Saline subcutaneous injection...   \n73                                                                                [glucocorticoid cream]   \n74   [Experimental Topical cream applied twice daily (or as needed), Marketed Topical cream applied t...   \n75   [Forty patients will be enrolled in the ILV-094 treatment arm. A loading IV dose of 600 mg of IL...   \n76                                               [1 x AQX-1125 Capsule daily, 1 x placebo capsule daily]   \n77   [Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally tw...   \n78   [Oral administration of low dose ASB17061 taken once daily for 28 consecutive days., Oral admini...   \n79                                                                            [Twice daily, Twice daily]   \n80   [AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days, Matching vehicle control, a...   \n81                                                                                                    []   \n82   [intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion...   \n83                                 [Subjects will apply fluocinonide cream 0.1% twice daily for 5 days.]   \n84   [Patients dosed with 20 mg orally of Apremilast BID for 3 months., Patients dosed with 30 mg ora...   \n85                                                                                                    []   \n86   [Approximately 40 male and female subjects (about 20 age 3 months to <13 years and 20 age 13 and...   \n87   [Participants with atopic dermatitis will receive desoximetasone and no calls., Participants wit...   \n88                          [Two administrations daily for 7 days, Two administrations daily for 7 days]   \n89   [AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days, Matching vehicle control, a...   \n90   [Participants applied vehicle cream twice daily (BID) for 8 weeks DB period., Participants appli...   \n91   [PF-06700841 0.1% cream applied once daily (QD), PF-06700841 0.3% cream applied once daily (QD),...   \n92   [Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily., Subjects were treated...   \n93   [Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for ...   \n94                                                [EpiCeram Skin Barrier Emulsion, Desonide Cream 0.05%]   \n95   [Topical Triamcinolone 0.1% ointment will be provided for twice daily application, during treatm...   \n96   [AN2728 Topical Ointment, 2% applied once daily for 29 days to a target lesion, and AN2728 Topic...   \n97   [Levocetirizine + Cetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for...   \n98   [Irradiation with PSOCT02 device emitting blue light at a wavelength of 453nm, contralateral unt...   \n99                                                                                 [tacrolimus ointment]   \n100                                                                                        [Montelukast]   \n101            [Parallel designed study. Split body treatment, Parallel study design. Split body study.]   \n102  [To evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream (twice per wee...   \n103  [This is a single arm study. Each subject will have 3 target lesions; one treated with TAC 0.1% ...   \n104  [Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 we...   \n105  [AN2898 ointment applied twice daily for 6 weeks to one target lesion, and AN2898 ointment vehic...   \n106                                                                                                   []   \n107  [The group received active medication (montelukast 4 mg or 5mg once daily) for 8 weeks followed ...   \n108  [Participants on this arm will consume peanut protein., Participants on this arm will avoid pean...   \n109  [Intervention: hydrocortisone 1% ointment will be applied to one patient's forearm, Intervention...   \n110                                                                                                   []   \n111                                                                                                   []   \n112  [All patients are received s.c. injections of secukinumab 300 mg at Week 0, 1, 2 and 3 during th...   \n113                                                         [bilateral comparison, bilateral comparison]   \n\n                                                                               InterventionArmGroupLabel  \\\n0                                        [Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]   \n1                                         [150 mg LY3375880, 50 mg LY3375880, 600 mg LY3375880, Placebo]   \n2    [1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...   \n3                                                                                      [QAW039, Placebo]   \n4    [125 milligrams (mg) Lebrikizumab - Every 4 Weeks (Q4W), 250 mg Lebrikizumab - Every 2 Weeks (Q2...   \n5                                                                    [OC000459 Tablets, Placebo Tablets]   \n6         [Ustekinumab 45 mg, Ustekinumab 90 mg, Placebo, Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg]   \n7    [1 mg Baricitinib, 1 mg Baricitinib Maximum Extended Enrollment Cohort, 2 mg Baricitinib, 2 mg B...   \n8    [1 mg Baricitinib, 2 milligram (mg) Baricitinib, 1 mg Baricitinib, 2 milligram (mg) Baricitinib,...   \n9                                                                                            [Alefacept]   \n10   [Placebo, Upadacitinib 15 mg, Upadacitinib 30 mg, Upadacitinib 7.5 mg, Placebo, Upadacitinib 15 ...   \n11   [Apremilast 40 mg, Placebo + Apremilast 40 mg, Apremilast 30 mg, Placebo + Apremilast 30 mg, Pla...   \n12   [Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Dupilum...   \n13   [2 mg Baricitinib, 4 Milligram (mg) Baricitinib, 2 mg Baricitinib, 4 Milligram (mg) Baricitinib,...   \n14                                                                           [Placebo, Dupilumab 300 mg]   \n15   [Dupilumab 300 mg every 2 weeks (q2w), Dupilumab 300 mg once weekly (qw), Dupilumab 300 mg every...   \n16   [Dupilumab 300 mg q2w, Dupilumab 300 mg qw, Dupilumab 300 mg q2w, Placebo qw, Dupilumab 300 mg q...   \n17   [Dupilumab 300 mg every 2 weeks (q2w), Dupilumab 300 mg qw, Dupilumab 300 mg every 2 weeks (q2w)...   \n18   [Part 1: MK-8226 0.3 mg/kg, Part 1: MK-8226 1 mg/kg, Part 1: MK-8226 10 mg/kg, Part 1: MK-8226 3...   \n19                                    [Dupilumab 300 mg QW, Placebo QW, Dupilumab 300 mg QW, Placebo QW]   \n20   [1 mg Baricitinib, 2 mg Baricitinib, 4 mg Baricitinib, 1 mg Baricitinib, 2 mg Baricitinib, 4 mg ...   \n21                                                                              [MOR106 320 mg, Placebo]   \n22   [Placebo (initial)non-respon-> Tralokinumab(continuation A), Tralokinumab(initial)non-respon-> T...   \n23                                [Dupilumab 300 mg Q2W, Placebo Q2W, Dupilumab 300 mg Q2W, Placebo Q2W]   \n24                                                                   [clobetasol propionate topical oil]   \n25                                                     [PF-04965842 100 mg, PF-04965842 200 mg, Placebo]   \n26                     [Group 1, Group 2, Group 3, Group 1, Group 2, Group 3, Group 1, Group 2, Group 3]   \n27                                                     [PF-04965842 100 mg, PF-04965842 200 mg, Placebo]   \n28                                                                                [Mepolizumab, Placebo]   \n29   [Initial treatment period - Tralokinumab Q2W, Maintenance treatment period - Tralokinumab Q2W, M...   \n30   [Initial treatment period - Tralokinumab Q2W, Maintenance treatment period - Tralokinumab Q2W, M...   \n31   [Oral Placebo + Placebo Inj followed by 100 mg PF-04965842, PF-04965842 100 mg + Placebo Inj fol...   \n32                                                                                      [Cyclosporine A]   \n33                                                    [Cohort 1, Cohort 2, Cohort 3, Cohort 4, Cohort 5]   \n34                                                      [Group A: 200 mg cohort, Group B: 400 mg cohort]   \n35                                                          [Baricitinib, Placebo, Baricitinib, Placebo]   \n36                                                                                    [GBR 830, Placebo]   \n37                             [Dupilumab 300 mg Q2W + TCS, Dupilumab 300 mg QW + TCS, Placebo QW + TCS]   \n38                                                                  [Group 1, Group 2, Group 3, Group 4]   \n39                                    [Dupilumab 200 mg qw, Placebo qw, Dupilumab 200 mg qw, Placebo qw]   \n40                                                                     [Dupilumab 300 mg qw, Placebo qw]   \n41                                                       [DSXS topical product, Placebo topical product]   \n42                                                                                             [ATI-502]   \n43   [GW870086 2.0% & FP 0.05%, GW870086 2.0% &amp; 0.2%, GW870086 0.2% & FP 0.05%, GW870086 2.0% &am...   \n44   [Ointment Left/Cream Right, Ointment Right/Cream Left, Ointment Left/Cream Right, Ointment Right...   \n45                                                                                [Secukinumab, Placebo]   \n46                                                                            [MEDI9929 280 mg, Placebo]   \n47                                               [Placebo, PF-04965842 100 mg QD, PF-04965842 200 mg QD]   \n48                                                                                [ZPL-3893787, Placebo]   \n49                              [Placebo, Tralokinumab Dose 1, Tralokinumab Dose 2, Tralokinumab Dose 3]   \n50   [92 Non-atopic controls vaccinated with Fluzone\u00ae Intradermal, Mild AD participants vaccinated wi...   \n51                                                                          [TMT Lotion, Placebo Lotion]   \n52                                 [Tralokinumab, Placebo, Placebo, Tralokinumab, Placebo, Tralokinumab]   \n53                                                        [High dose vitamin D, Standard dose vitamin D]   \n54                [Investigational OTC Cream, 0.05% Desonide Cream, 0.05% Desonide Cream, Placebo Cream]   \n55                                    [Cohort 1a, Cohort 2a, Cohort 3a, Cohort 1b, Cohort 2b, Cohort 3b]   \n56                                                                                [DSXS topical product]   \n57                                                                                  [Cohort 1, Cohort 2]   \n58                                                              [Treatment, Treatment, Placebo, Placebo]   \n59                [Dupilumab w/OLE, Placebo Comparator w/OLE, Dupilumab w/OLE, Placebo Comparator w/OLE]   \n60                                                                                   [SUN13834, Placebo]   \n61                                                     [pimecrolimus cream, pimecrolimus cream, placebo]   \n62                                                                               [Alitretinoin, Placebo]   \n63                           [TS-022 0.005% lotion, TS-022 0.010% lotion, TS-022 0.020% lotion, Vehicle]   \n64                                  [Standard of care (regular pillow at night), Chillow cooling pillow]   \n65   [Delgocitinib cream 1 mg/g, Delgocitinib cream 20 mg/g, Delgocitinib cream 3 mg/g, Delgocitinib ...   \n66   [Placebo Arm (Placebo first, Then Ustekinumab), Treatment Arm (Ustekinumab first, Then Placebo),...   \n67                                                                             [Fluocinonide Cream 0.1%]   \n68                                                               [0.5% Roflumilast Cream, Vehicle Cream]   \n69                                                                         [AN2728 Topical Ointment, 2%]   \n70                                                                                [11054-010, 10495-053]   \n71                                                               [0.3% OPA-15406, 1% OPA-15406, Placebo]   \n72                                                                               [Tralokinumab, Placebo]   \n73                                                                                         [Vanos Cream]   \n74                                                                                [19306-127, 19306-137]   \n75                                                                         [ILV-094, Placebo comparator]   \n76                                                                                   [AQX-1125, Placebo]   \n77                                                                         [TAU-284, ketotifen fumarate]   \n78                                [Low dose ASB17061, Placebo, Middle dose ASB17061, High dose ASB17061]   \n79                                                                               [1% OPA-15406, Placebo]   \n80                                               [AN2728 Topical Ointment, 2%, Matching vehicle control]   \n81                                                                                            [EPI, NEE]   \n82   [Crisaborole ointment 2% twice daily (BID) vs vehicle BID, Crisaborole ointment 2% twice daily (...   \n83                                                                                  [Fluocinonide cream]   \n84                                                                                [20 mg BID, 30 mg BID]   \n85   [LEO 29102 0.03 mg/g cream, LEO 29102 0.1 mg/g cream, LEO 29102 0.3 mg/g cream, LEO 29102 1.0 mg...   \n86                                                                     [topical desonide hydrogel 0.05%]   \n87   [Atopic Dermatitis Intervention, Psoriasis Intervention, Atopic Dermatitis Intervention, Control...   \n88                                                                                      [DF277, Placebo]   \n89                                               [AN2728 Topical Ointment, 2%, Matching vehicle control]   \n90   [DB: Ruxolitinib 0.15% Once Daily (QD), DB: Ruxolitinib 0.5% QD, DB: Ruxolitinib 1.5% QD, DB: Ru...   \n91   [PF-06700841 0.1% cream QD, PF-06700841 0.3% cream BID, PF-06700841 0.3% cream QD, PF-06700841 1...   \n92                                                               [0.3% OPA-15406, 1% OPA-15406, Placebo]   \n93                                                                   [Test, Placebo, Reference Standard]   \n94                                                                                                [1, 2]   \n95                                                                                           [Treatment]   \n96   [AN2728 Topical Ointment, 2% QD vs 0.5% QD, AN2728 Topical Ointment, 2% QD vs 0.5% QD, AN2728 To...   \n97                  [Levocetirizine, Cetirizine, Cetirizine, Levocetirizine, Cetirizine, Levocetirizine]   \n98                                                                                          [Blue light]   \n99                                                                                         [Active Drug]   \n100                                                                                               [1, 2]   \n101                                                                   [Hydrogel vehicle, Eucerin Lotion]   \n102                                                                  [fluticasone propionate, physiogel]   \n103                   [Patch + cream, patch alone, cream alone, Patch + cream, patch alone, cream alone]   \n104                                                                                         [Apremilast]   \n105  [AN2728 ointment, 2%, vs. ointment vehicle, AN2898 ointment, 1%, vs. ointment vehicle, AN2898 oi...   \n106                                                                                                   []   \n107  [Montelukast first, then placebo, Placebo first, then Montelukast, Montelukast first, then place...   \n108                                                                           [Peanut Consumption Group]   \n109                          [Experimental: oregano extract cream, Standard: Hydrocortisone 1% ointment]   \n110                                                                     [Treatment group A, Treatment B]   \n111                                                   [Crisaborole ointment, Placebo ointment (vehicle)]   \n112                                                                                        [Secukinumab]   \n113                                                                                               [1, 2]   \n\n                                                                                      OutcomeMeasureType  \\\n0    [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n1                 [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n2    [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n3                                                                                   [Primary, Secondary]   \n4    [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n5                                                                                   [Primary, Secondary]   \n6    [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n7    [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n8    [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n9                                                                                   [Primary, Secondary]   \n10   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n11                                      [Primary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n12   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n13   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n14     [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n15   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n16   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n17   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n18   [Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Se...   \n19   [Primary, Other Pre-specified, Other Pre-specified, Other Pre-specified, Other Pre-specified, Ot...   \n20   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n21                                                                       [Primary, Secondary, Secondary]   \n22   [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n23   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n24                                          [Primary, Primary, Other Pre-specified, Other Pre-specified]   \n25   [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n26   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n27   [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n28   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n29   [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n30   [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n31   [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n32                                                                                  [Primary, Secondary]   \n33   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n34   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n35                [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n36                    [Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n37   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n38   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n39   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n40   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n41                                                                                  [Primary, Secondary]   \n42                                                                                             [Primary]   \n43   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n44                                                             [Primary, Secondary, Other Pre-specified]   \n45   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n46   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n47   [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n48                                                                                  [Primary, Secondary]   \n49   [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n50   [Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Se...   \n51   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n52                                        [Primary, Primary, Secondary, Secondary, Secondary, Secondary]   \n53                                                                                  [Primary, Secondary]   \n54                                                                                    [Primary, Primary]   \n55   [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Other Pre-specified, O...   \n56                                                                                             [Primary]   \n57                    [Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n58                                                                                             [Primary]   \n59   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n60   [Primary, Primary, Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Second...   \n61                           [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n62   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n63                                       [Primary, Primary, Primary, Primary, Primary, Primary, Primary]   \n64                                                                                  [Primary, Secondary]   \n65                                                                       [Primary, Secondary, Secondary]   \n66                                                                                             [Primary]   \n67                                                                                  [Primary, Secondary]   \n68                                                                       [Primary, Secondary, Secondary]   \n69   [Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Prima...   \n70                                                            [Primary, Secondary, Secondary, Secondary]   \n71                                                                       [Primary, Secondary, Secondary]   \n72                            [Primary, Secondary, Secondary, Secondary, Secondary, Other Pre-specified]   \n73                                                                                  [Primary, Secondary]   \n74                                                            [Primary, Secondary, Secondary, Secondary]   \n75                                                            [Primary, Secondary, Secondary, Secondary]   \n76                                                 [Primary, Secondary, Secondary, Secondary, Secondary]   \n77                                                            [Primary, Secondary, Secondary, Secondary]   \n78   [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n79                                                                       [Primary, Secondary, Secondary]   \n80   [Primary, Primary, Primary, Primary, Secondary, Secondary, Secondary, Other Pre-specified, Other...   \n81   [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n82     [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n83                                                 [Primary, Secondary, Secondary, Secondary, Secondary]   \n84                                                            [Primary, Secondary, Secondary, Secondary]   \n85                                      [Primary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n86                                                                                             [Primary]   \n87                  [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n88                                                            [Primary, Secondary, Secondary, Secondary]   \n89   [Primary, Primary, Primary, Primary, Primary, Primary, Secondary, Secondary, Secondary, Other Pr...   \n90   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n91   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n92   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n93                                                              [Primary, Primary, Secondary, Secondary]   \n94                                                                                             [Primary]   \n95                                                                                             [Primary]   \n96   [Primary, Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Seco...   \n97                                                            [Primary, Secondary, Secondary, Secondary]   \n98   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Other Pre-specified, Other Pre-...   \n99                                                                       [Primary, Secondary, Secondary]   \n100                       [Secondary, Secondary, Primary, Primary, Primary, Primary, Primary, Secondary]   \n101                                                             [Primary, Primary, Secondary, Secondary]   \n102  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n103                                                                                 [Primary, Secondary]   \n104                                                                      [Primary, Secondary, Secondary]   \n105              [Primary, Primary, Primary, Primary, Primary, Other Pre-specified, Other Pre-specified]   \n106                                                           [Primary, Secondary, Secondary, Secondary]   \n107                                                                          [Primary, Primary, Primary]   \n108                            [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary]   \n109                                         [Primary, Primary, Primary, Secondary, Secondary, Secondary]   \n110                                                [Primary, Secondary, Secondary, Secondary, Secondary]   \n111  [Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Secondary, Secondary, S...   \n112  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n113                                                [Primary, Secondary, Secondary, Secondary, Secondary]   \n\n                                                                                     OutcomeMeasureTitle  \\\n0    [Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction Fr...   \n1    [Percentage of Participants Achieving Validated Investigator's Global Assessment for AD (vIGA-AD...   \n2    [Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 ...   \n3    [Change From Baseline in Eczema Area and Severity Index (EASI), Change From Baseline in Eczema A...   \n4    [Percent Change From Baseline in Eczema Area and Severity Index (EASI), Percentage of Participan...   \n5    [Change From Baseline in Eczema Area and Severity Index (EASI) Compared to Placebo at Week 16, R...   \n6    [Percent Change in Eczema Area Severity Index (EASI) Total Score From Baseline at Week 12, Numbe...   \n7    [Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 ...   \n8    [Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (2 mg Baricitin...   \n9    [Change in Eczema Area Severity Index (EASI) Score From Baseline (Week 1) to Week 16., Change in...   \n10   [Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16, Percent...   \n11   [Percentage Change From Baseline in the Eczema Area and Severity Index (EASI) Score at Week 12.,...   \n12   [Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16, Percent...   \n13   [Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 ...   \n14   [Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 12- Last Ob...   \n15   [Percentage of Participants With Investigator's Global Assessment (IGA) Score of \"0\" or \"1\" and ...   \n16   [Percentage of Participants With Investigator's Global Assessment (IGA) Score of \"0\" or \"1\" and ...   \n17   [Percentage of Participants With Investigator's Global Assessment (IGA) Score of \"0\" or \"1\" and ...   \n18   [Number of Participants Who Experienced at Least One Adverse Event, Number of Participants Who D...   \n19   [Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Percentage of Partic...   \n20   [Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (Placebo, 2 mg ...   \n21   [Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Event of Special...   \n22   [Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear)...   \n23   [Number of Participants With Investigator's Global Assessment (IGA) Score of \"0\" or \"1\" and Redu...   \n24   [Number of Participants With HPA Axis Suppression - Serum Cortisol Concentration (Cortrosyn Stim...   \n25   [Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (...   \n26   [Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16, Perce...   \n27   [Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (...   \n28   [Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 and at Le...   \n29   [Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at ...   \n30   [Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at ...   \n31   [Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (...   \n32                                                  [SCORAD Change Score, Change in Epidermal Thickness]   \n33   [Percentage of Participants Achieving the Investigator's Global Assessment (IGA) for Clear (0) o...   \n34   [Number of Patients With Treatment Emergent Adverse Events (TEAEs), Change in Eczema Area and Se...   \n35   [Percentage of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Inde...   \n36   [Incidence of Treatment-Emergent Adverse Events, Change From Baseline in Thickness of Lesional S...   \n37   [Percentage of Participants With Eczema Area and Severity Index (EASI) 75 (\u226575% Improvement From...   \n38   [Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24, Number of Par...   \n39   [Percent Change From Baseline in the Eczema Area Severity Index Score (EASI) to Week 16, Percent...   \n40   [Percentage of Participants With a Positive Response (\u22654-Fold Increase) to Tetanus Toxoid (the A...   \n41   [The Number of Patients in Each Treatment Group That Have Clinical Success, Change From Baseline...   \n42                  [Number of Subjects withTreatment-Emergent Adverse Events (Safety and Tolerability)]   \n43   [Change From Baseline Three Item Severity (TIS) Scores Between GW870086 (0.2% and 2%) Versus Pla...   \n44   [Efficacy of 0.1% Triamcinolone Containing Wet Wrap as an Ointment or as a Cream Formulation in ...   \n45   [Fold-Change in Epidermal Thickness of Lesional Skin, Fold-Change in K16 Expression of Lesional ...   \n46   [Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction Fro...   \n47   [Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear'...   \n48   [Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch), Change From...   \n49   [Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 12, ...   \n50   [Seroprotection, Non-Atopic Dermatitis (AD), Intradermal vs. Moderate to Severe Atopic Dermatiti...   \n51   [Per-Participant Daily Event Rate: Serious and Non-Serious Treatment Emergent Adverse Events (TE...   \n52   [Positive Anti-tetanus Response at Week 16, Positive Anti-meningococcal Response at Week 16, Par...   \n53         [Atopic Dermatitis Severity at the Completion of Treatment, Time to Restart Topical Steroids]   \n54   [Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis...   \n55   [Percent Change From Baseline in EASI Score in Cohort 3, Percent Change From Baseline in EASI Sc...   \n56                                                    [Number of Participants With HPA Axis Suppression]   \n57   [Pharmacokinetics (PK) of Dupilumab: Maximum Plasma Concentration Observed (Cmax) After Single A...   \n58                         [Change in Eczema Area and Severity Index (EASI)Scores According to Location]   \n59   [Comparison by Treatment Assignment in Staphylococcus Aureus Abundance on Lesional Skin, Compari...   \n60   [Baseline of Disease Characteristics Before Treatment With SUN13834 or Placebo in Adult Particip...   \n61   [Change From Baseline in the m-EASI (Eczema Area Severity Index) Score., The Time to Clearance o...   \n62   [Number of Participants Who Responded as Per Physician's Global Assessment (PGA) at Week 24, Per...   \n63   [Change in Pruritis Visual Analog Scale (VAS), Safety and Tolerability of TS-022 Topical Lotion ...   \n64   [Change in Sleep Quality as Measured by a Change in Pittsburgh Sleep Quality Index (PSQI) Survey...   \n65   [Investigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) Score of 0 (Clear) or 1 (Alm...   \n66                                                        [Proportion of SCORAD-50 Response at Week 16.]   \n67   [Change in Investigator Global Assessment of Atopic Dermatitis Severity From Baseline to Day 2/3...   \n68   [Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD), Change Fro...   \n69   [Number of Participants With Local Tolerability Symptoms According to Severity on Baseline, Numb...   \n70   [Eczema Area and Severity Index (EASI) Score on Day 43 - Change From Baseline, Eczema Area and S...   \n71   [Responder Rate of Investigator's Global Assesment (IGA) of Disease Severity, Change From Baseli...   \n72   [Change in Gene Expression Th2/IL-13, \"T22\"/IL-22, S100A7 and S100A8, Th1/IFN-gamma, and Th17/IL...   \n73                       [Change in Eczema Severity and Area Index, Change in Transepidermal Water Loss]   \n74   [Eczema Area and Severity Index (EASI), Interim Eczema Area and Severity Index (EASI), Assessmen...   \n75   [Percentage Change in SCORAD, The Percentage of Patients Who Achieve an Improvement of 50% or Gr...   \n76   [Change From Baseline in Total Lesion Symptom Score (TLSS), Change From Baseline in Investigator...   \n77   [Change From Baseline in Pruritus Score, Change From Baseline in Pruritus Score, Severity of Ato...   \n78   [Number of Investigator's Global Assessment (IGA) Responders at Day 29 Following Treatment With ...   \n79   [Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity, Change From Baselin...   \n80   [Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global...   \n81   [Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline, Investigator's Global At...   \n82   [Change From Baseline in Total Sign Score (TSS) in Target Lesions at Day 15: Crisaborole Ointmen...   \n83                                                                     [IGA, Actigraphy, EASI, BSA, VAS]   \n84   [Change in EASI Scores, Number of Participants in Each IGA Category, Change in Pruritus (Visual ...   \n85   [Absolute Change in Eczema Area and Severity Index (EASI) Score From Baseline (Last Observation ...   \n86                                                            [Investigator Global Assessment at Week 4]   \n87   [Investigator Global Assessment- Atopic Dermatitis, Investigator Global Assessment- Psoriasis, T...   \n88   [Analysis of the Itching Change at the End of Treatment., Change in Signs/ Symptoms, Change in M...   \n89   [Percentage of Participants Who Achieved Success in Investigator's Static Global Assessment (ISG...   \n90   [Mean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 i...   \n91   [Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Mu...   \n92   [Responder Rate of Investigator's Global Assessment(IGA) of Disease Severity at Week4, Change Fr...   \n93   [Proportion of Modified Intent to Treat Subjects With Success on Investigator's Global Assessmen...   \n94                                                   [Change From Baseline in Three Item Severity Score]   \n95   [Change in Blood and Tissue Levels of Biomarkers Following Treatment of Atopic Dermatitis With T...   \n96   [Improvement From Baseline in Atopic Dermatitis Severity Index (ADSI) Score at Day 8, Improvemen...   \n97   [Responder Status According to Pruritus Severity Score (Response = Mild or None in Pruritus Seve...   \n98   [Change From Baseline (Visit 2) of the Sum Score of Local Eczema Rating of the Target Area as Co...   \n99             [Adherence, The % Change From Baseline to Week 4 (or End of Treatment) in the IGA., EASI]   \n100  [Mean Change in Serum and Urinary Inflammatory Marker Levels, Mean Change in Serum IgE Levels, C...   \n101  [Percent Change of Trans Epidermal Water Loss (TEWL) With Use of Eucerin Lotion, Percent Change ...   \n102  [Time to the First Relapse of AD During the Maintenance Phase, Median Time to the First Relapse ...   \n103  [Change in Disease Severity: Percent Change in Mean EASI Score, Number of Adverse Events Associa...   \n104  [Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) ...   \n105  [Atopic Dermatitis Severity Index (ADSI) Score at Baseline (Day 1), Atopic Dermatitis Severity I...   \n106  [Bacteriological Culture, Skin Infection Rating Scale (SIRS), Investigator Assessment of Clinica...   \n107                           [Changes in SCORAD Index, Changes in Urinary LTE4, Changes in Urinary EDN]   \n108  [Number of Participants With Peanut Allergy at 60 Months of Age - by Skin Prick Test Stratum, Nu...   \n109  [The Clinical Efficacy Rated by the Patient or Caregiver on Days 0 and 25, Change of the Clinica...   \n110  [Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4, Pr...   \n111  [Change From Baseline in Lesion Total Sign Score (TSS) for Target Lesions Treated With Crisaboro...   \n112  [Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Wee...   \n113  [Change From Baseline in the Visual Analog Scale (VAS) Score for Pruritus (Itching) at 8 Weeks, ...   \n\n                                                                               OutcomeMeasureDescription  \\\n0    [IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical re...   \n1    [vIGA-AD measures participants' overall severity of their atopic dermatitis (AD), based on a sta...   \n2    [The IGA measures the investigator's global assessment of the participants overall severity of t...   \n3    [Investigators assessed presence and severity of erythema, induration/papulation, excoriation, a...   \n4    [The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease ...   \n5    [The EASI scoring system uses a defined process to grade the severity of the signs of eczema and...   \n6    [The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measur...   \n7    [The IGA measures the investigator's global assessment of the participant's overall severity of ...   \n8    [The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease ...   \n9    [The Eczema Area Severity Index (EASI) measures erythema (E), infiltration (I), excoriation (Ex)...   \n10   [EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessm...   \n11   [EASI is a validated composite scoring system integrating the proportion of the body region (are...   \n12   [The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measur...   \n13   [The IGA measures investigators global assessment of the participant's overall severity of their...   \n14   [The EASI score was used to measure the severity and extent of AD and measured erythema, infiltr...   \n15   [IGA is an assessment scale used to determine severity of AD and clinical response to treatment ...   \n16   [IGA is an assessment scale used to determine severity of AD and clinical response to treatment ...   \n17   [IGA is an assessment scale used to determine severity of AD and clinical response to treatment ...   \n18   [An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical in...   \n19   [Any untoward medical occurrence in a subject who received investigational medicinal product (IM...   \n20   [The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease ...   \n21   [An Adverse Events (AE) was any untoward medical occurrence, new or worsening of any pre-existin...   \n22   [IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0...   \n23   [The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point...   \n24   [30-minute Post-stimulation cortisol level \u226418 \u00b5g/100 mL at Day 0 means subject is not enrolled;...   \n25   [IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). ...   \n26   [The IGA was an assessment instrument used in clinical studies to rate the severity of AD global...   \n27   [IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). ...   \n28   [The IGA is a clinical tool for assessing the current state/severity of a participant's atopic d...   \n29   [The IGA is an instrument used in clinical trials to rate the severity of the subject's global A...   \n30   [The IGA is an instrument used in clinical trials to rate the severity of the subject's global A...   \n31   [IGA assessed severity of atopic dermatitis (AD) on a 5 point scale (0 to 4, higher scores indic...   \n32   [SCORAD (\"SCORing Atopic Dermatitis\") is a clinical tool for assessing the severity (i.e., exten...   \n33   [The IGA score quantifies the severity of participants' atopic dermatitis (AD). Scores range fro...   \n34   [Safety and tolerability endpoints were evaluated by monitoring all the adverse events from clin...   \n35   [The EASI 50, defined as \u2265 50% reduction from baseline in EASI score, assesses extent of disease...   \n36   [A treatment-emergent adverse event (TEAE) was defined as any new adverse event (AEs) or worseni...   \n37   [The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measure...   \n38   [EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation,...   \n39   [The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measur...   \n40   [A positive response was defined as a \u2265 4-fold increase from pre-vaccination at baseline in anti...   \n41   [Clinical Success defined using the following scores at Visit 4 (Day 28 \u00b1 2): At least a 2-grade...   \n42      [Treatment emergent adverse events (TEAEs)graded on a 3 point scale of mild, moderate or severe]   \n43   [Three target lesions were selected and each of the 3 target lesions were assessed separately us...   \n44   [Change in atopic dermatitis based on physician global assessment scale: 0=clear; 1=almost clear...   \n45   [Epidermal hyperplasia assessed using change in epidermal thickness at week 16 as compared to ba...   \n46   [The eczema area and severity index (EASI) evaluates 4 natural anatomical regions for severity (...   \n47   [The IGA of Atopic Dermatitis (AD) was scored on a 5-point scale (0-4), reflecting a global cons...   \n48   [The participant used the Pruritus NRS to rate his or her worst itch in the previous 12 hours. T...   \n49   [EASI evaluates 4 natural anatomical regions for severity and extent of key disease signs and fo...   \n50   [The difference in the percent of participants that achieved seroprotection against influenza B ...   \n51   [Per-participant daily event rate of TEAEs was calculated as the number of events per-participan...   \n52   [The antibody response to Tdap vaccine will be assessed by measuring serum anti-tetanus IgG by a...   \n53   [SCORAD at the 6 week study visit. The SCORAD (SCORing Atopic Dermatitis) is a clinical tool use...   \n54   [SCORAD (Severity Scoring of Atopic Dermatitis) Change from Baseline to Week 8 of atopic dermati...   \n55   [The EASI is a validated tool used to measure the severity and extent of atopic eczema (Eczema A...   \n56   [Hypothalamic Pituitary Adrenal (HPA) Axis Response to Cosyntropin demonstrating the absence or ...   \n57   [Peak dupilumab concentration in serum following single dose administration. Analysis was perfor...   \n58   [The proportion of affected body surface area (BSA) was estimated from 4 designated body regions...   \n59   [Staphylococcus aureus (S. aureus) abundance was measured by microbial DNA (femA qPCR) on lesion...   \n60   [Eczema Area and Severity Index (EASI) Score is a composite index including an assessment of dis...   \n61   [Eczema Area severity index (EASI) is a composition of scores based on area of eczema involved, ...   \n62   [The investigator assigned PGA grades according to a 5-point scale (clear [not detectable], almo...   \n63   [Patient reported outcome of pruritis measurement (0-100 mm/min-max)on a change in visual analog...   \n64   [The PSQI is a clinical survey used to measure sleep quality. Seven components related to sleep ...   \n65   [IGA-CHE is an instrument used in clinical trials to rate the severity of subject's global disea...   \n66   [Greater improvement from their baseline objective SCORAD (SCORing Atopic Dermatitis) at Week 16...   \n67   [Use of the Investigator's Global Assessment (IGA) score, a subjective scale measuring disease s...   \n68   [Modified Local SCORAD is the sum of 5 individual indexes; erythema, edema/papulation, oozing/cr...   \n69   [Local tolerability symptoms, burning or stinging, were classified according to severity as: 1) ...   \n70   [The surface and severity of eczema is measured using the Eczema Area and Severity Index (EASI)....   \n71   [The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or s...   \n72   [Change from baseline in cellular, and molecular markers in skin biopsies after treatment. Gene ...   \n73   [The eczema area and severity index (EAS I) is a validated composite score measuring physical si...   \n74   [A regional body surface area tabulation based on severity ranging from 0 (none) to 3 (severe), ...   \n75   [Percentage Change in the Scoring of Atopic Dermatitis (SCORAD) at week 12 compared to baseline ...   \n76   [The TLSS is an assessment of the severity of each of the following three signs: erythema, papul...   \n77   [The pruritus symptoms score were rated on 5-point scale ranging from 0 (none) to 4 (severe)., T...   \n78   [Participants with an IGA score of 0 or 1 were considered IGA responders. The investigator provi...   \n79   [The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or s...   \n80   [ISGA assessed the severity of AD (except scalp and venous access area) on a 5-point scale range...   \n81   [The surface and severity of eczema is measured using the Eczema Area and Severity Index (EASI)....   \n82   [Lesion TSS was an assessment of the target lesion severity, which was based on severity of 4 cl...   \n83   [Investigator's Global Assessment of atopic dermatitis integrates all lesions for overall score....   \n84   [The eczema area and severity index (EASI) is a composite score measuring physical signs of atop...   \n85   [The EASI is a composite score based on the evaluation of four characteristic atopic dermatitis ...   \n86   [The Investigator global assessment at Week 4 is based on an overall scale of 0-4 with 0 being c...   \n87   [Investigator's Global Assessment of atopic dermatitis integrates all lesions for overall score....   \n88   [The analysis of the itching change at the end of treatment (mean itching on days 4-8 compared t...   \n89   [ISGA assessed the severity of AD (except scalp) on a 5-point scale ranged from 0 (clear) to 4 (...   \n90   [EASI is a validated composite scoring system integrating the proportion of the body region (are...   \n91   [EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of...   \n92   [The investigator or sub investigator assessed the skin symptoms using IGA. The investigator or ...   \n93   [Investigator's Global Assessment of Disease Severity Scale: Clear (0) Minor residual discolorat...   \n94   [The average of the sum of scores for erythema, edema/papulation, and excoriation for two target...   \n95   [The blood and skin biomarkers to be evaluated include but are not limited to eosinophils, Immun...   \n96   [ADSI was used to assess the severity of atopic dermatitis (AD) based on five subscale scores of...   \n97   [A participant is a responder if the pruritus severity score is assessed as mild or none, otherw...   \n98   [The investigator rated the key symptoms erythema, induration/papulation/edema, excoriation, lic...   \n99   [adherence to topical therapy in children via MEMS cap in a \"real-life\" clinic population measur...   \n100  [Mean change in levels from baseline to study visit 4 (week 1 compared to week 9)for interleukin...   \n101  [The average of three sequential Tewameter 300 meter readings taken at a minimum of one minute i...   \n102  [Time to the first relapse of AD is defined as the number of days from start of the FP treatment...   \n103  [Percent change in mean EASI score week 0 to week 6: Each lesion was scored using a 12-point mod...   \n104  [Improvement in IGA (Investigator Global Assessment) by two or more points on a five point scale...   \n105  [ADSI score was used to measure the severity of participant's atopic dermatitis (AD) affected le...   \n106  [All participants were cultured for S.aureus (MRSA), S.aureus (MSSA) and S. pyogenes at Baseline...   \n107  [Changes of SCORAD(SCORing Atopic Dermatitis) index after taking Montelukast or placebo drug. SC...   \n108  [At 60 months of age, participants were given an oral food challenge Participants regarded as un...   \n109  [This was measured with two questions. The first one referred to the description of the lesion a...   \n110  [The EASI quantifies the severity of a participant's atopic dermatitis based on both lesion seve...   \n111  [The lesion TSS is an assessment of target lesion severity based on the severity of the followin...   \n112  [The DLQI is a ten item general dermatology disability index designed to assess health-related q...   \n113  [Subjects assessed the level of pruritus (itching) on the left and right sides of their body at ...   \n\n                                                                                 OutcomeMeasureTimeFrame  \\\n0    [Baseline and Week 16, Baseline and Week 16, Baseline and Week 16, Baseline and Week 16, Baselin...   \n1    [Week 16, Week 16, Week 16, Week 16, Baseline, Week 16, Baseline, Week 16, Week 52, Induction Pe...   \n2    [16 Weeks, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 We...   \n3                                                       [Baseline, 12 weeks, Baseline, 4 weeks, 8 weeks]   \n4    [Baseline, Week 16, Week 16, Week 16, Week 16, Week 16, Week 16, Baseline, Week 16, Baseline, We...   \n5                     [EASI was measured at baseline (week 0) and 16 weeks after dosing., over 16 weeks]   \n6    [Baseline and Week 12, Week 12, Baseline and Week 12, Baseline and Week 12, Week 2, 4, 8, 12, 16...   \n7    [16 Weeks, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 We...   \n8    [Week 16, Week 16, Week 16, Week 16, Baseline, Week 16, Week 16, 16 Weeks, Baseline, Week 16, Ba...   \n9                                                                 [Week 1 to week 16, Week 1 to week 16]   \n10   [Baseline and Week 16, Baseline and Week 16, Week 16, Baseline and Weeks 2, 8, and 16, Baseline ...   \n11   [Baseline to Week 12, Baseline to Week 12, Baseline to Week 12, Baseline to Week 4, Baseline to ...   \n12   [Baseline to Week 16, Week 16, Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to We...   \n13   [Week 16, Week 16, Week 16, Baseline, Week 16, Week 16, Week 16, Baseline, Week 16, Baseline, We...   \n14   [Baseline to Week 12, Week 12, Week 12, Baseline to Week 12, Baseline to Week 12, Baseline to We...   \n15   [Week 16, Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to We...   \n16   [Baseline to Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to...   \n17   [Week 16, Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to We...   \n18   [Up to 32 Weeks, Up to 12 Weeks, Baseline, Week 12, Baseline, 48 Hours, Week 2, Week 4, Week 12,...   \n19   [Baseline up to the end of study (up to Day 78), Day 29, Baseline up to Day 29, Day 29, Baseline...   \n20   [Week 16, Week 16, Week 16, Week 16, Baseline, Week 16, Week 16, Week 16, Baseline, Week 16, Bas...   \n21   [Day 1 up to Day 169/Early discontinuation(ED), Day 1, Day 4, Day 15, Day 29, Day 43, Day 57, Da...   \n22   [Week 16, Week 16, Week 0 to Week 16, Week 0 to Week 16, Week 0 to Week 16, Week 0 to Week 16, W...   \n23   [Baseline, Week 16, Baseline, Week 16, Baseline, Week 16, Baseline, Week 16, Baseline, Week 16, ...   \n24   [day 0 and day 15., Days 0, 1, 8 and 15, Days 0, 1, 8 and 15 Efficacy assessment, including ISGA...   \n25   [Baseline, Week 12, Baseline, Week 12, Baseline, Week 2, 4, 8, 12, Baseline, Week 2, 4, 12, Base...   \n26   [Week 16, Week 16, Baseline (Day 1), Week 16, Baseline (Day 1), Week 16, Week 16, Week 16, Week ...   \n27   [Baseline, Week 12, Baseline, Week 12, Baseline, Weeks 2, 4, 8 and 12, Baseline, Week 12, Baseli...   \n28   [Week 16, Baseline (Day 1) and Weeks 4, 8, 12, 16 and 20, Weeks 4, 8, 12, 16 and 20, Up to Week ...   \n29   [At Week 16, At Week 16, Week 0 to Week 16, Week 0 to Week 16, Week 0 to Week 16, At Week 52, At...   \n30   [At Week 16, At Week 16, Week 0 to Week 16, Week 0 to Week 16, Week 0 to Week 16, At Week 52, At...   \n31   [Baseline (the last measurement prior to first dosing on Day 1), Week 12, Baseline, Week 12, Bas...   \n32                                                                                  [12 weeks, 12 weeks]   \n33   [Baseline and Week 12, Baseline and Week 12, Baseline and all scheduled time points except Week ...   \n34   [From Visit 1 (Post-injection) until 7 days after the last administration of the study drug., Gr...   \n35   [Week 16, Baseline, Week 16, Baseline, Week 16, Baseline, Week 16, Baseline, Week 16, Baseline, ...   \n36   [16 weeks, Day 1, before dosing (baseline), and Day 29 and Day 71, after dosing., 71 days, Day 4...   \n37   [Baseline, Week 16, Baseline, Week 16, Baseline, Week 16, Baseline, Week 16, Baseline to Week 16...   \n38   [From Baseline to Week 24, Week 24, From Week 1 to Week 24, Baseline, Week 24, Baseline, Week 24...   \n39   [Baseline to Week 16, Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to Week 16, Ba...   \n40   [Week 16, Week 16, Week 16, Week 16, Week 16, Week 16, Baseline to Week 16, Baseline to Week 16,...   \n41                                                                                    [28 days, 28 days]   \n42                                                                                             [8 weeks]   \n43   [Baseline (Day 1) and Day 22, Days 2, 3, 7, and 14, Days 2, 3, 7, 14 and 22, Upto Day 21, Up to ...   \n44                                                                        [3-5 days, 3-5 days, 3-5 days]   \n45   [at Week 16, at Week 16, Week 4, Week 16, Week 32, Week 52, Week 4, Week 16, Week 32, Week 52, W...   \n46   [Baseline (Day 1) and Week 12, Baseline (Day 1) and Week 12, Baseline (Day 1) and Week 12, Basel...   \n47   [Baseline to Week 12, Baseline to Week 12, Baseline, Weeks 2, 4 and 12, Baseline to Week 12, Bas...   \n48                                                              [Baseline to Week 8, Baseline to Week 8]   \n49   [Baseline (Day 1) and Week 12, Week 12, From Study Drug Administration (Day 1) to Week 22, From ...   \n50   [Day 28 post vaccination, Day 28 Post Vaccination, Day 28 Post Vaccination, Day 28 post vaccinat...   \n51   [Day 0 to Day 8, Day 0 (after initiation of study treatment) through Day 8 (last day of study tr...   \n52   [Week 12 to Week 16, Week 12 to Week 16, Week 0 to Week 16, Week 0 to Week 16, Week 0 to Week 16...   \n53                                                                                    [6 weeks, 6 weeks]   \n54                                                              [Baseline to Week 8, Baseline to Week 8]   \n55   [Day 1 and Day 14, Days 1, 5, 8, 10, and 15, Day 14, Day 14, Day 1 to day 14, End of treatment (...   \n56                                                                                            [28 days.]   \n57   [Day 2, 4, 8, 15, 22, 29, 36, 43, and 50, Day 2, 4, 8, 15, 22, 29, 36, 43, and 50, Pre-dose on D...   \n58                                                                               [Baseline and 3 months]   \n59   [Day 28 (Post treatment initiation), Day 0 (Prior to treatment), 16 weeks, Day 0 (Prior to treat...   \n60   [Pre-dose, Day 8, Day 15, Day 22, Day 29, Follow Up Week 2 and Week 4 post-dose., Day 8, Day 15,...   \n61   [up to 15 days, assessed up to 30 days following drug application, up to one week, up to 15 days...   \n62   [Week 24 (end-of-treatment), Baseline (Week 0) and Week 24 (end-of-treatment), Week 24 (end-of-t...   \n63   [Baseline through Study Day 36 (Visit 7), Baseline through Study Day 36 (Visit 7), baseline thro...   \n64                                                    [Baseline and at 2 weeks, Baseline and at 2 weeks]   \n65                                          [Week 0 to Week 16., Week 0 to Week 16., Week 0 to Week 16.]   \n66                                                                                             [Week 16]   \n67                                                             [Baseline to 3 days, Baseline to 14 days]   \n68                                       [Baseline and Day 15, Baseline and Day 15, Baseline and Day 15]   \n69   [Baseline, Day 2, Day 4, Day 6, Day 8, Day 9, Day 15, Day 22, Day 29, Baseline (Day 1) up to Day...   \n70                      [Baseline to Day 43, Baseline to Day 15, Baseline to Day 43, Baseline to Day 43]   \n71                                                       [At Week 4, Baseline, Week 4, Baseline, Week 4]   \n72   [Baseline and Week 24, Week 24, Baseline and Week 24, Baseline and Week 24, Baseline and Week 24...   \n73                                                                                    [2 Weeks, 2 weeks]   \n74                                                     [3 weeks, Week 2, through Week 3, through Week 3]   \n75                                                              [12 weeks, 12 weeks, 12 weeks, 12 weeks]   \n76                                                    [12 weeks, 12 weeks, 12 weeks, 12 weeks, 12 weeks]   \n77                            [Baseline and 2 weeks, Baseline and 1 weeks, Baseline and 2 weeks, Week 2]   \n78   [Baseline up to 29 days after initial dose., Baseline up to 29 days after initial dose., Baselin...   \n79                                                       [At Week 4, Baseline, Week 4, Baseline, Week 4]   \n80   [Day 29, AEs: Baseline (Day 1) up to Day 29, SAEs: Baseline (Day 1) up to Day 36, Baseline, Day ...   \n81   [Baseline to Day 3, Baseline to Day 3, Baseline to Day 1, Baseline to Day 2, Baseline to Day 7, ...   \n82   [Baseline, Day 15, Baseline, Day 15, Baseline, Day 8, Baseline, Day 8, Day 15, Baseline, Day 2, ...   \n83                                                         [14 days, 14 days, 14 days, 14 days, 14 days]   \n84   [Mean change in EASI score measured at Baseline and Month 3, (if on 20mg arm) or Baseline and Mo...   \n85   [Baseline (Day 0) and end of treatment (Day 28), At end of treatment (Day 28), At end of treatme...   \n86                                                                                              [Week 4]   \n87                                  [1 week, 2 weeks, 1 week, 2 weeks, 1 week, 1 week, 2 weeks, 2 weeks]   \n88              [Baseline and days 4-8, Baseline and days 9-15, Baseline and day 8, Baseline and day 15]   \n89   [Day 29, AEs: Baseline (Day 1) up to Day 29, SAEs: Baseline (Day 1) up to Day 36, Baseline, Day ...   \n90   [Baseline and Week 4, Baseline and Week 4, Baseline and Week 4, Baseline, Week 2 and 8, Week 2, ...   \n91   [Baseline, Week 6, Baseline, Week 6, Baseline, Week 6, Baseline, Weeks 1, 2, 3, 4 and 6, Baselin...   \n92   [At Week 4, Baseline, Week 4, Baseline, Week 4, Baseline, Hour 156, Baseline, Week 4, Baseline, ...   \n93                                                                      [Day 15, Day 15, Day 15, Day 15]   \n94                                                                                 [Baseline to 6 weeks]   \n95                                                                                  [Baseline to Week 8]   \n96   [Baseline, Day 8, Baseline, Day 15, Baseline, Day 22, Baseline, Day 29, Baseline up to Day 29, B...   \n97   [Day 7 and 14, Baseline and at endpoint during the 14 day treatment period, At endpoint during t...   \n98   [at week 4, week 6, week 4, 6, week 6, week 4, 6, week 6, week 0, 2, 4, 6, week 0, 2, 4, 6, over...   \n99                                                                              [Week 4, Week 4, Week 4]   \n100  [Baseline and 9 weeks, Baseline and 9 weeks, Baseline and 9 weeks, Baseline and 9 weeks, Baselin...   \n101                         [Day 1 to Day 14, Day 1 to Day 14, Baseline to 14 days, Baseline to 14 days]   \n102  [From the start of treatment up to Week 20 during the Maintenance Phase, From the start of treat...   \n103                                                                         [Baseline, 6 weeks, 6 weeks]   \n104                                                                       [12 weeks, 12 weeks, 12 weeks]   \n105  [Baseline (Day 1), Day 14, Day 28, Day 42, Baseline (Day 1), Day 28, Baseline (Day 1), Day 14, D...   \n106                                                     [Day 1 and Day 7, Day 1 and Day 7, Day 7, Day 7]   \n107  [18 weeks after patient recruitment, 18 weeks after patient recruitment, 18 weeks after particip...   \n108                        [60 months, 60 months, 60 months, 60 months, 60 months, 60 months, 60 months]   \n109  [From baseline to day 25, Baseline to day 28, Baseline to day 28, Baseline to day 14, On day 7 a...   \n110  [Baseline (pre-dose on Day 1) and Week 4, Week 4, Baseline (pre-dose on Day 1) and Week 4, Basel...   \n111  [Baseline (Day 1), Day 15, Baseline (Day 1), Day 15, Baseline (Day 1), Day 15, Baseline (Day 1),...   \n112  [16 weeks, 52 weeks, 52 weeks, Week 16, Week 52, Week 16, Week 52, Week 16, Week 52, Week 16 and...   \n113                                                        [8 weeks, 8 weeks, 8 weeks, 8 weeks, 8 weeks]   \n\n                                                                                 OutcomeMeasurementValue  \\\n0    [2.4, 17.9, 24.4, 8.2, 38.1, 41.5, -23.6, -64.8, -65.9, -19.0, -45.5, -47.9, 9.4, 38.6, 48.8, 4....   \n1    [9.5, 5.0, 5.9, 4.8, 19.0, 15.0, 23.5, 0.0, 4.8, 5.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, -11.45, -4.9...   \n2    [4.5, 10.6, 13.8, 4.5, 8.8, 6.1, 12.8, 17.9, 21.1, 2.5, 6.4, 8.9, 13.0, -28.91, -41.68, -54.80, ...   \n3                                                             [-8.65, -6.95, -6.22, -5.89, -7.49, -5.61]   \n4    [-62.34, -69.21, -72.09, -41.12, 43.3, 56.1, 60.6, 24.3, 26.6, 33.7, 44.6, 15.3, 42.2, 61.2, 61....   \n5                                                                             [-3.8, -6.1, 2.879, 2.646]   \n6    [-37.54, -38.62, -39.39, 0, 0, 0, 8.97, 10.03, 8.71, -1.58, -1.68, -2.59, 10.43, 11.22, 9.45, -2...   \n7    [4.8, 11.4, 16.8, 4.8, 11.8, 8.8, 17.3, 18.7, 24.8, 4.8, 8.7, 10.6, 16.0, -34.82, -48.22, -51.89...   \n8    [8.2, 29.5, 5.4, 12.9, 24.0, 8.2, 12.9, 3.4, 7.5, 20.5, -34.07, -46.66, -54.37, 2.7, 3.4, 14.4, ...   \n9                                                                                              [26.4, 1]   \n10   [-23.0, -39.4, -61.7, -74.4, 9.8, 28.6, 52.4, 69.0, 2.4, 14.3, 31.0, 50.0, 1.7, -29.3, -46.0, -5...   \n11   [-10.98, -25.99, -31.57, 6.3, 3.4, 14.3, 32.8, 31.0, 42.9, -4.83, -10.00, -9.00, 30, 36, 44, 8, ...   \n12   [-75.5, -70.5, -67.4, -64.9, -46.7, -20.2, 33.3, 29.7, 27.9, 21.5, 12.3, 1.6, 50.8, 46.9, 42.6, ...   \n13   [14.7, 23.9, 30.6, 22.9, 43.1, 47.7, 13.8, 16.5, 24.3, -45.08, -58.16, -67.21, 7.3, 11.0, 18.0, ...   \n14   [-23.3, -74.0, 7.4, 40.0, 35.2, 85.5, -6.4, -19.9, -14.7, -49.5, -9.0, -27.4, -9.8, -35.0, -0.9,...   \n15   [10.3, 37.9, 37.2, 14.7, 51.3, 52.5, 12.3, 40.8, 40.3, 17.2, 46.8, 51.7, -26.8, -51.1, -49.0, 6....   \n16   [12.4, 38.7, 39.2, 23.2, 68.9, 63.9, 19.7, 58.8, 50.8, 27.8, 65.7, 62.5, 12.5, 36.0, 40.0, 21.6,...   \n17   [8.5, 36.1, 36.4, 11.9, 44.2, 48.1, 9.5, 36.0, 39.0, 12.8, 50.6, 49.1, -18.1, -47.2, -50.9, 6.3,...   \n18   [8, 6, 6, 7, 7, 10, 7, 0, 1, 1, 0, 0, 0, 1, -5.77, -8.40, -10.20, -7.78, -0.38, 1000, 3300, 9300...   \n19   [70.0, 57.1, 40.0, 28.6, 10.0, 0, 10.0, 0, 50.0, 100.0, -24.7, -70.7, 30.0, 52.4, -30.6, -52.5, ...   \n20   [17.2, 27.6, 31.5, 17.2, 22.6, 9.7, 12.9, 15.1, 21.7, 6.5, 8.6, 10.3, 14.1, -42.69, -60.34, -56....   \n21   [5, 11, 2, 1, 0, 0, 0, 1, 0.149, 61.150, 41.278, 39.473, 42.537, 40.934, 16.593, 9.775, 5.092, 2...   \n22   [98, 33, 141, 45, 113, 43, -37.7, -26.8, -11.7, -8.8, 2, 3, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, ...   \n23   [4, 22, 12, 47, 4, 32, 8, 43, -21.13, -48.59, -1.64, -3.84, -39.44, -75.23, -19.25, -37.76, -5.0...   \n24                                                         [0, 0, 0, 3, 0, 0, 5, 8, 0, 0, 0, 0, 0, 8, 0]   \n25   [23.7, 43.8, 7.9, 39.7, 62.7, 11.8, 20.4, 45.6, 2.7, 32.2, 58.8, 17.2, 34.3, 59.9, 14.4, 37.7, 5...   \n26   [11.4, 32.8, 29.5, 26.8, 69.7, 67.2, -48.6, -82.1, -78.4, -25.9, -54.6, -57.0, 21.1, 60.3, 67.5,...   \n27   [28.4, 38.1, 9.1, 44.5, 61.0, 10.4, 23.1, 35.3, 3.9, 31.4, 50.3, 3.9, 39.1, 51.6, 11.8, 39.7, 49...   \n28   [0, 2, -22.508, -24.556, -30.497, -43.904, -22.372, -42.464, -32.269, -31.921, 1.327, -63.938, 1...   \n29   [95, 14, 150, 25, 119, 20, -25.2, -14.7, -7.1, -5.0, 20, 14, 9, 28, 28, 10, 411, 133, 23, 8, 10,...   \n30   [131, 22, 196, 23, 144, 19, -28.1, -14.0, -8.8, -4.9, 32, 22, 7, 43, 38, 9, 364, 132, 10, 5, 10,...   \n31   [14.0, 36.6, 48.4, 36.5, 27.1, 58.7, 70.3, 58.1, 5.1, 5.9, 7.4, 2.4, 7.9, 8.4, 14.8, 3.3, 6.0, 1...   \n32                                                                                        [33.34, 79.70]   \n33   [6.3, 8.2, 12.3, 27.8, 44.5, -35.22, -31.13, -40.73, -59.04, -82.57, 0.0, 2.1, 2.0, 1.8, 3.7, 3....   \n34   [3, 6, 28.18, 29.79, 22.73, 7.35, 5.45, 22.44, 12.6, 47.1, 0, 7, 1, 11, 6.50, 7.91, 3.66, 2.51, ...   \n35   [37, 57, 61, -10.84, -16.44, -16.04, -45.87, -64.19, -64.69, -11.89, -23.87, -26.54, -0.9, -1.4,...   \n36   [29, 10, 1, 0, 2, 1, 4, 4, 140.56, 124.95, -14.90, -3.02, -26.51, -6.01, 0.67, 1.20, 0.62, 0.75,...   \n37   [29.6, 62.6, 59.1, -46.6, -79.8, -78.2, -25.4, -53.9, -51.7, -29.5, -62.4, -58.3, 14.3, 45.7, 40...   \n38   [-58.4, -72.2, -73.4, -69.2, 13, 23, 31, 20, 3, 9, 10, 6, 6, 19, 21, 17, 4, 19, 27, 22, 11, 22, ...   \n39   [-5.8, -75.2, 0, 37.0, 3.7, 51.9, -0.98, -3.64, -8.36, -56.44, -3.7, -25.2, -5.1, -36.4, -8.2, -...   \n40   [83.7, 83.3, 94.6, 95.6, 87.0, 86.7, 10.3, 44.3, 32.0, 72.2, 19.6, 53.6, -2.11, -4.24, -11.0, -2...   \n41                                                                              [21, 27, -13.81, -13.24]   \n42                                                                                                   [7]   \n43   [-1.99, -2.49, -1.61, -3.11, -0.37, -0.53, -0.45, -0.62, -0.91, -0.80, -0.94, -1.22, -1.43, -1.7...   \n44                                                                         [0.717, 0.589, 9, 16, 14, 39]   \n45   [1.15, 1.5, 1.18, -1, 1.14, -3.96, 1.36, -1.3, 0, 0, 2, 0, 0, 0, 3, 2, 0, 0, 0, 1, 1, 0, 0, 1, 0...   \n46   [48.2, 64.7, 19.8, 24.4, 24.48, 24.05, -11.23, -12.16, 12.8, 19.3, 58.66, 57.68, -19.35, -24.24,...   \n47   [24.5, 41.6, 46.2, 41.5, 68.5, 72.0, 12.6, 27.2, 38.6, 20.7, 31.5, 50.0, 29.8, 52.6, 55.4, -2.0,...   \n48                       [7.3, 7.26, 4.27, 4.6, -3.03, -2.66, 21.39, 20.44, 10.67, 15.06, -10.72, -5.38]   \n49   [-10.78, -13.67, -15.14, -15.72, 11.8, 11.6, 19.5, 26.7, 31, 36, 35, 30, 1, 3, 2, 0, 0, 1, 1, 0,...   \n50   [34.4, 22.5, 84.1, 86.4, 84.7, 73.3, 2.6, 2.0, 22.4, 37.7, 10.1, 9.7, 34.4, 33.7, 84.1, 92.5, 84...   \n51   [0.19, 0.34, 20, 15, 0.06, 0.09, 23, 16, 2.5, 2.2, 2.5, 2.2, 2.2, 1.9, 2.1, 1.9, 2.0, 1.7, 50.0,...   \n52                                 [80, 73, 74, 64, 33, 21, 52, 39, 112, 133, 2, 4, 1, 2, 103, 97, 1, 4]   \n53                                                                                  [33.1, 15.5, NA, NA]   \n54                                                               [-12.2, 9.3, -17.5, -6.0, -20.3, -18.0]   \n55   [-34.24, -34.29, -34.04, -31.03, -34.04, -15.77, -33.94, 3.66, -16.68, -4.96, -27.36, -21.41, -3...   \n56                                                                                         [3, 1, 16, 3]   \n57   [9.91, 14.3, 23.1, 32.4, 104, 160, 362, 330, 10.4, 17.2, 32.8, 42.1, 18.5, 28, 58.8, 60.3, -66.4...   \n58                                                                          [-1.06, -0.57, -4.94, -0.88]   \n59                                                                                       [86.01, 2608.4]   \n60   [12.59, 12.45, 6.01, 3.0, 3.1, 2.6, 2.2, 2.2, 1.9, 3.2, 4.0, 3.0, -1.66, -1.94, -2.88, -4.06, -3...   \n61                                                                              [5.04, 4.77, 9.22, 7.88]   \n62   [58, 14, 60, 30, 118, 44, -53.99, -29.86, 117, 41, -46.56, -24.20, 8.3, 16.9, 83.0, NA, 65.0, 11...   \n63   [-12.4, -15.5, -13.9, -6.2, 9, 11, 10, 11, -0.6, -0.5, -0.6, -0.6, -0.4, -0.5, -0.6, -0.2, -3.1,...   \n64                                                                                      [-1, -2, -1, -1]   \n65                        [11, 4, 19, 20, 4, -39.81, -35.93, -46.69, -41.99, -26.40, NA, NA, 82, 98, NA]   \n66                                                                                                [5, 3]   \n67                                                                                          [-0.72, 2.4]   \n68                                                          [-2.30, -1.75, -18.60, -12.69, -3.05, -1.50]   \n69   [10, 7, 6, 0, 17, 5, 1, 0, 18, 3, 2, 0, 18, 4, 1, 0, 20, 3, 0, 0, 18, 4, 1, 0, 19, 4, 0, 0, 21, ...   \n70                                                [-4.97, -5.01, -3.79, -4.14, 0.78, 0.73, -3.26, -3.29]   \n71                                        [44.58, 47.06, 18.07, -4.97, -6.07, 0.35, -0.80, -0.68, -0.33]   \n72                                          [-0.28, 0.49, 0, 0, 0, 64, 69, 57, 50, 59, 47, 58, 35, 8, 3]   \n73                                                                                         [6.01, 14.35]   \n74   [3.014, 3.359, 1.286, 1.621, 1.310, 1.298, 1.154, 1.064, 38, 38, 3, 4, 1.557, 1.208, 1.840, 1.53...   \n75                                                   [-18.8, -11.7, 22.2, 15.0, -13.8, -8.0, -0.6, -0.3]   \n76   [6.3, 6.6, -1.9, -1.9, 2.6, 2.8, -0.7, -0.8, 5.58, 5.35, -2.84, -2.12, 36.19, 37.21, -12.06, -11...   \n77                                              [-0.669, -0.638, -0.425, -0.510, -0.8, -0.7, 65.6, 65.1]   \n78   [20, 21, 19, 18, 1, 3, 7, 7, 19, 18, 12, 11, 13, 12, 14, 13, 6, 6, 4, 4, 1, 3, 1, 1, 18, 20, 18,...   \n79                                                            [38.46, 12.64, -4.17, -0.08, -0.65, -0.04]   \n80   [32.8, 25.4, 147, 50, 5, 1, 0, 0, 0, 0, 51.7, 40.6, NA, NA, 1.7, 1.6, -0.7, -0.4, 1.8, 1.9, -0.7...   \n81   [-1.783, -0.767, -0.441, -0.364, -0.672, -0.438, -1.194, -0.489, -2.410, -1.233, -2.403, -1.833,...   \n82   [7.7, 7.5, 7.1, 7.4, 6.2, 6.5, 7.1, 7.3, -4.5, -2.9, -4.8, -2.7, -3.5, -2.0, -4.7, -2.6, -4.3, -...   \n83                                                                               [1, 85.7, 2.2, 5.5, 41]   \n84                                        [-8.8, -8.2, 0, 1, 2, 8, 3, 1, 1, 0, -32.2, -13.4, -8.3, -6.3]   \n85   [-0.85, -2.13, -1.09, -2.86, -2.41, -2.50, -3.30, 6, 2, 5, 9, 10, 13, 12, 19, 22, 20, 16, 19, 17...   \n86                                                                                                 [2.3]   \n87                      [1.7, 1.5, 2.5, 2.3, 3.8, 4.7, 6.5, 5.8, 3.1, 1.2, 1.1, 1.2, 1.4, 1.3, 7.1, 5.1]   \n88                                              [-1.63, -1.25, -1.80, -1.32, -1.21, -0.78, -1.20, -0.77]   \n89   [31.4, 18.0, 150, 79, 3, 0, 0, 0, 0, 0, 4, 4, 48.7, 56.3, 23.8, 21.9, 19.6, 16.6, 7.9, 5.3, 48.5...   \n90   [-11.90, -71.57, -11.90, -44.92, -52.80, -66.72, -59.54, -44.92, -52.80, -66.72, -71.57, -4.84, ...   \n91   [-44.4, -58.3, -64.6, -70.1, -67.9, -47.6, -58.6, -75.0, 10.8, 29.7, 33.3, 40.5, 44.4, 13.9, 33....   \n92   [14.93, 22.39, 9.09, -2.32, -3.16, -0.15, -6.76, -6.28, 0.90, -0.43, -0.49, -0.06, -1.36, -2.90,...   \n93   [108, 115, 98, 105, 113, 95, 0, 0, 0, 1, 1, 1, 2, 5, 4, 121, 118, 135, 51, 50, 48, 24, 30, 15, 2...   \n94                                                                                          [-2.6, -3.6]   \n95                                                                                                    []   \n96   [8.22, 8.02, 8.13, 8.19, 2.80, 3.63, 4.33, 4.81, 4.02, 4.34, 4.51, 5.36, 3.86, 4.55, 4.70, 5.49,...   \n97                      [131, 134, 37, 38, 1.15, 1.21, 2.13, 2.20, 47, 52, 62, 54, 39, 47, 18, 15, 1, 1]   \n98   [-1.9, -1.3, -0.5, -0.5, 4.7, -0.9, 1.1, 0.3, -3.6, 1.2, -2.6, -15.6, -10.3, -19.6, -7.7, -4.0, ...   \n99                                                                            [56, 72, -33, -33, 2.1, 1]   \n100  [-9.0, -7.9, 2.3, -16.4, 30.9, -58.8, -2.1, -20.42, 100.5, 216.1, -2.0, 0.15, -.11, -.70, -.78, ...   \n101                                                                              [21.4, 4.2, 33.5, 32.3]   \n102  [NA, 142.0, NA, 142.0, 3, 30, 10, 32, 107, -0.4, 2.2, 0.0, 2.2, 2, 1, 2, 1, 2, 2, 2, 2, 1, 0, 39...   \n103                                                                                   [-47, -56, -61, 0]   \n104                                                                                            [2, 1, 2]   \n105  [8.0, 8.3, 8.0, 8.4, 3.8, 4.0, 5.4, 5.6, 2.6, 2.8, 4.3, 5.1, 3.5, 3.0, 3.1, 4.6, 71.4, 68.0, 14....   \n106  [13, 3, 16, 5, 0, 0, 10.0, 1.0, 12, 15, 2, 1.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00,...   \n107                                                              [-3.0, -5.7, -65.9, 87.7, 37.0, -195.8]   \n108  [36, 5, 18, 5, 54, 10, 7.6, 6.6, 50, 54, 106, 115, 134, 132, 71, 30, 96, 102, 28, 25, 22, 22, 29...   \n109                                               [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]   \n110                                    [-81.7, -29.9, 71.4, 20.6, 65.7, 11.8, -72.7, -30.2, -11.4, -4.1]   \n111  [-4.5, -2.1, -1.2787, -0.2881, -0.7295, -0.1849, -1.3267, -0.1994, -0.5484, 0.2128, -2.4495, -1....   \n112  [74.7, 71.3, 61.7, 70.8, 75.3, 73.3, 62.0, 71.9, 18.3, 19.1, 21.2, 19.2, 5.7, 6.3, 9.3, 6.7, 1.2...   \n113                                                     [-52.2, -36.2, 0, 0, 1, 0, -20.7, -14.7, 13, 13]   \n\n                                                                             OutcomeMeasureUnitOfMeasure  \n0    [Percentage of participants, Percentage of participants, Percent change, Percent change, Percent...  \n1    [Percentage of participants, Percentage of Participants, Percentage of participants, Percentage ...  \n2    [percentage of participants, percentage of participants, percentage of participants, percentage ...  \n3                                                                   [Score on a scale, Score on a scale]  \n4    [percent change, percentage of participants, percentage of participants, percentage of participa...  \n5                                                                             [units on a scale, flares]  \n6    [percent change, participants, units on a scale, units on a scale, participants, participants, p...  \n7    [percentage of participants, percentage of participants, percentage of participants, percentage ...  \n8    [percentage of participants, percentage of participants, percentage of participants, percentage ...  \n9                                                                [Scores on a scale., Scores on a scale]  \n10   [percent change, percentage of participants, percentage of participants, percent change, percent...  \n11   [percent change, percentage of participants, percentage of participants, percent change, partici...  \n12   [Percent change, Percentage of participants, Percentage of participants, Percent change, units o...  \n13   [percentage of participants, percentage of participants, percentage of participants, percent cha...  \n14   [percent change, percentage of participants, Percentage of participants, Units on a scale, Perce...  \n15   [percentage of participants, percentage of participants, percentage of participants, percentage ...  \n16   [percentage of participants, percentage of participants, percentage of participants, percentage ...  \n17   [percentage of participants, percentage of participants, percentage of participants, percentage ...  \n18   [participants, participants, Score on a scale, \u03bcg*hr/mL, \u03bcg*hr/mL, \u03bcg/mL, mL/day/kg, mL/kg, days...  \n19   [percentage of participants, percentage of participants, percent change, percentage of participa...  \n20   [percentage of participants, percentage of participants, percentage of participants, percentage ...  \n21                                        [Participants, microgram per milliliter (\u00b5g/mL), Participants]  \n22   [Participants, Participants, Participants, units on a scale, units on a scale, Participants, g, ...  \n23   [Participants, Participants, Participants, Participants, percentage change, units on a scale, pe...  \n24                                                            [Participants, Participants, Participants]  \n25   [percentage of participants, percentage of participants, percentage of participants, percentage ...  \n26   [Percentage of Participants, Percentage of Participants, Percent change, Percent change, Percent...  \n27   [percentage of participants, percentage of participants, percentage of participants, units on a ...  \n28   [Participants, Percent change, Participants, Participants, Participants, Billion cells per liter...  \n29   [Participants, Participants, Participants, units on a scale, units on a scale, Participants, Par...  \n30   [Participants, Participants, Participants, units on a scale, units on a scale, Participants, Par...  \n31   [Percentage of participants, Percentage of participants, Percentage of participants, Percentage ...  \n32                                                                            [Change Score, micrometer]  \n33   [percentage of participants, percent change, percentage of participants, percentage of participa...  \n34   [Participants, score on a scale, (\u03bcg/mL), Participants, Participants, score on a scale, score on...  \n35   [percentage of participants, units on a scale, units on a scale, units on a scale, units on a sc...  \n36   [Participants, micrometer, ratio, percentage of change from baseline, Participants, microgram/mL...  \n37   [Percentage of Participants, Percent Change, Percent Change, Percent Change, Percentage of parti...  \n38   [percentage change, Participants, Participants, Percentage change, units on a scale, Percentage ...  \n39   [percent change, percentage of participants, percentage of participants, units on a scale, perce...  \n40   [Percentage of participants, Percentage of participants, Percentage of participants, Percentage ...  \n41                                                                     [Participants, percentage of BSA]  \n42                                                                                        [Participants]  \n43   [Score on scale, Score on scale, Participants, Participants, Participants, Participants, Partici...  \n44                                                        [units on a scale, Participants, Participants]  \n45   [fold-change, fold-change, Participants, Participants, Participants, percentage change, percenta...  \n46   [Percentage of participants, Percentage of participants, units on a scale, Percentage of partici...  \n47   [Percentage of participants, Percentage of participants, Percentage of participants, Units on a ...  \n48                                                                  [score on a scale, score on a scale]  \n49   [units on a scale, Percentage of participants, Participants, Participants, Participants, Partici...  \n50   [percentage of participants, percentage of participants, percentage of participants, HAI antibod...  \n51   [events per-participant-day, Participants, events per-participant-day, Participants, units on a ...  \n52                           [Participants, Participants, Participants, Participants, AEs, Participants]  \n53                                                                              [score on a scale, days]  \n54                                                                  [units on a scale, units on a scale]  \n55   [percent change from baseline in EASI, percent change from baseline in EASI, participants, Perce...  \n56                                                                                        [Participants]  \n57   [mg/L, Day*mg/L, mg/L, percent change, percent change, Percent change, Percentage of subjects, P...  \n58                                                                                [Change in EASI Score]  \n59                                                                                           [rCFU/cm^2]  \n60   [score on a scale, units on a scale, percent change, units on a scale, percent change, units on ...  \n61   [units of a 0-12 scale, days, days, percentage of participants, percentage of participants, perc...  \n62   [Participants, Percent change, Participants, Percent change, Weeks, Weeks, Days, Participants, P...  \n63   [mm, participants, units on a scale, units on a scale, units on a scale, units on a scale, parti...  \n64                                                                  [units on a scale, units on a scale]  \n65                                                        [Participants, score on a scale, days, median]  \n66                                                                                        [Participants]  \n67                                                                 [Scores on a scale, units on a scale]  \n68                                                      [Scores on a scale, g/m^2/hr, Scores on a scale]  \n69   [participants, participants, participants, participants, participants, participants, participant...  \n70                              [units on a scale, units on a scale, units on a scale, units on a scale]  \n71                                      [percentage of participants, score on a scale, score on a scale]  \n72                 [z-score, percentage change, Participants, percent change, percentage change, events]  \n73                                                                                     [units, G/m^2/hr]  \n74                                  [units on a scale, participants, units on a scale, units on a scale]  \n75   [percentage change, percentage of participants, percentage decline in SCORAD score, score on a s...  \n76            [units on a scale, units on a scale, units on a scale, units on a scale, units on a scale]  \n77                    [units on a scale, units on a scale, units on a scale, percentage of participants]  \n78   [Participants, participants, Units on a scale, Percentage of BSA, Units on a scale, Units on a s...  \n79                                      [percentage of perticipants, score on a scale, score on a scale]  \n80   [percentage of participants, participants, participants, participants, percentage of participant...  \n81   [units on a scale, units on a scale, units on a scale, units on a scale, units on a scale, units...  \n82   [units on a scale, units on a scale, units on a scale, units on a scale, units on a scale, units...  \n83          [units on a scale, Movement count per hour, units on a scale, Percent BSA, units on a scale]  \n84                                  [units on a scale, participants, units on a scale, units on a scale]  \n85          [units on a scale, Participants, Participants, Participants, Participants, units on a scale]  \n86                                                                                    [units on a scale]  \n87   [units on a scale, units on a scale, units on a scale, units on a scale, units on a scale, units...  \n88                              [units on a scale, units on a scale, units on a scale, units on a scale]  \n89   [percentage of participants, participants, participants, participants, participants, percentage ...  \n90   [percent change, percent change, percent change, percent change, percentage of participants, per...  \n91   [Percent change, Percentage of participants, Units on a scale, Percentage of participants, Perce...  \n92   [percentage of participants, score on a scale, mm, score on a scale, score on a scale, percentag...  \n93                                              [Participants, Participants, Participants, Participants]  \n94                                                                                    [units on a scale]  \n95                                                                                                    []  \n96   [units on a scale, units on a scale, units on a scale, units on a scale, Participants, Participa...  \n97                                      [Participants, Units on a scale, Units on a scale, Participants]  \n98   [units on a scale, units on a scale, arbitrary units, arbitrary units, units on a scale, units o...  \n99                              [percentage of required applicaitons, % change in IGA, units on a scale]  \n100  [pg/ml, kU/L, Change of percentage in body involvement, units on a scale, units on a scale, unit...  \n101             [percent change, percent change, Percentage of participants, percentage of participants]  \n102  [Days, Days, Participants, Participants, Participants, Scores on a scale, Scores on a scale, Par...  \n103                                                                  [percentage change, Adverse events]  \n104                                                           [participants, participants, participants]  \n105  [units on a scale, units on a scale, units on a scale, units on a scale, percentage of participa...  \n106                                     [participants, units on a scale, participants, units on a scale]  \n107                                          [units on a scale, Urinary LTE4 (pg/ml), Urine EDN (ng/ml)]  \n108  [Participants, Participants, units on a scale, Participants, Participants, Participants, Partici...  \n109                               [participants, participants, participants, participants, participants]  \n110  [percent change, percentage of participants, percentage of participants, percent change, units o...  \n111  [units on a scale, log2(normalized expression), log2(normalized expression), log2(normalized exp...  \n112  [Percentage of participants, Percentage of participants, Percentage of participants, Percentage ...  \n113                           [percent change, Participants, Participants, percent change, Participants]  ",
                        "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Rank</th>\n      <th>NCTId</th>\n      <th>BriefTitle</th>\n      <th>Condition</th>\n      <th>Phase</th>\n      <th>StudyType</th>\n      <th>EnrollmentCount</th>\n      <th>StartDate</th>\n      <th>PrimaryCompletionDate</th>\n      <th>EligibilityCriteria</th>\n      <th>InterventionName</th>\n      <th>ArmGroupInterventionName</th>\n      <th>ArmGroupDescription</th>\n      <th>InterventionArmGroupLabel</th>\n      <th>OutcomeMeasureType</th>\n      <th>OutcomeMeasureTitle</th>\n      <th>OutcomeMeasureDescription</th>\n      <th>OutcomeMeasureTimeFrame</th>\n      <th>OutcomeMeasurementValue</th>\n      <th>OutcomeMeasureUnitOfMeasure</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>13</td>\n      <td>NCT03054428</td>\n      <td>Efficacy and Safety of Dupilumab in Participants \u226512 to &lt;18 Years of Age, With Moderate-to-sever...</td>\n      <td>Moderate-to-Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>251</td>\n      <td>March 21, 2017</td>\n      <td>April 4, 2018</td>\n      <td>Inclusion Criteria:\\n\\nMale or female \u226512 to &lt;18 years of age at time of screening visit\\nDiagno...</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Participants received placebo matching dupilumab once every 2 weeks (Q2W) (including doubling t...</td>\n      <td>[Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction Fr...</td>\n      <td>[IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical re...</td>\n      <td>[Baseline and Week 16, Baseline and Week 16, Baseline and Week 16, Baseline and Week 16, Baselin...</td>\n      <td>[2.4, 17.9, 24.4, 8.2, 38.1, 41.5, -23.6, -64.8, -65.9, -19.0, -45.5, -47.9, 9.4, 38.6, 48.8, 4....</td>\n      <td>[Percentage of participants, Percentage of participants, Percent change, Percent change, Percent...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>14</td>\n      <td>NCT03831191</td>\n      <td>A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>136</td>\n      <td>February 12, 2019</td>\n      <td>February 27, 2020</td>\n      <td>Inclusion Criteria:\\n\\nParticipants must have diagnosis of AD &gt;= 12 months according to the Amer...</td>\n      <td>[LY3375880, Placebo]</td>\n      <td>[Drug: LY3375880, Drug: LY3375880, Drug: LY3375880, Drug: Placebo]</td>\n      <td>[Induction Period:\\n\\nParticipants received 50 mg LY3375880 administered SC Q4W., Induction Peri...</td>\n      <td>[150 mg LY3375880, 50 mg LY3375880, 600 mg LY3375880, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Percentage of Participants Achieving Validated Investigator's Global Assessment for AD (vIGA-AD...</td>\n      <td>[vIGA-AD measures participants' overall severity of their atopic dermatitis (AD), based on a sta...</td>\n      <td>[Week 16, Week 16, Week 16, Week 16, Baseline, Week 16, Baseline, Week 16, Week 52, Induction Pe...</td>\n      <td>[9.5, 5.0, 5.9, 4.8, 19.0, 15.0, 23.5, 0.0, 4.8, 5.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, -11.45, -4.9...</td>\n      <td>[Percentage of participants, Percentage of Participants, Percentage of participants, Percentage ...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>15</td>\n      <td>NCT03334422</td>\n      <td>Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>615</td>\n      <td>November 27, 2017</td>\n      <td>December 12, 2018</td>\n      <td>Inclusion Criteria:\\n\\nHave been diagnosed with moderate to severe Atopic Dermatitis for at leas...</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[4mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every...</td>\n      <td>[1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 ...</td>\n      <td>[The IGA measures the investigator's global assessment of the participants overall severity of t...</td>\n      <td>[16 Weeks, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 We...</td>\n      <td>[4.5, 10.6, 13.8, 4.5, 8.8, 6.1, 12.8, 17.9, 21.1, 2.5, 6.4, 8.9, 13.0, -28.91, -41.68, -54.80, ...</td>\n      <td>[percentage of participants, percentage of participants, percentage of participants, percentage ...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>16</td>\n      <td>NCT01785602</td>\n      <td>Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic ...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>103</td>\n      <td>June 2013</td>\n      <td>November 2014</td>\n      <td>Key Inclusion Criteria:\\n\\nPresence of atopic dermatitis confirmed by Itchy skin condition in th...</td>\n      <td>[QAW039, Placebo]</td>\n      <td>[Drug: QAW039, Drug: Placebo]</td>\n      <td>[Participants received QAW039 450 mg daily by mouth., Participants received matching placebo to ...</td>\n      <td>[QAW039, Placebo]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[Change From Baseline in Eczema Area and Severity Index (EASI), Change From Baseline in Eczema A...</td>\n      <td>[Investigators assessed presence and severity of erythema, induration/papulation, excoriation, a...</td>\n      <td>[Baseline, 12 weeks, Baseline, 4 weeks, 8 weeks]</td>\n      <td>[-8.65, -6.95, -6.22, -5.89, -7.49, -5.61]</td>\n      <td>[Score on a scale, Score on a scale]</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>17</td>\n      <td>NCT03443024</td>\n      <td>A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>280</td>\n      <td>January 30, 2018</td>\n      <td>February 7, 2019</td>\n      <td>Inclusion Criteria:\\n\\nMale or female, 18 years or older.\\nChronic AD as defined by Hanifin and ...</td>\n      <td>[Lebrikizumab, Placebo]</td>\n      <td>[Biological: Lebrikizumab, Drug: Placebo, Biological: Lebrikizumab, Drug: Placebo, Biological: L...</td>\n      <td>[125 mg Lebrikizumab administered subcutaneously (SC) once Q4W.\\n\\nBaseline: Loading dose 250 mg...</td>\n      <td>[125 milligrams (mg) Lebrikizumab - Every 4 Weeks (Q4W), 250 mg Lebrikizumab - Every 2 Weeks (Q2...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percent Change From Baseline in Eczema Area and Severity Index (EASI), Percentage of Participan...</td>\n      <td>[The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease ...</td>\n      <td>[Baseline, Week 16, Week 16, Week 16, Week 16, Week 16, Week 16, Baseline, Week 16, Baseline, We...</td>\n      <td>[-62.34, -69.21, -72.09, -41.12, 43.3, 56.1, 60.6, 24.3, 26.6, 33.7, 44.6, 15.3, 42.2, 61.2, 61....</td>\n      <td>[percent change, percentage of participants, percentage of participants, percentage of participa...</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>18</td>\n      <td>NCT02002208</td>\n      <td>Effect of OC000459 on Moderate to Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>142</td>\n      <td>October 2013</td>\n      <td>September 2015</td>\n      <td>Inclusion Criteria:\\n\\nAtopic dermatitis as defined by a score of at least 9 on the Nottingham E...</td>\n      <td>[OC000459]</td>\n      <td>[Drug: OC000459, Drug: OC000459]</td>\n      <td>[50 mg orally once a day, Orally once a day]</td>\n      <td>[OC000459 Tablets, Placebo Tablets]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[Change From Baseline in Eczema Area and Severity Index (EASI) Compared to Placebo at Week 16, R...</td>\n      <td>[The EASI scoring system uses a defined process to grade the severity of the signs of eczema and...</td>\n      <td>[EASI was measured at baseline (week 0) and 16 weeks after dosing., over 16 weeks]</td>\n      <td>[-3.8, -6.1, 2.879, 2.646]</td>\n      <td>[units on a scale, flares]</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>19</td>\n      <td>NCT01945086</td>\n      <td>A Study of Ustekinumab (STELARA\u00ae) in Adult Japanese Participants With Severe Atopic Dermatitis</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>79</td>\n      <td>September 2013</td>\n      <td>December 2014</td>\n      <td>Inclusion Criteria:\\n\\nMust be Japanese\\nMust have a diagnosis of atopic dermatitis, with childh...</td>\n      <td>[Ustekinumab, Placebo, Concomitant topical medications for atopic dermatitis]</td>\n      <td>[Drug: Ustekinumab, Other: Concomitant topical medications for atopic dermatitis, Drug: Ustekinu...</td>\n      <td>[]</td>\n      <td>[Ustekinumab 45 mg, Ustekinumab 90 mg, Placebo, Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percent Change in Eczema Area Severity Index (EASI) Total Score From Baseline at Week 12, Numbe...</td>\n      <td>[The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measur...</td>\n      <td>[Baseline and Week 12, Week 12, Baseline and Week 12, Baseline and Week 12, Week 2, 4, 8, 12, 16...</td>\n      <td>[-37.54, -38.62, -39.39, 0, 0, 0, 8.97, 10.03, 8.71, -1.58, -1.68, -2.59, 10.43, 11.22, 9.45, -2...</td>\n      <td>[percent change, participants, units on a scale, units on a scale, participants, participants, p...</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>20</td>\n      <td>NCT03334396</td>\n      <td>A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>660</td>\n      <td>November 23, 2017</td>\n      <td>December 6, 2018</td>\n      <td>Inclusion Criteria:\\n\\nHave been diagnosed with moderate to severe Atopic Dermatitis for at leas...</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[4 mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally ever...</td>\n      <td>[1 mg Baricitinib, 1 mg Baricitinib Maximum Extended Enrollment Cohort, 2 mg Baricitinib, 2 mg B...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 ...</td>\n      <td>[The IGA measures the investigator's global assessment of the participant's overall severity of ...</td>\n      <td>[16 Weeks, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 Weeks, 16 Weeks, 16 Weeks, Baseline, 16 We...</td>\n      <td>[4.8, 11.4, 16.8, 4.8, 11.8, 8.8, 17.3, 18.7, 24.8, 4.8, 8.7, 10.6, 16.0, -34.82, -48.22, -51.89...</td>\n      <td>[percentage of participants, percentage of participants, percentage of participants, percentage ...</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>21</td>\n      <td>NCT03435081</td>\n      <td>A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>440</td>\n      <td>February 20, 2018</td>\n      <td>December 9, 2019</td>\n      <td>Inclusion Criteria:\\n\\nHave a diagnosis of atopic dermatitis (AD) at least 12 months before scre...</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Placebo]</td>\n      <td>[2 mg Baricitinib administered orally every day. Placebo administered orally to maintain the bli...</td>\n      <td>[1 mg Baricitinib, 2 milligram (mg) Baricitinib, 1 mg Baricitinib, 2 milligram (mg) Baricitinib,...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (2 mg Baricitin...</td>\n      <td>[The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease ...</td>\n      <td>[Week 16, Week 16, Week 16, Week 16, Baseline, Week 16, Week 16, 16 Weeks, Baseline, Week 16, Ba...</td>\n      <td>[8.2, 29.5, 5.4, 12.9, 24.0, 8.2, 12.9, 3.4, 7.5, 20.5, -34.07, -46.66, -54.37, 2.7, 3.4, 14.4, ...</td>\n      <td>[percentage of participants, percentage of participants, percentage of participants, percentage ...</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>22</td>\n      <td>NCT00832585</td>\n      <td>Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Se...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>5</td>\n      <td>January 2008</td>\n      <td>September 2009</td>\n      <td>Inclusion Criteria:\\n\\nSigned Informed Consent Form(s)\\nAge of l8 years or older\\nA diagnosis of...</td>\n      <td>[Alefacept]</td>\n      <td>[Drug: Alefacept]</td>\n      <td>[Amevive\u00ae has been shown to be a safe and effective agent in the treatment of psoriasis but may ...</td>\n      <td>[Alefacept]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[Change in Eczema Area Severity Index (EASI) Score From Baseline (Week 1) to Week 16., Change in...</td>\n      <td>[The Eczema Area Severity Index (EASI) measures erythema (E), infiltration (I), excoriation (Ex)...</td>\n      <td>[Week 1 to week 16, Week 1 to week 16]</td>\n      <td>[26.4, 1]</td>\n      <td>[Scores on a scale., Scores on a scale]</td>\n    </tr>\n    <tr>\n      <th>10</th>\n      <td>23</td>\n      <td>NCT02925117</td>\n      <td>A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>167</td>\n      <td>October 25, 2016</td>\n      <td>August 10, 2017</td>\n      <td>Inclusion Criteria:\\n\\nAtopic dermatitis with a diagnosis confirmed by a dermatologist (accordin...</td>\n      <td>[Upadacitinib, Placebo]</td>\n      <td>[Drug: Upadacitinib, Drug: Placebo, Drug: Upadacitinib, Drug: Placebo, Drug: Upadacitinib, Drug:...</td>\n      <td>[Participants randomized to receive placebo once daily (QD) for 16 weeks in Period 1. At Week 16...</td>\n      <td>[Placebo, Upadacitinib 15 mg, Upadacitinib 30 mg, Upadacitinib 7.5 mg, Placebo, Upadacitinib 15 ...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16, Percent...</td>\n      <td>[EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessm...</td>\n      <td>[Baseline and Week 16, Baseline and Week 16, Week 16, Baseline and Weeks 2, 8, and 16, Baseline ...</td>\n      <td>[-23.0, -39.4, -61.7, -74.4, 9.8, 28.6, 52.4, 69.0, 2.4, 14.3, 31.0, 50.0, 1.7, -29.3, -46.0, -5...</td>\n      <td>[percent change, percentage of participants, percentage of participants, percent change, percent...</td>\n    </tr>\n    <tr>\n      <th>11</th>\n      <td>24</td>\n      <td>NCT02087943</td>\n      <td>Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis</td>\n      <td>Dermatitis, Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>191</td>\n      <td>June 2014</td>\n      <td>October 2015</td>\n      <td>Inclusion Criteria:\\n\\nMales or females, aged \u2265 18 years (\u2265 20 for Japanese subjects) at the tim...</td>\n      <td>[Apremilast, Apremilast, Placebo, Placebo]</td>\n      <td>[Drug: Apremilast, Drug: Apremilast, Drug: Apremilast, Drug: Placebo, Drug: Apremilast, Drug: Pl...</td>\n      <td>[Apremilast 40 mg administered orally twice daily (BID) for 12 weeks (following dose titration) ...</td>\n      <td>[Apremilast 40 mg, Placebo + Apremilast 40 mg, Apremilast 30 mg, Placebo + Apremilast 30 mg, Pla...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Percentage Change From Baseline in the Eczema Area and Severity Index (EASI) Score at Week 12.,...</td>\n      <td>[EASI is a validated composite scoring system integrating the proportion of the body region (are...</td>\n      <td>[Baseline to Week 12, Baseline to Week 12, Baseline to Week 12, Baseline to Week 4, Baseline to ...</td>\n      <td>[-10.98, -25.99, -31.57, 6.3, 3.4, 14.3, 32.8, 31.0, 42.9, -4.83, -10.00, -9.00, 30, 36, 44, 8, ...</td>\n      <td>[percent change, percentage of participants, percentage of participants, percent change, partici...</td>\n    </tr>\n    <tr>\n      <th>12</th>\n      <td>31</td>\n      <td>NCT01859988</td>\n      <td>Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>380</td>\n      <td>May 2013</td>\n      <td>May 2014</td>\n      <td>The inclusion criteria included, but were not limited to, the following:\\n\\nChronic Atopic Derma...</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab, Drug: Placebo, Drug: Dupilumab, Drug: Placebo,...</td>\n      <td>[Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a...</td>\n      <td>[Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Dupilum...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16, Percent...</td>\n      <td>[The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measur...</td>\n      <td>[Baseline to Week 16, Week 16, Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to We...</td>\n      <td>[-75.5, -70.5, -67.4, -64.9, -46.7, -20.2, 33.3, 29.7, 27.9, 21.5, 12.3, 1.6, 50.8, 46.9, 42.6, ...</td>\n      <td>[Percent change, Percentage of participants, Percentage of participants, Percent change, units o...</td>\n    </tr>\n    <tr>\n      <th>13</th>\n      <td>37</td>\n      <td>NCT03733301</td>\n      <td>A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Mo...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>329</td>\n      <td>November 16, 2018</td>\n      <td>July 29, 2019</td>\n      <td>Inclusion Criteria:\\n\\nHave been diagnosed with moderate to severe atopic dermatitis for at leas...</td>\n      <td>[Baricitinib, Topical corticosteroid, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Topical corticosteroid, Drug: Placebo, Drug: Baricitinib, Drug: Topica...</td>\n      <td>[4 mg Baricitinib administered orally once daily in combination with topical corticosteroids (TC...</td>\n      <td>[2 mg Baricitinib, 4 Milligram (mg) Baricitinib, 2 mg Baricitinib, 4 Milligram (mg) Baricitinib,...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 ...</td>\n      <td>[The IGA measures investigators global assessment of the participant's overall severity of their...</td>\n      <td>[Week 16, Week 16, Week 16, Baseline, Week 16, Week 16, Week 16, Baseline, Week 16, Baseline, We...</td>\n      <td>[14.7, 23.9, 30.6, 22.9, 43.1, 47.7, 13.8, 16.5, 24.3, -45.08, -58.16, -67.21, 7.3, 11.0, 18.0, ...</td>\n      <td>[percentage of participants, percentage of participants, percentage of participants, percent cha...</td>\n    </tr>\n    <tr>\n      <th>14</th>\n      <td>39</td>\n      <td>NCT01548404</td>\n      <td>Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>109</td>\n      <td>April 2012</td>\n      <td>March 2013</td>\n      <td>Inclusion Criteria:\\n\\nThe inclusion criteria included, but were not limited to the following:\\n...</td>\n      <td>[Placebo, Dupilumab]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab]</td>\n      <td>[Placebo (for Dupilumab) once weekly for 12 weeks by subcutaneous (SC) injection., Dupilumab 300...</td>\n      <td>[Placebo, Dupilumab 300 mg]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 12- Last Ob...</td>\n      <td>[The EASI score was used to measure the severity and extent of AD and measured erythema, infiltr...</td>\n      <td>[Baseline to Week 12, Week 12, Week 12, Baseline to Week 12, Baseline to Week 12, Baseline to We...</td>\n      <td>[-23.3, -74.0, 7.4, 40.0, 35.2, 85.5, -6.4, -19.9, -14.7, -49.5, -9.0, -27.4, -9.8, -35.0, -0.9,...</td>\n      <td>[percent change, percentage of participants, Percentage of participants, Units on a scale, Perce...</td>\n    </tr>\n    <tr>\n      <th>15</th>\n      <td>42</td>\n      <td>NCT02277743</td>\n      <td>Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Der...</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>671</td>\n      <td>October 2014</td>\n      <td>November 2015</td>\n      <td>Inclusion Criteria:\\n\\nMale or female, 18 years or older\\nChronic AD (according to American Acad...</td>\n      <td>[Dupilumab, Placebo (for Dupilumab)]</td>\n      <td>[Drug: Placebo (for Dupilumab), Drug: Dupilumab, Drug: Dupilumab, Drug: Placebo (for Dupilumab)]</td>\n      <td>[Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a...</td>\n      <td>[Dupilumab 300 mg every 2 weeks (q2w), Dupilumab 300 mg once weekly (qw), Dupilumab 300 mg every...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants With Investigator's Global Assessment (IGA) Score of \"0\" or \"1\" and ...</td>\n      <td>[IGA is an assessment scale used to determine severity of AD and clinical response to treatment ...</td>\n      <td>[Week 16, Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to We...</td>\n      <td>[10.3, 37.9, 37.2, 14.7, 51.3, 52.5, 12.3, 40.8, 40.3, 17.2, 46.8, 51.7, -26.8, -51.1, -49.0, 6....</td>\n      <td>[percentage of participants, percentage of participants, percentage of participants, percentage ...</td>\n    </tr>\n    <tr>\n      <th>16</th>\n      <td>45</td>\n      <td>NCT02260986</td>\n      <td>Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Part...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>740</td>\n      <td>September 2014</td>\n      <td>August 2015</td>\n      <td>Key Inclusion Criteria:\\n\\nChronic AD that had been present for at least 3 years before the scre...</td>\n      <td>[Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)]</td>\n      <td>[Drug: Placebo (for Dupilumab), Other: Topical Corticosteroid (TCS), Drug: Dupilumab, Drug: Plac...</td>\n      <td>[Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a...</td>\n      <td>[Dupilumab 300 mg q2w, Dupilumab 300 mg qw, Dupilumab 300 mg q2w, Placebo qw, Dupilumab 300 mg q...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants With Investigator's Global Assessment (IGA) Score of \"0\" or \"1\" and ...</td>\n      <td>[IGA is an assessment scale used to determine severity of AD and clinical response to treatment ...</td>\n      <td>[Baseline to Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to...</td>\n      <td>[12.4, 38.7, 39.2, 23.2, 68.9, 63.9, 19.7, 58.8, 50.8, 27.8, 65.7, 62.5, 12.5, 36.0, 40.0, 21.6,...</td>\n      <td>[percentage of participants, percentage of participants, percentage of participants, percentage ...</td>\n    </tr>\n    <tr>\n      <th>17</th>\n      <td>49</td>\n      <td>NCT02277769</td>\n      <td>Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-...</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>708</td>\n      <td>November 30, 2014</td>\n      <td>October 31, 2015</td>\n      <td>Inclusion Criteria:\\n\\nChronic AD that has been present for at least 3 years before the screenin...</td>\n      <td>[Dupilumab, Placebo (for Dupilumab)]</td>\n      <td>[Drug: Placebo (for Dupilumab), Drug: Dupilumab, Drug: Placebo (for Dupilumab), Drug: Dupilumab]</td>\n      <td>[Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a...</td>\n      <td>[Dupilumab 300 mg every 2 weeks (q2w), Dupilumab 300 mg qw, Dupilumab 300 mg every 2 weeks (q2w)...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants With Investigator's Global Assessment (IGA) Score of \"0\" or \"1\" and ...</td>\n      <td>[IGA is an assessment scale used to determine severity of AD and clinical response to treatment ...</td>\n      <td>[Week 16, Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to We...</td>\n      <td>[8.5, 36.1, 36.4, 11.9, 44.2, 48.1, 9.5, 36.0, 39.0, 12.8, 50.6, 49.1, -18.1, -47.2, -50.9, 6.3,...</td>\n      <td>[percentage of participants, percentage of participants, percentage of participants, percentage ...</td>\n    </tr>\n    <tr>\n      <th>18</th>\n      <td>57</td>\n      <td>NCT01732510</td>\n      <td>A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-822...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 1</td>\n      <td>Interventional</td>\n      <td>65</td>\n      <td>December 21, 2012</td>\n      <td>October 20, 2014</td>\n      <td>Inclusion Criteria:\\n\\nBody weight &gt;=40 kg\\nClinical diagnosis of atopic dermatitis for at least...</td>\n      <td>[MK-8226, Placebo]</td>\n      <td>[Drug: MK-8226, Drug: MK-8226, Drug: MK-8226, Drug: MK-8226, Drug: Placebo, Drug: MK-8226, Drug:...</td>\n      <td>[MK-8226 administered intravenously (IV) at a weight-based dose every 2 weeks for a period of 12...</td>\n      <td>[Part 1: MK-8226 0.3 mg/kg, Part 1: MK-8226 1 mg/kg, Part 1: MK-8226 10 mg/kg, Part 1: MK-8226 3...</td>\n      <td>[Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Se...</td>\n      <td>[Number of Participants Who Experienced at Least One Adverse Event, Number of Participants Who D...</td>\n      <td>[An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical in...</td>\n      <td>[Up to 32 Weeks, Up to 12 Weeks, Baseline, Week 12, Baseline, 48 Hours, Week 2, Week 4, Week 12,...</td>\n      <td>[8, 6, 6, 7, 7, 10, 7, 0, 1, 1, 0, 0, 0, 1, -5.77, -8.40, -10.20, -7.78, -0.38, 1000, 3300, 9300...</td>\n      <td>[participants, participants, Score on a scale, \u03bcg*hr/mL, \u03bcg*hr/mL, \u03bcg/mL, mL/day/kg, mL/kg, days...</td>\n    </tr>\n    <tr>\n      <th>19</th>\n      <td>63</td>\n      <td>NCT01639040</td>\n      <td>Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topi...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>31</td>\n      <td>July 2012</td>\n      <td>December 2012</td>\n      <td>Inclusion Criteria:\\n\\nMale and female patients aged 18 years or older\\nChronic AD that had been...</td>\n      <td>[Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)]</td>\n      <td>[Drug: Placebo (for Dupilumab), Other: Topical Corticosteroid (TCS), Drug: Dupilumab, Other: Top...</td>\n      <td>[Placebo (for Dupilumab) once weekly (QW) for 4 weeks by subcutaneous injection with the backgro...</td>\n      <td>[Dupilumab 300 mg QW, Placebo QW, Dupilumab 300 mg QW, Placebo QW]</td>\n      <td>[Primary, Other Pre-specified, Other Pre-specified, Other Pre-specified, Other Pre-specified, Ot...</td>\n      <td>[Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Percentage of Partic...</td>\n      <td>[Any untoward medical occurrence in a subject who received investigational medicinal product (IM...</td>\n      <td>[Baseline up to the end of study (up to Day 78), Day 29, Baseline up to Day 29, Day 29, Baseline...</td>\n      <td>[70.0, 57.1, 40.0, 28.6, 10.0, 0, 10.0, 0, 50.0, 100.0, -24.7, -70.7, 30.0, 52.4, -30.6, -52.5, ...</td>\n      <td>[percentage of participants, percentage of participants, percent change, percentage of participa...</td>\n    </tr>\n    <tr>\n      <th>20</th>\n      <td>68</td>\n      <td>NCT03428100</td>\n      <td>A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderat...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>463</td>\n      <td>May 15, 2018</td>\n      <td>November 25, 2019</td>\n      <td>Inclusion Criteria:\\n\\nHave been diagnosed with moderate to severe Atopic Eczema (Atopic Dermati...</td>\n      <td>[Baricitinib, Placebo, Topical corticosteroid]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Topical corticosteroid, Drug: Baricitinib, Drug: Placeb...</td>\n      <td>[4 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Pl...</td>\n      <td>[1 mg Baricitinib, 2 mg Baricitinib, 4 mg Baricitinib, 1 mg Baricitinib, 2 mg Baricitinib, 4 mg ...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (Placebo, 2 mg ...</td>\n      <td>[The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease ...</td>\n      <td>[Week 16, Week 16, Week 16, Week 16, Baseline, Week 16, Week 16, Week 16, Baseline, Week 16, Bas...</td>\n      <td>[17.2, 27.6, 31.5, 17.2, 22.6, 9.7, 12.9, 15.1, 21.7, 6.5, 8.6, 10.3, 14.1, -42.69, -60.34, -56....</td>\n      <td>[percentage of participants, percentage of participants, percentage of participants, percentage ...</td>\n    </tr>\n    <tr>\n      <th>21</th>\n      <td>70</td>\n      <td>NCT03864627</td>\n      <td>A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topica...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>33</td>\n      <td>March 25, 2019</td>\n      <td>February 27, 2020</td>\n      <td>Inclusion Criteria:\\n\\nA BMI 18 - 40 kilogram per meter square (kg/m^2), inclusive.\\nDiagnosis o...</td>\n      <td>[MOR106, Placebo]</td>\n      <td>[Drug: Placebo, Drug: MOR106]</td>\n      <td>[Participants will receive MOR106 matching placebo via s.c. injection every other week on Day 1,...</td>\n      <td>[MOR106 320 mg, Placebo]</td>\n      <td>[Primary, Secondary, Secondary]</td>\n      <td>[Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Event of Special...</td>\n      <td>[An Adverse Events (AE) was any untoward medical occurrence, new or worsening of any pre-existin...</td>\n      <td>[Day 1 up to Day 169/Early discontinuation(ED), Day 1, Day 4, Day 15, Day 29, Day 43, Day 57, Da...</td>\n      <td>[5, 11, 2, 1, 0, 0, 0, 1, 0.149, 61.150, 41.278, 39.473, 42.537, 40.934, 16.593, 9.775, 5.092, 2...</td>\n      <td>[Participants, microgram per milliliter (\u00b5g/mL), Participants]</td>\n    </tr>\n    <tr>\n      <th>22</th>\n      <td>72</td>\n      <td>NCT03363854</td>\n      <td>Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatiti...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>380</td>\n      <td>February 22, 2018</td>\n      <td>March 8, 2019</td>\n      <td>Inclusion Criteria:\\n\\nAge 18 and above.\\nDiagnosis of AD as defined by the Hanifin and Rajka (1...</td>\n      <td>[Tralokinumab, Placebo]</td>\n      <td>[Drug: Tralokinumab, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, ...</td>\n      <td>[Week 0 to 16 (initial period):\\n\\nTralokinumab loading SC injection on Day 0 followed by tralok...</td>\n      <td>[Placebo (initial)non-respon-&gt; Tralokinumab(continuation A), Tralokinumab(initial)non-respon-&gt; T...</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear)...</td>\n      <td>[IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0...</td>\n      <td>[Week 16, Week 16, Week 0 to Week 16, Week 0 to Week 16, Week 0 to Week 16, Week 0 to Week 16, W...</td>\n      <td>[98, 33, 141, 45, 113, 43, -37.7, -26.8, -11.7, -8.8, 2, 3, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, ...</td>\n      <td>[Participants, Participants, Participants, units on a scale, units on a scale, Participants, g, ...</td>\n    </tr>\n    <tr>\n      <th>23</th>\n      <td>74</td>\n      <td>NCT03912259</td>\n      <td>Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>165</td>\n      <td>December 19, 2018</td>\n      <td>February 14, 2020</td>\n      <td>Inclusion criteria:\\n\\nMale or female, 18 years or older.\\nAD (according to American Academy of ...</td>\n      <td>[Dupilumab, Placebo, Emollient (moisturizer)]</td>\n      <td>[Drug: Placebo, Drug: Emollient (moisturizer), Drug: Dupilumab, Drug: Emollient (moisturizer)]</td>\n      <td>[Placebo matched to dupilumab 600 milligrams (mg) (loading dose), subcutaneously (SC) on Day 1 f...</td>\n      <td>[Dupilumab 300 mg Q2W, Placebo Q2W, Dupilumab 300 mg Q2W, Placebo Q2W]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Number of Participants With Investigator's Global Assessment (IGA) Score of \"0\" or \"1\" and Redu...</td>\n      <td>[The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point...</td>\n      <td>[Baseline, Week 16, Baseline, Week 16, Baseline, Week 16, Baseline, Week 16, Baseline, Week 16, ...</td>\n      <td>[4, 22, 12, 47, 4, 32, 8, 43, -21.13, -48.59, -1.64, -3.84, -39.44, -75.23, -19.25, -37.76, -5.0...</td>\n      <td>[Participants, Participants, Participants, Participants, percentage change, units on a scale, pe...</td>\n    </tr>\n    <tr>\n      <th>24</th>\n      <td>75</td>\n      <td>NCT03847389</td>\n      <td>Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 1, Phase 2</td>\n      <td>Interventional</td>\n      <td>8</td>\n      <td>September 9, 2019</td>\n      <td>May 2, 2020</td>\n      <td>Inclusion Criteria:\\n\\nMale or female subjects in good general health confirmed by medical histo...</td>\n      <td>[Clobetasol propionate 0.05% Topical Oil]</td>\n      <td>[Drug: Clobetasol propionate 0.05% Topical Oil]</td>\n      <td>[clobetasol propionate 0.05% topical oil applied as thin film twice daily for 2 weeks]</td>\n      <td>[clobetasol propionate topical oil]</td>\n      <td>[Primary, Primary, Other Pre-specified, Other Pre-specified]</td>\n      <td>[Number of Participants With HPA Axis Suppression - Serum Cortisol Concentration (Cortrosyn Stim...</td>\n      <td>[30-minute Post-stimulation cortisol level \u226418 \u00b5g/100 mL at Day 0 means subject is not enrolled;...</td>\n      <td>[day 0 and day 15., Days 0, 1, 8 and 15, Days 0, 1, 8 and 15 Efficacy assessment, including ISGA...</td>\n      <td>[0, 0, 0, 3, 0, 0, 5, 8, 0, 0, 0, 0, 0, 8, 0]</td>\n      <td>[Participants, Participants, Participants]</td>\n    </tr>\n    <tr>\n      <th>25</th>\n      <td>80</td>\n      <td>NCT03349060</td>\n      <td>Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Mo...</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>387</td>\n      <td>December 7, 2017</td>\n      <td>March 26, 2019</td>\n      <td>Inclusion Criteria:\\n\\n12 years of age or older with a minimum body weight of 40 kg\\nDiagnosis o...</td>\n      <td>[PF-04965842 100 mg, PF-04965842 200 mg, Placebo]</td>\n      <td>[Drug: PF-04965842 100 mg, Drug: PF-04965842 200 mg, Drug: Placebo]</td>\n      <td>[]</td>\n      <td>[PF-04965842 100 mg, PF-04965842 200 mg, Placebo]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (...</td>\n      <td>[IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). ...</td>\n      <td>[Baseline, Week 12, Baseline, Week 12, Baseline, Week 2, 4, 8, 12, Baseline, Week 2, 4, 12, Base...</td>\n      <td>[23.7, 43.8, 7.9, 39.7, 62.7, 11.8, 20.4, 45.6, 2.7, 32.2, 58.8, 17.2, 34.3, 59.9, 14.4, 37.7, 5...</td>\n      <td>[percentage of participants, percentage of participants, percentage of participants, percentage ...</td>\n    </tr>\n    <tr>\n      <th>26</th>\n      <td>81</td>\n      <td>NCT03345914</td>\n      <td>Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticostero...</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>367</td>\n      <td>November 17, 2017</td>\n      <td>June 20, 2019</td>\n      <td>Key Inclusion Criteria:\\n\\nDiagnosis of AD according to the American Academy of Dermatology cons...</td>\n      <td>[Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatmen...</td>\n      <td>[Drug: Dupilumab, Other: Background Treatment: Topical Corticosteroids, Other: Background Treatm...</td>\n      <td>[Participants will receive dupilumab, dosing regimen 1, Participants will receive dupilumab, dos...</td>\n      <td>[Group 1, Group 2, Group 3, Group 1, Group 2, Group 3, Group 1, Group 2, Group 3]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16, Perce...</td>\n      <td>[The IGA was an assessment instrument used in clinical studies to rate the severity of AD global...</td>\n      <td>[Week 16, Week 16, Baseline (Day 1), Week 16, Baseline (Day 1), Week 16, Week 16, Week 16, Week ...</td>\n      <td>[11.4, 32.8, 29.5, 26.8, 69.7, 67.2, -48.6, -82.1, -78.4, -25.9, -54.6, -57.0, 21.1, 60.3, 67.5,...</td>\n      <td>[Percentage of Participants, Percentage of Participants, Percent change, Percent change, Percent...</td>\n    </tr>\n    <tr>\n      <th>27</th>\n      <td>83</td>\n      <td>NCT03575871</td>\n      <td>Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Mod...</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>391</td>\n      <td>June 29, 2018</td>\n      <td>August 13, 2019</td>\n      <td>Inclusion Criteria:\\n\\n12 years of age or older with a minimum body weight of 40 kg\\nDiagnosis o...</td>\n      <td>[PF-04965842 100 mg, PF-04965842 200 mg, Placebo]</td>\n      <td>[Drug: PF-04965842 100 mg, Drug: PF-04965842 200 mg, Drug: Placebo]</td>\n      <td>[]</td>\n      <td>[PF-04965842 100 mg, PF-04965842 200 mg, Placebo]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (...</td>\n      <td>[IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). ...</td>\n      <td>[Baseline, Week 12, Baseline, Week 12, Baseline, Weeks 2, 4, 8 and 12, Baseline, Week 12, Baseli...</td>\n      <td>[28.4, 38.1, 9.1, 44.5, 61.0, 10.4, 23.1, 35.3, 3.9, 31.4, 50.3, 3.9, 39.1, 51.6, 11.8, 39.7, 49...</td>\n      <td>[percentage of participants, percentage of participants, percentage of participants, units on a ...</td>\n    </tr>\n    <tr>\n      <th>28</th>\n      <td>91</td>\n      <td>NCT03055195</td>\n      <td>Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>34</td>\n      <td>March 21, 2017</td>\n      <td>December 6, 2017</td>\n      <td>Inclusion Criteria\\n\\nAge between 18 and 70 years of age inclusive, at the time of signing the i...</td>\n      <td>[Mepolizumab 100 mg, Placebo matching mepolizumab]</td>\n      <td>[Drug: Mepolizumab 100 mg, Drug: Placebo matching mepolizumab]</td>\n      <td>[Eligible subjects will receive mepolizumab 100 mg subcutaneously every 4 weeks on Day 1, Week 4...</td>\n      <td>[Mepolizumab, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 and at Le...</td>\n      <td>[The IGA is a clinical tool for assessing the current state/severity of a participant's atopic d...</td>\n      <td>[Week 16, Baseline (Day 1) and Weeks 4, 8, 12, 16 and 20, Weeks 4, 8, 12, 16 and 20, Up to Week ...</td>\n      <td>[0, 2, -22.508, -24.556, -30.497, -43.904, -22.372, -42.464, -32.269, -31.921, 1.327, -63.938, 1...</td>\n      <td>[Participants, Percent change, Participants, Participants, Participants, Billion cells per liter...</td>\n    </tr>\n    <tr>\n      <th>29</th>\n      <td>93</td>\n      <td>NCT03131648</td>\n      <td>Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinuma...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>802</td>\n      <td>May 30, 2017</td>\n      <td>August 7, 2018</td>\n      <td>Inclusion Criteria:\\n\\nAge 18 and above\\nDiagnosis of AD as defined by the Hanifin and Rajka (19...</td>\n      <td>[Tralokinumab, Placebo]</td>\n      <td>[Drug: Tralokinumab, Drug: Placebo, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, Drug:...</td>\n      <td>[Week 0 to Week 16:\\n\\nTwo subcutaneous (SC) injections of tralokinumab as a loading dose on Day...</td>\n      <td>[Initial treatment period - Tralokinumab Q2W, Maintenance treatment period - Tralokinumab Q2W, M...</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at ...</td>\n      <td>[The IGA is an instrument used in clinical trials to rate the severity of the subject's global A...</td>\n      <td>[At Week 16, At Week 16, Week 0 to Week 16, Week 0 to Week 16, Week 0 to Week 16, At Week 52, At...</td>\n      <td>[95, 14, 150, 25, 119, 20, -25.2, -14.7, -7.1, -5.0, 20, 14, 9, 28, 28, 10, 411, 133, 23, 8, 10,...</td>\n      <td>[Participants, Participants, Participants, units on a scale, units on a scale, Participants, Par...</td>\n    </tr>\n    <tr>\n      <th>30</th>\n      <td>94</td>\n      <td>NCT03160885</td>\n      <td>Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinuma...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>794</td>\n      <td>June 12, 2017</td>\n      <td>September 4, 2018</td>\n      <td>Inclusion Criteria:\\n\\nAge 18 and above.\\nDiagnosis of AD as defined by the Hanifin and Rajka (1...</td>\n      <td>[Tralokinumab, Placebo]</td>\n      <td>[Drug: Tralokinumab, Drug: Placebo, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, Drug:...</td>\n      <td>[Week 0 to Week 16\\n\\nTwo subcutaneous (SC) injections of tralokinumab as a loading dose on Day ...</td>\n      <td>[Initial treatment period - Tralokinumab Q2W, Maintenance treatment period - Tralokinumab Q2W, M...</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at ...</td>\n      <td>[The IGA is an instrument used in clinical trials to rate the severity of the subject's global A...</td>\n      <td>[At Week 16, At Week 16, Week 0 to Week 16, Week 0 to Week 16, Week 0 to Week 16, At Week 52, At...</td>\n      <td>[131, 22, 196, 23, 144, 19, -28.1, -14.0, -8.8, -4.9, 32, 22, 7, 43, 38, 9, 364, 132, 10, 5, 10,...</td>\n      <td>[Participants, Participants, Participants, units on a scale, units on a scale, Participants, Par...</td>\n    </tr>\n    <tr>\n      <th>31</th>\n      <td>96</td>\n      <td>NCT03720470</td>\n      <td>Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderat...</td>\n      <td>Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>838</td>\n      <td>October 29, 2018</td>\n      <td>December 27, 2019</td>\n      <td>Inclusion Criteria:\\n\\nMale or female subjects aged 18 years or older at the time of informed co...</td>\n      <td>[PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo]</td>\n      <td>[Drug: PF-04965842 100 mg, Drug: Injectable Placebo, Drug: PF-04965842 200 mg, Drug: Injectable ...</td>\n      <td>[Once-daily oral PF-04965842 100 mg + Placebo injected subcutaneously once every 2 weeks from Da...</td>\n      <td>[Oral Placebo + Placebo Inj followed by 100 mg PF-04965842, PF-04965842 100 mg + Placebo Inj fol...</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (...</td>\n      <td>[IGA assessed severity of atopic dermatitis (AD) on a 5 point scale (0 to 4, higher scores indic...</td>\n      <td>[Baseline (the last measurement prior to first dosing on Day 1), Week 12, Baseline, Week 12, Bas...</td>\n      <td>[14.0, 36.6, 48.4, 36.5, 27.1, 58.7, 70.3, 58.1, 5.1, 5.9, 7.4, 2.4, 7.9, 8.4, 14.8, 3.3, 6.0, 1...</td>\n      <td>[Percentage of participants, Percentage of participants, Percentage of participants, Percentage ...</td>\n    </tr>\n    <tr>\n      <th>32</th>\n      <td>105</td>\n      <td>NCT01149759</td>\n      <td>Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy</td>\n      <td>Atopic Dermatitis</td>\n      <td>Not Applicable</td>\n      <td>Interventional</td>\n      <td>9</td>\n      <td>June 2010</td>\n      <td>December 2014</td>\n      <td>Inclusion Criteria:\\n\\nSevere AD (defined as having a mean SCORAD score&gt; 40,, with significant d...</td>\n      <td>[Cyclosporine A]</td>\n      <td>[Drug: Cyclosporine A]</td>\n      <td>[5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation a...</td>\n      <td>[Cyclosporine A]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[SCORAD Change Score, Change in Epidermal Thickness]</td>\n      <td>[SCORAD (\"SCORing Atopic Dermatitis\") is a clinical tool for assessing the severity (i.e., exten...</td>\n      <td>[12 weeks, 12 weeks]</td>\n      <td>[33.34, 79.70]</td>\n      <td>[Change Score, micrometer]</td>\n    </tr>\n    <tr>\n      <th>33</th>\n      <td>106</td>\n      <td>NCT02780167</td>\n      <td>Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>269</td>\n      <td>April 2016</td>\n      <td>March 2017</td>\n      <td>Inclusion Criteria:\\n\\nMale or female subjects between 18 75 years of age, inclusive, at time of...</td>\n      <td>[PF-04965842, PF-04965842, PF-04965842, PF-04965842, Placebo]</td>\n      <td>[Drug: PF-04965842, Drug: PF-04965842, Drug: PF-04965842, Drug: PF-04965842, Drug: Placebo]</td>\n      <td>[10 mg of PF-04965842 QD, 30 mg of PF-04965842 QD, 100 mg of PF-04965842 QD, 200 mg of PF-049658...</td>\n      <td>[Cohort 1, Cohort 2, Cohort 3, Cohort 4, Cohort 5]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants Achieving the Investigator's Global Assessment (IGA) for Clear (0) o...</td>\n      <td>[The IGA score quantifies the severity of participants' atopic dermatitis (AD). Scores range fro...</td>\n      <td>[Baseline and Week 12, Baseline and Week 12, Baseline and all scheduled time points except Week ...</td>\n      <td>[6.3, 8.2, 12.3, 27.8, 44.5, -35.22, -31.13, -40.73, -59.04, -82.57, 0.0, 2.1, 2.0, 1.8, 3.7, 3....</td>\n      <td>[percentage of participants, percent change, percentage of participants, percentage of participa...</td>\n    </tr>\n    <tr>\n      <th>34</th>\n      <td>111</td>\n      <td>NCT03496974</td>\n      <td>A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>38</td>\n      <td>May 21, 2018</td>\n      <td>December 4, 2018</td>\n      <td>Inclusion Criteria:\\n\\nWritten informed consent provided by the patient\\nAge 18 years or greater...</td>\n      <td>[Bermekimab Monoclonal Antibody 200 mg, Bermekimab Monoclonal Antibody 400 mg]</td>\n      <td>[Drug: Bermekimab Monoclonal Antibody 200 mg, Drug: Bermekimab Monoclonal Antibody 400 mg]</td>\n      <td>[The dose of bermekimab for Group A is 200 mg (2ml of the 100 mg/ml formulation), The dose of be...</td>\n      <td>[Group A: 200 mg cohort, Group B: 400 mg cohort]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Number of Patients With Treatment Emergent Adverse Events (TEAEs), Change in Eczema Area and Se...</td>\n      <td>[Safety and tolerability endpoints were evaluated by monitoring all the adverse events from clin...</td>\n      <td>[From Visit 1 (Post-injection) until 7 days after the last administration of the study drug., Gr...</td>\n      <td>[3, 6, 28.18, 29.79, 22.73, 7.35, 5.45, 22.44, 12.6, 47.1, 0, 7, 1, 11, 6.50, 7.91, 3.66, 2.51, ...</td>\n      <td>[Participants, score on a scale, (\u03bcg/mL), Participants, Participants, score on a scale, score on...</td>\n    </tr>\n    <tr>\n      <th>35</th>\n      <td>113</td>\n      <td>NCT02576938</td>\n      <td>A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>124</td>\n      <td>February 2016</td>\n      <td>February 2017</td>\n      <td>Inclusion Criteria:\\n\\nHave moderate-to-severe Atopic Dermatitis (AD), as determined by all of t...</td>\n      <td>[Baricitinib, Placebo, Triamcinolone (Optional)]</td>\n      <td>[Drug: Baricitinib, Drug: Triamcinolone (Optional), Drug: Placebo, Drug: Triamcinolone (Optional)]</td>\n      <td>[Administered once daily in multiple oral dose cohorts for 16 weeks\\n\\n(Triamcinolone 0.1% topic...</td>\n      <td>[Baricitinib, Placebo, Baricitinib, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Percentage of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Inde...</td>\n      <td>[The EASI 50, defined as \u2265 50% reduction from baseline in EASI score, assesses extent of disease...</td>\n      <td>[Week 16, Baseline, Week 16, Baseline, Week 16, Baseline, Week 16, Baseline, Week 16, Baseline, ...</td>\n      <td>[37, 57, 61, -10.84, -16.44, -16.04, -45.87, -64.19, -64.69, -11.89, -23.87, -26.54, -0.9, -1.4,...</td>\n      <td>[percentage of participants, units on a scale, units on a scale, units on a scale, units on a sc...</td>\n    </tr>\n    <tr>\n      <th>36</th>\n      <td>121</td>\n      <td>NCT02683928</td>\n      <td>To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-se...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>64</td>\n      <td>March 2016</td>\n      <td>June 2017</td>\n      <td>Inclusion Criteria:\\n\\nMale or female, 18 years or older\\nAtopic dermatitis involvement that of ...</td>\n      <td>[GBR 830, Placebo]</td>\n      <td>[Biological: GBR 830, Biological: Placebo]</td>\n      <td>[Two doses of GBR 830, 10 mg/kg (solution for infusion, prepared in normal saline) administered ...</td>\n      <td>[GBR 830, Placebo]</td>\n      <td>[Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Incidence of Treatment-Emergent Adverse Events, Change From Baseline in Thickness of Lesional S...</td>\n      <td>[A treatment-emergent adverse event (TEAE) was defined as any new adverse event (AEs) or worseni...</td>\n      <td>[16 weeks, Day 1, before dosing (baseline), and Day 29 and Day 71, after dosing., 71 days, Day 4...</td>\n      <td>[29, 10, 1, 0, 2, 1, 4, 4, 140.56, 124.95, -14.90, -3.02, -26.51, -6.01, 0.67, 1.20, 0.62, 0.75,...</td>\n      <td>[Participants, micrometer, ratio, percentage of change from baseline, Participants, microgram/mL...</td>\n    </tr>\n    <tr>\n      <th>37</th>\n      <td>127</td>\n      <td>NCT02755649</td>\n      <td>A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermat...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>325</td>\n      <td>January 31, 2016</td>\n      <td>January 4, 2017</td>\n      <td>Inclusion Criteria:\\n\\nMale or female, 18 years or older\\nSevere, Chronic AD, (according to Amer...</td>\n      <td>[Dupilumab, Matching Placebo]</td>\n      <td>[Drug: Matching Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Participants received one subcutaneous (SC) injection of dupilumab matching placebo once per we...</td>\n      <td>[Dupilumab 300 mg Q2W + TCS, Dupilumab 300 mg QW + TCS, Placebo QW + TCS]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants With Eczema Area and Severity Index (EASI) 75 (\u226575% Improvement From...</td>\n      <td>[The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measure...</td>\n      <td>[Baseline, Week 16, Baseline, Week 16, Baseline, Week 16, Baseline, Week 16, Baseline to Week 16...</td>\n      <td>[29.6, 62.6, 59.1, -46.6, -79.8, -78.2, -25.4, -53.9, -51.7, -29.5, -62.4, -58.3, 14.3, 45.7, 40...</td>\n      <td>[Percentage of Participants, Percent Change, Percent Change, Percent Change, Percentage of parti...</td>\n    </tr>\n    <tr>\n      <th>38</th>\n      <td>137</td>\n      <td>NCT03100344</td>\n      <td>Dose-ranging Study of Nemolizumab in Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>226</td>\n      <td>June 14, 2017</td>\n      <td>July 19, 2018</td>\n      <td>Inclusion Criteria:\\n\\nMale or female subjects \u2265 18 years (or legal age when higher)\\nChronic AD...</td>\n      <td>[Nemolizumab, Placebo]</td>\n      <td>[Drug: Nemolizumab, Drug: Nemolizumab, Drug: Nemolizumab, Drug: Placebo]</td>\n      <td>[Nemolizumab (low dose), Nemolizumab (medium dose), Nemolizumab (high dose), Nemolizumab placebo]</td>\n      <td>[Group 1, Group 2, Group 3, Group 4]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24, Number of Par...</td>\n      <td>[EASI is a composite score ranging from 0 to 72.The severity of erythema, induration/papulation,...</td>\n      <td>[From Baseline to Week 24, Week 24, From Week 1 to Week 24, Baseline, Week 24, Baseline, Week 24...</td>\n      <td>[-58.4, -72.2, -73.4, -69.2, 13, 23, 31, 20, 3, 9, 10, 6, 6, 19, 21, 17, 4, 19, 27, 22, 11, 22, ...</td>\n      <td>[percentage change, Participants, Participants, Percentage change, units on a scale, Percentage ...</td>\n    </tr>\n    <tr>\n      <th>39</th>\n      <td>138</td>\n      <td>NCT01979016</td>\n      <td>Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis ...</td>\n      <td>Atopic Dermatitis (AD)</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>54</td>\n      <td>December 31, 2013</td>\n      <td>December 31, 2014</td>\n      <td>Inclusion Criteria:\\n\\nMale or female, 18 years or older;\\nChronic AD that had been present for ...</td>\n      <td>[Dupilumab, Placebo, Background treatment]</td>\n      <td>[Drug: Placebo, Other: Background treatment, Drug: Dupilumab, Other: Background treatment]</td>\n      <td>[Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a...</td>\n      <td>[Dupilumab 200 mg qw, Placebo qw, Dupilumab 200 mg qw, Placebo qw]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percent Change From Baseline in the Eczema Area Severity Index Score (EASI) to Week 16, Percent...</td>\n      <td>[The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measur...</td>\n      <td>[Baseline to Week 16, Week 16, Baseline to Week 16, Baseline to Week 16, Baseline to Week 16, Ba...</td>\n      <td>[-5.8, -75.2, 0, 37.0, 3.7, 51.9, -0.98, -3.64, -8.36, -56.44, -3.7, -25.2, -5.1, -36.4, -8.2, -...</td>\n      <td>[percent change, percentage of participants, percentage of participants, units on a scale, perce...</td>\n    </tr>\n    <tr>\n      <th>40</th>\n      <td>139</td>\n      <td>NCT02210780</td>\n      <td>Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>194</td>\n      <td>August 5, 2014</td>\n      <td>September 15, 2015</td>\n      <td>Key Inclusion Criteria:\\n\\nMale or female adults ages 18 to 64 years with Chronic AD (according ...</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab]</td>\n      <td>[Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a...</td>\n      <td>[Dupilumab 300 mg qw, Placebo qw]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants With a Positive Response (\u22654-Fold Increase) to Tetanus Toxoid (the A...</td>\n      <td>[A positive response was defined as a \u2265 4-fold increase from pre-vaccination at baseline in anti...</td>\n      <td>[Week 16, Week 16, Week 16, Week 16, Week 16, Week 16, Baseline to Week 16, Baseline to Week 16,...</td>\n      <td>[83.7, 83.3, 94.6, 95.6, 87.0, 86.7, 10.3, 44.3, 32.0, 72.2, 19.6, 53.6, -2.11, -4.24, -11.0, -2...</td>\n      <td>[Percentage of participants, Percentage of participants, Percentage of participants, Percentage ...</td>\n    </tr>\n    <tr>\n      <th>41</th>\n      <td>140</td>\n      <td>NCT02595073</td>\n      <td>Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>124</td>\n      <td>September 4, 2015</td>\n      <td>January 17, 2017</td>\n      <td>Inclusion Criteria:\\n\\n- male and non-pregnant females, age 6 months or older, with a confirmed ...</td>\n      <td>[DSXS, Placebo]</td>\n      <td>[Drug: DSXS, Drug: Placebo]</td>\n      <td>[DSXS Active treatment, Placebo treatment]</td>\n      <td>[DSXS topical product, Placebo topical product]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[The Number of Patients in Each Treatment Group That Have Clinical Success, Change From Baseline...</td>\n      <td>[Clinical Success defined using the following scores at Visit 4 (Day 28 \u00b1 2): At least a 2-grade...</td>\n      <td>[28 days, 28 days]</td>\n      <td>[21, 27, -13.81, -13.24]</td>\n      <td>[Participants, percentage of BSA]</td>\n    </tr>\n    <tr>\n      <th>42</th>\n      <td>145</td>\n      <td>NCT03585296</td>\n      <td>A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>22</td>\n      <td>July 10, 2018</td>\n      <td>April 25, 2019</td>\n      <td>Inclusion Criteria:\\n\\nMale or non-pregnant, non-nursing female subjects \u2265 18 years old at the t...</td>\n      <td>[ATI-502]</td>\n      <td>[Drug: ATI-502]</td>\n      <td>[ATI-502 topical solution applied daily for four weeks.]</td>\n      <td>[ATI-502]</td>\n      <td>[Primary]</td>\n      <td>[Number of Subjects withTreatment-Emergent Adverse Events (Safety and Tolerability)]</td>\n      <td>[Treatment emergent adverse events (TEAEs)graded on a 3 point scale of mild, moderate or severe]</td>\n      <td>[8 weeks]</td>\n      <td>[7]</td>\n      <td>[Participants]</td>\n    </tr>\n    <tr>\n      <th>43</th>\n      <td>152</td>\n      <td>NCT01299610</td>\n      <td>A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also I...</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>25</td>\n      <td>December 1, 2010</td>\n      <td>March 1, 2011</td>\n      <td>Inclusion Criteria:\\n\\nSubjects with a diagnosis of atopic dermatitis who are otherwise healthy....</td>\n      <td>[GW870086 2.0%, GW870086 0.2%, FP 0.05%, Placebo]</td>\n      <td>[Drug: GW870086 2.0%, Drug: GW870086 0.2%, Drug: Placebo, Drug: GW870086 2.0%, Drug: FP 0.05%, D...</td>\n      <td>[GW870086 2.0%, GW870086 0.2% &amp;amp; Placebo each applied to a separate specific lesion for 21\u00b12 ...</td>\n      <td>[GW870086 2.0% &amp; FP 0.05%, GW870086 2.0% &amp;amp; 0.2%, GW870086 0.2% &amp; FP 0.05%, GW870086 2.0% &amp;am...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Change From Baseline Three Item Severity (TIS) Scores Between GW870086 (0.2% and 2%) Versus Pla...</td>\n      <td>[Three target lesions were selected and each of the 3 target lesions were assessed separately us...</td>\n      <td>[Baseline (Day 1) and Day 22, Days 2, 3, 7, and 14, Days 2, 3, 7, 14 and 22, Upto Day 21, Up to ...</td>\n      <td>[-1.99, -2.49, -1.61, -3.11, -0.37, -0.53, -0.45, -0.62, -0.91, -0.80, -0.94, -1.22, -1.43, -1.7...</td>\n      <td>[Score on scale, Score on scale, Participants, Participants, Participants, Participants, Partici...</td>\n    </tr>\n    <tr>\n      <th>44</th>\n      <td>166</td>\n      <td>NCT02680301</td>\n      <td>Topical Steroid Formulation and Wet Wraps</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>40</td>\n      <td>March 2016</td>\n      <td>March 2017</td>\n      <td>Inclusion Criteria:\\n\\nPatients between the ages of 3-17 experiencing a symmetric, bilateral fla...</td>\n      <td>[0.1% triamcinolone CREAM, 0.1% triamcinolone OINTMENT]</td>\n      <td>[Drug: 0.1% triamcinolone CREAM, Drug: 0.1% triamcinolone OINTMENT, Drug: 0.1% triamcinolone CRE...</td>\n      <td>[Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on right side and 0.1% triamcin...</td>\n      <td>[Ointment Left/Cream Right, Ointment Right/Cream Left, Ointment Left/Cream Right, Ointment Right...</td>\n      <td>[Primary, Secondary, Other Pre-specified]</td>\n      <td>[Efficacy of 0.1% Triamcinolone Containing Wet Wrap as an Ointment or as a Cream Formulation in ...</td>\n      <td>[Change in atopic dermatitis based on physician global assessment scale: 0=clear; 1=almost clear...</td>\n      <td>[3-5 days, 3-5 days, 3-5 days]</td>\n      <td>[0.717, 0.589, 9, 16, 14, 39]</td>\n      <td>[units on a scale, Participants, Participants]</td>\n    </tr>\n    <tr>\n      <th>45</th>\n      <td>172</td>\n      <td>NCT02594098</td>\n      <td>Secukinumab for Treatment of Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>41</td>\n      <td>November 2015</td>\n      <td>January 30, 2018</td>\n      <td>Inclusion Criteria:\\n\\nMale or female subject at least 18 years of age\\nIf female, the subject i...</td>\n      <td>[Secukinumab, Placebo]</td>\n      <td>[Drug: Secukinumab, Drug: Placebo]</td>\n      <td>[Secukinumab (300 mg) via subcutaneous injection using 2 prefilled syringes, Placebo via subcuta...</td>\n      <td>[Secukinumab, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Fold-Change in Epidermal Thickness of Lesional Skin, Fold-Change in K16 Expression of Lesional ...</td>\n      <td>[Epidermal hyperplasia assessed using change in epidermal thickness at week 16 as compared to ba...</td>\n      <td>[at Week 16, at Week 16, Week 4, Week 16, Week 32, Week 52, Week 4, Week 16, Week 32, Week 52, W...</td>\n      <td>[1.15, 1.5, 1.18, -1, 1.14, -3.96, 1.36, -1.3, 0, 0, 2, 0, 0, 0, 3, 2, 0, 0, 0, 1, 1, 0, 0, 1, 0...</td>\n      <td>[fold-change, fold-change, Participants, Participants, Participants, percentage change, percenta...</td>\n    </tr>\n    <tr>\n      <th>46</th>\n      <td>175</td>\n      <td>NCT02525094</td>\n      <td>Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>113</td>\n      <td>August 15, 2015</td>\n      <td>May 9, 2016</td>\n      <td>Inclusion Criteria:\\n\\nAD meeting Hanifin and Rajka criteria\\nAge 18-75 years inclusive at scree...</td>\n      <td>[MEDI9929, Placebo]</td>\n      <td>[Biological: MEDI9929, Biological: Placebo]</td>\n      <td>[Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, w...</td>\n      <td>[MEDI9929 280 mg, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants Achieving Greater Than or Equal to (&gt;=) 50 Percent (%) Reduction Fro...</td>\n      <td>[The eczema area and severity index (EASI) evaluates 4 natural anatomical regions for severity (...</td>\n      <td>[Baseline (Day 1) and Week 12, Baseline (Day 1) and Week 12, Baseline (Day 1) and Week 12, Basel...</td>\n      <td>[48.2, 64.7, 19.8, 24.4, 24.48, 24.05, -11.23, -12.16, 12.8, 19.3, 58.66, 57.68, -19.35, -24.24,...</td>\n      <td>[Percentage of participants, Percentage of participants, units on a scale, Percentage of partici...</td>\n    </tr>\n    <tr>\n      <th>47</th>\n      <td>176</td>\n      <td>NCT03796676</td>\n      <td>JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>287</td>\n      <td>February 18, 2019</td>\n      <td>April 8, 2020</td>\n      <td>Inclusion Criteria:\\n\\nAged between 12 and to 17 with a minimum body weight of 40 kg\\nDiagnosis ...</td>\n      <td>[Placebo, PF-04965842, PF04965842]</td>\n      <td>[Drug: Placebo, Drug: PF-04965842, Drug: PF04965842]</td>\n      <td>[Placebo, active, active]</td>\n      <td>[Placebo, PF-04965842 100 mg QD, PF-04965842 200 mg QD]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear'...</td>\n      <td>[The IGA of Atopic Dermatitis (AD) was scored on a 5-point scale (0-4), reflecting a global cons...</td>\n      <td>[Baseline to Week 12, Baseline to Week 12, Baseline, Weeks 2, 4 and 12, Baseline to Week 12, Bas...</td>\n      <td>[24.5, 41.6, 46.2, 41.5, 68.5, 72.0, 12.6, 27.2, 38.6, 20.7, 31.5, 50.0, 29.8, 52.6, 55.4, -2.0,...</td>\n      <td>[Percentage of participants, Percentage of participants, Percentage of participants, Units on a ...</td>\n    </tr>\n    <tr>\n      <th>48</th>\n      <td>180</td>\n      <td>NCT02424253</td>\n      <td>A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>98</td>\n      <td>May 18, 2015</td>\n      <td>January 2016</td>\n      <td>Inclusion Criteria:\\n\\nMales and females aged 18-65 years inclusive with physician documented hi...</td>\n      <td>[ZPL-3893787, Placebo]</td>\n      <td>[Drug: ZPL-3893787, Drug: Placebo]</td>\n      <td>[30 mg ZPL-3893787 orally once daily for 8 weeks., 1 capsule orally once daily for 8 weeks.]</td>\n      <td>[ZPL-3893787, Placebo]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch), Change From...</td>\n      <td>[The participant used the Pruritus NRS to rate his or her worst itch in the previous 12 hours. T...</td>\n      <td>[Baseline to Week 8, Baseline to Week 8]</td>\n      <td>[7.3, 7.26, 4.27, 4.6, -3.03, -2.66, 21.39, 20.44, 10.67, 15.06, -10.72, -5.38]</td>\n      <td>[score on a scale, score on a scale]</td>\n    </tr>\n    <tr>\n      <th>49</th>\n      <td>182</td>\n      <td>NCT02347176</td>\n      <td>Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>204</td>\n      <td>January 23, 2015</td>\n      <td>November 27, 2015</td>\n      <td>Inclusion Criteria:\\n\\nPhysician diagnosis of atopic dermatitis for greater than (&gt;) 1 year\\nAto...</td>\n      <td>[Placebo, Tralokinumab Dose 1, Tralokinumab Dose 2, Tralokinumab Dose 3]</td>\n      <td>[Other: Placebo, Biological: Tralokinumab Dose 1, Biological: Tralokinumab Dose 2, Biological: T...</td>\n      <td>[Placebo matched to Tralokinumab will be administered subcutaneously to participants once every ...</td>\n      <td>[Placebo, Tralokinumab Dose 1, Tralokinumab Dose 2, Tralokinumab Dose 3]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 12, ...</td>\n      <td>[EASI evaluates 4 natural anatomical regions for severity and extent of key disease signs and fo...</td>\n      <td>[Baseline (Day 1) and Week 12, Week 12, From Study Drug Administration (Day 1) to Week 22, From ...</td>\n      <td>[-10.78, -13.67, -15.14, -15.72, 11.8, 11.6, 19.5, 26.7, 31, 36, 35, 30, 1, 3, 2, 0, 0, 1, 1, 0,...</td>\n      <td>[units on a scale, Percentage of participants, Participants, Participants, Participants, Partici...</td>\n    </tr>\n    <tr>\n      <th>50</th>\n      <td>183</td>\n      <td>NCT01737710</td>\n      <td>Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Not Applicable</td>\n      <td>Interventional</td>\n      <td>368</td>\n      <td>October 2012</td>\n      <td>May 2013</td>\n      <td>Inclusion Criteria:\\n\\nEnrolled in the ADRN Registry study;\\nActive, mild to severe AD (lesions ...</td>\n      <td>[Fluzone\u00ae Intradermal Vaccine, Fluzone\u00ae (Intramuscular) vaccine]</td>\n      <td>[Biological: Fluzone\u00ae Intradermal Vaccine, Biological: Fluzone\u00ae Intradermal Vaccine, Biological:...</td>\n      <td>[Non-atopic controls who will receive a single dose of the seasonal 2012-2013 Fluzone\u00ae Intraderm...</td>\n      <td>[92 Non-atopic controls vaccinated with Fluzone\u00ae Intradermal, Mild AD participants vaccinated wi...</td>\n      <td>[Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Se...</td>\n      <td>[Seroprotection, Non-Atopic Dermatitis (AD), Intradermal vs. Moderate to Severe Atopic Dermatiti...</td>\n      <td>[The difference in the percent of participants that achieved seroprotection against influenza B ...</td>\n      <td>[Day 28 post vaccination, Day 28 Post Vaccination, Day 28 Post Vaccination, Day 28 post vaccinat...</td>\n      <td>[34.4, 22.5, 84.1, 86.4, 84.7, 73.3, 2.6, 2.0, 22.4, 37.7, 10.1, 9.7, 34.4, 33.7, 84.1, 92.5, 84...</td>\n      <td>[percentage of participants, percentage of participants, percentage of participants, HAI antibod...</td>\n    </tr>\n    <tr>\n      <th>51</th>\n      <td>184</td>\n      <td>NCT03151148</td>\n      <td>Targeted Microbiome Transplant in Atopic Dermatitis</td>\n      <td>Atopic Dermatitis (AD)</td>\n      <td>Phase 1, Phase 2</td>\n      <td>Interventional</td>\n      <td>54</td>\n      <td>September 28, 2017</td>\n      <td>May 14, 2019</td>\n      <td>Inclusion Criteria:\\n\\nIndividuals who meet all of the following criteria are eligible for enrol...</td>\n      <td>[TMT Lotion, Placebo Lotion]</td>\n      <td>[Biological: TMT Lotion, Drug: Placebo Lotion]</td>\n      <td>[The targeted microbiome transplant (TMT) lotion will be provided in single-dose sealed packets....</td>\n      <td>[TMT Lotion, Placebo Lotion]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Per-Participant Daily Event Rate: Serious and Non-Serious Treatment Emergent Adverse Events (TE...</td>\n      <td>[Per-participant daily event rate of TEAEs was calculated as the number of events per-participan...</td>\n      <td>[Day 0 to Day 8, Day 0 (after initiation of study treatment) through Day 8 (last day of study tr...</td>\n      <td>[0.19, 0.34, 20, 15, 0.06, 0.09, 23, 16, 2.5, 2.2, 2.5, 2.2, 2.2, 1.9, 2.1, 1.9, 2.0, 1.7, 50.0,...</td>\n      <td>[events per-participant-day, Participants, events per-participant-day, Participants, units on a ...</td>\n    </tr>\n    <tr>\n      <th>52</th>\n      <td>191</td>\n      <td>NCT03562377</td>\n      <td>Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Tria...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>215</td>\n      <td>July 13, 2018</td>\n      <td>September 17, 2019</td>\n      <td>Inclusion Criteria:&gt;\\n\\nAge 18 to 54 years&gt;\\nDiagnosis of AD as defined by Hanifin and Rajka (19...</td>\n      <td>[Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine]</td>\n      <td>[Drug: Tralokinumab, Biological: Tdap vaccine, Biological: Meningococcal vaccine, Drug: Placebo,...</td>\n      <td>[Week 0 to 16:&gt; Tralokinumab will be given as subcutaneous injections. &gt;\\n\\n&gt; Subjects will rece...</td>\n      <td>[Tralokinumab, Placebo, Placebo, Tralokinumab, Placebo, Tralokinumab]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Positive Anti-tetanus Response at Week 16, Positive Anti-meningococcal Response at Week 16, Par...</td>\n      <td>[The antibody response to Tdap vaccine will be assessed by measuring serum anti-tetanus IgG by a...</td>\n      <td>[Week 12 to Week 16, Week 12 to Week 16, Week 0 to Week 16, Week 0 to Week 16, Week 0 to Week 16...</td>\n      <td>[80, 73, 74, 64, 33, 21, 52, 39, 112, 133, 2, 4, 1, 2, 103, 97, 1, 4]</td>\n      <td>[Participants, Participants, Participants, Participants, AEs, Participants]</td>\n    </tr>\n    <tr>\n      <th>53</th>\n      <td>199</td>\n      <td>NCT01337635</td>\n      <td>Vitamin D Deficiency and Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Not Applicable</td>\n      <td>Interventional</td>\n      <td>7</td>\n      <td>November 2010</td>\n      <td>December 2012</td>\n      <td>Inclusion Criteria:\\n\\nSerum 25-hydroxyvitamin D level &lt;20 ng/ml (&lt;50 nmol/L)\\nDiagnosed with at...</td>\n      <td>[Vitamin D]</td>\n      <td>[Drug: Vitamin D, Drug: Vitamin D]</td>\n      <td>[Treatment with cholecalciferol 400 IU daily at home., Treatment with ergocalciferol 300,000 IU ...</td>\n      <td>[High dose vitamin D, Standard dose vitamin D]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[Atopic Dermatitis Severity at the Completion of Treatment, Time to Restart Topical Steroids]</td>\n      <td>[SCORAD at the 6 week study visit. The SCORAD (SCORing Atopic Dermatitis) is a clinical tool use...</td>\n      <td>[6 weeks, 6 weeks]</td>\n      <td>[33.1, 15.5, NA, NA]</td>\n      <td>[score on a scale, days]</td>\n    </tr>\n    <tr>\n      <th>54</th>\n      <td>206</td>\n      <td>NCT03386032</td>\n      <td>8-Week Atopic Dermatitis (AD) Treatment Study</td>\n      <td>Atopic Dermatitis Eczema</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>65</td>\n      <td>November 27, 2017</td>\n      <td>August 18, 2018</td>\n      <td>Inclusion Criteria:\\n\\nIs a generally healthy, male or female, 12-65 years old, inclusive;\\nDiag...</td>\n      <td>[Investigational OTC Cream, 0.05% Desonide, Placebo Cream]</td>\n      <td>[Drug: Investigational OTC Cream, Other: Placebo Cream, Drug: 0.05% Desonide, Other: Placebo Cream]</td>\n      <td>[Investigational Over the Counter (OTC) Cream will be applied topically, twice daily, for 8 week...</td>\n      <td>[Investigational OTC Cream, 0.05% Desonide Cream, 0.05% Desonide Cream, Placebo Cream]</td>\n      <td>[Primary, Primary]</td>\n      <td>[Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis...</td>\n      <td>[SCORAD (Severity Scoring of Atopic Dermatitis) Change from Baseline to Week 8 of atopic dermati...</td>\n      <td>[Baseline to Week 8, Baseline to Week 8]</td>\n      <td>[-12.2, 9.3, -17.5, -6.0, -20.3, -18.0]</td>\n      <td>[units on a scale, units on a scale]</td>\n    </tr>\n    <tr>\n      <th>55</th>\n      <td>210</td>\n      <td>NCT02795832</td>\n      <td>A Study to Determine the Safety &amp; Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects Wi...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 1, Phase 2</td>\n      <td>Interventional</td>\n      <td>53</td>\n      <td>June 2016</td>\n      <td>March 1, 2017</td>\n      <td>Inclusion Criteria:\\n\\nHealthy males or females, aged between 18 and 55 years, inclusive (health...</td>\n      <td>[ZPL-5212372 1% w/w Ointment BID, Placebo Ointment BID]</td>\n      <td>[Drug: ZPL-5212372 1% w/w Ointment BID, Drug: Placebo Ointment BID, Drug: ZPL-5212372 1% w/w Oin...</td>\n      <td>[ZPL-5212372 1% w/w Ointment BID, Placebo Ointment BID, ZPL-5212372 1% w/w Ointment BID, Placebo...</td>\n      <td>[Cohort 1a, Cohort 2a, Cohort 3a, Cohort 1b, Cohort 2b, Cohort 3b]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Other Pre-specified, O...</td>\n      <td>[Percent Change From Baseline in EASI Score in Cohort 3, Percent Change From Baseline in EASI Sc...</td>\n      <td>[The EASI is a validated tool used to measure the severity and extent of atopic eczema (Eczema A...</td>\n      <td>[Day 1 and Day 14, Days 1, 5, 8, 10, and 15, Day 14, Day 14, Day 1 to day 14, End of treatment (...</td>\n      <td>[-34.24, -34.29, -34.04, -31.03, -34.04, -15.77, -33.94, 3.66, -16.68, -4.96, -27.36, -21.41, -3...</td>\n      <td>[percent change from baseline in EASI, percent change from baseline in EASI, participants, Perce...</td>\n    </tr>\n    <tr>\n      <th>56</th>\n      <td>213</td>\n      <td>NCT02595008</td>\n      <td>Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients ...</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>24</td>\n      <td>August 28, 2015</td>\n      <td>February 22, 2017</td>\n      <td>Inclusion Criteria:\\n\\nPatients with a definite clinical diagnosis of stable atopic dermatitis\\n...</td>\n      <td>[DSXS]</td>\n      <td>[Drug: DSXS]</td>\n      <td>[treatment with DSXS twice daily for 28 days]</td>\n      <td>[DSXS topical product]</td>\n      <td>[Primary]</td>\n      <td>[Number of Participants With HPA Axis Suppression]</td>\n      <td>[Hypothalamic Pituitary Adrenal (HPA) Axis Response to Cosyntropin demonstrating the absence or ...</td>\n      <td>[28 days.]</td>\n      <td>[3, 1, 16, 3]</td>\n      <td>[Participants]</td>\n    </tr>\n    <tr>\n      <th>57</th>\n      <td>218</td>\n      <td>NCT02407756</td>\n      <td>A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Ag...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>78</td>\n      <td>March 31, 2015</td>\n      <td>March 31, 2016</td>\n      <td>Key Inclusion Criteria:\\n\\nMale or female patients \u22656 to &lt;18 years of age with a diagnosis of 1....</td>\n      <td>[Dupilumab]</td>\n      <td>[Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Cohort 1 will receive dupilumab dosing regimen 1, Cohort 2 will receive dupilumab dosing regime...</td>\n      <td>[Cohort 1, Cohort 2]</td>\n      <td>[Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Pharmacokinetics (PK) of Dupilumab: Maximum Plasma Concentration Observed (Cmax) After Single A...</td>\n      <td>[Peak dupilumab concentration in serum following single dose administration. Analysis was perfor...</td>\n      <td>[Day 2, 4, 8, 15, 22, 29, 36, 43, and 50, Day 2, 4, 8, 15, 22, 29, 36, 43, and 50, Pre-dose on D...</td>\n      <td>[9.91, 14.3, 23.1, 32.4, 104, 160, 362, 330, 10.4, 17.2, 32.8, 42.1, 18.5, 28, 58.8, 60.3, -66.4...</td>\n      <td>[mg/L, Day*mg/L, mg/L, percent change, percent change, Percent change, Percentage of subjects, P...</td>\n    </tr>\n    <tr>\n      <th>58</th>\n      <td>223</td>\n      <td>NCT00179959</td>\n      <td>The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>31</td>\n      <td>September 2005</td>\n      <td>March 2011</td>\n      <td>Inclusion Criteria:\\n\\n6 months to 17 years of age\\nModerate to severe atopic dermatitis\\n\\nExcl...</td>\n      <td>[Sodium hypochlorite (bleach) baths, Mupirocin ointment, Water, Petrolatum Ointment]</td>\n      <td>[Drug: Sodium hypochlorite (bleach) baths, Drug: Mupirocin ointment, Drug: Water, Drug: Petrolat...</td>\n      <td>[Intranasal mupirocin ointment and sodium hypochlorite (bleach) baths, Intranasal petrolatum oin...</td>\n      <td>[Treatment, Treatment, Placebo, Placebo]</td>\n      <td>[Primary]</td>\n      <td>[Change in Eczema Area and Severity Index (EASI)Scores According to Location]</td>\n      <td>[The proportion of affected body surface area (BSA) was estimated from 4 designated body regions...</td>\n      <td>[Baseline and 3 months]</td>\n      <td>[-1.06, -0.57, -4.94, -0.88]</td>\n      <td>[Change in EASI Score]</td>\n    </tr>\n    <tr>\n      <th>59</th>\n      <td>236</td>\n      <td>NCT03389893</td>\n      <td>Effect of Dupilumab (Anti-IL4R\u03b1) on the Host-Microbe Interface in Atopic Dermatitis</td>\n      <td>Atopic Dermatitis (AD)</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>72</td>\n      <td>July 11, 2018</td>\n      <td>April 3, 2020</td>\n      <td>Inclusion Criteria:\\n\\nMust be able to understand and provide informed consent\\nChronic AD, (acc...</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Dupilumab, Drug: Placebo, Drug: Dupilumab, Drug: Placebo]</td>\n      <td>[Participants will receive a loading dose of dupilumab (two 300 mg subcutaneous (subcut) injecti...</td>\n      <td>[Dupilumab w/OLE, Placebo Comparator w/OLE, Dupilumab w/OLE, Placebo Comparator w/OLE]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Comparison by Treatment Assignment in Staphylococcus Aureus Abundance on Lesional Skin, Compari...</td>\n      <td>[Staphylococcus aureus (S. aureus) abundance was measured by microbial DNA (femA qPCR) on lesion...</td>\n      <td>[Day 28 (Post treatment initiation), Day 0 (Prior to treatment), 16 weeks, Day 0 (Prior to treat...</td>\n      <td>[86.01, 2608.4]</td>\n      <td>[rCFU/cm^2]</td>\n    </tr>\n    <tr>\n      <th>60</th>\n      <td>240</td>\n      <td>NCT00717769</td>\n      <td>A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects ...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>270</td>\n      <td>July 16, 2008</td>\n      <td>April 9, 2009</td>\n      <td>Inclusion Criteria:\\n\\nMale or female participants between 18 and 65 years of age.\\nA diagnosis ...</td>\n      <td>[SUN13834, Placebo]</td>\n      <td>[Drug: SUN13834, Drug: Placebo]</td>\n      <td>[]</td>\n      <td>[SUN13834, Placebo]</td>\n      <td>[Primary, Primary, Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Second...</td>\n      <td>[Baseline of Disease Characteristics Before Treatment With SUN13834 or Placebo in Adult Particip...</td>\n      <td>[Eczema Area and Severity Index (EASI) Score is a composite index including an assessment of dis...</td>\n      <td>[Pre-dose, Day 8, Day 15, Day 22, Day 29, Follow Up Week 2 and Week 4 post-dose., Day 8, Day 15,...</td>\n      <td>[12.59, 12.45, 6.01, 3.0, 3.1, 2.6, 2.2, 2.2, 1.9, 3.2, 4.0, 3.0, -1.66, -1.94, -2.88, -4.06, -3...</td>\n      <td>[score on a scale, units on a scale, percent change, units on a scale, percent change, units on ...</td>\n    </tr>\n    <tr>\n      <th>61</th>\n      <td>245</td>\n      <td>NCT00119158</td>\n      <td>Combination Therapy for Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>90</td>\n      <td>October 2004</td>\n      <td>June 2005</td>\n      <td>Inclusion Criteria:\\n\\nAge 2 to 65 years\\nClinical diagnosis of (Atopic Dermatitis) AD according...</td>\n      <td>[Combination of pimecrolimus and fluticasone, pimecrolimus]</td>\n      <td>[Drug: pimecrolimus, Drug: Combination of pimecrolimus and fluticasone, Drug: pimecrolimus]</td>\n      <td>[Placebo cream]</td>\n      <td>[pimecrolimus cream, pimecrolimus cream, placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Change From Baseline in the m-EASI (Eczema Area Severity Index) Score., The Time to Clearance o...</td>\n      <td>[Eczema Area severity index (EASI) is a composition of scores based on area of eczema involved, ...</td>\n      <td>[up to 15 days, assessed up to 30 days following drug application, up to one week, up to 15 days...</td>\n      <td>[5.04, 4.77, 9.22, 7.88]</td>\n      <td>[units of a 0-12 scale, days, days, percentage of participants, percentage of participants, perc...</td>\n    </tr>\n    <tr>\n      <th>62</th>\n      <td>254</td>\n      <td>NCT00817063</td>\n      <td>Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema</td>\n      <td>Eczema</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>599</td>\n      <td>January 8, 2009</td>\n      <td>April 26, 2012</td>\n      <td>Inclusion Criteria:\\n\\nall types of chronic hand eczema, lasting for at least 6 months since ini...</td>\n      <td>[alitretinoin, Placebo]</td>\n      <td>[Drug: alitretinoin, Drug: Placebo]</td>\n      <td>[Patients will receive alitretinoin 30mg capsule for up to 24 weeks, Patients will receive place...</td>\n      <td>[Alitretinoin, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Number of Participants Who Responded as Per Physician's Global Assessment (PGA) at Week 24, Per...</td>\n      <td>[The investigator assigned PGA grades according to a 5-point scale (clear [not detectable], almo...</td>\n      <td>[Week 24 (end-of-treatment), Baseline (Week 0) and Week 24 (end-of-treatment), Week 24 (end-of-t...</td>\n      <td>[58, 14, 60, 30, 118, 44, -53.99, -29.86, 117, 41, -46.56, -24.20, 8.3, 16.9, 83.0, NA, 65.0, 11...</td>\n      <td>[Participants, Percent change, Participants, Percent change, Weeks, Weeks, Days, Participants, P...</td>\n    </tr>\n    <tr>\n      <th>63</th>\n      <td>261</td>\n      <td>NCT00914186</td>\n      <td>Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>122</td>\n      <td>June 2009</td>\n      <td>May 2010</td>\n      <td>Inclusion Criteria:\\n\\nAdults, males or females, 18 - 65 years of age at the time of obtaining t...</td>\n      <td>[TS022, Vehicle]</td>\n      <td>[Drug: Vehicle, Drug: TS022, Drug: TS022, Drug: TS022]</td>\n      <td>[]</td>\n      <td>[TS-022 0.005% lotion, TS-022 0.010% lotion, TS-022 0.020% lotion, Vehicle]</td>\n      <td>[Primary, Primary, Primary, Primary, Primary, Primary, Primary]</td>\n      <td>[Change in Pruritis Visual Analog Scale (VAS), Safety and Tolerability of TS-022 Topical Lotion ...</td>\n      <td>[Patient reported outcome of pruritis measurement (0-100 mm/min-max)on a change in visual analog...</td>\n      <td>[Baseline through Study Day 36 (Visit 7), Baseline through Study Day 36 (Visit 7), baseline thro...</td>\n      <td>[-12.4, -15.5, -13.9, -6.2, 9, 11, 10, 11, -0.6, -0.5, -0.6, -0.6, -0.4, -0.5, -0.6, -0.2, -3.1,...</td>\n      <td>[mm, participants, units on a scale, units on a scale, units on a scale, units on a scale, parti...</td>\n    </tr>\n    <tr>\n      <th>64</th>\n      <td>264</td>\n      <td>NCT01132651</td>\n      <td>Cooling Pillow for Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Not Applicable</td>\n      <td>Interventional</td>\n      <td>9</td>\n      <td>May 2010</td>\n      <td>December 2010</td>\n      <td>Inclusion Criteria:\\n\\nDiagnosis of AD by dermatologist\\nAD located on the head and neck\\nInvest...</td>\n      <td>[Current standard eczema treatment and standard pillow at night, Chillow cooling pillow]</td>\n      <td>[Other: Chillow cooling pillow, Other: Current standard eczema treatment and standard pillow at ...</td>\n      <td>[This group of subjects will follow their current eczema regimen with the addition of using the ...</td>\n      <td>[Standard of care (regular pillow at night), Chillow cooling pillow]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[Change in Sleep Quality as Measured by a Change in Pittsburgh Sleep Quality Index (PSQI) Survey...</td>\n      <td>[The PSQI is a clinical survey used to measure sleep quality. Seven components related to sleep ...</td>\n      <td>[Baseline and at 2 weeks, Baseline and at 2 weeks]</td>\n      <td>[-1, -2, -1, -1]</td>\n      <td>[units on a scale, units on a scale]</td>\n    </tr>\n    <tr>\n      <th>65</th>\n      <td>265</td>\n      <td>NCT03683719</td>\n      <td>Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delg...</td>\n      <td>Chronic Hand Eczema</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>258</td>\n      <td>November 28, 2018</td>\n      <td>March 6, 2020</td>\n      <td>Key Inclusion Criteria:\\n\\nAge 18 years or above.\\nDiagnosis of chronic hand eczema defined as h...</td>\n      <td>[Delgocitinib cream, Delgocitinib cream vehicle]</td>\n      <td>[Drug: Delgocitinib cream, Drug: Delgocitinib cream, Drug: Delgocitinib cream, Drug: Delgocitini...</td>\n      <td>[Delgocitinib cream applied twice daily for 16 weeks., Delgocitinib cream applied twice daily fo...</td>\n      <td>[Delgocitinib cream 1 mg/g, Delgocitinib cream 20 mg/g, Delgocitinib cream 3 mg/g, Delgocitinib ...</td>\n      <td>[Primary, Secondary, Secondary]</td>\n      <td>[Investigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) Score of 0 (Clear) or 1 (Alm...</td>\n      <td>[IGA-CHE is an instrument used in clinical trials to rate the severity of subject's global disea...</td>\n      <td>[Week 0 to Week 16., Week 0 to Week 16., Week 0 to Week 16.]</td>\n      <td>[11, 4, 19, 20, 4, -39.81, -35.93, -46.69, -41.99, -26.40, NA, NA, 82, 98, NA]</td>\n      <td>[Participants, score on a scale, days, median]</td>\n    </tr>\n    <tr>\n      <th>66</th>\n      <td>272</td>\n      <td>NCT01806662</td>\n      <td>Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>32</td>\n      <td>March 2013</td>\n      <td>March 2015</td>\n      <td>Inclusion Criteria:\\n\\nAre male or female and ages 18-75.\\nHave moderate to severe AD (as determ...</td>\n      <td>[Ustekinumab, Placebo]</td>\n      <td>[Drug: Ustekinumab, Other: Placebo, Drug: Ustekinumab, Other: Placebo]</td>\n      <td>[Since there is a crossover design, each patient will be in the treatment arm for 16 weeks of th...</td>\n      <td>[Placebo Arm (Placebo first, Then Ustekinumab), Treatment Arm (Ustekinumab first, Then Placebo),...</td>\n      <td>[Primary]</td>\n      <td>[Proportion of SCORAD-50 Response at Week 16.]</td>\n      <td>[Greater improvement from their baseline objective SCORAD (SCORing Atopic Dermatitis) at Week 16...</td>\n      <td>[Week 16]</td>\n      <td>[5, 3]</td>\n      <td>[Participants]</td>\n    </tr>\n    <tr>\n      <th>67</th>\n      <td>273</td>\n      <td>NCT01049243</td>\n      <td>A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Derma...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>20</td>\n      <td>March 2009</td>\n      <td>September 2009</td>\n      <td>Inclusion Criteria:\\n\\nMale or female with mild to severe atopic dermatitis, 12 years of age or ...</td>\n      <td>[Fluocinonide Cream 0.1%]</td>\n      <td>[Drug: Fluocinonide Cream 0.1%]</td>\n      <td>[Fluocinonide Cream 0.1% open label]</td>\n      <td>[Fluocinonide Cream 0.1%]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[Change in Investigator Global Assessment of Atopic Dermatitis Severity From Baseline to Day 2/3...</td>\n      <td>[Use of the Investigator's Global Assessment (IGA) score, a subjective scale measuring disease s...</td>\n      <td>[Baseline to 3 days, Baseline to 14 days]</td>\n      <td>[-0.72, 2.4]</td>\n      <td>[Scores on a scale, units on a scale]</td>\n    </tr>\n    <tr>\n      <th>68</th>\n      <td>278</td>\n      <td>NCT01856764</td>\n      <td>Topical Roflumilast in Adults With Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>40</td>\n      <td>June 2013</td>\n      <td>March 2014</td>\n      <td>Inclusion Criteria:\\n\\nIs male or female between 18 to 65 years of age, inclusive, with atopic d...</td>\n      <td>[0.5% Roflumilast Cream, Vehicle Cream]</td>\n      <td>[Drug: 0.5% Roflumilast Cream, Drug: Vehicle Cream]</td>\n      <td>[Roflumilast 0.5%, cream, topically, twice daily for up to 15 days., Roflumilast formulation veh...</td>\n      <td>[0.5% Roflumilast Cream, Vehicle Cream]</td>\n      <td>[Primary, Secondary, Secondary]</td>\n      <td>[Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD), Change Fro...</td>\n      <td>[Modified Local SCORAD is the sum of 5 individual indexes; erythema, edema/papulation, oozing/cr...</td>\n      <td>[Baseline and Day 15, Baseline and Day 15, Baseline and Day 15]</td>\n      <td>[-2.30, -1.75, -18.60, -12.69, -3.05, -1.50]</td>\n      <td>[Scores on a scale, g/m^2/hr, Scores on a scale]</td>\n    </tr>\n    <tr>\n      <th>69</th>\n      <td>279</td>\n      <td>NCT01652885</td>\n      <td>Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 1, Phase 2</td>\n      <td>Interventional</td>\n      <td>23</td>\n      <td>July 2012</td>\n      <td>October 2012</td>\n      <td>Inclusion Criteria:\\n\\nMale or female 12 to 17 years of age, inclusive\\nClinical diagnosis of at...</td>\n      <td>[AN2728 Topical Ointment, 2%]</td>\n      <td>[Drug: AN2728 Topical Ointment, 2%]</td>\n      <td>[AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days]</td>\n      <td>[AN2728 Topical Ointment, 2%]</td>\n      <td>[Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Prima...</td>\n      <td>[Number of Participants With Local Tolerability Symptoms According to Severity on Baseline, Numb...</td>\n      <td>[Local tolerability symptoms, burning or stinging, were classified according to severity as: 1) ...</td>\n      <td>[Baseline, Day 2, Day 4, Day 6, Day 8, Day 9, Day 15, Day 22, Day 29, Baseline (Day 1) up to Day...</td>\n      <td>[10, 7, 6, 0, 17, 5, 1, 0, 18, 3, 2, 0, 18, 4, 1, 0, 20, 3, 0, 0, 18, 4, 1, 0, 19, 4, 0, 0, 21, ...</td>\n      <td>[participants, participants, participants, participants, participants, participants, participant...</td>\n    </tr>\n    <tr>\n      <th>70</th>\n      <td>280</td>\n      <td>NCT00886587</td>\n      <td>To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Not Applicable</td>\n      <td>Interventional</td>\n      <td>82</td>\n      <td>April 2009</td>\n      <td>June 2009</td>\n      <td>Inclusion Criteria:\\n\\nPost-menarchal female subjects must have a negative urine pregnancy test\\...</td>\n      <td>[F# 11054-010, F# 10495-053]</td>\n      <td>[Device: F# 11054-010, Device: F# 10495-053]</td>\n      <td>[F# 11054-010 Investigational Device, F# 10495-053 Atopiclair]</td>\n      <td>[11054-010, 10495-053]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Eczema Area and Severity Index (EASI) Score on Day 43 - Change From Baseline, Eczema Area and S...</td>\n      <td>[The surface and severity of eczema is measured using the Eczema Area and Severity Index (EASI)....</td>\n      <td>[Baseline to Day 43, Baseline to Day 15, Baseline to Day 43, Baseline to Day 43]</td>\n      <td>[-4.97, -5.01, -3.79, -4.14, 0.78, 0.73, -3.26, -3.29]</td>\n      <td>[units on a scale, units on a scale, units on a scale, units on a scale]</td>\n    </tr>\n    <tr>\n      <th>71</th>\n      <td>284</td>\n      <td>NCT03911401</td>\n      <td>Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>251</td>\n      <td>May 7, 2019</td>\n      <td>December 13, 2019</td>\n      <td>Inclusion Criteria:\\n\\nDiagnosis of AD based on the Japanese Dermatological Association's criter...</td>\n      <td>[0.3% OPA-15406, 1% OPA-15406, Placebos]</td>\n      <td>[Drug: 0.3% OPA-15406, Drug: 1% OPA-15406, Drug: Placebos]</td>\n      <td>[Twice daily, Twice daily, Twice daily]</td>\n      <td>[0.3% OPA-15406, 1% OPA-15406, Placebo]</td>\n      <td>[Primary, Secondary, Secondary]</td>\n      <td>[Responder Rate of Investigator's Global Assesment (IGA) of Disease Severity, Change From Baseli...</td>\n      <td>[The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or s...</td>\n      <td>[At Week 4, Baseline, Week 4, Baseline, Week 4]</td>\n      <td>[44.58, 47.06, 18.07, -4.97, -6.07, 0.35, -0.80, -0.68, -0.33]</td>\n      <td>[percentage of participants, score on a scale, score on a scale]</td>\n    </tr>\n    <tr>\n      <th>72</th>\n      <td>285</td>\n      <td>NCT02684097</td>\n      <td>A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata</td>\n      <td>Alopecia Areata</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>22</td>\n      <td>January 2016</td>\n      <td>November 28, 2017</td>\n      <td>Inclusion Criteria:\\n\\nMale or female, aged from 18 to 75 years, inclusively at the time of sign...</td>\n      <td>[Tralokinumab, Placebo]</td>\n      <td>[Drug: Tralokinumab, Drug: Placebo]</td>\n      <td>[Tralokinumab subcutaneous injection every two weeks for 24 weeks, Saline subcutaneous injection...</td>\n      <td>[Tralokinumab, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Other Pre-specified]</td>\n      <td>[Change in Gene Expression Th2/IL-13, \"T22\"/IL-22, S100A7 and S100A8, Th1/IFN-gamma, and Th17/IL...</td>\n      <td>[Change from baseline in cellular, and molecular markers in skin biopsies after treatment. Gene ...</td>\n      <td>[Baseline and Week 24, Week 24, Baseline and Week 24, Baseline and Week 24, Baseline and Week 24...</td>\n      <td>[-0.28, 0.49, 0, 0, 0, 64, 69, 57, 50, 59, 47, 58, 35, 8, 3]</td>\n      <td>[z-score, percentage change, Participants, percent change, percentage change, events]</td>\n    </tr>\n    <tr>\n      <th>73</th>\n      <td>286</td>\n      <td>NCT00819507</td>\n      <td>VANOS Cream and Skin Barrier Function</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>25</td>\n      <td>January 2009</td>\n      <td>January 2010</td>\n      <td>Inclusion Criteria:\\n\\nDiagnosis of AD according to Hanifin-Rajka criteria (see Appendix B)\\nAge...</td>\n      <td>[Fluocinonide]</td>\n      <td>[Drug: Fluocinonide]</td>\n      <td>[glucocorticoid cream]</td>\n      <td>[Vanos Cream]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[Change in Eczema Severity and Area Index, Change in Transepidermal Water Loss]</td>\n      <td>[The eczema area and severity index (EAS I) is a validated composite score measuring physical si...</td>\n      <td>[2 Weeks, 2 weeks]</td>\n      <td>[6.01, 14.35]</td>\n      <td>[units, G/m^2/hr]</td>\n    </tr>\n    <tr>\n      <th>74</th>\n      <td>287</td>\n      <td>NCT01326910</td>\n      <td>Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema</td>\n      <td>Atopic Dermatitis</td>\n      <td>Not Applicable</td>\n      <td>Interventional</td>\n      <td>90</td>\n      <td>March 2011</td>\n      <td>May 2011</td>\n      <td>Inclusion Criteria:\\n\\nChildren ages 6 mo- 18 years\\nAny ethnicity\\nDiagnosed with atopic dermat...</td>\n      <td>[Colloidal Oatmeal, Topical Cream]</td>\n      <td>[Drug: Colloidal Oatmeal, Device: Topical Cream]</td>\n      <td>[Experimental Topical cream applied twice daily (or as needed), Marketed Topical cream applied t...</td>\n      <td>[19306-127, 19306-137]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Eczema Area and Severity Index (EASI), Interim Eczema Area and Severity Index (EASI), Assessmen...</td>\n      <td>[A regional body surface area tabulation based on severity ranging from 0 (none) to 3 (severe), ...</td>\n      <td>[3 weeks, Week 2, through Week 3, through Week 3]</td>\n      <td>[3.014, 3.359, 1.286, 1.621, 1.310, 1.298, 1.154, 1.064, 38, 38, 3, 4, 1.557, 1.208, 1.840, 1.53...</td>\n      <td>[units on a scale, participants, units on a scale, units on a scale]</td>\n    </tr>\n    <tr>\n      <th>75</th>\n      <td>288</td>\n      <td>NCT01941537</td>\n      <td>Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-09...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>60</td>\n      <td>October 2013</td>\n      <td>February 2016</td>\n      <td>-Inclusion Criteria:\\n\\nSigned and dated an IRB-approved informed consent form before any study-...</td>\n      <td>[ILV-094, Placebo Comparator]</td>\n      <td>[Drug: ILV-094, Drug: Placebo Comparator]</td>\n      <td>[Forty patients will be enrolled in the ILV-094 treatment arm. A loading IV dose of 600 mg of IL...</td>\n      <td>[ILV-094, Placebo comparator]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Percentage Change in SCORAD, The Percentage of Patients Who Achieve an Improvement of 50% or Gr...</td>\n      <td>[Percentage Change in the Scoring of Atopic Dermatitis (SCORAD) at week 12 compared to baseline ...</td>\n      <td>[12 weeks, 12 weeks, 12 weeks, 12 weeks]</td>\n      <td>[-18.8, -11.7, 22.2, 15.0, -13.8, -8.0, -0.6, -0.3]</td>\n      <td>[percentage change, percentage of participants, percentage decline in SCORAD score, score on a s...</td>\n    </tr>\n    <tr>\n      <th>76</th>\n      <td>290</td>\n      <td>NCT02324972</td>\n      <td>Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>54</td>\n      <td>December 2014</td>\n      <td>November 2015</td>\n      <td>Inclusion Criteria:\\n\\nMale or female aged from 18 to 65 years old\\nConfirmed clinical diagnosis...</td>\n      <td>[AQX-1125, Placebo]</td>\n      <td>[Drug: AQX-1125, Drug: Placebo]</td>\n      <td>[1 x AQX-1125 Capsule daily, 1 x placebo capsule daily]</td>\n      <td>[AQX-1125, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Change From Baseline in Total Lesion Symptom Score (TLSS), Change From Baseline in Investigator...</td>\n      <td>[The TLSS is an assessment of the severity of each of the following three signs: erythema, papul...</td>\n      <td>[12 weeks, 12 weeks, 12 weeks, 12 weeks, 12 weeks]</td>\n      <td>[6.3, 6.6, -1.9, -1.9, 2.6, 2.8, -0.7, -0.8, 5.58, 5.35, -2.84, -2.12, 36.19, 37.21, -12.06, -11...</td>\n      <td>[units on a scale, units on a scale, units on a scale, units on a scale, units on a scale]</td>\n    </tr>\n    <tr>\n      <th>77</th>\n      <td>292</td>\n      <td>NCT01840605</td>\n      <td>A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis</td>\n      <td>Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>303</td>\n      <td>March 2013</td>\n      <td>November 2013</td>\n      <td>Inclusion Criteria:\\n\\nPatients aged between 7 and 15 years\\nPatients giving assent and whose le...</td>\n      <td>[Bepotastine besilate, ketotifen fumarate]</td>\n      <td>[Drug: Bepotastine besilate, Drug: ketotifen fumarate]</td>\n      <td>[Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally tw...</td>\n      <td>[TAU-284, ketotifen fumarate]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Change From Baseline in Pruritus Score, Change From Baseline in Pruritus Score, Severity of Ato...</td>\n      <td>[The pruritus symptoms score were rated on 5-point scale ranging from 0 (none) to 4 (severe)., T...</td>\n      <td>[Baseline and 2 weeks, Baseline and 1 weeks, Baseline and 2 weeks, Week 2]</td>\n      <td>[-0.669, -0.638, -0.425, -0.510, -0.8, -0.7, 65.6, 65.1]</td>\n      <td>[units on a scale, units on a scale, units on a scale, percentage of participants]</td>\n    </tr>\n    <tr>\n      <th>78</th>\n      <td>294</td>\n      <td>NCT01756898</td>\n      <td>Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjec...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>370</td>\n      <td>November 28, 2012</td>\n      <td>January 14, 2014</td>\n      <td>Inclusion Criteria:\\n\\nAdult subjects ages 18 to 65 years\\nA diagnosis of atopic dermatitis (AD)...</td>\n      <td>[5 mg ASB17061, Placebo, 10 mg ASB17061, 20 mg ASB17061]</td>\n      <td>[Drug: 5 mg ASB17061, Drug: 10 mg ASB17061, Drug: 20 mg ASB17061, Drug: Placebo]</td>\n      <td>[Oral administration of low dose ASB17061 taken once daily for 28 consecutive days., Oral admini...</td>\n      <td>[Low dose ASB17061, Placebo, Middle dose ASB17061, High dose ASB17061]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Number of Investigator's Global Assessment (IGA) Responders at Day 29 Following Treatment With ...</td>\n      <td>[Participants with an IGA score of 0 or 1 were considered IGA responders. The investigator provi...</td>\n      <td>[Baseline up to 29 days after initial dose., Baseline up to 29 days after initial dose., Baselin...</td>\n      <td>[20, 21, 19, 18, 1, 3, 7, 7, 19, 18, 12, 11, 13, 12, 14, 13, 6, 6, 4, 4, 1, 3, 1, 1, 18, 20, 18,...</td>\n      <td>[Participants, participants, Units on a scale, Percentage of BSA, Units on a scale, Units on a s...</td>\n    </tr>\n    <tr>\n      <th>79</th>\n      <td>296</td>\n      <td>NCT03908970</td>\n      <td>Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>364</td>\n      <td>March 25, 2019</td>\n      <td>December 28, 2019</td>\n      <td>Inclusion Criteria:\\n\\nDiagnosis of AD based on the Japanese Dermatological Association's criter...</td>\n      <td>[1% OPA-15406, Placebos]</td>\n      <td>[Drug: 1% OPA-15406, Drug: Placebos]</td>\n      <td>[Twice daily, Twice daily]</td>\n      <td>[1% OPA-15406, Placebo]</td>\n      <td>[Primary, Secondary, Secondary]</td>\n      <td>[Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity, Change From Baselin...</td>\n      <td>[The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or s...</td>\n      <td>[At Week 4, Baseline, Week 4, Baseline, Week 4]</td>\n      <td>[38.46, 12.64, -4.17, -0.08, -0.65, -0.04]</td>\n      <td>[percentage of perticipants, score on a scale, score on a scale]</td>\n    </tr>\n    <tr>\n      <th>80</th>\n      <td>297</td>\n      <td>NCT02118766</td>\n      <td>Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 ...</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>763</td>\n      <td>March 2014</td>\n      <td>April 2015</td>\n      <td>Inclusion Criteria:\\n\\nMales or females 2 years and older\\nHas a clinical diagnosis of AD accord...</td>\n      <td>[AN2728 Topical Ointment, 2%, Matching vehicle control]</td>\n      <td>[Drug: AN2728 Topical Ointment, 2%, Drug: Matching vehicle control]</td>\n      <td>[AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days, Matching vehicle control, a...</td>\n      <td>[AN2728 Topical Ointment, 2%, Matching vehicle control]</td>\n      <td>[Primary, Primary, Primary, Primary, Secondary, Secondary, Secondary, Other Pre-specified, Other...</td>\n      <td>[Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global...</td>\n      <td>[ISGA assessed the severity of AD (except scalp and venous access area) on a 5-point scale range...</td>\n      <td>[Day 29, AEs: Baseline (Day 1) up to Day 29, SAEs: Baseline (Day 1) up to Day 36, Baseline, Day ...</td>\n      <td>[32.8, 25.4, 147, 50, 5, 1, 0, 0, 0, 0, 51.7, 40.6, NA, NA, 1.7, 1.6, -0.7, -0.4, 1.8, 1.9, -0.7...</td>\n      <td>[percentage of participants, participants, participants, participants, percentage of participant...</td>\n    </tr>\n    <tr>\n      <th>81</th>\n      <td>298</td>\n      <td>NCT02120833</td>\n      <td>A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin</td>\n      <td>Eczema</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>51</td>\n      <td>March 2014</td>\n      <td>November 2014</td>\n      <td>Inclusion Criteria\\n\\nAble to comprehend and follow the requirements of the study (including ava...</td>\n      <td>[EpiCeram\u00ae Skin Barrier Emulsion, Colloidal Oatmeal Cream]</td>\n      <td>[Device: EpiCeram\u00ae Skin Barrier Emulsion, Drug: Colloidal Oatmeal Cream]</td>\n      <td>[]</td>\n      <td>[EPI, NEE]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n      <td>[Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline, Investigator's Global At...</td>\n      <td>[The surface and severity of eczema is measured using the Eczema Area and Severity Index (EASI)....</td>\n      <td>[Baseline to Day 3, Baseline to Day 3, Baseline to Day 1, Baseline to Day 2, Baseline to Day 7, ...</td>\n      <td>[-1.783, -0.767, -0.441, -0.364, -0.672, -0.438, -1.194, -0.489, -2.410, -1.233, -2.403, -1.833,...</td>\n      <td>[units on a scale, units on a scale, units on a scale, units on a scale, units on a scale, units...</td>\n    </tr>\n    <tr>\n      <th>82</th>\n      <td>302</td>\n      <td>NCT03954158</td>\n      <td>Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Parti...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>81</td>\n      <td>June 15, 2019</td>\n      <td>December 16, 2019</td>\n      <td>Inclusion Criteria:\\n\\nMale or female participants ages; Cohort 1: 12 years and older at the tim...</td>\n      <td>[Crisaborole ointment 2%, Vehicle, Crisaborole ointment 2%, Vehicle]</td>\n      <td>[Drug: Crisaborole ointment 2%, Drug: Vehicle, Drug: Crisaborole ointment 2%, Drug: Vehicle]</td>\n      <td>[intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion...</td>\n      <td>[Crisaborole ointment 2% twice daily (BID) vs vehicle BID, Crisaborole ointment 2% twice daily (...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Change From Baseline in Total Sign Score (TSS) in Target Lesions at Day 15: Crisaborole Ointmen...</td>\n      <td>[Lesion TSS was an assessment of the target lesion severity, which was based on severity of 4 cl...</td>\n      <td>[Baseline, Day 15, Baseline, Day 15, Baseline, Day 8, Baseline, Day 8, Day 15, Baseline, Day 2, ...</td>\n      <td>[7.7, 7.5, 7.1, 7.4, 6.2, 6.5, 7.1, 7.3, -4.5, -2.9, -4.8, -2.7, -3.5, -2.0, -4.7, -2.6, -4.3, -...</td>\n      <td>[units on a scale, units on a scale, units on a scale, units on a scale, units on a scale, units...</td>\n    </tr>\n    <tr>\n      <th>83</th>\n      <td>303</td>\n      <td>NCT01469767</td>\n      <td>Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>10</td>\n      <td>February 1, 2012</td>\n      <td>August 17, 2013</td>\n      <td>Inclusion Criteria:\\n\\nMale or female with mild to severe atopic dermatitis, 12 years of age or ...</td>\n      <td>[Fluocinonide cream]</td>\n      <td>[Drug: Fluocinonide cream]</td>\n      <td>[Subjects will apply fluocinonide cream 0.1% twice daily for 5 days.]</td>\n      <td>[Fluocinonide cream]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[IGA, Actigraphy, EASI, BSA, VAS]</td>\n      <td>[Investigator's Global Assessment of atopic dermatitis integrates all lesions for overall score....</td>\n      <td>[14 days, 14 days, 14 days, 14 days, 14 days]</td>\n      <td>[1, 85.7, 2.2, 5.5, 41]</td>\n      <td>[units on a scale, Movement count per hour, units on a scale, Percent BSA, units on a scale]</td>\n    </tr>\n    <tr>\n      <th>84</th>\n      <td>305</td>\n      <td>NCT01393158</td>\n      <td>Apremilast for Atopic Dermatitis - A Pilot Study in Adults</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>16</td>\n      <td>May 2009</td>\n      <td>July 2011</td>\n      <td>Inclusion Criteria:\\n\\nDisease severity of Moderate, Severe, or Very Severe by Investigator Glob...</td>\n      <td>[Apremilast]</td>\n      <td>[Drug: Apremilast, Drug: Apremilast]</td>\n      <td>[Patients dosed with 20 mg orally of Apremilast BID for 3 months., Patients dosed with 30 mg ora...</td>\n      <td>[20 mg BID, 30 mg BID]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Change in EASI Scores, Number of Participants in Each IGA Category, Change in Pruritus (Visual ...</td>\n      <td>[The eczema area and severity index (EASI) is a composite score measuring physical signs of atop...</td>\n      <td>[Mean change in EASI score measured at Baseline and Month 3, (if on 20mg arm) or Baseline and Mo...</td>\n      <td>[-8.8, -8.2, 0, 1, 2, 8, 3, 1, 1, 0, -32.2, -13.4, -8.3, -6.3]</td>\n      <td>[units on a scale, participants, units on a scale, units on a scale]</td>\n    </tr>\n    <tr>\n      <th>85</th>\n      <td>311</td>\n      <td>NCT01037881</td>\n      <td>LEO 29102 Cream in the Treatment of Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>183</td>\n      <td>December 2009</td>\n      <td>June 2010</td>\n      <td>Inclusion Criteria:\\n\\nClinical diagnosis of atopic dermatitis defined according to Hanifin and ...</td>\n      <td>[LEO 29102, Elidel\u00ae]</td>\n      <td>[Drug: LEO 29102, Drug: LEO 29102, Drug: LEO 29102, Drug: LEO 29102, Drug: LEO 29102, Drug: LEO ...</td>\n      <td>[]</td>\n      <td>[LEO 29102 0.03 mg/g cream, LEO 29102 0.1 mg/g cream, LEO 29102 0.3 mg/g cream, LEO 29102 1.0 mg...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Absolute Change in Eczema Area and Severity Index (EASI) Score From Baseline (Last Observation ...</td>\n      <td>[The EASI is a composite score based on the evaluation of four characteristic atopic dermatitis ...</td>\n      <td>[Baseline (Day 0) and end of treatment (Day 28), At end of treatment (Day 28), At end of treatme...</td>\n      <td>[-0.85, -2.13, -1.09, -2.86, -2.41, -2.50, -3.30, 6, 2, 5, 9, 10, 13, 12, 19, 22, 20, 16, 19, 17...</td>\n      <td>[units on a scale, Participants, Participants, Participants, Participants, units on a scale]</td>\n    </tr>\n    <tr>\n      <th>86</th>\n      <td>312</td>\n      <td>NCT00690833</td>\n      <td>Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>41</td>\n      <td>August 2007</td>\n      <td>December 2007</td>\n      <td>Inclusion Criteria:\\n\\nMale or female, age 3 months or greater.\\nSubjects must have diagnosis of...</td>\n      <td>[topical desonide hydrogel 0.05%]</td>\n      <td>[Drug: topical desonide hydrogel 0.05%]</td>\n      <td>[Approximately 40 male and female subjects (about 20 age 3 months to &lt;13 years and 20 age 13 and...</td>\n      <td>[topical desonide hydrogel 0.05%]</td>\n      <td>[Primary]</td>\n      <td>[Investigator Global Assessment at Week 4]</td>\n      <td>[The Investigator global assessment at Week 4 is based on an overall scale of 0-4 with 0 being c...</td>\n      <td>[Week 4]</td>\n      <td>[2.3]</td>\n      <td>[units on a scale]</td>\n    </tr>\n    <tr>\n      <th>87</th>\n      <td>313</td>\n      <td>NCT03050294</td>\n      <td>Evaluating Treatment Resistant Dermatitis TaroIIR</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>24</td>\n      <td>February 1, 2017</td>\n      <td>June 1, 2017</td>\n      <td>Inclusion Criteria:\\n\\nMale or female \u226518 years of age at baseline visit.\\n\\nDocumentation of pl...</td>\n      <td>[Phone calls, Desoximetasone 0.25% spray]</td>\n      <td>[Drug: Desoximetasone 0.25% spray, Behavioral: Phone calls, Drug: Desoximetasone 0.25% spray, Dr...</td>\n      <td>[Participants with atopic dermatitis will receive desoximetasone and no calls., Participants wit...</td>\n      <td>[Atopic Dermatitis Intervention, Psoriasis Intervention, Atopic Dermatitis Intervention, Control...</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Investigator Global Assessment- Atopic Dermatitis, Investigator Global Assessment- Psoriasis, T...</td>\n      <td>[Investigator's Global Assessment of atopic dermatitis integrates all lesions for overall score....</td>\n      <td>[1 week, 2 weeks, 1 week, 2 weeks, 1 week, 1 week, 2 weeks, 2 weeks]</td>\n      <td>[1.7, 1.5, 2.5, 2.3, 3.8, 4.7, 6.5, 5.8, 3.1, 1.2, 1.1, 1.2, 1.4, 1.3, 7.1, 5.1]</td>\n      <td>[units on a scale, units on a scale, units on a scale, units on a scale, units on a scale, units...</td>\n    </tr>\n    <tr>\n      <th>88</th>\n      <td>317</td>\n      <td>NCT01996748</td>\n      <td>Clinical Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in the Treatment o...</td>\n      <td>Otic Eczema</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>135</td>\n      <td>February 2012</td>\n      <td>March 2012</td>\n      <td>Inclusion Criteria:\\n\\n12 years or older\\nClinical diagnosis of otic eczema suitable for local t...</td>\n      <td>[DF277, Placebo]</td>\n      <td>[Drug: DF277, Drug: Placebo]</td>\n      <td>[Two administrations daily for 7 days, Two administrations daily for 7 days]</td>\n      <td>[DF277, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Analysis of the Itching Change at the End of Treatment., Change in Signs/ Symptoms, Change in M...</td>\n      <td>[The analysis of the itching change at the end of treatment (mean itching on days 4-8 compared t...</td>\n      <td>[Baseline and days 4-8, Baseline and days 9-15, Baseline and day 8, Baseline and day 15]</td>\n      <td>[-1.63, -1.25, -1.80, -1.32, -1.21, -0.78, -1.20, -0.77]</td>\n      <td>[units on a scale, units on a scale, units on a scale, units on a scale]</td>\n    </tr>\n    <tr>\n      <th>89</th>\n      <td>318</td>\n      <td>NCT02118792</td>\n      <td>Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 ...</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>764</td>\n      <td>March 2014</td>\n      <td>April 2015</td>\n      <td>Inclusion Criteria:\\n\\nMales or females 2 years and older\\nHas a clinical diagnosis of Atopic De...</td>\n      <td>[AN2728 Topical Ointment, 2%, Matching vehicle control]</td>\n      <td>[Drug: AN2728 Topical Ointment, 2%, Drug: Matching vehicle control]</td>\n      <td>[AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days, Matching vehicle control, a...</td>\n      <td>[AN2728 Topical Ointment, 2%, Matching vehicle control]</td>\n      <td>[Primary, Primary, Primary, Primary, Primary, Primary, Secondary, Secondary, Secondary, Other Pr...</td>\n      <td>[Percentage of Participants Who Achieved Success in Investigator's Static Global Assessment (ISG...</td>\n      <td>[ISGA assessed the severity of AD (except scalp) on a 5-point scale ranged from 0 (clear) to 4 (...</td>\n      <td>[Day 29, AEs: Baseline (Day 1) up to Day 29, SAEs: Baseline (Day 1) up to Day 36, Baseline, Day ...</td>\n      <td>[31.4, 18.0, 150, 79, 3, 0, 0, 0, 0, 0, 4, 4, 48.7, 56.3, 23.8, 21.9, 19.6, 16.6, 7.9, 5.3, 48.5...</td>\n      <td>[percentage of participants, participants, participants, participants, participants, percentage ...</td>\n    </tr>\n    <tr>\n      <th>90</th>\n      <td>323</td>\n      <td>NCT03011892</td>\n      <td>A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to ...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>307</td>\n      <td>January 9, 2017</td>\n      <td>January 10, 2018</td>\n      <td>Inclusion Criteria:\\n\\nParticipants diagnosed with atopic dermatitis (AD) as defined by the Hani...</td>\n      <td>[Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD, Ruxolitinib 1...</td>\n      <td>[Drug: Vehicle Cream BID, Drug: Triamcinolone 0.1% Cream BID, Drug: Vehicle Cream BID, Drug: Rux...</td>\n      <td>[Participants applied vehicle cream twice daily (BID) for 8 weeks DB period., Participants appli...</td>\n      <td>[DB: Ruxolitinib 0.15% Once Daily (QD), DB: Ruxolitinib 0.5% QD, DB: Ruxolitinib 1.5% QD, DB: Ru...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Mean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 i...</td>\n      <td>[EASI is a validated composite scoring system integrating the proportion of the body region (are...</td>\n      <td>[Baseline and Week 4, Baseline and Week 4, Baseline and Week 4, Baseline, Week 2 and 8, Week 2, ...</td>\n      <td>[-11.90, -71.57, -11.90, -44.92, -52.80, -66.72, -59.54, -44.92, -52.80, -66.72, -71.57, -4.84, ...</td>\n      <td>[percent change, percent change, percent change, percent change, percentage of participants, per...</td>\n    </tr>\n    <tr>\n      <th>91</th>\n      <td>325</td>\n      <td>NCT03903822</td>\n      <td>Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 ...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>292</td>\n      <td>May 13, 2019</td>\n      <td>May 7, 2020</td>\n      <td>Inclusion Criteria:\\n\\nClinical diagnosis of Atopic Dermatitis for at least 3 months\\nInvestigat...</td>\n      <td>[PF-06700841, Vehicle (Placebo)]</td>\n      <td>[Drug: PF-06700841, Drug: PF-06700841, Drug: PF-06700841, Drug: PF-06700841, Drug: PF-06700841, ...</td>\n      <td>[PF-06700841 0.1% cream applied once daily (QD), PF-06700841 0.3% cream applied once daily (QD),...</td>\n      <td>[PF-06700841 0.1% cream QD, PF-06700841 0.3% cream BID, PF-06700841 0.3% cream QD, PF-06700841 1...</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Mu...</td>\n      <td>[EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of...</td>\n      <td>[Baseline, Week 6, Baseline, Week 6, Baseline, Week 6, Baseline, Weeks 1, 2, 3, 4 and 6, Baselin...</td>\n      <td>[-44.4, -58.3, -64.6, -70.1, -67.9, -47.6, -58.6, -75.0, 10.8, 29.7, 33.3, 40.5, 44.4, 13.9, 33....</td>\n      <td>[Percent change, Percentage of participants, Units on a scale, Percentage of participants, Perce...</td>\n    </tr>\n    <tr>\n      <th>92</th>\n      <td>326</td>\n      <td>NCT02914548</td>\n      <td>Study of OPA-15406 Ointment in Patients With Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>200</td>\n      <td>September 2016</td>\n      <td>June 2017</td>\n      <td>Inclusion Criteria:\\n\\nDiagnosis of atopic dermatitis based on the criteria of Hanifin and Rajka...</td>\n      <td>[OPA-15406, Placebo]</td>\n      <td>[Drug: OPA-15406, Drug: OPA-15406, Drug: Placebo]</td>\n      <td>[Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily., Subjects were treated...</td>\n      <td>[0.3% OPA-15406, 1% OPA-15406, Placebo]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Responder Rate of Investigator's Global Assessment(IGA) of Disease Severity at Week4, Change Fr...</td>\n      <td>[The investigator or sub investigator assessed the skin symptoms using IGA. The investigator or ...</td>\n      <td>[At Week 4, Baseline, Week 4, Baseline, Week 4, Baseline, Hour 156, Baseline, Week 4, Baseline, ...</td>\n      <td>[14.93, 22.39, 9.09, -2.32, -3.16, -0.15, -6.76, -6.28, 0.90, -0.43, -0.49, -0.06, -1.36, -2.90,...</td>\n      <td>[percentage of participants, score on a scale, mm, score on a scale, score on a scale, percentag...</td>\n    </tr>\n    <tr>\n      <th>93</th>\n      <td>333</td>\n      <td>NCT03107611</td>\n      <td>Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel\u00ae Cream, 1% in Mild to Moderate Atopic ...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>654</td>\n      <td>February 29, 2016</td>\n      <td>May 15, 2017</td>\n      <td>Inclusion Criteria:\\n\\nNon-immuno compromised male or female aged 8 years and older\\nClinical di...</td>\n      <td>[Pimecrolimus Cream, 1%, Placebo Cream, Pimecrolimus Cream, 1%]</td>\n      <td>[Drug: Pimecrolimus Cream, 1%, Drug: Pimecrolimus Cream, 1%, Drug: Placebo Cream]</td>\n      <td>[Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for ...</td>\n      <td>[Test, Placebo, Reference Standard]</td>\n      <td>[Primary, Primary, Secondary, Secondary]</td>\n      <td>[Proportion of Modified Intent to Treat Subjects With Success on Investigator's Global Assessmen...</td>\n      <td>[Investigator's Global Assessment of Disease Severity Scale: Clear (0) Minor residual discolorat...</td>\n      <td>[Day 15, Day 15, Day 15, Day 15]</td>\n      <td>[108, 115, 98, 105, 113, 95, 0, 0, 0, 1, 1, 1, 2, 5, 4, 121, 118, 135, 51, 50, 48, 24, 30, 15, 2...</td>\n      <td>[Participants, Participants, Participants, Participants]</td>\n    </tr>\n    <tr>\n      <th>94</th>\n      <td>335</td>\n      <td>NCT00828412</td>\n      <td>Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>100</td>\n      <td>March 2009</td>\n      <td>August 2009</td>\n      <td>Inclusion Criteria:\\n\\nat least 3 months of age and less than 13 years of age\\natopic dermatitis...</td>\n      <td>[EpiCeram Skin Barrier Emulsion, Desonide Cream 0.05%]</td>\n      <td>[Device: EpiCeram Skin Barrier Emulsion, Drug: Desonide Cream 0.05%]</td>\n      <td>[EpiCeram Skin Barrier Emulsion, Desonide Cream 0.05%]</td>\n      <td>[1, 2]</td>\n      <td>[Primary]</td>\n      <td>[Change From Baseline in Three Item Severity Score]</td>\n      <td>[The average of the sum of scores for erythema, edema/papulation, and excoriation for two target...</td>\n      <td>[Baseline to 6 weeks]</td>\n      <td>[-2.6, -3.6]</td>\n      <td>[units on a scale]</td>\n    </tr>\n    <tr>\n      <th>95</th>\n      <td>336</td>\n      <td>NCT02317276</td>\n      <td>A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticostero...</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>11</td>\n      <td>December 2014</td>\n      <td>April 6, 2017</td>\n      <td>Inclusion Criteria:\\n\\nMale or female patients 18-75 years of age\\nAD diagnosed by the Rajka/Han...</td>\n      <td>[Triamcinolone 0.1%]</td>\n      <td>[Drug: Triamcinolone 0.1%]</td>\n      <td>[Topical Triamcinolone 0.1% ointment will be provided for twice daily application, during treatm...</td>\n      <td>[Treatment]</td>\n      <td>[Primary]</td>\n      <td>[Change in Blood and Tissue Levels of Biomarkers Following Treatment of Atopic Dermatitis With T...</td>\n      <td>[The blood and skin biomarkers to be evaluated include but are not limited to eosinophils, Immun...</td>\n      <td>[Baseline to Week 8]</td>\n      <td>[]</td>\n      <td>[]</td>\n    </tr>\n    <tr>\n      <th>96</th>\n      <td>339</td>\n      <td>NCT01602341</td>\n      <td>Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>86</td>\n      <td>August 2012</td>\n      <td>January 2013</td>\n      <td>Inclusion Criteria:\\n\\nMale or female 12 to 17 years of age, inclusive\\nClinical diagnosis of at...</td>\n      <td>[AN2728 Topical Ointment, 2% QD, AN2728 Topical Ointment, 0.5% QD, AN2728 Topical Ointment, 2% B...</td>\n      <td>[Drug: AN2728 Topical Ointment, 2% QD, Drug: AN2728 Topical Ointment, 0.5% QD, Drug: AN2728 Topi...</td>\n      <td>[AN2728 Topical Ointment, 2% applied once daily for 29 days to a target lesion, and AN2728 Topic...</td>\n      <td>[AN2728 Topical Ointment, 2% QD vs 0.5% QD, AN2728 Topical Ointment, 2% QD vs 0.5% QD, AN2728 To...</td>\n      <td>[Primary, Primary, Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Seco...</td>\n      <td>[Improvement From Baseline in Atopic Dermatitis Severity Index (ADSI) Score at Day 8, Improvemen...</td>\n      <td>[ADSI was used to assess the severity of atopic dermatitis (AD) based on five subscale scores of...</td>\n      <td>[Baseline, Day 8, Baseline, Day 15, Baseline, Day 22, Baseline, Day 29, Baseline up to Day 29, B...</td>\n      <td>[8.22, 8.02, 8.13, 8.19, 2.80, 3.63, 4.33, 4.81, 4.02, 4.34, 4.51, 5.36, 3.86, 4.55, 4.70, 5.49,...</td>\n      <td>[units on a scale, units on a scale, units on a scale, units on a scale, Participants, Participa...</td>\n    </tr>\n    <tr>\n      <th>97</th>\n      <td>340</td>\n      <td>NCT00375713</td>\n      <td>Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal\u00ae (Levocetirizine) vs Zyr...</td>\n      <td>Dermatitis</td>\n      <td>Phase 3</td>\n      <td>Interventional</td>\n      <td>466</td>\n      <td>October 2005</td>\n      <td>May 2006</td>\n      <td>Inclusion Criteria:\\n\\nSubjects diagnosed as having atopic dermatitis, contact dermatitis, pruri...</td>\n      <td>[Levocetirizine, Cetirizine, Placebo-Levocetirizine, Placebo-Cetirizine, Standard topical steroi...</td>\n      <td>[Drug: Levocetirizine, Drug: Placebo-Cetirizine, Drug: Standard topical steroid (1% hydrocortiso...</td>\n      <td>[Levocetirizine + Cetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for...</td>\n      <td>[Levocetirizine, Cetirizine, Cetirizine, Levocetirizine, Cetirizine, Levocetirizine]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Responder Status According to Pruritus Severity Score (Response = Mild or None in Pruritus Seve...</td>\n      <td>[A participant is a responder if the pruritus severity score is assessed as mild or none, otherw...</td>\n      <td>[Day 7 and 14, Baseline and at endpoint during the 14 day treatment period, At endpoint during t...</td>\n      <td>[131, 134, 37, 38, 1.15, 1.21, 2.13, 2.20, 47, 52, 62, 54, 39, 47, 18, 15, 1, 1]</td>\n      <td>[Participants, Units on a scale, Units on a scale, Participants]</td>\n    </tr>\n    <tr>\n      <th>98</th>\n      <td>344</td>\n      <td>NCT02002871</td>\n      <td>Blue Light for Treating Eczema</td>\n      <td>Eczema</td>\n      <td>Not Applicable</td>\n      <td>Interventional</td>\n      <td>21</td>\n      <td>October 2013</td>\n      <td>March 2014</td>\n      <td>Inclusion Criteria:\\n\\nSigned and dated informed consent prior to any study-mandated procedure\\n...</td>\n      <td>[PSO-CT02 device]</td>\n      <td>[Device: PSO-CT02 device]</td>\n      <td>[Irradiation with PSOCT02 device emitting blue light at a wavelength of 453nm, contralateral unt...</td>\n      <td>[Blue light]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Other Pre-specified, Other Pre-...</td>\n      <td>[Change From Baseline (Visit 2) of the Sum Score of Local Eczema Rating of the Target Area as Co...</td>\n      <td>[The investigator rated the key symptoms erythema, induration/papulation/edema, excoriation, lic...</td>\n      <td>[at week 4, week 6, week 4, 6, week 6, week 4, 6, week 6, week 0, 2, 4, 6, week 0, 2, 4, 6, over...</td>\n      <td>[-1.9, -1.3, -0.5, -0.5, 4.7, -0.9, 1.1, 0.3, -3.6, 1.2, -2.6, -15.6, -10.3, -19.6, -7.7, -4.0, ...</td>\n      <td>[units on a scale, units on a scale, arbitrary units, arbitrary units, units on a scale, units o...</td>\n    </tr>\n    <tr>\n      <th>99</th>\n      <td>354</td>\n      <td>NCT00654355</td>\n      <td>Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Re...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>30</td>\n      <td>April 2008</td>\n      <td>September 2009</td>\n      <td>Inclusion Criteria:\\n\\nMale or female subjects age 2-15.\\nStable or worsening atopic dermatitis ...</td>\n      <td>[tacrolimus ointment]</td>\n      <td>[Drug: tacrolimus ointment]</td>\n      <td>[tacrolimus ointment]</td>\n      <td>[Active Drug]</td>\n      <td>[Primary, Secondary, Secondary]</td>\n      <td>[Adherence, The % Change From Baseline to Week 4 (or End of Treatment) in the IGA., EASI]</td>\n      <td>[adherence to topical therapy in children via MEMS cap in a \"real-life\" clinic population measur...</td>\n      <td>[Week 4, Week 4, Week 4]</td>\n      <td>[56, 72, -33, -33, 2.1, 1]</td>\n      <td>[percentage of required applicaitons, % change in IGA, units on a scale]</td>\n    </tr>\n    <tr>\n      <th>100</th>\n      <td>356</td>\n      <td>NCT00557284</td>\n      <td>Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>20</td>\n      <td>March 2008</td>\n      <td>May 2009</td>\n      <td>Inclusion Criteria:\\n\\nMild to moderate atopic dermatitis involving greater than or equal to 5% ...</td>\n      <td>[Montelukast, Placebo]</td>\n      <td>[Drug: Montelukast, Drug: Placebo]</td>\n      <td>[Montelukast]</td>\n      <td>[1, 2]</td>\n      <td>[Secondary, Secondary, Primary, Primary, Primary, Primary, Primary, Secondary]</td>\n      <td>[Mean Change in Serum and Urinary Inflammatory Marker Levels, Mean Change in Serum IgE Levels, C...</td>\n      <td>[Mean change in levels from baseline to study visit 4 (week 1 compared to week 9)for interleukin...</td>\n      <td>[Baseline and 9 weeks, Baseline and 9 weeks, Baseline and 9 weeks, Baseline and 9 weeks, Baselin...</td>\n      <td>[-9.0, -7.9, 2.3, -16.4, 30.9, -58.8, -2.1, -20.42, 100.5, 216.1, -2.0, 0.15, -.11, -.70, -.78, ...</td>\n      <td>[pg/ml, kU/L, Change of percentage in body involvement, units on a scale, units on a scale, unit...</td>\n    </tr>\n    <tr>\n      <th>101</th>\n      <td>359</td>\n      <td>NCT01065714</td>\n      <td>A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons Wi...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>20</td>\n      <td>February 2010</td>\n      <td>November 2010</td>\n      <td>Inclusion Criteria:\\n\\nDefinitive diagnosis of atopic dermatitis as characterized by Hanifin and...</td>\n      <td>[Hydrogel vehicle, Eucerin Lotion]</td>\n      <td>[Drug: Hydrogel vehicle, Drug: Eucerin Lotion]</td>\n      <td>[Parallel designed study. Split body treatment, Parallel study design. Split body study.]</td>\n      <td>[Hydrogel vehicle, Eucerin Lotion]</td>\n      <td>[Primary, Primary, Secondary, Secondary]</td>\n      <td>[Percent Change of Trans Epidermal Water Loss (TEWL) With Use of Eucerin Lotion, Percent Change ...</td>\n      <td>[The average of three sequential Tewameter 300 meter readings taken at a minimum of one minute i...</td>\n      <td>[Day 1 to Day 14, Day 1 to Day 14, Baseline to 14 days, Baseline to 14 days]</td>\n      <td>[21.4, 4.2, 33.5, 32.3]</td>\n      <td>[percent change, percent change, Percentage of participants, percentage of participants]</td>\n    </tr>\n    <tr>\n      <th>102</th>\n      <td>360</td>\n      <td>NCT01915914</td>\n      <td>A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Flutic...</td>\n      <td>Skin Diseases</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>107</td>\n      <td>December 23, 2013</td>\n      <td>February 15, 2015</td>\n      <td>Inclusion Criteria:\\n\\nSpecific information regarding warnings, precautions, contraindications, ...</td>\n      <td>[Fluticasone propionate]</td>\n      <td>[Drug: Fluticasone propionate, Drug: Fluticasone propionate]</td>\n      <td>[To evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream (twice per wee...</td>\n      <td>[fluticasone propionate, physiogel]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Time to the First Relapse of AD During the Maintenance Phase, Median Time to the First Relapse ...</td>\n      <td>[Time to the first relapse of AD is defined as the number of days from start of the FP treatment...</td>\n      <td>[From the start of treatment up to Week 20 during the Maintenance Phase, From the start of treat...</td>\n      <td>[NA, 142.0, NA, 142.0, 3, 30, 10, 32, 107, -0.4, 2.2, 0.0, 2.2, 2, 1, 2, 1, 2, 2, 2, 2, 1, 0, 39...</td>\n      <td>[Days, Days, Participants, Participants, Participants, Scores on a scale, Scores on a scale, Par...</td>\n    </tr>\n    <tr>\n      <th>103</th>\n      <td>361</td>\n      <td>NCT00924508</td>\n      <td>Hydrogel Patch for the Treatment of Eczema</td>\n      <td>Eczema</td>\n      <td>Not Applicable</td>\n      <td>Interventional</td>\n      <td>23</td>\n      <td>July 2008</td>\n      <td>September 2011</td>\n      <td>Inclusion Criteria:\\n\\nSubject has signed the informed consent form and Health Insurance Portabi...</td>\n      <td>[hydrogel patch, Triamcinolone (TAC) 0.1% cream]</td>\n      <td>[Device: hydrogel patch, Drug: Triamcinolone (TAC) 0.1% cream]</td>\n      <td>[This is a single arm study. Each subject will have 3 target lesions; one treated with TAC 0.1% ...</td>\n      <td>[Patch + cream, patch alone, cream alone, Patch + cream, patch alone, cream alone]</td>\n      <td>[Primary, Secondary]</td>\n      <td>[Change in Disease Severity: Percent Change in Mean EASI Score, Number of Adverse Events Associa...</td>\n      <td>[Percent change in mean EASI score week 0 to week 6: Each lesion was scored using a 12-point mod...</td>\n      <td>[Baseline, 6 weeks, 6 weeks]</td>\n      <td>[-47, -56, -61, 0]</td>\n      <td>[percentage change, Adverse events]</td>\n    </tr>\n    <tr>\n      <th>104</th>\n      <td>365</td>\n      <td>NCT00931242</td>\n      <td>Study of Apremilast in Atopic or Contact Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>10</td>\n      <td>June 2009</td>\n      <td>March 2010</td>\n      <td>Inclusion Criteria:\\n\\nMust understand and voluntarily sign an informed consent form.\\nMust be m...</td>\n      <td>[Apremilast]</td>\n      <td>[Drug: Apremilast]</td>\n      <td>[Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 we...</td>\n      <td>[Apremilast]</td>\n      <td>[Primary, Secondary, Secondary]</td>\n      <td>[Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) ...</td>\n      <td>[Improvement in IGA (Investigator Global Assessment) by two or more points on a five point scale...</td>\n      <td>[12 weeks, 12 weeks, 12 weeks]</td>\n      <td>[2, 1, 2]</td>\n      <td>[participants, participants, participants]</td>\n    </tr>\n    <tr>\n      <th>105</th>\n      <td>372</td>\n      <td>NCT01301508</td>\n      <td>Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Derm...</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>46</td>\n      <td>May 2011</td>\n      <td>November 11, 2011</td>\n      <td>Inclusion Criteria:\\n\\nClinical diagnosis of atopic dermatitis that has been clinically stable f...</td>\n      <td>[AN2728 ointment, 2%, AN2898 ointment, 1%, AN2898 ointment vehicle, AN2728 ointment vehicle]</td>\n      <td>[Drug: AN2898 ointment, 1%, Drug: AN2898 ointment vehicle, Drug: AN2728 ointment, 2%, Drug: AN27...</td>\n      <td>[AN2898 ointment applied twice daily for 6 weeks to one target lesion, and AN2898 ointment vehic...</td>\n      <td>[AN2728 ointment, 2%, vs. ointment vehicle, AN2898 ointment, 1%, vs. ointment vehicle, AN2898 oi...</td>\n      <td>[Primary, Primary, Primary, Primary, Primary, Other Pre-specified, Other Pre-specified]</td>\n      <td>[Atopic Dermatitis Severity Index (ADSI) Score at Baseline (Day 1), Atopic Dermatitis Severity I...</td>\n      <td>[ADSI score was used to measure the severity of participant's atopic dermatitis (AD) affected le...</td>\n      <td>[Baseline (Day 1), Day 14, Day 28, Day 42, Baseline (Day 1), Day 28, Baseline (Day 1), Day 14, D...</td>\n      <td>[8.0, 8.3, 8.0, 8.4, 3.8, 4.0, 5.4, 5.6, 2.6, 2.8, 4.3, 5.1, 3.5, 3.0, 3.1, 4.6, 71.4, 68.0, 14....</td>\n      <td>[units on a scale, units on a scale, units on a scale, units on a scale, percentage of participa...</td>\n    </tr>\n    <tr>\n      <th>106</th>\n      <td>376</td>\n      <td>NCT01064947</td>\n      <td>Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic De...</td>\n      <td>Atopic Dermatitis</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>29</td>\n      <td>February 2010</td>\n      <td>January 2012</td>\n      <td>Inclusion Criteria:\\n\\nFemale subjects of childbearing potential must have a negative urine preg...</td>\n      <td>[Retapamulin 1%]</td>\n      <td>[]</td>\n      <td>[]</td>\n      <td>[]</td>\n      <td>[Primary, Secondary, Secondary, Secondary]</td>\n      <td>[Bacteriological Culture, Skin Infection Rating Scale (SIRS), Investigator Assessment of Clinica...</td>\n      <td>[All participants were cultured for S.aureus (MRSA), S.aureus (MSSA) and S. pyogenes at Baseline...</td>\n      <td>[Day 1 and Day 7, Day 1 and Day 7, Day 7, Day 7]</td>\n      <td>[13, 3, 16, 5, 0, 0, 10.0, 1.0, 12, 15, 2, 1.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00,...</td>\n      <td>[participants, units on a scale, participants, units on a scale]</td>\n    </tr>\n    <tr>\n      <th>107</th>\n      <td>382</td>\n      <td>NCT00903357</td>\n      <td>The Effectiveness of Montelukast on Atopic Dermatitis in Koreans</td>\n      <td>Atopic Dermatitis</td>\n      <td>Not Applicable</td>\n      <td>Interventional</td>\n      <td>54</td>\n      <td>August 2009</td>\n      <td>August 2010</td>\n      <td>Inclusion Criteria:\\n\\nThe ages of 2 to 6 years old, 54 children with moderate to severe atopic ...</td>\n      <td>[Montelukast first, then placebo, Placebo first, then Montelukast]</td>\n      <td>[Drug: Montelukast first, then placebo, Drug: Placebo first, then Montelukast, Drug: Montelukast...</td>\n      <td>[The group received active medication (montelukast 4 mg or 5mg once daily) for 8 weeks followed ...</td>\n      <td>[Montelukast first, then placebo, Placebo first, then Montelukast, Montelukast first, then place...</td>\n      <td>[Primary, Primary, Primary]</td>\n      <td>[Changes in SCORAD Index, Changes in Urinary LTE4, Changes in Urinary EDN]</td>\n      <td>[Changes of SCORAD(SCORing Atopic Dermatitis) index after taking Montelukast or placebo drug. SC...</td>\n      <td>[18 weeks after patient recruitment, 18 weeks after patient recruitment, 18 weeks after particip...</td>\n      <td>[-3.0, -5.7, -65.9, 87.7, 37.0, -195.8]</td>\n      <td>[units on a scale, Urinary LTE4 (pg/ml), Urine EDN (ng/ml)]</td>\n    </tr>\n    <tr>\n      <th>108</th>\n      <td>383</td>\n      <td>NCT00329784</td>\n      <td>Promoting Tolerance to Peanut in High-Risk Children</td>\n      <td>Eczema</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>640</td>\n      <td>December 2006</td>\n      <td>May 2014</td>\n      <td>Inclusion Criteria:\\n\\nAble to consume solid food\\nAllergy to eggs and/or severe eczema\\nInforme...</td>\n      <td>[Peanut Consumption Group]</td>\n      <td>[Biological: Peanut Consumption Group]</td>\n      <td>[Participants on this arm will consume peanut protein., Participants on this arm will avoid pean...</td>\n      <td>[Peanut Consumption Group]</td>\n      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Number of Participants With Peanut Allergy at 60 Months of Age - by Skin Prick Test Stratum, Nu...</td>\n      <td>[At 60 months of age, participants were given an oral food challenge Participants regarded as un...</td>\n      <td>[60 months, 60 months, 60 months, 60 months, 60 months, 60 months, 60 months]</td>\n      <td>[36, 5, 18, 5, 54, 10, 7.6, 6.6, 50, 54, 106, 115, 134, 132, 71, 30, 96, 102, 28, 25, 22, 22, 29...</td>\n      <td>[Participants, Participants, units on a scale, Participants, Participants, Participants, Partici...</td>\n    </tr>\n    <tr>\n      <th>109</th>\n      <td>388</td>\n      <td>NCT02289989</td>\n      <td>Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis</td>\n      <td>Atopic Dermatitis</td>\n      <td>Not Applicable</td>\n      <td>Interventional</td>\n      <td>1</td>\n      <td>November 2014</td>\n      <td>January 2017</td>\n      <td>Inclusion Criteria:\\n\\nMale or non-pregnant female subjects aged 2-17 years of age.\\nIndividuals...</td>\n      <td>[Oregano extract cream, Hydrocortisone]</td>\n      <td>[Drug: Hydrocortisone, Drug: Oregano extract cream]</td>\n      <td>[Intervention: hydrocortisone 1% ointment will be applied to one patient's forearm, Intervention...</td>\n      <td>[Experimental: oregano extract cream, Standard: Hydrocortisone 1% ointment]</td>\n      <td>[Primary, Primary, Primary, Secondary, Secondary, Secondary]</td>\n      <td>[The Clinical Efficacy Rated by the Patient or Caregiver on Days 0 and 25, Change of the Clinica...</td>\n      <td>[This was measured with two questions. The first one referred to the description of the lesion a...</td>\n      <td>[From baseline to day 25, Baseline to day 28, Baseline to day 28, Baseline to day 14, On day 7 a...</td>\n      <td>[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]</td>\n      <td>[participants, participants, participants, participants, participants]</td>\n    </tr>\n    <tr>\n      <th>110</th>\n      <td>392</td>\n      <td>NCT02001181</td>\n      <td>Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>69</td>\n      <td>December 2013</td>\n      <td>September 2014</td>\n      <td>Inclusion Criteria:\\n\\nHave a clinical diagnosis of atopic dermatitis (also known as atopic ecze...</td>\n      <td>[Tofacitinib ointment 20mg/g, Placebo ointment (Vehicle)]</td>\n      <td>[Drug: Tofacitinib ointment 20mg/g, Drug: Placebo ointment (Vehicle)]</td>\n      <td>[]</td>\n      <td>[Treatment group A, Treatment B]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4, Pr...</td>\n      <td>[The EASI quantifies the severity of a participant's atopic dermatitis based on both lesion seve...</td>\n      <td>[Baseline (pre-dose on Day 1) and Week 4, Week 4, Baseline (pre-dose on Day 1) and Week 4, Basel...</td>\n      <td>[-81.7, -29.9, 71.4, 20.6, 65.7, 11.8, -72.7, -30.2, -11.4, -4.1]</td>\n      <td>[percent change, percentage of participants, percentage of participants, percent change, units o...</td>\n    </tr>\n    <tr>\n      <th>111</th>\n      <td>397</td>\n      <td>NCT03233529</td>\n      <td>Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis</td>\n      <td>Dermatitis, Atopic</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>40</td>\n      <td>July 31, 2017</td>\n      <td>May 4, 2018</td>\n      <td>Inclusion Criteria:\\n\\nConfirmed diagnosis of active atopic dermatitis (AD) with at least 6 mont...</td>\n      <td>[Crisaborole ointment 2% BID, Placebo ointment (vehicle)]</td>\n      <td>[Drug: Crisaborole ointment 2% BID, Drug: Placebo ointment (vehicle)]</td>\n      <td>[]</td>\n      <td>[Crisaborole ointment, Placebo ointment (vehicle)]</td>\n      <td>[Primary, Primary, Primary, Primary, Primary, Primary, Primary, Primary, Secondary, Secondary, S...</td>\n      <td>[Change From Baseline in Lesion Total Sign Score (TSS) for Target Lesions Treated With Crisaboro...</td>\n      <td>[The lesion TSS is an assessment of target lesion severity based on the severity of the followin...</td>\n      <td>[Baseline (Day 1), Day 15, Baseline (Day 1), Day 15, Baseline (Day 1), Day 15, Baseline (Day 1),...</td>\n      <td>[-4.5, -2.1, -1.2787, -0.2881, -0.7295, -0.1849, -1.3267, -0.1994, -0.5484, 0.2128, -2.4495, -1....</td>\n      <td>[units on a scale, log2(normalized expression), log2(normalized expression), log2(normalized exp...</td>\n    </tr>\n    <tr>\n      <th>112</th>\n      <td>398</td>\n      <td>NCT02752776</td>\n      <td>A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.</td>\n      <td>Plaque Psoriasis</td>\n      <td>Phase 4</td>\n      <td>Interventional</td>\n      <td>1660</td>\n      <td>March 17, 2016</td>\n      <td>March 28, 2018</td>\n      <td>Inclusion Criteria:\\n\\nMen or women aged at least 18 years at time of Screening.\\nModerate to se...</td>\n      <td>[Secukinumab]</td>\n      <td>[Drug: Secukinumab]</td>\n      <td>[All patients are received s.c. injections of secukinumab 300 mg at Week 0, 1, 2 and 3 during th...</td>\n      <td>[Secukinumab]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n      <td>[Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Wee...</td>\n      <td>[The DLQI is a ten item general dermatology disability index designed to assess health-related q...</td>\n      <td>[16 weeks, 52 weeks, 52 weeks, Week 16, Week 52, Week 16, Week 52, Week 16, Week 52, Week 16 and...</td>\n      <td>[74.7, 71.3, 61.7, 70.8, 75.3, 73.3, 62.0, 71.9, 18.3, 19.1, 21.2, 19.2, 5.7, 6.3, 9.3, 6.7, 1.2...</td>\n      <td>[Percentage of participants, Percentage of participants, Percentage of participants, Percentage ...</td>\n    </tr>\n    <tr>\n      <th>113</th>\n      <td>401</td>\n      <td>NCT00143819</td>\n      <td>Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis</td>\n      <td>Psoriasis</td>\n      <td>Phase 2</td>\n      <td>Interventional</td>\n      <td>13</td>\n      <td>September 2005</td>\n      <td>February 2010</td>\n      <td>Inclusion Criteria\\n\\nMust be at least 18 years of age\\nHave psoriasis or eczema on both sides o...</td>\n      <td>[Neuroskin Forte, Placebo Application]</td>\n      <td>[Drug: Neuroskin Forte, Drug: Placebo Application]</td>\n      <td>[bilateral comparison, bilateral comparison]</td>\n      <td>[1, 2]</td>\n      <td>[Primary, Secondary, Secondary, Secondary, Secondary]</td>\n      <td>[Change From Baseline in the Visual Analog Scale (VAS) Score for Pruritus (Itching) at 8 Weeks, ...</td>\n      <td>[Subjects assessed the level of pruritus (itching) on the left and right sides of their body at ...</td>\n      <td>[8 weeks, 8 weeks, 8 weeks, 8 weeks, 8 weeks]</td>\n      <td>[-52.2, -36.2, 0, 0, 1, 0, -20.7, -14.7, 13, 13]</td>\n      <td>[percent change, Participants, Participants, percent change, Participants]</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {
                "scrolled": false
            },
            "cell_type": "code",
            "source": "ad_outcome_table = atopic_derm.build_outcome_table()\nad_outcome_table.shape",
            "execution_count": 17,
            "outputs": [
                {
                    "output_type": "execute_result",
                    "execution_count": 17,
                    "data": {
                        "text/plain": "(652, 12)"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "tokenize_column(ad_outcome_table, 'OutcomeMeasureTitle', 'OutcomeMeasureTitleTokenized')",
            "execution_count": 18,
            "outputs": []
        },
        {
            "metadata": {},
            "cell_type": "code",
            "source": "print(ad_outcome_table.shape)\nad_outcome_table.head()",
            "execution_count": 21,
            "outputs": [
                {
                    "output_type": "stream",
                    "text": "(652, 13)\n",
                    "name": "stdout"
                },
                {
                    "output_type": "execute_result",
                    "execution_count": 21,
                    "data": {
                        "text/plain": "         NCTId  \\\n0  NCT03054428   \n1  NCT03054428   \n2  NCT03054428   \n3  NCT03054428   \n4  NCT03054428   \n\n                                                                                            BriefTitle  \\\n0  Efficacy and Safety of Dupilumab in Participants \u226512 to <18 Years of Age, With Moderate-to-sever...   \n1  Efficacy and Safety of Dupilumab in Participants \u226512 to <18 Years of Age, With Moderate-to-sever...   \n2  Efficacy and Safety of Dupilumab in Participants \u226512 to <18 Years of Age, With Moderate-to-sever...   \n3  Efficacy and Safety of Dupilumab in Participants \u226512 to <18 Years of Age, With Moderate-to-sever...   \n4  Efficacy and Safety of Dupilumab in Participants \u226512 to <18 Years of Age, With Moderate-to-sever...   \n\n     Phase      InterventionName  \\\n0  Phase 3  [Dupilumab, Placebo]   \n1  Phase 3  [Dupilumab, Placebo]   \n2  Phase 3  [Dupilumab, Placebo]   \n3  Phase 3  [Dupilumab, Placebo]   \n4  Phase 3  [Dupilumab, Placebo]   \n\n                            ArmGroupInterventionName  \\\n0  [Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n1  [Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n2  [Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n3  [Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n4  [Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n\n                                         InterventionArmGroupLabel  \\\n0  [Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]   \n1  [Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]   \n2  [Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]   \n3  [Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]   \n4  [Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]   \n\n  OutcomeMeasureType  \\\n0            Primary   \n1            Primary   \n2          Secondary   \n3          Secondary   \n4          Secondary   \n\n                                                                                   OutcomeMeasureTitle  \\\n0  Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction Fro...   \n1  Percentage of Participants With Eczema Area and Severity Index (EASI)-75 (\u226575% Improvement From ...   \n2                                                Percent Change From Baseline in EASI Score at Week 16   \n3  Percent Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NR...   \n4  Percentage of Participants With Improvement (Reduction \u22653 Points) of Weekly Average of Daily Pea...   \n\n                                                                             OutcomeMeasureDescription  \\\n0  IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical res...   \n1  The EASI score was used to measure the severity and extent of AD and measures erythema, infiltra...   \n2  The Eczema Area and Severity Index (EASI) score was used to measure the severity and extent of A...   \n3  Peak Pruritus NRS is an assessment tool used by subjects to report intensity of pruritus (itch) ...   \n4  Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (it...   \n\n  OutcomeMeasureTimeFrame OutcomeMeasurementValue OutcomeMeasureUnitOfMeasure  \\\n0    Baseline and Week 16       [2.4, 17.9, 24.4]  Percentage of participants   \n1    Baseline and Week 16       [8.2, 38.1, 41.5]  Percentage of participants   \n2    Baseline and Week 16   [-23.6, -64.8, -65.9]              Percent change   \n3    Baseline and Week 16   [-19.0, -45.5, -47.9]              Percent change   \n4     Baseline to Week 16       [9.4, 38.6, 48.8]  Percentage of participants   \n\n                                                                          OutcomeMeasureTitleTokenized  \n0  [percentage, of, participants, with, investigator's, global, assessment, iga, 0, or, 1, and, red...  \n1  [percentage, of, participants, with, eczema, area, and, severity, index, easi)-75, \u226575%, improve...  \n2                                     [percent, change, from, baseline, in, easi, score, at, week, 16]  \n3  [percent, change, from, baseline, in, weekly, average, of, daily, peak, pruritus, numerical, rat...  \n4  [percentage, of, participants, with, improvement, reduction, \u22653, points, of, weekly, average, of...  ",
                        "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>NCTId</th>\n      <th>BriefTitle</th>\n      <th>Phase</th>\n      <th>InterventionName</th>\n      <th>ArmGroupInterventionName</th>\n      <th>InterventionArmGroupLabel</th>\n      <th>OutcomeMeasureType</th>\n      <th>OutcomeMeasureTitle</th>\n      <th>OutcomeMeasureDescription</th>\n      <th>OutcomeMeasureTimeFrame</th>\n      <th>OutcomeMeasurementValue</th>\n      <th>OutcomeMeasureUnitOfMeasure</th>\n      <th>OutcomeMeasureTitleTokenized</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>NCT03054428</td>\n      <td>Efficacy and Safety of Dupilumab in Participants \u226512 to &lt;18 Years of Age, With Moderate-to-sever...</td>\n      <td>Phase 3</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]</td>\n      <td>Primary</td>\n      <td>Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction Fro...</td>\n      <td>IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical res...</td>\n      <td>Baseline and Week 16</td>\n      <td>[2.4, 17.9, 24.4]</td>\n      <td>Percentage of participants</td>\n      <td>[percentage, of, participants, with, investigator's, global, assessment, iga, 0, or, 1, and, red...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>NCT03054428</td>\n      <td>Efficacy and Safety of Dupilumab in Participants \u226512 to &lt;18 Years of Age, With Moderate-to-sever...</td>\n      <td>Phase 3</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]</td>\n      <td>Primary</td>\n      <td>Percentage of Participants With Eczema Area and Severity Index (EASI)-75 (\u226575% Improvement From ...</td>\n      <td>The EASI score was used to measure the severity and extent of AD and measures erythema, infiltra...</td>\n      <td>Baseline and Week 16</td>\n      <td>[8.2, 38.1, 41.5]</td>\n      <td>Percentage of participants</td>\n      <td>[percentage, of, participants, with, eczema, area, and, severity, index, easi)-75, \u226575%, improve...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>NCT03054428</td>\n      <td>Efficacy and Safety of Dupilumab in Participants \u226512 to &lt;18 Years of Age, With Moderate-to-sever...</td>\n      <td>Phase 3</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]</td>\n      <td>Secondary</td>\n      <td>Percent Change From Baseline in EASI Score at Week 16</td>\n      <td>The Eczema Area and Severity Index (EASI) score was used to measure the severity and extent of A...</td>\n      <td>Baseline and Week 16</td>\n      <td>[-23.6, -64.8, -65.9]</td>\n      <td>Percent change</td>\n      <td>[percent, change, from, baseline, in, easi, score, at, week, 16]</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>NCT03054428</td>\n      <td>Efficacy and Safety of Dupilumab in Participants \u226512 to &lt;18 Years of Age, With Moderate-to-sever...</td>\n      <td>Phase 3</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]</td>\n      <td>Secondary</td>\n      <td>Percent Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NR...</td>\n      <td>Peak Pruritus NRS is an assessment tool used by subjects to report intensity of pruritus (itch) ...</td>\n      <td>Baseline and Week 16</td>\n      <td>[-19.0, -45.5, -47.9]</td>\n      <td>Percent change</td>\n      <td>[percent, change, from, baseline, in, weekly, average, of, daily, peak, pruritus, numerical, rat...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>NCT03054428</td>\n      <td>Efficacy and Safety of Dupilumab in Participants \u226512 to &lt;18 Years of Age, With Moderate-to-sever...</td>\n      <td>Phase 3</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants With Improvement (Reduction \u22653 Points) of Weekly Average of Daily Pea...</td>\n      <td>Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (it...</td>\n      <td>Baseline to Week 16</td>\n      <td>[9.4, 38.6, 48.8]</td>\n      <td>Percentage of participants</td>\n      <td>[percentage, of, participants, with, improvement, reduction, \u22653, points, of, weekly, average, of...</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {
                "scrolled": false
            },
            "cell_type": "code",
            "source": "search_results_ad = search_outcomes(ad_outcome_table, 'OutcomeMeasureTitleTokenized')\nsearch_results_ad",
            "execution_count": 26,
            "outputs": [
                {
                    "output_type": "stream",
                    "name": "stdout",
                    "text": "Enter your search term here: \nIGA 0 or 1\n\nSearching outcomes that contain the following key terms:\n\n['iga', '0', 'or', '1']\n"
                },
                {
                    "output_type": "execute_result",
                    "execution_count": 26,
                    "data": {
                        "text/plain": "    index        NCTId  \\\n0       0  NCT03054428   \n1      20  NCT03334422   \n2      21  NCT03334422   \n3      43  NCT03334422   \n4      44  NCT03334422   \n5      45  NCT03334422   \n6      67  NCT03334422   \n7      68  NCT03334396   \n8      69  NCT03334396   \n9      91  NCT03334396   \n10     93  NCT03435081   \n11    115  NCT03435081   \n12    116  NCT03733301   \n13    140  NCT03733301   \n14    222  NCT03428100   \n15    229  NCT03428100   \n16    248  NCT03363854   \n17    265  NCT03363854   \n18    293  NCT03349060   \n19    338  NCT03345914   \n20    360  NCT03575871   \n21    366  NCT03575871   \n22    379  NCT03131648   \n23    384  NCT03131648   \n24    396  NCT03160885   \n25    401  NCT03160885   \n26    413  NCT03720470   \n27    416  NCT03720470   \n28    450  NCT02755649   \n29    465  NCT03796676   \n\n                                                                                             BriefTitle  \\\n0   Efficacy and Safety of Dupilumab in Participants \u226512 to <18 Years of Age, With Moderate-to-sever...   \n1                Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n2                Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n3                Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n4                Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n5                Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n6                Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n7              A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n8              A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n9              A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis   \n10   A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis   \n11   A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis   \n12  A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Mo...   \n13  A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Mo...   \n14  A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderat...   \n15  A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderat...   \n16  Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatiti...   \n17  Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatiti...   \n18  Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Mo...   \n19  Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticostero...   \n20  Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Mod...   \n21  Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Mod...   \n22  Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinuma...   \n23  Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinuma...   \n24  Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinuma...   \n25  Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinuma...   \n26  Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderat...   \n27  Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderat...   \n28  A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermat...   \n29                  JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis   \n\n      Phase  \\\n0   Phase 3   \n1   Phase 3   \n2   Phase 3   \n3   Phase 3   \n4   Phase 3   \n5   Phase 3   \n6   Phase 3   \n7   Phase 3   \n8   Phase 3   \n9   Phase 3   \n10  Phase 3   \n11  Phase 3   \n12  Phase 3   \n13  Phase 3   \n14  Phase 3   \n15  Phase 3   \n16  Phase 3   \n17  Phase 3   \n18  Phase 3   \n19  Phase 3   \n20  Phase 3   \n21  Phase 3   \n22  Phase 3   \n23  Phase 3   \n24  Phase 3   \n25  Phase 3   \n26  Phase 3   \n27  Phase 3   \n28  Phase 3   \n29  Phase 3   \n\n                                                                                       InterventionName  \\\n0                                                                                  [Dupilumab, Placebo]   \n1                                                                                [Baricitinib, Placebo]   \n2                                                                                [Baricitinib, Placebo]   \n3                                                                                [Baricitinib, Placebo]   \n4                                                                                [Baricitinib, Placebo]   \n5                                                                                [Baricitinib, Placebo]   \n6                                                                                [Baricitinib, Placebo]   \n7                                                                                [Baricitinib, Placebo]   \n8                                                                                [Baricitinib, Placebo]   \n9                                                                                [Baricitinib, Placebo]   \n10                                                                               [Baricitinib, Placebo]   \n11                                                                               [Baricitinib, Placebo]   \n12                                                       [Baricitinib, Topical corticosteroid, Placebo]   \n13                                                       [Baricitinib, Topical corticosteroid, Placebo]   \n14                                                       [Baricitinib, Placebo, Topical corticosteroid]   \n15                                                       [Baricitinib, Placebo, Topical corticosteroid]   \n16                                                                              [Tralokinumab, Placebo]   \n17                                                                              [Tralokinumab, Placebo]   \n18                                                    [PF-04965842 100 mg, PF-04965842 200 mg, Placebo]   \n19  [Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatmen...   \n20                                                    [PF-04965842 100 mg, PF-04965842 200 mg, Placebo]   \n21                                                    [PF-04965842 100 mg, PF-04965842 200 mg, Placebo]   \n22                                                                              [Tralokinumab, Placebo]   \n23                                                                              [Tralokinumab, Placebo]   \n24                                                                              [Tralokinumab, Placebo]   \n25                                                                              [Tralokinumab, Placebo]   \n26                [PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo]   \n27                [PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo]   \n28                                                                        [Dupilumab, Matching Placebo]   \n29                                                                   [Placebo, PF-04965842, PF04965842]   \n\n                                                                               ArmGroupInterventionName  \\\n0                                                     [Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n1   [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n2   [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n3   [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n4   [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n5   [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n6   [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n7   [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n8   [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n9   [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...   \n10                  [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Placebo]   \n11                  [Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Placebo]   \n12  [Drug: Baricitinib, Drug: Topical corticosteroid, Drug: Placebo, Drug: Baricitinib, Drug: Topica...   \n13  [Drug: Baricitinib, Drug: Topical corticosteroid, Drug: Placebo, Drug: Baricitinib, Drug: Topica...   \n14  [Drug: Baricitinib, Drug: Placebo, Drug: Topical corticosteroid, Drug: Baricitinib, Drug: Placeb...   \n15  [Drug: Baricitinib, Drug: Placebo, Drug: Topical corticosteroid, Drug: Baricitinib, Drug: Placeb...   \n16  [Drug: Tralokinumab, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, ...   \n17  [Drug: Tralokinumab, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, ...   \n18                                  [Drug: PF-04965842 100 mg, Drug: PF-04965842 200 mg, Drug: Placebo]   \n19  [Drug: Dupilumab, Other: Background Treatment: Topical Corticosteroids, Other: Background Treatm...   \n20                                  [Drug: PF-04965842 100 mg, Drug: PF-04965842 200 mg, Drug: Placebo]   \n21                                  [Drug: PF-04965842 100 mg, Drug: PF-04965842 200 mg, Drug: Placebo]   \n22  [Drug: Tralokinumab, Drug: Placebo, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, Drug:...   \n23  [Drug: Tralokinumab, Drug: Placebo, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, Drug:...   \n24  [Drug: Tralokinumab, Drug: Placebo, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, Drug:...   \n25  [Drug: Tralokinumab, Drug: Placebo, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, Drug:...   \n26  [Drug: PF-04965842 100 mg, Drug: Injectable Placebo, Drug: PF-04965842 200 mg, Drug: Injectable ...   \n27  [Drug: PF-04965842 100 mg, Drug: Injectable Placebo, Drug: PF-04965842 200 mg, Drug: Injectable ...   \n28                                           [Drug: Matching Placebo, Drug: Dupilumab, Drug: Dupilumab]   \n29                                                 [Drug: Placebo, Drug: PF-04965842, Drug: PF04965842]   \n\n                                                                              InterventionArmGroupLabel  \\\n0                                       [Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]   \n1   [1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...   \n2   [1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...   \n3   [1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...   \n4   [1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...   \n5   [1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...   \n6   [1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...   \n7   [1 mg Baricitinib, 1 mg Baricitinib Maximum Extended Enrollment Cohort, 2 mg Baricitinib, 2 mg B...   \n8   [1 mg Baricitinib, 1 mg Baricitinib Maximum Extended Enrollment Cohort, 2 mg Baricitinib, 2 mg B...   \n9   [1 mg Baricitinib, 1 mg Baricitinib Maximum Extended Enrollment Cohort, 2 mg Baricitinib, 2 mg B...   \n10  [1 mg Baricitinib, 2 milligram (mg) Baricitinib, 1 mg Baricitinib, 2 milligram (mg) Baricitinib,...   \n11  [1 mg Baricitinib, 2 milligram (mg) Baricitinib, 1 mg Baricitinib, 2 milligram (mg) Baricitinib,...   \n12  [2 mg Baricitinib, 4 Milligram (mg) Baricitinib, 2 mg Baricitinib, 4 Milligram (mg) Baricitinib,...   \n13  [2 mg Baricitinib, 4 Milligram (mg) Baricitinib, 2 mg Baricitinib, 4 Milligram (mg) Baricitinib,...   \n14  [1 mg Baricitinib, 2 mg Baricitinib, 4 mg Baricitinib, 1 mg Baricitinib, 2 mg Baricitinib, 4 mg ...   \n15  [1 mg Baricitinib, 2 mg Baricitinib, 4 mg Baricitinib, 1 mg Baricitinib, 2 mg Baricitinib, 4 mg ...   \n16  [Placebo (initial)non-respon-> Tralokinumab(continuation A), Tralokinumab(initial)non-respon-> T...   \n17  [Placebo (initial)non-respon-> Tralokinumab(continuation A), Tralokinumab(initial)non-respon-> T...   \n18                                                    [PF-04965842 100 mg, PF-04965842 200 mg, Placebo]   \n19                    [Group 1, Group 2, Group 3, Group 1, Group 2, Group 3, Group 1, Group 2, Group 3]   \n20                                                    [PF-04965842 100 mg, PF-04965842 200 mg, Placebo]   \n21                                                    [PF-04965842 100 mg, PF-04965842 200 mg, Placebo]   \n22  [Initial treatment period - Tralokinumab Q2W, Maintenance treatment period - Tralokinumab Q2W, M...   \n23  [Initial treatment period - Tralokinumab Q2W, Maintenance treatment period - Tralokinumab Q2W, M...   \n24  [Initial treatment period - Tralokinumab Q2W, Maintenance treatment period - Tralokinumab Q2W, M...   \n25  [Initial treatment period - Tralokinumab Q2W, Maintenance treatment period - Tralokinumab Q2W, M...   \n26  [Oral Placebo + Placebo Inj followed by 100 mg PF-04965842, PF-04965842 100 mg + Placebo Inj fol...   \n27  [Oral Placebo + Placebo Inj followed by 100 mg PF-04965842, PF-04965842 100 mg + Placebo Inj fol...   \n28                            [Dupilumab 300 mg Q2W + TCS, Dupilumab 300 mg QW + TCS, Placebo QW + TCS]   \n29                                              [Placebo, PF-04965842 100 mg QD, PF-04965842 200 mg QD]   \n\n   OutcomeMeasureType  \\\n0             Primary   \n1             Primary   \n2           Secondary   \n3           Secondary   \n4             Primary   \n5           Secondary   \n6           Secondary   \n7             Primary   \n8           Secondary   \n9           Secondary   \n10          Secondary   \n11          Secondary   \n12            Primary   \n13          Secondary   \n14          Secondary   \n15          Secondary   \n16            Primary   \n17          Secondary   \n18            Primary   \n19            Primary   \n20            Primary   \n21          Secondary   \n22            Primary   \n23          Secondary   \n24            Primary   \n25          Secondary   \n26            Primary   \n27          Secondary   \n28          Secondary   \n29            Primary   \n\n                                                                                    OutcomeMeasureTitle  \\\n0   Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction Fro...   \n1   Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n2   Percentage of Participants Achieving IGA of 0 or 1 With a \u2265 2 Point Improvement (Placebo, 1mg Ba...   \n3   Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n4   Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n5   Percentage of Participants Achieving IGA of 0 or 1 With a \u2265 2 Point Improvement (Placebo, 1mg Ba...   \n6   Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n7   Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n8   Percentage of Participants Achieving IGA of 0 or 1 With a \u2265 2 Point Improvement (Placebo, 1 mg B...   \n9   Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n10  Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n11  Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n12  Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...   \n13                      Percentage of Participants Achieving IGA of 0 or 1 With a \u2265 2 Point Improvement   \n14                      Percentage of Participants Achieving IGA of 0 or 1 With a \u2265 2 Point Improvement   \n15                      Percentage of Participants Achieving IGA of 0 or 1 With a >=2-point Improvement   \n16  Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) ...   \n17  Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) ...   \n18  Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0...   \n19             Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16   \n20  Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0...   \n21  Percentage of Participants Achieving IGA Response of Clear (0) or Almost Clear (1) and >=2 Point...   \n22  Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at W...   \n23  Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at W...   \n24  Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at W...   \n25  Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at W...   \n26  Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0...   \n27  Percentage of Participants Achieving IGA Response of Clear (0) or Almost Clear (1) and a Reducti...   \n28  Percentage of Participants With Investigator Global Assessment (IGA) 0 or 1 (on the 0 to 4 IGA S...   \n29  Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' ...   \n\n                                                                              OutcomeMeasureDescription  \\\n0   IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical res...   \n1   The IGA measures the investigator's global assessment of the participants overall severity of th...   \n2   The IGA measures the investigator's global assessment of the participants overall severity of th...   \n3   The IGA measures the investigator's global assessment of the participants overall severity of th...   \n4   The IGA measures the investigator's global assessment of the participants overall severity of th...   \n5   The IGA measures the investigator's global assessment of the participants overall severity of th...   \n6   The IGA measures the investigator's global assessment of the participants overall severity of th...   \n7   The IGA measures the investigator's global assessment of the participant's overall severity of t...   \n8   The IGA measures the investigator's global assessment of the participant's overall severity of t...   \n9   The IGA measures the investigator's global assessment of the participant's overall severity of t...   \n10  The IGA measures the investigator's global assessment of the participant's overall severity of t...   \n11  The IGA measures the investigator's global assessment of the participant's overall severity of t...   \n12  The IGA measures investigators global assessment of the participant's overall severity of their ...   \n13  The IGA measures the investigator's global assessment of the participant's overall severity of t...   \n14  The IGA measures the investigator's global assessment of the participant's overall severity of t...   \n15  The IGA measures the investigator's global assessment of the participant's overall severity of t...   \n16  IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 ...   \n17  IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 ...   \n18  IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). S...   \n19  The IGA was an assessment instrument used in clinical studies to rate the severity of AD globall...   \n20  IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). S...   \n21  IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). S...   \n22  The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD...   \n23  The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD...   \n24  The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD...   \n25  The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD...   \n26  IGA assessed severity of atopic dermatitis (AD) on a 5 point scale (0 to 4, higher scores indica...   \n27  IGA assessed severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). S...   \n28  IGA is an assessment scale used to determine severity of AD and clinical response to treatment o...   \n29                                                                                                  NaN   \n\n                                                    OutcomeMeasureTimeFrame  \\\n0                                                      Baseline and Week 16   \n1                                                                  16 Weeks   \n2                                                                  16 Weeks   \n3                                                                   4 Weeks   \n4                                                                  16 Weeks   \n5                                                                  16 Weeks   \n6                                                                   4 Weeks   \n7                                                                  16 Weeks   \n8                                                                  16 Weeks   \n9                                                                   4 Weeks   \n10                                                                  Week 16   \n11                                                                   Week 4   \n12                                                                  Week 16   \n13                                                                   Week 4   \n14                                                                  Week 16   \n15                                                                  Week 24   \n16                                                                  Week 16   \n17                                                                  Week 32   \n18                                                        Baseline, Week 12   \n19                                                                  Week 16   \n20                                                        Baseline, Week 12   \n21                                              Baseline, Weeks 2, 4, and 8   \n22                                                               At Week 16   \n23                                                               At Week 52   \n24                                                               At Week 16   \n25                                                               At Week 52   \n26  Baseline (the last measurement prior to first dosing on Day 1), Week 12   \n27                                            Baseline, Week 2, 4, 8 and 16   \n28                                                        Baseline, Week 16   \n29                                                      Baseline to Week 12   \n\n                                                                             OutcomeMeasurementValue  \\\n0                                                                                  [2.4, 17.9, 24.4]   \n1                                                                             [4.5, 10.6, 13.8, 4.5]   \n2                                                                             [8.8, 6.1, 12.8, 17.9]   \n3                                                                    [-16.28, -8.94, -11.21, -23.25]   \n4                                                                             [4.5, 10.6, 13.8, 4.5]   \n5                                                                             [8.8, 6.1, 12.8, 17.9]   \n6                                                                    [-16.28, -8.94, -11.21, -23.25]   \n7                                                                             [4.8, 11.4, 16.8, 4.8]   \n8                                                                            [11.8, 8.8, 17.3, 18.7]   \n9                                                                    [-13.85, -5.67, -12.98, -10.80]   \n10                                                                                 [12.9, 24.0, 8.2]   \n11                                                                           [-17.15, -9.24, -18.87]   \n12                                                                                [14.7, 23.9, 30.6]   \n13                                                                          [-16.75, -26.55, -27.25]   \n14                                                                            [21.7, 6.5, 8.6, 10.3]   \n15                                                                          [13.0, 35.5, 45.2, 51.4]   \n16                                                                 [98, 33, 141, 45, 113, 43, -37.7]   \n17                                                               [2.7, 3.6, 2.7, 3.4, 2.7, 3.5, 2.7]   \n18                                        [23.7, 43.8, 7.9, 39.7, 62.7, 11.8, 20.4, 45.6, 2.7, 32.2]   \n19                                                                                [11.4, 32.8, 29.5]   \n20                                              [28.4, 38.1, 9.1, 44.5, 61.0, 10.4, 23.1, 35.3, 3.9]   \n21                                            [35.7, 55.3, 10.5, 58.7, 78.4, 28.6, 66.2, 82.5, 34.6]   \n22                                                                                          [95, 14]   \n23                                                                                          [20, 14]   \n24                                                                                         [131, 22]   \n25                                                                                          [32, 22]   \n26              [14.0, 36.6, 48.4, 36.5, 27.1, 58.7, 70.3, 58.1, 5.1, 5.9, 7.4, 2.4, 7.9, 8.4, 14.8]   \n27        [25.4, 39.5, 20.5, 12.0, 25.5, 44.1, 21.9, 13.2, 30.6, 43.8, 23.6, 15.7, 31.4, 45.7, 24.5]   \n28                                                                                [13.9, 40.2, 39.1]   \n29  [24.5, 41.6, 46.2, 41.5, 68.5, 72.0, 12.6, 27.2, 38.6, 20.7, 31.5, 50.0, 29.8, 52.6, 55.4, -2.0]   \n\n   OutcomeMeasureUnitOfMeasure  \\\n0   Percentage of participants   \n1   percentage of participants   \n2   percentage of participants   \n3   percentage of participants   \n4   percentage of participants   \n5   percentage of participants   \n6   percentage of participants   \n7   percentage of participants   \n8   percentage of participants   \n9   percentage of participants   \n10  percentage of participants   \n11  percentage of participants   \n12  percentage of participants   \n13  percentage of participants   \n14  percentage of participants   \n15  percentage of participants   \n16                Participants   \n17                Participants   \n18  percentage of participants   \n19  Percentage of Participants   \n20  percentage of participants   \n21  percentage of participants   \n22                Participants   \n23                Participants   \n24                Participants   \n25                Participants   \n26  Percentage of participants   \n27  Percentage of participants   \n28  Percentage of Participants   \n29  Percentage of participants   \n\n                                                                           OutcomeMeasureTitleTokenized  \n0   [percentage, of, participants, with, investigator's, global, assessment, iga, 0, or, 1, and, red...  \n1   [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  \n2   [percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, \u2265, 2, point, improvement, ...  \n3   [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  \n4   [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  \n5   [percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, \u2265, 2, point, improvement, ...  \n6   [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  \n7   [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  \n8   [percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, \u2265, 2, point, improvement, ...  \n9   [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  \n10  [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  \n11  [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  \n12  [percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...  \n13      [percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, \u2265, 2, point, improvement]  \n14      [percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, \u2265, 2, point, improvement]  \n15        [percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, >=2-point, improvement]  \n16  [participants, with, investigator's, global, assessment, iga, score, of, 0, clear, or, 1, almost...  \n17  [participants, with, investigator's, global, assessment, iga, score, of, 0, clear, or, 1, almost...  \n18  [percentage, of, participants, achieving, investigator's, global, assessment, iga, response, of,...  \n19  [percentage, of, participants, with, investigator's, global, assessment, iga, 0, or, 1, at, week...  \n20  [percentage, of, participants, achieving, investigator's, global, assessment, iga, response, of,...  \n21  [percentage, of, participants, achieving, iga, response, of, clear, 0, or, almost, clear, 1, and...  \n22  [subjects, with, investigator's, global, assessment, iga, score, of, 0, clear, or, 1, almost, cl...  \n23  [subjects, with, investigator's, global, assessment, iga, score, of, 0, clear, or, 1, almost, cl...  \n24  [subjects, with, investigator's, global, assessment, iga, score, of, 0, clear, or, 1, almost, cl...  \n25  [subjects, with, investigator's, global, assessment, iga, score, of, 0, clear, or, 1, almost, cl...  \n26  [percentage, of, participants, achieving, investigator's, global, assessment, iga, response, of,...  \n27  [percentage, of, participants, achieving, iga, response, of, clear, 0, or, almost, clear, 1, and...  \n28  [percentage, of, participants, with, investigator, global, assessment, iga, 0, or, 1, on, the, 0...  \n29  [percentage, of, participants, achieving, investigator's, global, assessment, iga, response, of,...  ",
                        "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>index</th>\n      <th>NCTId</th>\n      <th>BriefTitle</th>\n      <th>Phase</th>\n      <th>InterventionName</th>\n      <th>ArmGroupInterventionName</th>\n      <th>InterventionArmGroupLabel</th>\n      <th>OutcomeMeasureType</th>\n      <th>OutcomeMeasureTitle</th>\n      <th>OutcomeMeasureDescription</th>\n      <th>OutcomeMeasureTimeFrame</th>\n      <th>OutcomeMeasurementValue</th>\n      <th>OutcomeMeasureUnitOfMeasure</th>\n      <th>OutcomeMeasureTitleTokenized</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>0</td>\n      <td>NCT03054428</td>\n      <td>Efficacy and Safety of Dupilumab in Participants \u226512 to &lt;18 Years of Age, With Moderate-to-sever...</td>\n      <td>Phase 3</td>\n      <td>[Dupilumab, Placebo]</td>\n      <td>[Drug: Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Dupilumab 200 mg or 300 mg Q2W, Dupilumab 300 mg Q4W, Placebo]</td>\n      <td>Primary</td>\n      <td>Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction Fro...</td>\n      <td>IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical res...</td>\n      <td>Baseline and Week 16</td>\n      <td>[2.4, 17.9, 24.4]</td>\n      <td>Percentage of participants</td>\n      <td>[percentage, of, participants, with, investigator's, global, assessment, iga, 0, or, 1, and, red...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>20</td>\n      <td>NCT03334422</td>\n      <td>Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...</td>\n      <td>Primary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures the investigator's global assessment of the participants overall severity of th...</td>\n      <td>16 Weeks</td>\n      <td>[4.5, 10.6, 13.8, 4.5]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>21</td>\n      <td>NCT03334422</td>\n      <td>Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving IGA of 0 or 1 With a \u2265 2 Point Improvement (Placebo, 1mg Ba...</td>\n      <td>The IGA measures the investigator's global assessment of the participants overall severity of th...</td>\n      <td>16 Weeks</td>\n      <td>[8.8, 6.1, 12.8, 17.9]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, \u2265, 2, point, improvement, ...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>43</td>\n      <td>NCT03334422</td>\n      <td>Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures the investigator's global assessment of the participants overall severity of th...</td>\n      <td>4 Weeks</td>\n      <td>[-16.28, -8.94, -11.21, -23.25]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>44</td>\n      <td>NCT03334422</td>\n      <td>Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...</td>\n      <td>Primary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures the investigator's global assessment of the participants overall severity of th...</td>\n      <td>16 Weeks</td>\n      <td>[4.5, 10.6, 13.8, 4.5]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>45</td>\n      <td>NCT03334422</td>\n      <td>Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving IGA of 0 or 1 With a \u2265 2 Point Improvement (Placebo, 1mg Ba...</td>\n      <td>The IGA measures the investigator's global assessment of the participants overall severity of th...</td>\n      <td>16 Weeks</td>\n      <td>[8.8, 6.1, 12.8, 17.9]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, \u2265, 2, point, improvement, ...</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>67</td>\n      <td>NCT03334422</td>\n      <td>Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1mg Baricitinib, 2mg Baricitinib, 4 Milligram (mg) Baricitinib, 1mg Baricitinib, 2mg Baricitini...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures the investigator's global assessment of the participants overall severity of th...</td>\n      <td>4 Weeks</td>\n      <td>[-16.28, -8.94, -11.21, -23.25]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>68</td>\n      <td>NCT03334396</td>\n      <td>A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1 mg Baricitinib, 1 mg Baricitinib Maximum Extended Enrollment Cohort, 2 mg Baricitinib, 2 mg B...</td>\n      <td>Primary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures the investigator's global assessment of the participant's overall severity of t...</td>\n      <td>16 Weeks</td>\n      <td>[4.8, 11.4, 16.8, 4.8]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>69</td>\n      <td>NCT03334396</td>\n      <td>A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1 mg Baricitinib, 1 mg Baricitinib Maximum Extended Enrollment Cohort, 2 mg Baricitinib, 2 mg B...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving IGA of 0 or 1 With a \u2265 2 Point Improvement (Placebo, 1 mg B...</td>\n      <td>The IGA measures the investigator's global assessment of the participant's overall severity of t...</td>\n      <td>16 Weeks</td>\n      <td>[11.8, 8.8, 17.3, 18.7]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, \u2265, 2, point, improvement, ...</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>91</td>\n      <td>NCT03334396</td>\n      <td>A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Pl...</td>\n      <td>[1 mg Baricitinib, 1 mg Baricitinib Maximum Extended Enrollment Cohort, 2 mg Baricitinib, 2 mg B...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures the investigator's global assessment of the participant's overall severity of t...</td>\n      <td>4 Weeks</td>\n      <td>[-13.85, -5.67, -12.98, -10.80]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n    <tr>\n      <th>10</th>\n      <td>93</td>\n      <td>NCT03435081</td>\n      <td>A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Placebo]</td>\n      <td>[1 mg Baricitinib, 2 milligram (mg) Baricitinib, 1 mg Baricitinib, 2 milligram (mg) Baricitinib,...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures the investigator's global assessment of the participant's overall severity of t...</td>\n      <td>Week 16</td>\n      <td>[12.9, 24.0, 8.2]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n    <tr>\n      <th>11</th>\n      <td>115</td>\n      <td>NCT03435081</td>\n      <td>A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Baricitinib, Drug: Placebo, Drug: Placebo]</td>\n      <td>[1 mg Baricitinib, 2 milligram (mg) Baricitinib, 1 mg Baricitinib, 2 milligram (mg) Baricitinib,...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures the investigator's global assessment of the participant's overall severity of t...</td>\n      <td>Week 4</td>\n      <td>[-17.15, -9.24, -18.87]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n    <tr>\n      <th>12</th>\n      <td>116</td>\n      <td>NCT03733301</td>\n      <td>A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Mo...</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Topical corticosteroid, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Topical corticosteroid, Drug: Placebo, Drug: Baricitinib, Drug: Topica...</td>\n      <td>[2 mg Baricitinib, 4 Milligram (mg) Baricitinib, 2 mg Baricitinib, 4 Milligram (mg) Baricitinib,...</td>\n      <td>Primary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a \u2265 2...</td>\n      <td>The IGA measures investigators global assessment of the participant's overall severity of their ...</td>\n      <td>Week 16</td>\n      <td>[14.7, 23.9, 30.6]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, of, 0, or, 1,...</td>\n    </tr>\n    <tr>\n      <th>13</th>\n      <td>140</td>\n      <td>NCT03733301</td>\n      <td>A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Mo...</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Topical corticosteroid, Placebo]</td>\n      <td>[Drug: Baricitinib, Drug: Topical corticosteroid, Drug: Placebo, Drug: Baricitinib, Drug: Topica...</td>\n      <td>[2 mg Baricitinib, 4 Milligram (mg) Baricitinib, 2 mg Baricitinib, 4 Milligram (mg) Baricitinib,...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving IGA of 0 or 1 With a \u2265 2 Point Improvement</td>\n      <td>The IGA measures the investigator's global assessment of the participant's overall severity of t...</td>\n      <td>Week 4</td>\n      <td>[-16.75, -26.55, -27.25]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, \u2265, 2, point, improvement]</td>\n    </tr>\n    <tr>\n      <th>14</th>\n      <td>222</td>\n      <td>NCT03428100</td>\n      <td>A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderat...</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo, Topical corticosteroid]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Topical corticosteroid, Drug: Baricitinib, Drug: Placeb...</td>\n      <td>[1 mg Baricitinib, 2 mg Baricitinib, 4 mg Baricitinib, 1 mg Baricitinib, 2 mg Baricitinib, 4 mg ...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving IGA of 0 or 1 With a \u2265 2 Point Improvement</td>\n      <td>The IGA measures the investigator's global assessment of the participant's overall severity of t...</td>\n      <td>Week 16</td>\n      <td>[21.7, 6.5, 8.6, 10.3]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, \u2265, 2, point, improvement]</td>\n    </tr>\n    <tr>\n      <th>15</th>\n      <td>229</td>\n      <td>NCT03428100</td>\n      <td>A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderat...</td>\n      <td>Phase 3</td>\n      <td>[Baricitinib, Placebo, Topical corticosteroid]</td>\n      <td>[Drug: Baricitinib, Drug: Placebo, Drug: Topical corticosteroid, Drug: Baricitinib, Drug: Placeb...</td>\n      <td>[1 mg Baricitinib, 2 mg Baricitinib, 4 mg Baricitinib, 1 mg Baricitinib, 2 mg Baricitinib, 4 mg ...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving IGA of 0 or 1 With a &gt;=2-point Improvement</td>\n      <td>The IGA measures the investigator's global assessment of the participant's overall severity of t...</td>\n      <td>Week 24</td>\n      <td>[13.0, 35.5, 45.2, 51.4]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, iga, of, 0, or, 1, with, a, &gt;=2-point, improvement]</td>\n    </tr>\n    <tr>\n      <th>16</th>\n      <td>248</td>\n      <td>NCT03363854</td>\n      <td>Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatiti...</td>\n      <td>Phase 3</td>\n      <td>[Tralokinumab, Placebo]</td>\n      <td>[Drug: Tralokinumab, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, ...</td>\n      <td>[Placebo (initial)non-respon-&gt; Tralokinumab(continuation A), Tralokinumab(initial)non-respon-&gt; T...</td>\n      <td>Primary</td>\n      <td>Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) ...</td>\n      <td>IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 ...</td>\n      <td>Week 16</td>\n      <td>[98, 33, 141, 45, 113, 43, -37.7]</td>\n      <td>Participants</td>\n      <td>[participants, with, investigator's, global, assessment, iga, score, of, 0, clear, or, 1, almost...</td>\n    </tr>\n    <tr>\n      <th>17</th>\n      <td>265</td>\n      <td>NCT03363854</td>\n      <td>Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatiti...</td>\n      <td>Phase 3</td>\n      <td>[Tralokinumab, Placebo]</td>\n      <td>[Drug: Tralokinumab, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, ...</td>\n      <td>[Placebo (initial)non-respon-&gt; Tralokinumab(continuation A), Tralokinumab(initial)non-respon-&gt; T...</td>\n      <td>Secondary</td>\n      <td>Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) ...</td>\n      <td>IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 ...</td>\n      <td>Week 32</td>\n      <td>[2.7, 3.6, 2.7, 3.4, 2.7, 3.5, 2.7]</td>\n      <td>Participants</td>\n      <td>[participants, with, investigator's, global, assessment, iga, score, of, 0, clear, or, 1, almost...</td>\n    </tr>\n    <tr>\n      <th>18</th>\n      <td>293</td>\n      <td>NCT03349060</td>\n      <td>Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Mo...</td>\n      <td>Phase 3</td>\n      <td>[PF-04965842 100 mg, PF-04965842 200 mg, Placebo]</td>\n      <td>[Drug: PF-04965842 100 mg, Drug: PF-04965842 200 mg, Drug: Placebo]</td>\n      <td>[PF-04965842 100 mg, PF-04965842 200 mg, Placebo]</td>\n      <td>Primary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0...</td>\n      <td>IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). S...</td>\n      <td>Baseline, Week 12</td>\n      <td>[23.7, 43.8, 7.9, 39.7, 62.7, 11.8, 20.4, 45.6, 2.7, 32.2]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, response, of,...</td>\n    </tr>\n    <tr>\n      <th>19</th>\n      <td>338</td>\n      <td>NCT03345914</td>\n      <td>Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticostero...</td>\n      <td>Phase 3</td>\n      <td>[Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatmen...</td>\n      <td>[Drug: Dupilumab, Other: Background Treatment: Topical Corticosteroids, Other: Background Treatm...</td>\n      <td>[Group 1, Group 2, Group 3, Group 1, Group 2, Group 3, Group 1, Group 2, Group 3]</td>\n      <td>Primary</td>\n      <td>Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16</td>\n      <td>The IGA was an assessment instrument used in clinical studies to rate the severity of AD globall...</td>\n      <td>Week 16</td>\n      <td>[11.4, 32.8, 29.5]</td>\n      <td>Percentage of Participants</td>\n      <td>[percentage, of, participants, with, investigator's, global, assessment, iga, 0, or, 1, at, week...</td>\n    </tr>\n    <tr>\n      <th>20</th>\n      <td>360</td>\n      <td>NCT03575871</td>\n      <td>Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Mod...</td>\n      <td>Phase 3</td>\n      <td>[PF-04965842 100 mg, PF-04965842 200 mg, Placebo]</td>\n      <td>[Drug: PF-04965842 100 mg, Drug: PF-04965842 200 mg, Drug: Placebo]</td>\n      <td>[PF-04965842 100 mg, PF-04965842 200 mg, Placebo]</td>\n      <td>Primary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0...</td>\n      <td>IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). S...</td>\n      <td>Baseline, Week 12</td>\n      <td>[28.4, 38.1, 9.1, 44.5, 61.0, 10.4, 23.1, 35.3, 3.9]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, response, of,...</td>\n    </tr>\n    <tr>\n      <th>21</th>\n      <td>366</td>\n      <td>NCT03575871</td>\n      <td>Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Mod...</td>\n      <td>Phase 3</td>\n      <td>[PF-04965842 100 mg, PF-04965842 200 mg, Placebo]</td>\n      <td>[Drug: PF-04965842 100 mg, Drug: PF-04965842 200 mg, Drug: Placebo]</td>\n      <td>[PF-04965842 100 mg, PF-04965842 200 mg, Placebo]</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving IGA Response of Clear (0) or Almost Clear (1) and &gt;=2 Point...</td>\n      <td>IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). S...</td>\n      <td>Baseline, Weeks 2, 4, and 8</td>\n      <td>[35.7, 55.3, 10.5, 58.7, 78.4, 28.6, 66.2, 82.5, 34.6]</td>\n      <td>percentage of participants</td>\n      <td>[percentage, of, participants, achieving, iga, response, of, clear, 0, or, almost, clear, 1, and...</td>\n    </tr>\n    <tr>\n      <th>22</th>\n      <td>379</td>\n      <td>NCT03131648</td>\n      <td>Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinuma...</td>\n      <td>Phase 3</td>\n      <td>[Tralokinumab, Placebo]</td>\n      <td>[Drug: Tralokinumab, Drug: Placebo, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, Drug:...</td>\n      <td>[Initial treatment period - Tralokinumab Q2W, Maintenance treatment period - Tralokinumab Q2W, M...</td>\n      <td>Primary</td>\n      <td>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at W...</td>\n      <td>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD...</td>\n      <td>At Week 16</td>\n      <td>[95, 14]</td>\n      <td>Participants</td>\n      <td>[subjects, with, investigator's, global, assessment, iga, score, of, 0, clear, or, 1, almost, cl...</td>\n    </tr>\n    <tr>\n      <th>23</th>\n      <td>384</td>\n      <td>NCT03131648</td>\n      <td>Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinuma...</td>\n      <td>Phase 3</td>\n      <td>[Tralokinumab, Placebo]</td>\n      <td>[Drug: Tralokinumab, Drug: Placebo, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, Drug:...</td>\n      <td>[Initial treatment period - Tralokinumab Q2W, Maintenance treatment period - Tralokinumab Q2W, M...</td>\n      <td>Secondary</td>\n      <td>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at W...</td>\n      <td>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD...</td>\n      <td>At Week 52</td>\n      <td>[20, 14]</td>\n      <td>Participants</td>\n      <td>[subjects, with, investigator's, global, assessment, iga, score, of, 0, clear, or, 1, almost, cl...</td>\n    </tr>\n    <tr>\n      <th>24</th>\n      <td>396</td>\n      <td>NCT03160885</td>\n      <td>Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinuma...</td>\n      <td>Phase 3</td>\n      <td>[Tralokinumab, Placebo]</td>\n      <td>[Drug: Tralokinumab, Drug: Placebo, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, Drug:...</td>\n      <td>[Initial treatment period - Tralokinumab Q2W, Maintenance treatment period - Tralokinumab Q2W, M...</td>\n      <td>Primary</td>\n      <td>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at W...</td>\n      <td>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD...</td>\n      <td>At Week 16</td>\n      <td>[131, 22]</td>\n      <td>Participants</td>\n      <td>[subjects, with, investigator's, global, assessment, iga, score, of, 0, clear, or, 1, almost, cl...</td>\n    </tr>\n    <tr>\n      <th>25</th>\n      <td>401</td>\n      <td>NCT03160885</td>\n      <td>Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinuma...</td>\n      <td>Phase 3</td>\n      <td>[Tralokinumab, Placebo]</td>\n      <td>[Drug: Tralokinumab, Drug: Placebo, Drug: Tralokinumab, Drug: Tralokinumab, Drug: Placebo, Drug:...</td>\n      <td>[Initial treatment period - Tralokinumab Q2W, Maintenance treatment period - Tralokinumab Q2W, M...</td>\n      <td>Secondary</td>\n      <td>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at W...</td>\n      <td>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD...</td>\n      <td>At Week 52</td>\n      <td>[32, 22]</td>\n      <td>Participants</td>\n      <td>[subjects, with, investigator's, global, assessment, iga, score, of, 0, clear, or, 1, almost, cl...</td>\n    </tr>\n    <tr>\n      <th>26</th>\n      <td>413</td>\n      <td>NCT03720470</td>\n      <td>Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderat...</td>\n      <td>Phase 3</td>\n      <td>[PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo]</td>\n      <td>[Drug: PF-04965842 100 mg, Drug: Injectable Placebo, Drug: PF-04965842 200 mg, Drug: Injectable ...</td>\n      <td>[Oral Placebo + Placebo Inj followed by 100 mg PF-04965842, PF-04965842 100 mg + Placebo Inj fol...</td>\n      <td>Primary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0...</td>\n      <td>IGA assessed severity of atopic dermatitis (AD) on a 5 point scale (0 to 4, higher scores indica...</td>\n      <td>Baseline (the last measurement prior to first dosing on Day 1), Week 12</td>\n      <td>[14.0, 36.6, 48.4, 36.5, 27.1, 58.7, 70.3, 58.1, 5.1, 5.9, 7.4, 2.4, 7.9, 8.4, 14.8]</td>\n      <td>Percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, response, of,...</td>\n    </tr>\n    <tr>\n      <th>27</th>\n      <td>416</td>\n      <td>NCT03720470</td>\n      <td>Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderat...</td>\n      <td>Phase 3</td>\n      <td>[PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo]</td>\n      <td>[Drug: PF-04965842 100 mg, Drug: Injectable Placebo, Drug: PF-04965842 200 mg, Drug: Injectable ...</td>\n      <td>[Oral Placebo + Placebo Inj followed by 100 mg PF-04965842, PF-04965842 100 mg + Placebo Inj fol...</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants Achieving IGA Response of Clear (0) or Almost Clear (1) and a Reducti...</td>\n      <td>IGA assessed severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). S...</td>\n      <td>Baseline, Week 2, 4, 8 and 16</td>\n      <td>[25.4, 39.5, 20.5, 12.0, 25.5, 44.1, 21.9, 13.2, 30.6, 43.8, 23.6, 15.7, 31.4, 45.7, 24.5]</td>\n      <td>Percentage of participants</td>\n      <td>[percentage, of, participants, achieving, iga, response, of, clear, 0, or, almost, clear, 1, and...</td>\n    </tr>\n    <tr>\n      <th>28</th>\n      <td>450</td>\n      <td>NCT02755649</td>\n      <td>A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermat...</td>\n      <td>Phase 3</td>\n      <td>[Dupilumab, Matching Placebo]</td>\n      <td>[Drug: Matching Placebo, Drug: Dupilumab, Drug: Dupilumab]</td>\n      <td>[Dupilumab 300 mg Q2W + TCS, Dupilumab 300 mg QW + TCS, Placebo QW + TCS]</td>\n      <td>Secondary</td>\n      <td>Percentage of Participants With Investigator Global Assessment (IGA) 0 or 1 (on the 0 to 4 IGA S...</td>\n      <td>IGA is an assessment scale used to determine severity of AD and clinical response to treatment o...</td>\n      <td>Baseline, Week 16</td>\n      <td>[13.9, 40.2, 39.1]</td>\n      <td>Percentage of Participants</td>\n      <td>[percentage, of, participants, with, investigator, global, assessment, iga, 0, or, 1, on, the, 0...</td>\n    </tr>\n    <tr>\n      <th>29</th>\n      <td>465</td>\n      <td>NCT03796676</td>\n      <td>JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis</td>\n      <td>Phase 3</td>\n      <td>[Placebo, PF-04965842, PF04965842]</td>\n      <td>[Drug: Placebo, Drug: PF-04965842, Drug: PF04965842]</td>\n      <td>[Placebo, PF-04965842 100 mg QD, PF-04965842 200 mg QD]</td>\n      <td>Primary</td>\n      <td>Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' ...</td>\n      <td>NaN</td>\n      <td>Baseline to Week 12</td>\n      <td>[24.5, 41.6, 46.2, 41.5, 68.5, 72.0, 12.6, 27.2, 38.6, 20.7, 31.5, 50.0, 29.8, 52.6, 55.4, -2.0]</td>\n      <td>Percentage of participants</td>\n      <td>[percentage, of, participants, achieving, investigator's, global, assessment, iga, response, of,...</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
                    },
                    "metadata": {}
                }
            ]
        },
        {
            "metadata": {
                "scrolled": false
            },
            "cell_type": "code",
            "source": "plot_outcome_search(search_results_ad)",
            "execution_count": 27,
            "outputs": [
                {
                    "output_type": "display_data",
                    "data": {
                        "text/plain": "<Figure size 1008x432 with 1 Axes>",
                        "image/png": "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\n"
                    },
                    "metadata": {
                        "needs_background": "light"
                    }
                }
            ]
        },
        {
            "metadata": {},
            "cell_type": "markdown",
            "source": "For future iterations of this project, I will determine a method to reconcile endpoints that were reported inconsistently (variations in spelling / grammar / word choice, but pertaining to the same outcome measure) to be able to chart which endpoints were reported most/least frequently across the clinical trials within the Query.\n\nThe example below represents the type of functionality I intend to add to this tool in future iterations."
        },
        {
            "metadata": {
                "scrolled": false
            },
            "cell_type": "code",
            "source": "query1 = Query()\nquery1.build_query()\n\nstudy_table = query1.build_study_table(query1.get_url())\noutcome_table = query1.build_outcome_table()\noutcome_table_primary = outcome_table[outcome_table['OutcomeMeasureType'].str.match('.*[Pp]rimary.*')]\n\noutcome_tracker = {}\noutcome_track(outcome_table_primary['OutcomeMeasureTitle'], outcome_tracker)\noutcome_tracker_df = pd.Series(outcome_tracker).to_frame('Frequency').reset_index().sort_values(by='Frequency', ascending=False).reset_index().drop(columns='level_0')\n\nplot_outcomes(outcome_tracker_df, query1)",
            "execution_count": 44,
            "outputs": [
                {
                    "output_type": "stream",
                    "name": "stdout",
                    "text": "\n\nEnter the search query term: \n\nsevere atopic dermatitis\n\n\nSearch Term: \n\nsevere atopic dermatitis\n\n\n\n\nQuerying up to 1,000 trials from clinicaltrials.gov with the following url...\n\nhttps://clinicaltrials.gov/api/query/study_fields?expr=severe+atopic+dermatitis&fields=NCTId%2CBriefTitle%2CCondition%2CPhase%2CStudyType%2CEnrollmentCount%2CStartDate%2CPrimaryCompletionDate%2CEligibilityCriteria%2CInterventionName%2CArmGroupInterventionName%2CArmGroupDescription%2CInterventionArmGroupLabel%2COutcomeMeasureType%2COutcomeMeasureTitle%2COutcomeMeasureDescription%2COutcomeMeasureTimeFrame%2COutcomeMeasurementValue%2COutcomeMeasureUnitOfMeasure&min_rnk=1&max_rnk=1000&fmt=json\n\n\n"
                },
                {
                    "output_type": "stream",
                    "text": "/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:52: FutureWarning: pandas.io.json.json_normalize is deprecated, use pandas.json_normalize instead\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:56: FutureWarning: pandas.io.json.json_normalize is deprecated, use pandas.json_normalize instead\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:84: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n/opt/conda/envs/Python-3.7-main/lib/python3.7/site-packages/ipykernel/__main__.py:82: SettingWithCopyWarning: \nA value is trying to be set on a copy of a slice from a DataFrame\n\nSee the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
                    "name": "stderr"
                },
                {
                    "output_type": "display_data",
                    "data": {
                        "text/plain": "<Figure size 2592x720 with 1 Axes>",
                        "image/png": "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\n"
                    },
                    "metadata": {
                        "needs_background": "light"
                    }
                }
            ]
        }
    ],
    "metadata": {
        "kernelspec": {
            "name": "python3",
            "display_name": "Python 3.7",
            "language": "python"
        },
        "language_info": {
            "name": "python",
            "version": "3.7.10",
            "mimetype": "text/x-python",
            "codemirror_mode": {
                "name": "ipython",
                "version": 3
            },
            "pygments_lexer": "ipython3",
            "nbconvert_exporter": "python",
            "file_extension": ".py"
        },
        "metadata": {
            "interpreter": {
                "hash": "59a4d4b4478b5f20e331a2a4cc8c12e2d26aa12bbd9e314e40fe03f165a80710"
            }
        }
    },
    "nbformat": 4,
    "nbformat_minor": 5
}